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ABSTRACT 
This thesis has addressed the issue of primary care prescribing in different European 
countries. The first hypothesis investigated was: that the planned implementation of a 
multinational consensus-based European Formulary in primary care will result in more 
rational prescribing. A controlled trial involved 235 GPs from eight European countries 
with half the GPs participating in an educational intervention. This comprised 
dissemination of the Formulary and discussion of antibiotic and NSAID prescribing. 
Details of 101,544 doctor-patient consultations were collated and prescribing was 
compared and contrasted, before (Phase 1) and after the intervention (Phase 11), using 
performance indicators. This included measurement of the prescribing concordance with 
drugs recommended in the Formulary which increased by 2.9% (SEM 0.7) between 
Phases I to 11 in the intervention group and decreased by 1.3% (SEM 0.6) in the control 
group. This difference was found to be highly significant (p <0.001). Although some 
changes in clinical practice occurred, more notable differences were found in prescribing 
patterns between countries. 
A second hypothesis followed: that identification of the main influences on the 
participating GPs'prescribing will assist in the explanation of the varying effects of the 
Formulary in the different countries. A two-stage Delphi questionnaire study asked the 
GPs to identify the factors which they perceived to influence their prescribing and to rate 
their importance. The most important influences were drug related characteristics in six 
countries, followed by education/information and then patient factors. Pharmaceutical 
industrial factors were considered the least important influence in six countries, which 
followed regulatory factors in five countries. More influential factors appeared to be in 
the GPs' control, rather than ones imposed by national health care systems, regulation 
and government. 
The results show that the extent of Formulary adoption varied in different European 
countries. There remains a continuing place for the promotion of rational prescribing 
principally through education and information, including prescribing guidelines. Future 
initiatives may be more appropriate within countries but require adequate and sustained 
professional and government support. 
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Introduction 
CHAPTER ONE 
INTRODUCTION 
1.1 BACKGROUND 
The concept of a European Formulary was first conceived at an international 
conference in Bielefeld in former West Germany in 1987 with the theme Fewer Drugs 
Better Treatment. From the surge in interest that followed, a European Formulary 
Group (EFG) was established to carry forward the pioneering operation to develop the 
European Formulary. By the end of 1991, a prototype European Formulary was 
produced with ten members of the EFG forming an Editorial Board. Eighteen months 
later, a framework European Formulary was developed resembling the version 
ultimately used for field testing. Up until 1993, the EFG had no success in acquiring 
independent financial support in order to help pursue the exercise. 
At that time opinion was divided among members of the Editorial Board as to what 
the future held for the European Formulary. Some considered that the ultimate test to 
prove the validity and worth of the Formulary was to measure its degree of acceptability 
and use among general practitioners (GPs) in different countries. Only by obtaining 
feedback from GPs with different views could a future European Formulary be shaped. 
Other members were not entirely satisfied with what might be perceived by peers as a 
'substandard' Formulary for practical use being circulated among clinicians. They 
preferred the idea of building on the framework Formulary, facilitated by medical 
literature and discussion with the ultimate aim of compiling a definitive European 
Formulary. The result of a successful grant proposal for the former idea to determine 
whether the European Formulary could be successful in improving cost-effective 
prescribing paved the way for the future direction of the venture. The proposal acquired 
independent BIOMED (Biomedical and Health Research) funding which became 
available in the summer of 1994 and I took up the post of junior research associate as 
the only full-time employee associated with the study at the end of January 1995. 
Formulary development needs to be an ongoing process but with the time-lag 
between applying for funding and getting the project up and running, update of the 
framework European Formulary had not been sustained. This fact, coupled with the 
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complication that not all members of the Editorial Board either opted to participate in 
the BIOMED study or to recruit a colleague to take their place, led to problems in 
merging the two separate agendas. The compromise reached was that those individuals 
not participating in the newly funded study would still be invited along to annual 
meetings where a proportion of time would be allocated to the continued development 
of the European Formulary but they would receive no financial support from the project 
grant. 
The first of three annual BIOMED project meetings to take place in Newcastle 
upon Tyne, England was at the end of April 1995. My input for these meetings 
included discussion of the progress of the study, planning of the content and 
implementation of the educational intervention, and feedback on the prescribing data. 
The initial three months prior to the first meeting, since I had taken up the research post, 
were primarily devoted to constructing diagnoses and drug coding frames. The drug 
coding frame was initially compiled from drug entities only available in the UK, so it 
required constant updating as alternative drugs available in other countries were 
prescribed. In preparation for the co-ordinators' meeting, a sample of data from each of 
the countries was coded, processed and manipulated in order to provide some basic 
initial feedback as well as to report on some of the problems encountered in the data 
analyses. As NSAIDs were one of the areas of prescribing which it was proposed to 
target, I performed a literature search on NSAIDs in order to contribute to discussion on 
how the educational intervention was to be formulated and structured. 
As my research work progressed, I saw that the European Formulary project and 
analyses of the data being collated could be utilised into challenging exercises for both 
continuing education and professional development. Subsequently, I registered for the 
degree of doctor of philosophy in November 1995, initially on a full-time basis until 
termination of my research contract in July 1997 and thereafter, self-funding as a part- 
time student. In the 18 months that followed my higher degree registration until 
termination of the BIOMED funding, I was able to develop an understanding and vision 
of how I could carry forward and consolidate the pioneering multidisciplinary 
collaborative development of the European Formulary and subsequent BIOMED 
controlled-study into its effect, to culminate in this thesis. 
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1.2 MAIN HYPOTHESES 
Two major hypotheses were investigated in this thesis, these were that: 
1. the planned implementation of a multinational consensus-based European 
Formulary in primary care will result in more rational prescribing. 
2. identification of the main influences on the participating GPs' prescribing will 
assist in the explanation of the varying effects of the Formulary in the different 
countries. 
Three areas of literature review are covered at the opening of this thesis and 
additional literature review was found to be necessary for inclusion at the start of each 
drug and morbidity results section relating to the investigation of the first hypothesis. A 
further literature review section comparing the main features of European Health Care 
Systems with a summary, conclusions and implications for prescribing research is 
presented in Annex 1. Throughout the thesis tables are located at the end of the 
Chapters. 
A framework of the research conducted in this thesis and how if fits into the wider 
context can be seen in Figure 1.1. In summary, this thesis has compared and contrasted 
prescribing patterns between the participating European countries and has assessed the 
prescribing performance prior to and after the implementation of an educational 
intervention. The area associated with influences on GP prescribing has also been 
explored and an attempt has been made to categorise influencing factors and to rank 
their perceived importance. 
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CHAPTER TWO 
REVIEW OF THE LITERATURE 
2.1 PRESCRIBING PATTERNS AND FORMULARIES 
"I shudder to think of the ceaseless cascade of medicine which is pouring down 
British throats at the present time ". (Aneurin Bevan 1949) 
2.1.1 Introduction 
In response to a patient's presenting complaint, a problem solving process will 
begin which may well result in a prescription. A prescription communicates the 
patient's drug treatment selected by the prescriber to the pharmacist who is responsible 
for dispensing it. Prescribing is a major clinical responsibility and is one of the core 
functions of the doctor. 1 Over the past fifteen years though, there has been an 
increasing amount of published drug utilization research which has questioned aspects 
of prescribing practice at regional, national and global levels. 2 Some of these problems 
which are expanded on below include: 
I. polypharmacy prescribing 
drug prescribing not related to diagnosis 
3. the prescribing of inappropriate often not therapeutic dosages 
4. the prescribing of unnecessary drugs. 
Other aspects such as the susceptibility of doctors to pharmaceutical industrial 
promotion3 will be discussed in Section 2.2.8. 
Polypharmacy prescribing refers to the situation when a patient is being supplied 
with several drugs which may potentially interact with each other, or when a drug may 
be being taken to reduce the side-effects of another. 4 Elderly patients with their 
multiple diseases are particularly susceptible to incremental prescribing which greatly 
increases the risk of drug interactions as well as other possible adverse reactions which 
can lead to iatrogenic disease and subsequent hospital admissions. 5 At the end of the 
1980s, a study was performed by a multidisciplinary team of researchers to investigate 
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multiple medication use by over 2,800 elderly patients in Dubbo, New South Wales, 
Australia. Results of multivariate statistical analyses revealed that polypharmacy was 
significantly predicted by recent hospitalisation, increasing age, female sex and 
increasing depression. 5 Widowhood and loneliness may cause or aggravate symptoms 
of social stress and can sometimes result in the unnecessary and inappropriate 
prescribing of psychotropic drugs. 6 Young individuals have also been found to be 
exposed to polypharmacy. A study to investigate the cost burden and extent of 
medication use by 1,450 outpatients who were up to 16 years of age was conducted by 
two medical doctors in a Nigerian University Teaching Hospital in the mid 1980S. 7 
Five drugs on average were prescribed for each patient and an increasing number of 
drugs prescribed per patient was found to potentiate poor compliance with drug regimes. 
Drugs used by elderly patients which have often been found to be associated with 
polypharmacy include cardiovascular, analgesic8 and non-steroidal anti-inflammatory 
drugs (NSAIDs)9. In younger patients, polypharmacy predominantly involves anti- 
asthma drugs, anti-ulcer drugs and psychotropics. 8 Implementing an effective repeat 
prescribing system could help to identify those patients at risk from polypharmacy 
prescribing. The issuing of a standard number of days' duration of treatment for items 
taken regularly, may help to reduce confusion and increase compliance with drug 
regimes. 10 
The inappropriate prescribing of antibiotics in diarrhoea is a commonly reported 
example of drug prescribing not related to diagnosis, particularly in third world 
countries. 2 In parts of Indonesia, virtually every patient with simple diarrhoea or 
common upper respiratory infections is treated with one or more antibiotics. 11 As a 
result,, 60% of the drug cost of treating these common illnesses is due to anti-bacterial 
agents. In the early 1990s a survey by epidemiologists in Mexico City interviewed 
housewives of 1,659 households to identify antibiotic misuse in diarrhoea. Patients with 
diarrhoea who consulted a physician were found to be six times more likely to be treated 
with an antibiotic than those patients not consulting. 12 Self-medication was also 
associated with a higher risk of using an inadequate drug or dose and treatment was 
likely to be taken for less than the recommended duration. As the data was based on 
information obtained from interviews with housewives about the previous two week 
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history of family members presenting with diarrhoea, there may have been an element 
of recall bias in this study. 
Prescribing of inappropriate dosages has also been found to be a particular 
problem in a review of published prescribing studies. A multi-disciplinary team of 
health service researchers in Manchester organised a panel of 10 experts in the field of 
prescribing to define indicators of prescribing appropriateness in general practice-13 
Nineteen indicators were identified and their prevalence was rated in 62 prescribing 
studies published between 1980-95, using the then current issue of the British National 
Formulary (BNF) as the reference standard. 'Inappropriate drug dosages which were 
outside the advised therapeutic range' was consistently the highest rate indicator 
recorded. Such dosages were found to be common with respect to thyroid stimulating 
hormone and narrow therapeutic index drugs such as digoxin, lithium, theophylline and 
warfarin. 
Other drugs have also been found to be prescribed in subtherapeutic doses, for 
example antidepressants. The pattern of psychotropic drug use by 2,414 residents in 46 
nursing homes in Sydney was investigated by researchers in the psychogeriatric services 
department of a local hospital. 14 Of the 377 patients identified taking regular 
antidepressants, at least half the antidepressant doses were found to be subtherapeutic. 
The paper did not discuss the duration of treatment and it is possible that some of these 
apparently subtherapeutic doses may have been reducing doses which can be prescribed 
to prevent patient withdrawal. 6 Identifying the type of prescriber may help explain 
some differences found in the treatment strategies in depression. Analysis of a postal 
questionnaire circulated throughout England in 1993 compared the management of 
depression by 89 geriatricians and 72 old age psychiatrists. 15 Although the former 
might be more up to date with current practice and new drug developments, the survey 
found that the geriatricians were more likely to suggest antidepressant dosages which 
were subtherapeutic. The research was performed by a team of psychiatrists and it is 
possible that they would not wish to publish findings suggesting criticism towards their 
own specialisation. 
In 1994, Glaeske, a pharmacist working for the German Sick Funds and a 
government prescribing adviser, considered that over 30% of all prescriptions in the 
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former West Germany in 1992 were unnecessary. 16 Forty-four drug groups were 
identified which he perceived to be of 'doubtful use' amounting to 247.5 million 
prescriptions, representing almost one third of the total number dispensed in that year. 
These drug groups included combinations of antitussives, coronary vasodilators and 
certain migraine drug combinations. Reasons for this poor quality prescribing were 
considered to be misleading drug information and too many drugs on the market 
'blinding' the prescriber. Of the approximately 57,000 drugs on the German market in 
1994, only 12,000 were licensed with proof of efficacy, reliability and high 
pharmaceutical standard in order to fulfil the criteria of the German Drug Act. 
A study in Montreal, Canada in 1997 assessed the management by 112 physicians 
of two clinical cases using standardised elderly patients with NSAIDs. 17 The first case 
was chronic hip pain due to early osteoarthritis and the second NSAID related 
gastropathy. Unnecessary prescribing of NSAIDs were found to be written in over 40% 
of the doctor-patient consultations. 
2.1.2 Drug expenditure and prescribing patterns 
The availabilityI8 and cost of drugs on the market varies from country to 
country. 19 The same drugs may also have different marketing authorisations in 
different countries. 20 Government and industrial price and profit controls are largely 
responsible for determining the cost of drugs in different countries. 21 The quality of 
prescribing is also considered to vary between countries. 22,23 In addition, there are 
deep rooted variations in medical culture and training between countries. 24,25 
In the epidemiology of disease, cultural factors can be causal,, contributory or 
protective in their relation to ill-health. Some of these cultural factors include: the 
economic situation, family structure, contraceptive patterns, population policy, diet and 
religion. 25 Comparing medical culture between four similarly developed Western 
industrialised nations namely France, Germany, the United Kingdom (UK) and the 
United States (US) reveals marked variations. 24 The French attribute the origin of 
many diseases to the liver, even referring to migraines as 'liver crises'. In contrast, the 
Germans believe that the source of many medical conditions is the heart and when a 
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German doctor describes a patient as having 'cardiac insufficiency', this may simply 
mean that the patient is tired. In the US, the human body is generally perceived to 
function like a machine. Hence in order to fix' the machine, surgical intervention is 
practised more commonly than in Europe and in the early 1980s American rates for 
frequency of coronary bypass were 28 times that of some European countries. Unlike 
the French and Germans, the British have traditionally preferred to place the cause of 
disease outside their bodies, they disregard the belief in a certain reserve of health that 
can be drawn upon i. e. terrain. Consequently, the British appear to be a fairly 
conservative race both in paying relatively little attention to their bodies and in tending 
to favour previously tried and tested treatment strategies rather than the adoption of new 
ones. The British also have a tradition for being overly concerned about their bowels 
and regard daily bowel evacuation as almost a religious necessity which has incurred a 
disproportionately high use of laxatives. 24 
With respect to differences in medical training between countries, between 1986 
and 1990,, three WHO Working Groups were set up to investigate the spread of clinical 
pharmacology throughout Europe. 26 Clinical pharmacology was considered to be 
fundamentally important in many aspects of health care delivery, particularly with 
respect to influencing rational drug use. In the 21 countries participating in the survey, 
there were marked differences with the UK leading the way with 29 clinical 
pharmacology departments compared with Turkey at the other extreme where there was 
no such formal department. The idea of a clinical pharmacologist running clinics in a 
general practice in Whickham, Tyne and Wear, UK had been experimented with in the 
mid 1970s. Their purpose had been to review medication and future patient 
management and the results of the pilot study appeared positive. 
27 
All the factors referred to contribute to drug consumption and drug expenditure 
being highly irregular from country to country. With growing economic pressures to 
contain costs, much attention is now focused on analysing prescribing patterns and drug 
consumption both within and between countries. By 1985, the global drug bill was 
estimated at US $100 billion annually. 
28 In one decade between 1976 and 1985, 
despite developing countries increasing their share of the world's population from 63% 
to 75%, their proportion of the global drug bill decreased by 20% to US $15-20 billion. 
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In 1997, the world pharmaceutical market was $297 billion and 80% of this was 
consumed by 10% of the world population. 
Over the past decade, the primary care prescribing bill in England has more than 
doubled, increasing from f 1.87 billion to f4.37 billion in 1997, representing 10% of all 
NHS expenditure. 29 Repeat prescribing alone was estimated to amount to E2.5 billion 
(7%) of all NHS expenditure in 1993.30,31 In the UK, seven out of ten consultations in 
primary care with a general practitioner result in a prescription being issued30 and 
consequently such acute and repeat prescribing is responsible for the consumption of 
vast NHS resources. Over the past few years, the annual prescribing bill has been rising 
at approximately 10% each year gross32 which represents a real increase against 
relatively low rates of inflation. 
Between European countries, the quantity of prescribing and annual drug costs per 
head have been found to vary widely and are increasing (Table 2.1). From Table 2.1 it 
can be seen that doctors in the UK tend to prescribe a low average number of items per 
patient per anum, although this is slowly increasing with time. Despite the earlier 
figures indicating the seemingly high cost of prescribing in Britain, doctors there are 
actually more conservative in what they prescribe compared with most of their 
European colleagues. At the beginning of this decade, only 50 drugs accounted for 50% 
of the total NHS drug expenditure and 300 drugs represented 80% of this. 33 Whereas 
almost one third of Italian drug expenditure during 1991 was on medicines introduced 
within the previous five years, which compares with 17% of German, 13% of French 
but only 9% of UK expenditure. 30 
Less affluent European countries such as Greece and Portugal spend much more on 
pharmaceuticals relative to their total health budgets compared with wealthier countries 
in the community. 21 Total per capita spending on all medicines in Britain falls well 
below the average spent in Western European countries; however there is no evidence to 
suggest that either lower than average expenditure or reduced drug availability is 
detrimental to the health of the population in the UK. At a global level, the UK market 
represents only 3% of the world pharmaceutical sales but it carries an international 
influence that is markedly out of proportion to its volume. 34 
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Prescribing has also been found to vary widely within countries. England, for 
example, is divided into 8 Regions which are further divided into Health Authorities 
(HAs). 32 The average total cost per patient per annum in 1998-1999 varied between 
E73.11 in Ealing, Hammersmith & Hounslow HA and f 130.40 in North West Anglia 
HA (national average L98.35). In the same year, the average number of prescriptions 
dispensed per patient per annum also varied between 6.69 in Kensington, Chelsea and 
Westminster HA compared to 13.51 in Barnsley HA and Doncaster HA (national 
average 10.03 items). 32 One of the reasons for these differences is that GPs are treating 
increasing numbers of elderly patients who tend to be more numerous in certain 
locations. The average woman over 75 years of age has been found to be prescribed up 
to twelve times the quantity of medicines of a young man. 35 Many of the factors which 
have been identified as influencing prescribing and therefore contribute to an 
explanation of why variations exist are discussed in a later review section (Section 2.2). 
Prescribing patterns and drug expenditure are also likely to be influenced by over 
the counter (OTC) medicine sales. In 1992, OTC sales accounted for nearly a fifth of 
the total value of medicines on the market in northern countries such as UK, Denmark 
and Germany. 21 In Portugal, France, Spain and Italy OTC medicines represent only 5- 
10% of sales. Over the last few years the OTC market has expanded all over Europe 
with a corresponding promotion of self-medication by the governments in the majority 
of European countries. 18 The main purposes of this has been an attempt to reduce the 
cost burden on insurance and national health care systems, thereby pushing the cost onto 
the consumer. 
One problem with some of these reported inter-country comparisons is that the 
information often comes from a variety of independent sources, as a consequence of 
which drug consumption, cost and associated statistical data may not always be directly 
comparable. For example, data comparing the average number of prescriptions per head 
would vary whether this reflected actual drug consumption or the theoretical number of 
prescribed items written. It has been estimated that between 5 and 10% of prescriptions 
written are not dispensed. 
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2.1.3 Rational prescribing 
To ensure optimal use of often scarce health system resources, prescribing should 
be responsible and rational. In 1973 Parish, then a senior medical research fellow in 
Swansea, considered that responsible prescribing was based on a clear clinical need and 
that the actions of the prescriber should be defended to both peers and patients. 37 He 
defined rational prescribing as being appropriate for the patient, effective, safe and 
economical. This has been an important statement which others have developed. A few 
years later in 1978, Taylor, an academic general practitioner from Aberdeen, endorsed a 
similar definition of rational prescribing to that of Parish. 38 More recently, van 
Zwanenberg emphasised that prescribing should be acceptable to the patient and that the 
two most important criteria in prescribing were the appropriateness of drug prescribing 
and the choice of drug / preparation. 39 Patient acceptability can be important; for 
example, the taste, appearance, dosage schedule and side-effect profile are all features 
which can effect patient concordance. 40 
In 1995 the definition of rational prescribing was refined by Barber a professor of 
pharmacy practice at London University School of Pharmacy. 41 He proposed that the 
main aims of a prescriber should be to: maximise effectiveness; minimise risk; minimise 
cost (by taking account not only drug costs but also associated costs such as necessary 
laboratory monitoring) and respect patient choices. He acknowledged that trade-offs 
may often need to be made between conflicting aims and that, depending on the 
situation, patient choice may be the most important consideration. 
Two pharmacists have more recently performed a qualitative study interviewing 23 
GPs from two health authorities in the south of England to analyse why doctors may 
continue to prescribe in ways which do not fit the ideal of rational prescribing. 42 They 
revealed that prescribing is often performed in an irrational way as a coping strategy for 
a variety of reasons including busy workload, to maintain a doctor-patient relationship 
and to reduce the risk of medico-legal challenge. The following is a quote from a GP 
who issued a prescription to alleviate a distressing situation. 
"A patient came to me ... who has cancer and was waitingfor chemotherapy. She 
got a sore throat. I knew that she was terrified that her chemotherapy would be 
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cancelled ... She was convinced she would never get better ftom the sore throat and it 
was some other sort of cancer. And I gave her antibiotics more or less without even 
bothering to look at it. I mean, I did look at it but I was going to give her antibiotics 
anyway because she had got herseýf into such a tiz - but they were entirely to calm her 
down. " 
The above case does not necessarily mean that the GP disagrees with the criteria of 
rational prescribing but in certain situations may find prescribing the most rational 
option. This research left the authors wondering whether it was the definition of 
rational prescribing which has turned into rigid health policy that was wrong, rather than 
the doctor. 42 
Health service researchers in Manchester published a review on the appropriateness 
of prescribing with respect to healthcare in 1997.43 They differentiated between 
rational and appropriate prescribing by suggesting that the former could be considered 
to be a process whereas the latter was an outcome. Appropriate prescribing was thus 
defined as an outcome of a process of decision-making that maximises net individual 
health gains within society's available resources. 
2.1.3.1 Key political strategies to improve prescribing in the UK 
Generic prescribing was advocated as one mechanism of reducing prescribing 
expenditure back in 1959 by the Hinchcliffe Committee which was set up to investigate 
the cost of NHS prescribing in Britain. 44 Another of the Hinchcliffle recommendations 
resulted in the introduction of the Prescribers' Journal. 
Current law controlling the production and distribution of medicines in the UK 
was introduced following The Medicines Act 1968.45 This ensured that no medicine 
could be marketed without a product licence (now referred to as marketing 
authorisation) and that medicines may only be manufactured by the holder of a 
manufacturer's licence. The Act was particularly relevant to the prescribing of 
medicines as it was the benchmark for ensuring a comprehensive standard for the 
efficacy, safety and quality of all medicines. 
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In 1982, the Greenfield Report concluded that there remained advantages to be 
gained from generic prescribing and the report went as far as recommending that 
community pharmacists should substitute generic drugs for proprietary products on 
prescriptions as hospital pharmacists do. To date this recommendation has not been 
implemented. 46 
Governinent concern about the cost of prescribing has resulted in several measures 
which focus on containing cost. In April 1985, the government introduced the Limited 
List or Selected List which restricted prescribing of some categories of medicines within 
the NHS. The intention was to eliminate many heavily prescribed non-advertised 
pharmacy only (P) and general sales list (GSL) medicines from GP prescriptions and 
encourage the public to purchase them instead. During the first month after the 
introduction of the Limited list, two health care professional academics in the 
Department of General Practice, University of Aberdeen recorded the actions taken by 
17 GPs when a recent banned drug would have formerly been prescribed. They found 
the prevalence of patient contacts affected by the new regulations to be relatively low 
and of these, approximately half the patients received the same active drug under a 
different name. 47 This study was only carried out in the short term and the results may 
not have been an accurate assessment of the impact of the Limited List. In the first year 
which followed its introduction, the UK government claimed and reported saving over 
f 75 million. 48 The accuracy of this estimate was debatable though and Gilleghan, a GP 
in Edinburgh and one of the key leaders in the general practice formulary movement in 
the UK,, was of the opinion that the Limited List had not demonstrated an overall 
reduction in drug costs. 49 
In 1992,, the government planned to extend the Selected List. To facilitate this 
process, the Advisory Committee on Drugs which included extensive professional 
representation was established. 
34 Two years later, the group were only able to 
recommend that topical NSAIDs which at the time cost more than 0 per 100g should 
be 'blacklisted'. This resulted in a swift response by manufacturers to reduce their 
prices and consequently a new Selected List was not produced. The Committee 
considered that the 'blacklist' focused excessively on drug costs and did nothing to 
improve prescribing and suggested that a positive ('white') Selected List might be more 
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successful but to date this has not been adopted. Positive lists are currently more 
commonly used by other European governments to intervene in the pharmaceutical 
market rather than negative lists. 18 
Consideration of extending the Selected List was part of the NHS reforms 
introduced in 1991 to address the problem of escalating NHS costs of which prescribing 
costs represented a major contributor. 50 Two initiatives were introduced to provide 
GPs with incentives to reduce prescribing costs. Firstly, GP practices were invited to 
become 'fundholding' and were given a drugs budget with the power to reinvest any 
savings that they could make in other services to their patients. Secondly, for non- 
fundholding practices an indicative prescribing scheme was introduced in the form of an 
estimated financial target based on previous spending. These budgets and financial 
targets were set and monitored by Health Authority medical and pharmaceutical 
prescribing advisers with the aid of PACT data. 51 
In the UK in 1994 the Audit Commission published one of the most in-depth 
documents to date on prescribing. 3 0,52 The Commission's strategy for prescribing 
suggested that E425 million could be potentially saved in general practice prescribing. 
Those consulted included staff at 54 practices, regional and hospital pharmacists and 
many professional bodies. Prescribing was evaluated in the 54 practices and a model 
was developed that could be compared with national averages. The difference between 
the model and real life formed the basis of its calculations on cost. In order to achieve 
rational prescribing, the report recommended: less over-prescribing of, for example, 
ulcer healing drugs; reducing the prescribing of drugs of limited clinical value such as 
vasodilators; substituting comparable but cheaper drugs, for example, expensive 
NSAIDs with cheaper ones; more prescribing of generic alternatives to brands and 
justifiably appropriate use of expensive preparations including modified release 
formulations. The Commission did accept that in order to achieve this, prescribing 
behaviour will have to be changed over a period of time. 
Following the change in British government in May 1997 Primary Care Groups 
(PCGs) were proposed in a White Paper published in December of that year. 53 This 
was the beginning of the phasing out of fundholding for practices and from April V 
1999 all GPs have had to join PCGs which usually consist of about 50 GPs covering a 
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population of approximately 100,000 within the same geographical area. In the past, 
health authority budgets for hospital, general practice medicine, pharmaceutical services 
and other primary care areas were separate but PCGs now receive a global sum for all 
these services. 54 This has the advantage of allowing the movement of funds between 
different budgets, although each PCG will have a ceiling on its prescribing. Should this 
be breached then other areas of health care expenditure, such as the budget for hospital 
and community services will have to be curtailed, but savings can be reinvested in the 
health care of the local community. Each PCG board will have a member who takes a 
lead on prescribing and it is anticipated that significant change should be visible within 
the first year of operation. 55 
2.1.3.2 Assessing rational prescribing 
In 1977, Mapes, a medical sociologist at Swansea University, attempted to assess 
the criteria of effectiveness and safety in the definition of rational prescribing by 
analysing a random sample of approximately 1,000 prescribed items from each of 116 
doctors. 56 He found that the writers of large numbers of relatively inexpensive 
prescriptions tended to display conservatism and postulated that with increased 
workload, conservative doctors show a tendency to recall drugs that they learned about 
in their early training. In contrast, incaution was found to be associated with a declared 
dependence on pharmaceutical industry literature, with the tendency to leave 
prescription writing to ancillary personnel and with prescriptions having inadequate or 
no directions. The data demonstrated that prescription analyses can be useful for 
exposing distinct differences at either end of the spectrum of rationality but also 
showing that prescribing by some doctors at different times displays both conservatism 
and incaution. There was some selection bias in the study as all the practitioners were 
relatively young and had become principals in general practice in 1969. 
A multi-disciplinary pharmacist / GP research team in Dundee categorised 
prescription errors into four classes of severity and investigated the frequency of their 
occurrence by eight GPs in three practices. 
57 Although there were only found to be 504 
errors from 15,916 prescriptions, it was estimated that each doctor is still likely to have 
on average 260 errors which require correction each year. The study also found that 
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doctors who make minor nuisance and trivial errors are the ones more likely to make 
major errors and potentially serious mistakes. 
In 1987, van Zwanenberg et al, academic GPs from the Newcastle Medical School9 
attempted to study the effectiveness of educational interventions on the prescribing of 
12 GPs but acknowledged that there was difficulty in identifying valid measures of 
Parish's and Taylor's definition of rational prescribing. 58 The results indicated that 
prescribing habits of GPs can be changed if they are given information and have the 
opportunity to discuss rational prescribing. They found that measuring the proportion of 
patients not receiving a prescription, the proportion of items prescribed generically and 
the proportion of new and repeat prescriptions falling within an agreed local formulary 
were a useful framework for assessing rational prescribing. There was some selection 
bias in this study with all the participating doctors aged between 29 and 36 years and 
therefore not truly representative of the GP population. 
One major disadvantage of these various studies is that there is no single 
methodological approach which can be adopted to assess prescribing competency. The 
research which has been carried out often has one recurring limitation, for example with 
respect to the number of GP participants mainly due to the limited resources available. 
One of the attractions of using the proportion of drugs prescribed generically as a crude 
indicator of rational prescribing (Section 2.1.3) is that, subsequent to the Newcastle 
study above58' this can now be potentially measured on a continuous basis for all GPs 
in the UK by using systems such as Prescribing Analysis and Cost (PACT) and Scottish 
Prescribing Analysis (SPA) described below. 59 Generic prescribing is one example of 
where interventions to improve GP prescribing habits have been successful and 
maintained compared with the effects of other interventions. 60 
One of the most important factors which has encouraged the assessment of 
prescribing by GPs is the widespread concern over the rate of increase in drug 
expenditure across Europe. 
61 The introduction of computers has enabled the Central 
Prescription Pricing Authority in England to produce a revolutionary method of 
analysing the prescribing patterns of all GPs. Prescription Analysis and Cost (PACT) 
was introduced to GPs in England and Wales in 198840 and in Scotland, a similar 
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system began in 1990 called Scottish Prescribing Analysis (SPA). PACT and SPA data 
records every prescription issued and it enables GPs to: 
0 review their prescribing habits and costs, 
0 develop and monitor practice formularies and prescribing policies 
within the practice, 
0 compare their prescribing with that of their colleagues in the same 
Health Authority area and also nationally, 
0 improve the cost effectiveness of prescribing within the practice. 
All GPs receive PACT data at quarterly intervals and until 1995 it was available in 
three levels of increasing complexity and now similar information is available in two 
formats. The breakdowns of prescribing analysis data are gradually being introduced 
into other European countries. 62 
Since 1990, each GP in Britain is now given an indicative budget for each year's 
prescribing based on several factors including the size of the practice and the number of 
registered patients. 51 Associated with this, Health Authority prescribing advisers have 
the role of assisting GPs to develop more rational and cost-effective prescribing. With 
the aid of PACT data, prescribing advisers can monitor the total cost and trends over 
time for the district and for individual practices. Through the mechanism of an annual 
review with each practice, the adviser can influence the quality as well as the cost of 
prescribing. With continuous monitoring and feedback, it is expected that improved 
prescribing will follow. 63 
Since the introduction of PACT and SPA, prescribing analysis has expanded and 
diversified in the UK but access to more in-depth sophisticated information is limited. 
The information contained within PACT is a simple cost listing, not related to morbidity 
levels or quality of prescribing, and this must be recognised when interpreting the data. 
There is no information on patient numbers, doses, length of treatment, consultation 
rates, referrals or treatment outcomes, including failures. 64 In addition, PACT data 
does not contain any information on prescribing in hospitals and it excludes private 
prescriptions and drugs that a patient does not have dispensed. 65 Patients are 
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categorised as prescribing units (PUs) within PACT data but the adjustment for age is 
not ideal with all patients 65 years and over being classed as three PUs compared with 
all other patients who are classified as one PU. ASTRO-PUs and STAR-PUs have been 
derived from the computerised records of general practices which indicate that the 
simple weightings are inadequate. 3 5,66 ASTRO-PUs make allowances for age, sex and 
temporary residents and STAR-PUs are specific therapeutic group age-sex related PUs. 
To overcome some of the limitations of PACT, one study in the North East of 
England attempted to apply professionally derived numeric standards of prescribing 
performance based on PACT. 67 Eight GPs of different ages and practice environments 
met on three occasions and by an informal consensus decision-making method selected 
13 quality markers which were then applied to all 518 practices in the region. The study 
proved that realistic indicators to assess prescribing quality can be set but it is debatable 
whether these standards could be used right across the country. 
Using cost as one of the measures of rational prescribing is a particularly 
complicated aspect to investigate and involves many aspects of pharmacoeconomics. 
Economic studies should include all costs associated with the treatment or intervention, 
and those of monitoring and follow-up, as well as the estimated costs of adverse effects 
and treatment failures. The main four methods of analysiS68 available are: 
a) Cost-minimisation analyses. These are used in two circumstances: firstly, where it 
is known for example that different treatment strategies generate exactly the same health 
care benefits and only the costs differ; secondly, where one option is superior in terms 
of both clinical effectiveness and costs in terms of hospitalisation for example. 
b) Cost-effectiveness analyses. These are particularly useful for comparisons of 
directly competing drugs and therapies when weighing up the price of achieving extra 
benefit from using one treatment which is superior to another. This can be expressed in 
units such as cost per infection cured, cost per unit of cholesterol reduction or cost per 
year of life saved. 
C) cost-utility analyses. These can be used to measure the patients' perspective of the 
various health changes produced by an intervention. Comparative assessments of the 
net cost per quality-adjusted life year are the most familiar form of cost-utility analysis. 
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This measure has the advantage in that it can be used to make broad comparisons of the 
'health gain' achieved from devoting resources to different health care interventions. 
d) Cost-benefit analyses. These involve determining health benefits in monetary terms 
and such analyses are often applied in order to optimise the use of a health care budget. 
Additionally, they can be used to assess, for example, the benefit achieved from the 
provision of extra resources to health screening. 
All of the above measures differ in the way they handle the benefits of health care. 
In recent years, there has been a growing trend to widen the criteria upon which drug 
selection is based by incorporating more emphasis on patient acceptability. If the 
patient is not satisfied, concordance is likely to be impaired. This is a fairly challenging 
task on the part of the health care professional - such as in convincing patients that a 
generic drug is in no way inferior therapeutically to the branded equivalent when the 
former may appear less glamorous. 69 
In the fature,, it is likely that prescribing performance will be monitored even more 
closely because of the importance of patient and financial outcomes. 59 Prescribing 
assessment in primary care needs to be linked closer to morbidity, health outcomes and 
hospital admissions and computer software may one day enable this to happen. 
Meanwhile, GPs should perform regular medical audit to check for example that their 
system for reviewing patients on long term medication works and continues to do so. In 
order to optimise rational prescribing and perform medical audit, the use of a drug 
formulary can prove invaluable. 
2.1.4 Formularies and essential drugs 
The concept of essential drugs is that in a given situation, there is a list of drugs 
which are the most needed for the health care of the majority of the population and 
therefore should be available at all times in adequate amounts and in the proper dosage 
forms. 70 Similarly, formularies in their most basic form consist of a limited list of 
drugs with their profiles and they are intended to guide doctors in their prescribing. 71 
Formularies may also be more sophisticated by containing additional important 
prescribing information to help doctors with drug selection. 72 
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Essential drugs lists were created in an attempt to extend the accessibility of the 
most necessary drugs to populations whose basic health needs could not be met by the 
existing supply system. 71 The World Health Organisation (WHO) Action Programme 
on Essential Drugs intends firstly to ensure the regular supply of safe and effective 
drugs and vaccines of acceptable quality at the lowest possible cost and secondly to 
promote the rational use of drugs. 28 
There are many similarities between a therapeutic formulary and an essential drugs 
list. Firstly, the basic criteria for drug selection are those based on evidence of efficacy 
and safety ensuring that the drug has a favourable benefit / risk profile. Where two or 
more drugs appear to be similar, choice should be made on a cost / benefit ratio and 
drug availability should also be considered. They should be tailored to local 
requirements as the range of drugs that must be considered vital to a community will 
vary both with the actual prevalence of particular disorders and with views of how these 
can be prevented, diagnosed and treated. Preferably there should be some input into the 
formulary development from the doctors who will be the users when prescribing and 
from pharmacists who are able to provide relevant valuable advice and are also affected 
by the range of drugs likely to be requested. If formularies and essential drug lists are to 
remain useful, it is crucially important that a mechanism for periodic updating is 
established. 
The main difference between an essential drugs list for use in developing countries 
and a formulary in a developed country is that the former is often trying to create the 
best approach to therapy from the limited resources available. 70 In contrast, the latter is 
attempting to select the most suitable medicines from a wide choice of drugs. 
2.1.4.1 Formulary evolution 
Formularies containing herbal remedies were recorded by Dioscorides, a surgeon in 
the Roman army at the time of the Emperor Nero as far back as AD 100.73 In Britain, 
herbal formularies have existed for over 500 years. 74 
In 19 11. the National Health Insurance (NHI) Act was passed and since then the 
number of local formularies containing simple medicaments with lists of ingredients 
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began to increase. 75 This increase was in response to a need for doctors and 
pharmacists to have access to more practical information about medicines than that 
limited to pharmacopoeias. 
After two years collaboration between the British Medical Association (BMA) and 
the then Retail Pharmacists Union, a nation-wide formulary was compiled in 1929 for 
all NHI doctors. 75 The formulary contained 295 monographs and for the first time 
included 'notes for guidance in prescribing'. Although the NHI Scheme only covered 
community medical services, most of the larger hospitals also had their own formularies 
and prescribers were restricted to using drugs listed in the formulary for both in-patients 
and out-patients. 
In 1941, a small committee was appointed to prepare a National War Formulary 
(NVvT). 76 The formulary listed 380 preparations, sufficient in range to meet the 
ordinary requirements for therapeutics, and it was intended for use by prescribers in 
both primary and secondary care. As previously, the main titles were in Latin and the 
doses given in the Apothecary system. 
A few years later in 1948, the National Health Service (NHS) was established in the 
UK. The Pharmaceutical Society and the BMA, the two non-governmental bodies 
which had been most closely associated with the production of the NVvT, continued the 
publication of a British National Formulary (BNF) for use throughout the NHS. 76 
Under the direction of a Joint Formulary Committee new editions of the BNF were 
produced about every three years until 1976. During this time much detailed discussion 
took place and the content and style of the formulary changed drastically. English 
replaced Latin, the metric system replaced the apothecaries' system and monographs on 
new and important drugs such as antibiotics gradually replaced traditional tonics and 
mixtures. By the end of the 1960s, there was a flood of new drugs introduced and 
updating the formulary against the tide of industrial innovation became extremely 
challenging. Producing a revised BNF once every three years was not enough to 
maintain widespread acceptance and eventually the BNF was perceived by doctors as 
being increasingly less relevant. 
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At this time, the Monthly Index of Medical Specialities (MIMS) was being 
published under the auspices of the pharmaceutical industry and in 1976 it was 
estimated that 80% of prescribing was done using the Index and only 20% with the 
BNF. 75 This led to a demand for a new type of formulary and together with 
representation on the Joint Formulary Committee of the Department of Health it was 
agreed that the British National Formulary should: 
" no longer be selective 
" contain information about all the drugs available for doctors to prescribe 
" give information about the price of medicines 
" be easy to use 
" be handy to fit into a coat pocket 
" be kept up to date76 
Since 1981 , the BNF 
has been published in a new format with six sections. While 
doctors and pharmacists welcomed the new BNF, the media and pharmaceutical 
industry were antagonistic. The new BNF format has been published every six 
months75 and since 1997,, an on-line version of the BNF has been available. This has 
the added advantages of being easily accessed in the doctor-patient consultation as well 
as in the pharmacy and it facilitates even more regular update of necessary drug 
changes. 
21.4.2 The global perspective 
Before the major revision of the BNF took place in the mid 1970s formularies 
began to proliferate in other parts of the world as can be seen in Table 2.2. 
2.1.5 Formulary development with particular reference to the UK 
Formularies are designed to offer good quality independent information, with drug 
recommendations based on efficacy, safety and cost without compromising patient 
care-4 Both general practice77-81 and hospital formularies82-85 are available which are 
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tailored to the needs of prescribers depending on the branch of health care in which they 
practice. 
In setting up a local primary care formulary, it is important to establish and agree a 
number of factors at the outset. Firstly, the aims of the exercise need to be realistic and 
achievable and they should be ranked in order of priority. For example, is the formulary 
intended to be simply a list of approved drugs or a more detailed manual providing 
guidance on prescribing? Secondly, it is necessary to define the intended scope of the 
formulary as it needs to be representative of the range of its proposed clinical activity. 86 
However,, it must be sufficiently detailed to allow choice of drug, but not so large that it 
fails to eliminate excessive duplication. 87 The proposed target of one published 
formulary, for example, has been to recommend treatment for 90% of patients 
presenting in primary care. 78 Thirdly, the procedures and funding for ongoing update 
and review are also best agreed and established at the start. Finally, to ensure deadlines 
are met, the precise roles and expectations of all those involved in development need to 
be clearly specified at the outset. 
In recent years, there has been steadily increasing political pressure to improve 
prescribing and one proposal by a former British government has been to encourage 
GPs to develop their own practice formulary. 46 As GPs in the UK are independent 
contractors it can be difficult for Health Authorities to enforce the use of formularies. A 
frequent reservation expressed by some doctors is the fear that formularies devised by 
other people could be imposed on them so it is better for doctors to be involved and 
prepare their own formulary based on their experience and needs. 88 The onset of 
fundholding practices in 1991 inspired many GPs to develop their own practice 
formularies as it provided them with the financial incentive to control their prescribing 
budget and the opportunity to reap the rewards of reducing prescribing costs. 89 
2.1.5.1 Preparation of ajormulary 
Use and acceptance of a formulary is strongly related to a wide network of actively 
participating GPs. 
90 In order to be successful, a practice formulary must reflect the 
views of its users and provide them with a sense of ownership. This was endorsed by 
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the Department of Health in 1990.91 However, the extent of potential users 
involvement depends upon the amount of time that they are prepared to put into its 
development. 
A different approach is required in hospitals due to the majority of users being 
junior medical staff, many of whom rotate every six months. 92 Despite no real 
opportunity for these users to have much input, hospital formularies have been found to 
be both acceptable to hospital staff and effective in improving the quality of prescribing 
while effecting cost savings. 93,94 This probably reflects the hierarchical structure of 
hospitals with prescribing restrictions being placed on junior staff while more senior 
colleagues in particular specialities may be permitted the use of certain non-formulary 
drugs. From an educational perspective, the restricted choice of drugs in both general 
practice and hospital formularies Permits prescribers to gain useful experience with a 
narrower range of drugs. 95,96 If prescribing formularies can help doctors to prescribe 
from a narrower range of drugs selected for efficacy, safety and economy, this can then 
lead to more rational prescribing. 
Hospital formularies are required to be used by a large number of prescribers in a 
wide range of specialities and so they tend to have a greater choice of drug preparations 
than general practice formularies. Hospital multidisciplinary Drug and Therapeutic 
Committees (DTC) have the responsibility of production, revision and management of 
formularies in hospitals. 97 Arrangements usually exist for liaison with the different 
hospital departments so that input can be provided from a wide range of expertise. The 
DTC has to maximise awareness and co-operation and in so doing smoothly implement 
established hospital drug policies. 
Successful construction of formularies involves multidisciplinary activity to 
maximise clinical drug usage and cost containment. Pharmacists and GPs have been 
found to successfully work together in developing formularies and this is one of the 
many roles of practice pharmacists who are now widely based in GP surgeries. 9 8-103 
Pharmacists, for example, have access to relevant literature and the skills needed to 
evaluate PACT data and apply the information to the decision making process. 40 They 
can identify those drugs which are causing high cost prescribing, detect the uptake of 
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new drugs and monitor prescribing performance indicators. By making 
recommendations to prescribers, pharmacist can help to develop rational practice 
prescribing policies. 
In two separate studies undertaken in England and Scotland examining GPs' 
awareness of drug costs, it was found that in both cases GPs tended to overestimate the 
cost of inexpensive preparations and underestimate the cost of expensive ones. 104-106 
A study of Italian GPs' knowledge of prescription costs found them to also overstate the 
price of cheaper drugs but to be more aware of the expensive ones than GPs in the UK 
studies. 62 Physicians' perceptions of drug costs have been found to influence their 
prescribing behaviour so rational prescribing could be enhanced by GPs working with 
pharmacists and by the provision of better information to GPs about drug costs. 107,108 
Questionnaire surveys involving both the pharmacy and medical professions, by 
two separate pharmacy practice research departments in the early 1990s, revealed a 
willingness to collaborate in formulary development. 109-111 One of the surveys 
analysed responses from 161 GPs and community pharmacists from Enfield and 
Haringey and North Yorkshire former Family Health Service Authorities and found 
pharmacists to be more convinced that formularies would improve GPs' prescribing 
than did the GPs. 109 Positive attitudes are vital if the use of general practice 
formularies is to be extended in line with, for example, estimates in Northern Ireland 
predicting that the number of practices actively using formularies would increase from 
50% in 1995/96 to 75% by 1997/98.110 The accuracy of this estimation is uncertain 
though as a questionnaire in 1993 was sent to all 983 GPs in Northern Ireland to 
investigate their opinions of the then current edition of the Royal College of General 
Practitioners Practice Formulary produced in the Province. 112 The responses indicated 
that 32% of those doctors who received the formulary used it, although 89% considered 
a formulary useful in general practice. 
Traditionally, drug selection criteria in formulary development have focused on 
efficacy, safety and cost. 
93 On producing a formulary, it is important to define and 
agree criteria. It should be emphasised that formulary preparation is not an agenda with 
the purpose of giving the patient cheaper and less than optimal medication. Concern 
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about cost-effective health care should not simply result in a search for the lowest cost 
solution. In fact, an attempt to rationalise prescribing may not always lead to financial 
savings if the intention is to optimise the management of conditions such as asthma and 
depression. 113 
2.1.5.2 Production of aformulary 
A formulary must convey a professional image with its users in order to achieve 
credibility and this will contribute to the effect of the formulary. To optimise its use, 
the design of the formulary needs to permit quick and easy reference. These factors 
apply to all formularies and are especially important where potential users have not been 
involved in the development process. 
Decisions will need to be made about the size and presentation of the formulary, for 
example whether it needs to be carried by doctors around a hospital or whether the 
intended use is in the GP consulting room. 87 The formulary will need to have good 
classification and index systems to facilitate cross-referencing. Information on prices 
should be considered whether in the form of actual prices or treatment courses but will 
only be relevant at the time of writing, unless updated. Prices fluctuate with time and 
are inappropriate for international comparisons. Also a formulary is most efficient if it 
encourages generic prescribing. 95 
In some hospitals a full time formulary pharmacist is employed but in the primary 
care setting GPs may find it easier to adapt a pre-existing formulary and use it as a 
model which can be tailored to their local needs. This has the advantage of saving time 
although the educational benefits might not be quite as great. 90 Alternatively, GPs may 
attempt to consult a local hospital formulary for reference and guidance which can help 
maintain continuity in treatment when patients are admitted to hospital or discharged. 
Model formularies differ in style, although the range of drugs they contain is 
usually very similar. In the UK towards the end of the 1980s, there were three main 
(model' formularies available at little cost which could be easily adopted. In Newcastle 
upon Tyne, 'A Basic Formulary for General Practice'l 
14 was among the first to be 
published. The first edition discussed treatment for 34 common conditions in general 
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practice and contained 137 drugs. The Royal College of General Practitioners Practice 
Formulary in Northern Irelandl 15 contained over 200 drugs as well as discussion about 
good prescribing practice and the potential pitfalls of prescribing. Finally in Scotland, 
the Lothian Formulary 116 was produced by the Regional Faculty of the Royal College 
of General Practitioners. This included 330 preparations, many branded, with brief 
guidance on use and unwanted effects. All three were problem-orientated formularies 
and contained information about dosage, formulations, cost and notes about treatment. 
Cross-referencing is made easier with both the Northern Ireland and the Lothian 
Formularies as they used the BNF classification system. Each of these formularies has 
undergone revision with the publishing of subsequent editions. 
2.1.5.3 Maintaining aformulary 
The assessment of formulary performance must always be based on the original 
aims. 87 The wider the range of conditions a formulary intends to recommend treatment 
for, the more difficult it will be to achieve higher levels of formulary adherence. 
Adherence targets must be realistic and repeat prescribing is going to be less amenable 
to change than new prescribing. In order to assess the success of the formulary, it will 
therefore need to be monitored. This involves determining the level of non-formulary 
usage, identifying the drugs concerned and the reasons for them being prescribed. The 
level of generic prescribing can also be monitored as most formularies give priority to 
generic names rather than proprietary names. 
Formularies can be updated in one of two ways, either in a continual on-going 
process or in episodes when the current edition becomes dated. Time constraints and 
limited manpower often determine the likely approach but the frequency of revision 
needs to be established. Analysis of PACT and SPA can help with monitoring and 
updating of primary care formularies as well as detecting any areas which will need 
revising. 117 
One of the most important aspects of formulary maintenance is that there needs to 
be a procedure for dealing with new drugs on the market. 87 New drugs are often 
introduced to hospitals first, enabling specialist hospital staff to gain early and 
sometimes detailed experience with the new product. Use by consultant staff will 
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usually lead to use in the community and this can have major unplanned cost 
consequences for primary care as well as conflict between health care professionals. To 
make allowances for this, health authorities have often 'top sliced' a proportion of the 
prescribing budget for such products. 118 
In order to balance value for money in the health service with the innovations of the 
pharmaceutical industry, there have been suggestions for the introduction of an 
additional step into the drug licensing process between the identification of a new 
technology and its formal inclusion into main stream use. 119 Both Australia and 
individual provinces in Canada have taken this approach, requiring economic 
evaluations on new products prior to making reimbursement decisions. 118 In the 
future, it is hoped that collaboration between groups such as the National Prescribing 
centre (NPQ 119, the UK Drug Information Pharmacists Group (UKDIPG) 119 and the 
National Institute of Clinical Excellence (NICE) 120 will help lead on how to introduce 
new drugs into a cash limited health service. 
* The NPC was established in 1996 to promote high quality, cost-effective 
prescribing through a co-ordinated programme of activities aimed at all 
relevant employees within the NHS. 
* The UKDIPG was formed over 20 years ago and its remit includes the 
provision of strategic information on medicines to NHS staff within both 
primary and secondary care. 
e The NICE was set up in 1999 by the government to give guidance to the 
NHS in England and Wales on the clinical and cost-effectiveness of new and 
existing clinical interventions. 
2.1.5.4 Implementing aformulary 
Whether in hospitals or in primary care, managing the on-going development of a 
formulary is mainly governed by local factors, politics and professional relationships, 
especially between doctors and pharmacists. 
87 It is important to maintain awareness of 
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the formulary system and to develop a mechanism for introducing the formulary system 
to new staff. 
Ideally, in the first place, the formulary should be appropriately launched and 
consideration should be given to the timing of this. 86 In the hospital environment for 
example, there could be an advertising campaign, both internal and external to the 
hospital, as a form of communication to raise awareness in an attempt to increase its 
credibility. 121 In primary care, whether there has or has not been multidisciplinary 
collaboration in formulary development, it promotes good professional relationships if 
local community pharmacists are informed before its implementation. Local medical 
and pharmaceutical advisers will also be keen to know of formulary development 
progress and may well be able to offer support and resources. 
2.1.6 The effect of formularies and attitudes to them 
In 1984, GPs in Bristol described how their practice used a computerised repeat 
prescribing system to produce reports of drugs prescribed as a starting point for the 
compilation of the practice formulary. 122 The authors maintained that this process 
would allow production of a formulary without restricting drug choice. No data 
however were given on which to base this conclusion and no patient experiences before 
and after implementation of the formulary recommendations were described. 
Twelve months later, Green, another GP in England described the creation, 
implementation and monitoring of a general practice formulary. 123 Using the 
prescribing data of each GP in the practice, the formulary was built up over a period of 
one year selecting drugs based on current prescribing practice. It aimed to cover 80- 
90% of common conditions, providing treatment for 70-80% of cases. Prescribing was 
monitored prior to and following the implementation of the formulary, focusing on 
antacids, laxatives, hypnotics and sedatives, cough preparations and analgesics. Results 
indicated that changes in line with the recommendations occurred in all therapeutic 
areas, with changes persisting for one year after formulary introduction, generating 
considerable savings. No data relating to patient experiences following formulary 
introduction were presented. 
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The model formulary of Grant et al described earlier was developed with the help 
of a select group of 19 GPs, responsible for undergraduate teaching at Newcastle 
Medical School. 124 The same GPs then recorded prescriptions issued to patients over a 
two week period, with 10 further GPs acting as controls also performing the same 
exercise. Results indicated that involvement in formulary development was associated 
with higher levels of prescribing recommended agents. Formulary adherence was 
significantly higher for acute rather than repeat prescribing, highlighting the additional 
difficulties associated with changing established therapies. This study did not however 
analyse prescribing trends over a period of time. 
The same academic GPs in Newcastle assessed the prescribing of a group of 12 
young prescribers later on that year, before and after an educational intervention 
focusing on rational prescribing. 58 No members of the group had previously been 
involved with formulary development. Analysis of recorded prescribing data for 150 
consecutive patient consultations by each of the participants before and after the 
intervention indicated that there was a significant increase in formulary prescribing. No 
control group was included in this study but the results indicate that the actual 
educational aspects of involvement in formulary development may themselves lead to 
improved prescribing. 
In 1987, a multi-disciplinary team of researchers in the Medical School at Dundee 
reported on similar work. 125 Prescribing data were again used to assess formulary 
success, with data indicating that the use of formulary medicines increased on 
introduction and was maintained in the following year. This study also involved regular 
feedback of performance to prescribers which may well have influenced subsequent 
prescribing behaviour. 
More recently in 1996, a study was performed to investigate influences on 
prescribing of all non-fundholding practices by health service researchers in the North 
region of England-126 It was found that of the 348 (78%) practices that responded, 
31% had a written or computerised prescribing policy or formulary but that only 85% of 
these reported that the practice 'always or usually' used it. 
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About the same time, pharmacist researchers interviewed practice managers or a GP 
in 75% of practices in Southampton and south west Hampshire to identify their use of 
practice formularies. 127 Only 48% of practices had a formulary, the majority of which 
(63%) only covered drug choice in certain therapeutic areas. The main criteria for drugs 
included were: efficacy, patient compliance, lack of side effects, prescriber familiarity, 
generic availability and cost. 
None of these aforementioned studies went into any detail about the effectiveness 
of the formularies in either achieving rational prescribing or patient acceptability. 
It has been recognised that adherence to practice formularies may be reduced when 
patients are discharged from hospital on non-formulary drugs. 30 In addition, adherence 
to hospital formularies might be reduced with patients admitted to secondary care on 
non-hospital formulary drugs. The transfer of prescribing from secondary to primary 
care makes a substantial impact upon the financial framework for primary care 
prescribing. The transfer of prescribing should be done in the best interest of patients 
and not be done to ease pressure on drug budgets. As a result, the development and use 
of joint formularies between primary and secondary care have been widely 
advocated46,95,128,129 
One of the first areas to establish a joint drug formulary was in the Grampian region 
in Scotland. 13 0 The formulary team consisted of four GPs, three pharmacists and two 
clinical pharmacolo gists. Forty-nine randomly selected GPs out of 50 were positive 
about accepting a copy of the existing hospital formulary upon invitation. Based on this 
interest, GPs were invited to comment on draft guidelines for each group of drugs to be 
included. Sixty GPs expressed an interest, resulting in the completion and distribution 
of the formulary in 1992 and a further revision took place in 1995.131 Drugs in the 
formulary were listed in therapeutic category, following BNF classification. Within 
each section, first choice drugs were highlighted, along with information about 
recommended drugs. A special indications category was used for those drugs not 
recommended as first-line, fulfilling the following criteria: used in special situations, 
specialist supervision required, less favourable side-effect profile and more expensive 
than first choice agents. 
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Adherence to the Grampian Joint Formulary as measured by research pharmacists 
when patients were admitted to hospital was 84%. 132 The study did however have 
several limitations in that the patients were elderly, being admitted to hospital and 
mainly receiving repeat prescriptions; hence, they might not be representative of the 
total patient population nor of comprehensive prescribing in general practice. 
2.1.6.1 The effect of formularies on health outcomes 
Very little work has measured the effect of implementing drug formularies on 
health outcomes such as symptom control or health related quality of life. 
Field, a medical researcher at the end of the 1980s determined whether the 
introduction of a formulary was acceptable to doctors and whether any changes 
implemented as a result would be acceptable to patients. 133 A formulary was 
developed in one practice, aiming to cover 50% of prescribing, with three neighbouring 
practices acting as controls. Doctors' attitudes toward formularies were measured prior 
to and following formulary introduction. Results indicated that those in the active 
practice were more in favour of the use of a formulary and with its introduction - there 
was a statistically significant increase in prescriptions from the formulary over the 
course of the two years. Groups of 90-100 consecutive patients per year for three years 
receiving repeat prescriptions without consultation in all four practices were selected 
and interviewed to measure satisfaction with therapy. Those patients in whom therapy 
had changed (17.7%) were less satisfied than those where no change had occurred; 
however,, the data presented did not demonstrate that those less satisfied belonged to the 
active practice, nor that the change was actually as a result of implementing formulary 
recommendations. 
More recently other medical researchers in Dundee, measured patient satisfaction 
upon the introduction of a generic formulary in one practice. 134 Questionnaires were 
sent to a random sample of 280 patients where therapy had been changed to the 
formulary recommendation, including substitution of a generic equivalent. A response 
rate of 60% was obtained, with 46% being either slightly or very unhappy with the 
change, although this was thought to be associated with inadequate communication 
relating to the change. Semi-structured interviews conducted with 16 patients, one week 
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and six months following the change showed that almost all patients were aware that 
reducing expenditure was at least part of the reason for the change but that none felt that 
the trial of a cheaper medicine to be unreasonable. 
In 1992, Pearce and Begg, health service researchers in the UK, reviewed the 
literature relating to formularies in primary and secondary care and identified that no 
research focused on the area of change in health outcomes arising as a result of such 
developments. 135 Since the beginning of the 1990s though, the importance of patient 
outcome measures in clinical trials in the US has drastically increased. 13 6 Drugs have 
traditionally been marketed on the basis of superior efficacy and/or safety but outcomes 
research attempts to predict better medium or long term cost-effectiveness compared 
with competitor products for treatments. Clinical trials increasingly have to measure the 
criteria which are summarised in Table 2.3. 
Outcomes research assesses a new drug's cost effectiveness by examining a range 
of costs including: direct medical costs, direct non medical costs, indirect costs such as 
lost earnings due to morbidity, and intangible costs such as those related to pain. In 
addition, improved patient quality of life, increased functional performance, general 
health perceptions and satisfaction with care are all considered relevant in lowering 
health costs. Also important to assess is the degree of improved patient compliance 
with the dosing regime which may reduce costs by minimising the length of time the 
patient receives the drug. The better the patient's life quality, the lower the long-term 
treatment costs will be to the healthcare provider. In the US, one survey of formulary 
committee members indicated that they would pay an additional 10% or more in drug 
acquisition prices if the quality of life scores for a new drug were superior to other 
competitor products. 13 6 
2.1.7 A European Formulary for General Practice 
As discussed earlier in this chapter, the availability, quantity and quality of 
prescribing varies throughout Europe. However, if it is agreed that drug selection 
should be made predominantly on the evidence of efficacy and safety, one would expect 
only relatively minor differences in drug utilization to occur within a homogenous 
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population. Where large differences are found, it is reasonable to assume that factors 
external to the influence of clinical Pharmacology and pharmacotherapy are prevalent. 
One attempt to contain this situation was the development of a European Formulary 
subsequent to a conference in Bielefeld in 1987 (Section 1.1). Enthusiastic delegates 
consisting of doctors and pharmacists met on several occasions over the following six 
years until in 1994, a draft European Formulary with Appendix (providing the reference 
based justification for drug selection) had been developed. 
The aims of the formulary were to; 
1. Cover the majority of conditions seen by GPs (minimum of 90%). 
2. Provide simple adequate and appropriate treatment for most patients 
(minimum of 90%) with common conditions requiring the prescription of a 
drug. 
3. Be acceptable and useful to diverse groups of general practitioners throughout 
Europe and facilitate the free movement of practitioners. 
4. Use generic name drugs. 
5. Generally exclude drugs introduced within the last 5 years, except where 
valid trials show strong evidence of advantages over well-tried preparations. 
6. Use cost of drugs as an important criterion for their selection. 
7. Be compiled by GPs, clinical pharmacologists and pharmacists using best 
practice and scientifically based evidence from journals of repute. 
8. Avoid recommending drug treatment where specialist advice is indicated. 
9. Rank order the drugs, but avoid dictating to doctors using the formulary. 
10. Be a useful tool for students, doctors, pharmacists to discuss and improve 
prescribing. 137 
in Britain, detailed prescribing information and advice is provided by the British 
National Formulary (BNF). 6 Although an extremely valuable reference guide, it does 
not focus on stepwise approaches to treatment strategies based on evidence. In addition, 
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although unit prices of drugs are included, the BNF does not really focus on the issue of 
cost-effective prescribing. 
In contrast to the BNF which refers to all the drugs available on prescription in the 
UK at the time of publication, the European Formulary is specifically aimed at 
prescribing in General Practice. A study by researchers in the department of general 
practice in Leicester analysed 6,595 prescription items to investigate the effectiveness of 
prescribing by comparing those that were hand-written by GPs against computer issued 
prescriptions to see whether they conformed to BNF guidelines. 13 8 The results were 
disappointing with over 40% of the hand-written items not adhering to the guidelines for 
formulation and strength. Computer generated prescriptions on the other hand were 
found to be much more accurate but failed to satisfy guidelines on directions and 
quantity in over 90% of cases. The fact that the European Formulary is focused on 
prescribing in general practice is important as it has the potential to be more tailored to 
GPs' needs and requirements 
Since the single European market in 1993, implementation of a European 
Formulary could promote seamless patient care and stability for patients throughout 
Europe and give confidence to movement of health care professionals between one 
country and another. For this to happen though there would need to be almost universal 
agreement on drug selection. 
Although both general practice and hospital formularies are known to exist in 
several countries, there is relatively little published work detailing their development, 
use and influence on prescribing. The next section reviews the literature on the factors 
that influence the prescribing process. 
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2.2 INFLUENCES ON PRESCRIBING 
"A desire to take medicines is, perhaps, the greatest feature which distinguishes 
manftom other animals ". (Sir William Osler 1891) 
2.2.1 Introduction 
The writing of a prescription is influenced by a multitude of factors which 
intertwine causing the prescribing process to become highly complex. An appreciation 
and understanding of the mechanisms involved in this pathway is very important 
especially as drug therapy is the most frequently used intervention in general practice 
medicine. The BNF states that: 'Medicines should be prescribed only when they are 
essential and in all cases the benefit of administering the medicine should be considered 
in relation to the risk involved., 6 This statement complements the main criteria for 
rational prescribing (Section 2.1.3) which dictate that a drug should be necessary, 
effective, safe and economic. 37 
The influences on prescribing discussed in this chapter are largely written from a 
UK perspective, although there has been work published outside the UK on factors 
influencing drug choice and some of this is referred to. The major factors influencing 
prescribing will each be reviewed separately; they can be considered under the 
following headings: 
I. Regulatory measures 
Information 
3. Education 
Pharmaceutical industry 
5. Hospital 
Society 
7. Patients 
8. Prescriber and workplace 
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2.2.2 Overview of prescribing influences 
In 1975 Hemminiki, a Finnish medical sociologist, was one of the first to review 
the literature on the factors influencing drug prescribing. 13 9 She highlighted six main 
sources of influence, namely: education, advertising, colleagues, control and regulatory 
measures, demands from society and patients and finally doctors' characteristics. Most 
of the studies cited were observational and none were large scale controlled-studies. 
One of the potential limitations with retrospective observational studies which examine 
prescribing from medical records is that the researcher may not be able to focus on the 
factors associated with the actual decision to prescribe. 140 Hemminiki's review 
concluded that the medical and scientific literature lacked data on the factors affecting 
drug prescribing and their relative importance, but it was recognised that pharmaceutical 
companies influenced doctors in many ways and other non-medical factors played a 
substantial part in the influencing process. 13 9 
Two years later in 1977, Mapes, a British professor of medical sociology at 
Swansea University, reviewed the literature on the methodological approaches used to 
investigate prescribing influences. 56 He identified the application of both qualitative 
methods, such as the measurement of physicians' attitudes, and quantitative methods, 
such as the measurement of prescribing volume. Mapes carried out a study using 
prescription data from a cohort of 116 GPs and identified 90 characteristics to help 
determine the 'prescribing type' of a physician. By factor and discrimination statistical 
analyses, differences between physicians' prescribing habits could be made on the basis 
of five characteristics: sex of GP, membership or otherwise of the Royal College of 
General Practitioners (RCGP), proportion of scripts written by non-medical practice 
staff, proportion of scripts with inadequate/no directions to the pharmacist and doctor 
opinion as to the usefulness of different sources of drug information. This study design 
was limited in that it focused on factors which influenced effective and safe prescribing 
only and did not explore factors which influence the other criteria for rational 
prescribing. In addition, the GP sample was neither random nor representative in terms 
of age and sex. 
Cooperstock and Parnell, researchers at the Addiction Research Foundation,, 
Toronto, Canada, published a review in 1982 of studies from the previous fifteen years 
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on psychotropic drug use in Australia, Canada, Europe and the USA. 141 Their main 
findings, that females received twice as many psychotropic drug prescriptions as males 
and that drug use was higher among older age groups, were consistent among the 
different populations studied. The authors also found that consumption and the 
associated 'popularity' of some psychotropics had declined while other drugs had 
evidently replaced them, in part due to stricter regulatory controls of some drug groups 
in certain countries. The review was restricted to analysing the demographic prevalence 
and patterns of psychotropics which neither explain the exact reasons for drug use nor 
the meaning of it. Nevertheless, with the ultimate aim of finding causal relationships, 
establishing correlations from demographic data is a necessary step in the investigating 
process. Consensus agreement with definitions of relevant terminology in therapeutic 
areas such as psychotropic medicine, as well as comparable drug and diagnostic 
classification systems, would be beneficial in the future evaluation of prescribing 
influences. To perform a more in-depth investigation, the researchers suggested that 
future studies should focus on: studies of high-risk populations, health measures, social 
lifestyles, OTC medicine consumption, frequency of physician visits, comparability of 
benzodiazepines with alcohol use and the economic cost to health care systems of 
psychotropic drugs, especially with respect to developing countries. 
At the end of the 1980s, McPherson, an academic GP at Oxford University, 
postulated that the impact of different sources of variation in medical intervention will 
depend on the level of data collection (Table 2.4). 251 From Table 2.4 in the analysis of 
variation between GPs (column 4), it might be hypothesised that professional 
characteristics (row 4), such as clinical style or judgement, are likely to exert a major 
influence on medical practice variation, other things being equal. At this same level, 
aspects of the health system (row 3) and characteristics of the population (row 2) are 
less important since it is assumed that to a degree they will be standardised within a 
given country. However, they will become much more significant in explaining 
differences at the level of cross-country comparison (column 1). Patterns of morbidity 
could be expected to show a certain similarity across countries at a comparable level of 
social and economic development but to exhibit greater variability at the regional and 
practitioner level (row 1). 
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The information in Table 2.4 could have particular relevance for explaining 
prescribing variation in general practice and a multidisciplinary team of community 
health researchers from the Auckland Medical School attempted to test it at the GP 
level. 142 Relevant indicators from New Zealand general practice were used to 
represent the four sources of variation in Table 2.4 and data were obtained on completed 
records of nearly 9,500 patient encounters from a representative sample of 115 GPs- 
Levels of prescribing and the distribution of drug patterns across diagnostic groupings 
were found to be broadly comparable to results drawn from international benchmark 
data. Information was also gathered on seven measures of prescribing activity in the 
areas of volume, script detail and therapeutic choice and these were subjected to 
multivariate statistical analyses. From this, the overall analysis indicated that the main 
influences were diagnosis followed by practitioner identity. The prescribing task could 
be considered as a process of decision-making in which 'core' judgements such as the 
decision to prescribe and the choice of drug are highly predictable and influenced by 
diagnosis. The prescribing of antibiotics and psychotropics in the study followed this 
predictable pattern, but the prescribing of analgesics was less predictable, possibly 
because of their less precise therapeutic action. In contrast, peripheral features of the 
task, for example choosing a combination drug or prescribing generically, are less 
determinate and more subject to clinical discretion. Limitations of the study are firstly 
that this was a single sample study restricted in time and place and secondly the status 
of diagnosis as a measure of morbidity data is problematic. Therefore, the data have to 
be interpreted with a degree of caution. Finally, some important indicators of health 
system variation were not investigated, such as pharmacoeconomic factors and OTC 
drug use and availability, although these are fairly constant within a country. 
The influence of prison inmates' clinical (diagnosis, impairment level and 
hospitalisation history) and social (gender, race and social class) characteristics as well 
as prison setting factors on the appropriateness of psychiatric prescribing have been 
examined in a New York prison. 
140 The study examined which of these characteristics 
predominate by investigating two perspectives: a psychiatric perspective which argues 
that patient clinical characteristics are found to account for the prescription of 
psychiatric medicines and a social control perspective which argues that non-clinical 
factors predominate in drug prescribing decisions. Measures were taken on a twelve per 
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cent random sample of 36,144 inmates in New York State and the relative influence of 
the different variables were examined by multivariate analysis. Overall, the results 
indicated that psychiatric impairments, measured in terms of levels of depression, 
manifest symptomatology, agitation and prior psychiatric hospitalisation, were found to 
be highly significant predictors of drug prescription. These findings suggest that patient 
clinical characteristics predominated in the psychiatric medication prescription process. 
Social factors were found to influence the decision to prescribe medication for mildly 
impaired inmates. The study was limited in that prescribing was examined 
retrospectively and did not focus on factors associated with the actual decision to 
prescribe. The study is an investigation of patient characteristics in high security 
psychiatric units and the findings may not apply to patient populations in the wider 
community. 
In 1995, Denig, a pharmacist, and Professor Haaijer-Ruskamp, a medical 
sociologist from the Netherlands, published a review of the influence of cost on 
prescribing decisions. 107 They summarised studies which involved groups of 
prescribers, rating criteria for drug selection. To facilitate the comparison, all studies 
were converted to the same ten point scale. The results showed cost to be a reasonably 
important criterion but always considerably less so than considerations of efficacy, 
adverse drug reactions and the prescribers' experience of particular drugs. 
Opinion is divided as to how significant a part cost should play in the prescribing 
process. On the one hand, GPs should morally prescribe cost-effectively and the 
prescribing of expensive drugs should be critically justified. On the other hand, 
prescribers might feel that they should have the right to prescribe freely within the 
therapeutic spectrum and that cost reductions can have a negative impact on the quality 
of health care. 
Until recently, doctors have generally been unaware of the costs of drugs and could 
claim with confidence that cost was not a major consideration in their prescribing 
decisions. 108 With an increasing number of GPs now believing that prescribing costs 
should be taken into account when deciding on the best treatment for an individual 
patient, possibly an increased emphasis should be made at the undergraduate level. 108 
Prescribing costs are not constant however and fluctuate with time. 
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2.2.3 Factors influencing the decision whether to prescribe or not 
At the beginning of this decade, Bradley, an academic GP, observed that attempts 
to establish influences on prescribing practice have tended to concentrate on which drug 
should be prescribed rather than on whether to prescribe a drug at all. 143 Prior to the 
drug selection process, the prescriber must initially decide whether or not to even issue a 
prescription. The decision by a physician not to prescribe is not an easy one although it 
may appear perfectly logical on pharmacological grounds alone. If a patient is not 
satisfied, the doctor-patient relationship becomes threatened which may result in either a 
fonnal complaint, a decision to change the GP or in extreme cases pursuit of medico- 
legal action. Consequently many physicians feel pressurised to 'play safe' and would 
rather over-prescribe than prescribe too little. 144 
One of the commonest areas of dilemma for GPs is in the prescribing of antibiotics 
for acute respiratory tract infections. Most infections of the respiratory tract are self 
limiting and often viral in origin with antibiotic treatment not being indicated. The 
results of bacteriological investigations which may indicate the need for antibiotic 
treatment often take several days to occur and so treatment has to be started on a best 
guess basis. Either type of diagnosis is therefore based on probability rather than 
certainty. Placebo-controlled studies have even shown that there is little or no benefit in 
treating respiratory symptoms in previously well patients. 145 If a decision is made not 
to issue a prescription, the consequence can be that more of the GPs' time will be 
required to explain adequately to the patient the reasons why. Some GPs believe that 
prescribing a relatively cheap antibiotic, for example amoxycillin, with few potential 
side-effects is the simplest solution. However, the inappropriate use of antibiotics helps 
to build up resistance to the drug and should the prescriber not be cost-conscious, then 
newer expensive antibiotics may be prescribed contributing to the wasted millions of 
pounds estimated to be spent on this group of drugs in the UK alone. 30 
In 1976, Howie, an academic GP in Scotland, hypothesised that clinical and social 
considerations interact in the decision-making process of doctors to determine whether 
or not a prescription is issued. 
146 He tested this hypothesis by studying the clinical 
judgement and antibiotic prescription use of GPs. Booklets were posted to 1,000 GPs 
containing transparencies showing varying degrees of redness of throat relating to 16 
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patients but with variable social and psychological information. From an approximately 
60% response rate, he found that the variations in social and psychological history 
presented had resulted in significantly different prescribing practices among the doctors. 
A study by academic physicians in Nottingham published in 1997 investigated 
factors influencing patient reconsultation in the month following initial management of 
lower respiratory tract infections (LRTls) in general practice. 147 The commonly 
perceived belief that the prescribing of antibiotics reduces reconsultation was the main 
stimuli for this research. Contrary to this belief though, the research revealed that 
reconsultation appeared not to be influenced by the prescribing of antibiotics. 
Reconsultation was found to be common in acute LRTI which supports the findings of 
other studies148,149 and this was associated with the presence of previous ill health, 
dyspnoea and a heightened consulting habit. 
To explore the dilemmas surrounding decisions taken about whether or not to 
prescribe, Bradley interviewed 51% of the general practice principals in one English 
region. 150,151 Drug groups which most often led to uncomfortable feelings included 
antibiotics, cardiovascular drugs, NSAIDs and psychotropics. Patient expectations, 
their ethnicity and social class, clinical appropriateness, and preserving the doctor- 
patient relationship were found to be the important reasons given for influencing 
decisions. The main reasons for feeling discomfort included concerns about drugs, 
personal expectations, peer influences, appropriateness of treatment and uncertainty. 
2.2.4 Factors influencing the uptake of a drug 
Miller, an academic pharmacist from the US, summarised the stages in the uptake 
or adoption of a new drug by a prescriber in Figure 2.1 152 The most important step to 
have been identified in drug adoption is that between the first awareness of a drug and 
the decision to use it. These findings suggest that there is a considerable difference 
between communication mechanisms that inform physicians of up to date developments 
and those that persuade physicians to take them on board. 
Evidence suggests that new practices may be adopted by physicians more rapidly 
than old practices are discarded. Winkler et al, non-medical researchers in Los Angeles, 
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concluded that whereas various factors may heighten physicians' awareness of 
assessment information, a restricted set of influences may actually lead them to alter 
their practices. 153 Educating prescribers face-to-face has been reported to be the single 
most effective method for influencing their decisions, 154 especially when it involves a 
regular re-enforcement component. 
Williamson, a non-medical academic in Liverpool, had earlier suggested that where 
the adoption of a drug represents little risk, the prescribing doctor is often willing to 
prescribe on the basis of information provided by the pharmaceutical manufacturer, 
thereby initially relinquishing his personal independent evaluation. 155 
Twenty years ago, Strickland-Hodge, a research pharmacist in the West Midlands, 
found that 'commercial' information was used more at the awareness stage in drug 
adoption, providing the first information about a new drug. 156 Commercial 
information seemed to be preferred by older doctors who had a minimum first degree 
qualification who did not specialise and who had no immediate contact with colleagues 
as they were practising alone. 'Professional' sources of information such as medical 
journals were used more to evaluate a new drug when the prescriber was actively 
considering prescribing one. 
In the early 1980s, Peay and Peay, two Australian academic psychologists, found 
similar results from studying the preference for information sources in the adoption of 
new drugs by 124 doctors. 15 7 At the stage when doctors are acquiring the information 
needed to prescribe, younger doctors were found to more frequently seek out the 
ýactive' source of journals, while the older doctors tended to continually rely on the 
4passive' source of drug representatives otherwise known as detailmen. In this study, 
doctors practising alone were not found to rely on drug representatives any more than 
doctors working in group practices, although they were reported to have a wider range 
of literature based sources. 
In 1988, Denig et al hypothesised that physicians select drugs by a process of 
reasoned action i. e. weighing up the pros and cons before a drug choice is made. 
144 
This is difficult to prove when 'directly' asking physicians about their decision criteria 
as much of the prescribing process occurs subconsciously. The researchers therefore 
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investigated this hypothesis by testing a drug choice model for the treatment of irritable 
bowel syndrome (IBS) and renal colic on 169 physicians. Medication was the only 
treatment option analysed and so the influence of patient demand on the decision 
whether or not to prescribe was not considered. Prescribing decisions seemed to be 
particularly influenced by the professional environment of the GP and by prescribers' 
past experience. The authors concluded that their findings may be useful when trying to 
change prescribing behaviour as the importance of the professional environment 
suggests that educational programmes in groups might be more effective than targeting 
individuals alone. 
In a separate paper, the same authors described the approach of providing 
physicians with hypothetical patients for whom relevant and irrelevant information is 
varied systematically as 'clinical judgement analysis'. 154 Bradley, when looking at 
uncomfortable prescribing decisions, used a similar term by describing GPs as using 
'reasoned thought' in arriving at a decision. 150 He found that many GPs were 
attempting to balance out several disparate considerations and in so doing worked out 
what to do for the best, following a rationale that was not just purely pharmacological 
but could be described as a combination of rational behaviour and habit. 
2.2.5 Drug regulation 
In the UK, the influence from drug regulation is largely punitive and has been 
centred on the Medicines Act 1968.45 The Act is primarily concerned with the safety, 
quality and efficacy of medicinal products and covers the licensing of manufacturers, of 
products and of wholesalers. Medicinal products are pharmacy only (P) unless the 
licensing authority has taken statutory measures to classify them on the general sales list 
(GSL), if considered to be sufficiently safe. Medicines inappropriate for self- 
medication may be restricted and classified as prescription only medicines (POMs). 
Classification has an influence on prescribing as patients are increasingly encouraged to 
purchase medicines which do not require a prescription. 
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2.2.5.1 NHS Drug Tariff and the Limited List 
Historically, doctors' freedom to prescribe medicinal products for their patients has 
in general been respected and left unchallenged in the UK until recent time. As 
mentioned previously (Section 2.1.4.1), in 1911 a National Formulary was developed 
which limited and restricted prescriptions for low paid workers entitled to NHI. Within 
the context of the British NHS, a GP's prescribing of dressings, appliances, and reagents 
has been restricted to those approved items listed in the Drug Tariff. 158 Items in the 
grey area of 'borderline substances', which includes some special foods and cosmetics, 
could be prescribed but might be subject to justification by the prescriber depending on 
the detailed guidelines on 'borderline substances'. 
The selected 'Limited List' imposed in April 1985 by the Secretary of State for 
Health was of much significance as it created control of a kind not previously applied in 
the NHS. The intention was to eliminate many heavily prescribed OTC medicines from 
GP prescriptions and encourage the public to purchase them instead. 48 
2.2.5.2 Prescription charges 
NHS prescription charges have also been used to contain prescribing. In 1952 
when the NHS was four years old, a modest charge of 5p per form was introduced and 
was intended to make a contribution towards health services costs, encourage people to 
value more what was supplied and also to inhibit, unofficially, surgery malingerers. 
Currently the charge per item has risen to f-6.00, although 85% of prescriptions 
dispensed are exempt from charges. 29 Many medicines available for self-medication 
are noticeably priced somewhat below the prescription charge. 
The charges should act as a disincentive to prescribe medicines which can be 
bought without a prescription and which may well cost the patient less than the NHS 
charge. As a counter influence on prescribing, prescription charges can encourage 
larger quantities to be both prescribed and expected by the patient. 
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2.2-5.3 Generic prescribing 
Generic name prescribing, which has been encouraged by successive governments, 
is economically motivated in order to effect financial savings. The Government's 
position is complicated by the nation's need to maintain its high profiled, very 
successful pharmaceutical industry which contributes greatly to the UK balance of 
payments. Generic drug name products have almost no supportive advertising other 
than the indirect promotion through independently evaluated sources of information like 
the BNF, Drug and Therapeutics Bulletin and Prescribers' Journal. 
A generically written prescription is one that has been written using the British 
Approved Names (BAN). These drug names have syllables characteristic of the 
particular class of drug but the names are invariably longer and not as easily 
remembered as many proprietary names. 29 
In the UK, encouragement to prescribe generically has resulted in an increase in the 
number of NHS generic prescriptions dispensed. In England, items prescribed 
generically have risen from 39% in 1987 to 60% in 1997 and items dispensed 
generically have risen from 34% to 49%. 29 This mismatch is primarily due to GPs 
using generic names for medicines still under patent. 
The extent to which financial savings can be made from generic prescribing is often 
poorly understood by GPs. Issues of the MeReC Bulletinl59,, the centre pages of PACT 
reports32 and more recently Bandolier160 provide useful practical information in this 
respect. Pharmacists can also advise GPs with regard to drugs where significant savings 
can be made and advise about the significance or otherwise of bio-inequivalence. At 
present, generic substitution is not allowed on NHS prescriptions in primary care but is 
well established in secondary care. 
2.2.5.4 Prescribing advisers 
Health Authorities (HAs) have a legitimate interest in the question of cost and 
quality which arise from the prescribing of drugs. In order to increase the professional 
advice available to GPs, pharmacists and to the HAs, medical and pharmaceutical 
advisers have been appointed by the HAs. 
51,91 The HA advisers are expected to visit 
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GP practices, particularly those where over-prescribing is said to occur, to discuss 
prescribing habits as part of the indicative prescribing scheme. For an assessment of 
practice demography and factors such as the number of patients with medical disorders 
requiring expensive medication, both the practice and the HA will be advised on 
indicative prescribing amounts. 
The pharmaceutical adviser's role also includes acting as a facilitator, to bring 
about greater co-operation between pharmacists and their local GPs. Other areas which 
are recognised as benefiting from pharmaceutical advice include formulary development 
at a practice level, reinforcing confidence in generic products, advising on individual 
prescribing problems, offering advice to GPs on product choice and maintaining links 
with drug usage and prescribing policies in hospitals and at a regional level. 91 
2.2.6 Information sources 
In 1977,, Dingwall, a GP in Scotland, stated that GPs needed easily accessible, 
reliable, unbiased information about new drug trials presented to them by an 
independent authority. 161 Over the past two decades this has been achieved in part by 
the following developments: formularies have become more widely established; 
consensus and/or evidence-based guidelines have been drawn up in many areas of 
practice; hospital pharmacies provide drug information services for both primary and 
secondary care; prescribing analysis data is routinely distributed to every GP in the UK; 
many practice pharmacists are now located in GP practices to review patient medication 
and run clinics, and computer technology as a medium for information provision and 
transfer continues to gather momentum. In addition, independent evaluated information 
is regularly published and is widely available and HAs also distribute free drug 
information bulletins including relevant topical issues. In the UK, the Drug and 
Therapeutics Bulletin is now provided free of charge to medical students in the latter 
part of their studies. However getting the most out of information sources within a 
limited time period still remains very challenging for many doctors. GPs are often 
saturated with material and the difficulty lies in information selection rather than access. 
With the ever increasing mass of conflicting claims and counter-claims about the 
relative effectiveness of competing drugs, not many GPs have the time to adequately 
analyse published drug trials. 
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Different types of information source appear to generate different levels of success 
with respect to changing prescribing practice. Haaijer-Ruskamp found that printed 
information has limited success in isolation and that there is a need to reinforce this with 
other methods of education and communication such as by face-to-face interaction. 154 
In 1983, Avorn and Sournerai, researchers at the Department of Social Medicine 
and Health Policy, Harvard Medical School published a study which investigated 
whether physician background characteristics and the quality of a number of educational 
exposures influenced a reduction in the excessive use of three drug groups. 162 They 
recruited a four State sample of 435 doctors randomised to control and intervention 
groups, interventions consisted of printed educational materials and face-to-face visits 
by clinical pharmacists. Results showed that the rate of prescribing change was 
independent of most of the physicians' background characteristics including age, 
locality, where qualified, previous level of Prescribing and practice size. A follow-up 
reinforcement visit was a strong independent predictor of prescribing change and an 
increase from one to two visits was associated with an approximate doubling in the 
effect of the program. 
The same researchers used the aforementioned study to establish the principles of 
educational outreach or 'academic detailing' in order to improve physicians' clinical 
decision-making and enhance the quality and cost-effectiveness of care. 163 They 
analysed the techniques of pharmaceutical industrial marketing and expertise in 
targeting physician communication and behaviour. The authors identified the following 
as the most important techniques to carry out academic detailing: 
* interviews to investigate knowledge and current prescribing patterns 
* focusing programmes on certain groups of GPs and their opinion leaders 
e defining clear educational and behavioural objectives 
e presenting arguments for and against issues, citing key clinical trials and 
establishing credibility 
* stimulating active physician participation in educational interactions 
9 using concise graphic educational materials 
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" highlighting and repeating the essential messages 
" providing positive reinforcement of improved practices in follow up visits. 
Prescribers in the UK have also been shown to be influenced by short 
professionally produced presentations of information delivered by an academic 
pharmacist 'representative'. In Leeds, a project was designed to encourage a rational 
approach to NSAID prescribing in an intervention group of 101 randomly selected 
GPs. 164 The average prescribing cost of the intervention group doctors decreased 
compared with the control group and there was a significant increase in the prescribing 
of the recommended agents in the intervention group. 
Two fundholding GP practices in the Midlands participated in a study published in 
1997 to see whether a therapeutics advisory service provided by a consultant clinical 
pharmacologist and a clinical pharmacist could facilitate cost-effective prescribing. 165 
A range of techniques were used to bring about change including: audit, peer review, 
feedback, guidelines, target-setting and small group teaching. Although the standard of 
prescribing dramatically improved, a saving in prescribing costs did not always follow. 
For example, the changes in prescribing for hypertension resulted in improved control 
of blood pressure but the overall treatment costs increased from 12-15%. Initial cost 
savings may be sustained but more appropriate prescribing and improved patient care 
should and must be recognised as being of paramount importance. In this case, the GPs 
found it so useful to have outside experts objectively assessing their prescribing that for 
at least a further twelve months period they opted to continue to purchase this 
educational facility and advice. This study did not include a control group so some 
degree of caution has to be made when interpreting the impact of the intervention. 
This study also found that progress in therapeutics relied on a combination of 
willingness to explain to patients the need for change, familiarity within agreed 
guidelines and appropriate outcomes for the treatment at the time of the 
1ý 
consultation. 165 To help implement this strategy, copies of flow charts were 
incorporated into patient records. Since 1995, an NHS Executive funded campaign 
called PRODIGY (Prescribing Rationally with Decision Support in General Practice) 
has been testing information like this with patient specific decision support incorporated 
into computer software accessible at the time of consultation. 166 As computer 
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technology has diversified in recent years, several studies167-170 have indicated the 
potential benefits of computer decision support systems which use an underlying 
knowledge base of clinical information to present the GP with advice relevant to 
specific clinical decisions. 
PRODIGY is a combination of active and passive systems helping doctors to make 
prescribing choices, predominantly based on drug efficacy. 171 Interim results 
published in the autumn of 1996 looked positive with 94% of GPs in 137 voluntary 
practices rating the scheme worthwhile. 172 Despite receiving a very mixed reception 
throughout the medical profession and by the pharmaceutical industryl73, by the 
autumn of 1998., PRODIGY had achieved one of its early aims by being given DoH 
support for extension throughout the UK. PRODIGY is actually based on a similar 
system which was developed in the Netherlands but was abandoned there after initial 
experimentation. 174 
In 1990, a study in Derbyshire surveyed 463 GPs' perceived use of drug 
information. 175 Similar results were found to a study discussed earlier by Peay and 
Peay which looked at differences in the preference for information sources among 
doctors in the USA. 157 In this case, the BNF and MIMS (printed sources) and fellow 
GP colleagues (personal source) were predominantly the most frequently used sources. 
Drug firm mailings, drug advertisements and non-professional journals were all ranked 
above professional journals indicating the potentially powerful influence of the 
pharmaceutical industry, although this study only looked at perceived use and not at 
how plausible GPs thought the information sources to be. One limitation to this and 
similar studies is that the researchers often compile their own list of possible influences, 
thereby introducing an inevitable element of bias. 
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2.2.7 Education 
2.2.7.1 Undergraduate 
With modern advances in research and development, there is constant production of 
new drugs and a large growth in the range of formulated products. Consequently, 
doctors throughout their working life will experience many dramatic changes in the 
availability of drugs within their country. 
A study previously referred to which investigated the establishment of clinical 
pharmacology departments across 21 European countries revealed marked differences 
suggesting that more attention needs to be focused on establishing a sounder education 
base during the training of medical students. 26 
A paper on prescribing in general practice in the UK from the early 1980s by 
Brodie et al (backgrounds in clinical pharmacology and pharmacy), criticised 
undergraduate medical education for placing too little emphasis on clinical 
pharmacology and the critical evaluation of scientific papers and advertising 
material. 176 
In the USA, aspects of medical education have also been questioned. Meyer, an 
academic doctor in Pennsylvania, suggested that an early essential training in 
pharmacology should be followed in clinical medicine with greater attention paid to 
emphasising the basic principles and important facts necessary for rational 
prescribing. 177 
An international randomised control trial assessed the impact of a short course in 
pharmacotherapy by 219 medical students from five continents. 178 The intervention 
students received a short problem-based training course and a WHO manual on the 
principles of rational prescribing whereas the controls received neither. Both groups 
were tested before training, immediately after and six months later. The study group 
performed better than controls in all patient problems and importantly the effect was 
maintained at least six months later. 
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A few years ago, twenty seven medical schools in the UK were questioned about 
current and future teaching of undergraduate clinical pharmacology and 
therapeutics. 179,180 Opinions were divided with respect to whether there was a role 
for a national core curriculum in the UK. The most important items of core knowledge 
were considered to be prescribing for the elderly, management of overdose and adverse 
drug reactions; these were taught in the majority of institutions. 
In the UK in recent years, there has been a number of reports increasingly 
recognising that the delivery of optimum healthcare to patients requires a 
multidisciplinary approach. 4,30,46,91 There could be considerable benefit from 
increasing the integration between the undergraduate medical curriculum and those of 
other vocational health care disciplines. Currently, only medical and dental students 
benefit from a widely implemented joint education in the UK. However at Kings 
College London, inter-professional clinical education of medical and pharmacy students 
has been tried and found to be a successful method of clinical teaching with nearly all 
the students finding the interaction beneficial. 181 In some countries, for example in 
India and Thailand, students have a core curriculum in medico-pharmaceutical sciences 
and then specialise into pharmacy or medicine later in their programmes. 
Although no undergraduate course can be considered responsible for the future 
prescribing practices of qualified doctors, one of the main purposes of undergraduate 
medical training should be to educate students to keep abreast of changes in their field 
and equip them with the necessary skills to adapt to change. 
2.2.7.2 Postgraduate 
Continuing education is vital for physicians in order to maximise their knowledge, 
keep up-to-date and deliver quality care to the patient. Terms such as life-long learning 
and continuing professional development (CPD) are now established and recognised. 
Different countries place different emphases on continuing education; in the UK for 
example, it is a mandatory requirement, whereas in other countries such as Finland, it is 
left to the discretion of the physician. In 1980, Evered, a doctor, and Williams, a 
librarian both based in London, published a review of papers from the previous twenty 
years in an attempt to measure the success of postgraduate education. 
182 From 51 
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papers, objective data were found in only eleven and just four included adequate control 
data. The authors concluded overall that knowledge acquired from postgraduate courses 
was only likely to be retained if subjected to periodic reinforcement. 
In the Netherlands, Haaijer-Ruskamp and Denig found marked differences in their 
success after experimenting with different educational approaches: printed material 
only, one-to-one education, targeted lectures, feedback without comment, and feedback 
with group discussion. 154 Of these, the most successful individual method was either 
one-to-one education with an academic detailer/education modifier or group discussion 
with feedback,, but the authors found that no single approach was as effective as a 
combination of techniques. 
Attitudes towards postgraduate education seem to be very mixed among physicians. 
While it has been reported that many doctors find continuous education beneficial 15 7, a 
survey of 1,161 practitioners in Scotland showed that if the financial incentive for 
participation in continuing education was removed, the attendance at meetings would be 
noticeably reduced. 183 The same survey also revealed that doctors found the topics 
covered at meetings provided by pharmaceutical companies to be more interesting than 
non-commercial postgraduate meetings. 
Regarding the method and style of teaching, Brigley et al, medics involved in 
teaching public health in London, have recently criticised the emphasis of formal 
didactic teaching and academic knowledge in continuing education because of its low 
educational value and failure to change professional practice. 184 Their opinion is that a 
more systematic and coherent approach is required - learning by reflective practice thus 
improving self-development. 
In Germany and the Netherlands, continuing education is taking place in the style 
of pharmacotherapy circles for GPs. 185,186 The concept is based on quality assurance 
in medical care and consists of: assessment, problem selection, problem analysis, 
formulation of guidelines and repeated evaluation stages with the goal of optimising 
prescribing behaviour and reducing costs. Participating groups consisting of seven to 
ten GPs and a pharmacist meet about four times a year. 
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Bradley has argued that doctors need additional knowledge and skills to those 
usually taught under the traditional headings of clinical pharmacology and 
therapeutics. 187 However, a randomised control trial of continuing medical education 
in the US back in the early 1980s found that better knowledge does not guarantee better 
prescribing behaviour. 188 Physicians know that prescribing antibiotics for acute viral 
RTIs is irrational, but pharmacology alone will not change these prescribing habits. 
Education in how to avoid prescribing when it is not clinically indicated is needed, so 
that skills must be acquired to deal with pressures from patients, colleagues, industry 
and from funders of health care. 18 7 
2.2.8 Pharmaceutical industry 
The potential influences on a doctor's prescribing start during medical 
undergraduate education and throughout this period, they may be exposed to many 
pharmaceutical industrial sponsored events. Recent Governments in the UK and USA 
have encouraged universities to attract an ever larger proportion of their annual funding, 
especially for research, from industrial and commercial sponsorship which may 
inevitably lead to some compromise and a reduction in objective independence. In 
addition, difficulties and shortage of funding for continuing education have led to the 
wider use and attraction of pharmaceutical industry sponsorship. Sponsorship can be in 
a variety of forms, including: 
" unrestricted donations to providers; 
" sPecialised programmes for lectures, meetings and symposia; 
" sPecialised programmes combined with non-educational gifts. 189 
In the UK, the Governinent through the Voluntary Price Regulation Scheme 
(VPRS) contains the prices of ethical prescription products purchased by the NHS and 
also restricts manufacturers' spending on drug promotion to a maximum of 17% of 
sales. Nevertheless, with the pharmaceutical industry probably being the most 
successful manufacturing industry in the UK, for those companies whose annual sales 
are in excess of f400 million such as Glaxo190, this figure of seventeen per cent can 
represent a very large sum of money. 
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In the UK, it has been reported that the pharmaceutical industry has a network of 
6,000 drug representatives and spends f 570m per anum on drug promotion which is 
equal to approximately f 12,000 per GP and yet prescribing is still considered to be 
conservative compared with other countries. 4 These figures compare with an estimate 
of less than 200 HA prescribing advisers in post, mid 1998 and in the region of f4m per 
anurn spent by the DoH on educating doctors. Drug representatives target prescribers in 
a direct manner relying on good communication techniques and sophisticated salesman- 
like strategies. 152 
Like all public companies, pharmaceutical companies have share-holders to satisfy 
and therefore need to be successful in promoting and selling their products, whereas the 
purchasers of these products have to satisfy patients who ultimately require value for 
money. Prescribers are often dependent on drug companies when they require 
information about a new drug and there is thus a great need for careful regulation of the 
advice and information given to GPs by the pharmaceutical industry. This is 
particularly so in countries where there is no mandatory postgraduate education. 
Consequently, this can present a potential conflict of interest between purchasers, 
providers and patients. Governments are conscious that changes in the balance between 
these interests can dramatically influence their popularity as well as affecting the 
exchequer balance of payment. 
A study carried out by a multidisciplinary research team from the Harvard Medical 
School in the 1970s investigated the relative influence on prescribing influences of 
scientific versus commercial sources in the USA. 162 A random sample of GPs were 
interviewed about their beliefs about vasodilator drugs and propoxyphene where results 
of clinical trials suggested that they both had limited proven clinical value but were 
heavily advertised as being effective. Denial of industrial influence and yet believing 
that a drug of limited proven clinical value is effective is contradictory, suggesting that 
scientific literature was not the source of such views. The results found that physicians 
were generally unaware that they were strongly influenced by commercial information 
sources. For vasodilators, there was a significant tendency for those who believed in 
these drugs to report greater reliance on commercial sources. Nonetheless 48% of those 
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who believed vasodilators to be effective treatment for senile dementia also stated that 
they were influenced more by scientific sources than commercial sources. 
Another study performed by Orlowski,, a paediatrician, and Wateska, a hospital 
pharmacist, in Cleveland, USA looked at the effects of pharmaceutical company all 
expenses paid trips to attend symposia at popular sunbelt vacation sites. 3 The two drug 
promotions investigated concerned an intravenous antibiotic and an intravenous 
cardiovascular drug, both for use in hospitals only. By tracking the pharmacy inventory 
usage reports before and after the symposia against two control drugs intended to be 
replaced by them, the usage of the two promotional drugs was found to significantly 
increase after the symposium and this was also significantly different from their impact 
nationally. These alterations in prescribing patterns occurred even though the majority 
of physicians who attended the symposia believed that such enticements would not alter 
their prescribing patterns. The nature of advertising is such that physicians often deny 
the relative importance of commercial sources either because they believe they are 
unaware of them or because they are reluctant to admit to being influenced by non- 
scientific sources. 
One of the criteria in the 1968 Medicines Act45 requires manufacturers to supply 
an official data sheet on a product sometime within the 15 months preceding any form 
of marketing promotion to doctors and pharmacists. Most promotional mailings include 
a copy of relevant data sheet(s) to ensure legal compliance. The Data Sheet 
Compendium (DSC) which contains most major manufacturers products is a useful 
source of drug information and is supplied free of charge to all general practitioners, 
dentists and pharmacies and is updated annually. 191 Physicians who prescribe for an 
indication outside the product licence do so entirely on their own responsibility and 
liability. 
As part of an ethical defence and standards established by pharmaceutical 
companies, the Association of the British Pharmaceutical Industry (ABPI) of which the 
vast majority of pharmaceutical companies are members, also has its own 'code of 
practice' which is published in the DSC. The code of practice was first drawn up in 
1958 and is revised in consultation with medical and pharmaceutical professional 
bodies, the Medicines Control Agency (MCA) and the DoH. Its aim is to ensure that 
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the promotion of medicines to members of health professions is carried out in a 
responsible, ethical and professional manner. The code of practice is very detailed in all 
aspects of advertising, claims, definitions of appropriate terminology, for example it 
states that 'an "inexpensive" gift means one that has cost the donor company no more 
than 15 excluding VAT and gifts must be inexpensive and relevant to the recipients 
work'. 191 
A successful research based pharmaceutical industry has become essential to ensure 
major advances and innovations in drug research and development. Heavy research 
investment in the UK has resulted in the discovery and development of five of the 
current top twenty medicines world-wide. No Government has been willing to invest on 
the same scale. Satisfying shareholders on the one hand and providing value for money 
in a competitive market, whilst making financial savings to cover the cost of research 
and development for future innovative drugs is a fine line and one needs to bear in mind 
that the ethical and moral standards of global business and professional health care 
practice may well be different. 192 
2.2.9 Hospital 
The Greenfield Report of 1982 and the Audit Commission Report of 1994 have 
both stated that the influence and events that take place in hospitals strongly influence 
GP prescribing. 3 0,46 Estimates range from as low as ten per cent to as much as forty 
per cent of general practice prescribing being influenced but precisely how and to what 
degree remain unclear. 30,193 
It seems logical that hospital prescribing has some influence on prescribing in 
primary care as all medical students traditionally spend a major part of their training in 
the secondary care environment. Also, when patients are discharged into the 
community, GPs are generally unwilling to change any hospital initiated prescribing 
without reference back to the hospital. 
194 Some GPs may also decide to adopt some of 
the prescribing strategies of hospital physicians, especially the prescribing by 
consultants Who might be perceived as the 'gold standard' as they are 'specialists' in a 
particular field of medicine. The resulting economic effect on the primary care budget 
can be profound, especially when the medicines are required for the long term treatment 
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of a chronic condition. 118,119 This effect can be further potentiated as many drug 
companies disguise the cost of their drugs, making some of them market loss leaders by 
offering major discounts to hospital pharmacies compared with the wholesale costs to 
pharmacies in primary care. 
A study carried out by academic pharmacists in Brighton looking at how hospital 
doctors and GPs rated the different factors involved in choosing an NSAID for a 
formulary revealed subtle differences in their approaches to drug selection. 195 Hospital 
doctors were primarily concerned with drug efficacy compared with their GP colleagues 
who were relatively more concerned with possible side-effects than the potential 
benefits of a drug and tended to rate past experience more highly. The study only 
involved a total of 44 doctors and the hospital cohort studied were of younger age than 
their GP counterparts. The study also revealed that dispensing doctors were equally 
influenced by hospital pharmacists as by community pharmacists which may reflect the 
promotion and availability of hospital-based drug information services directly to GPs. 
2.2.10 Society 
The two main aspects of society which have the potential to influence prescribing 
are culture (Section 2.1.2) and the mass media. Media can influence prescribing in two 
ways: either through negative publicity causing downward prescribing trends or product 
advertising having the reverse effects. Research at the Prescription Pricing Authority 
(PPA) in Newcastle upon Tyne focusing on downward prescribing trends in the early to 
mid 1990s, found that television and newspapers seemed to have the greatest influence 
on this outcome. 196 
One of the most damaging media reports with detrimental consequences was the 
(I pill scare' in the UK towards the end of 1995. The UK Committee on Safety of 
Medicines (CSM), anticipated that publication was about to take place of three studies 
which were likely to cause public alarm, held a press conference announcing that 
'combined oral contraceptives' (COCs) containing gestodene or desogestrel (third 
generation) should only be used by women who are intolerant of other COCs and 
prepared to accept an increased risk of thromboembolism'. 
197 Unfortunately, such was 
the media hype that considerable public anxiety resulted and a substantial number of 
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women, both in the UK and abroad, stopped taking the pill with the inevitable 
consequence of increases in pregnancies and abortions throughout Europe and the rest 
of the world. 198 Despite the adverse effect of venous thromboembolism (VTE) 
appearing to be statistically significant, there was doubt as to whether this was clinically 
significant. 199 VTE is so rare that the population to demonstrate that the third 
generation OCs double the risk of death from VTE compared with second generation 
OCs would be greater than the total number of women using OCs in the UK and 
Netherlands combined. 
The media is a powerful means of communication and there have been other drug- 
related reports that have done nothing to instil confidence into the public. 200 
Unfortunately, media reports are often misleading and are largely written to attract 
attention - this may counteract and complicate the work of many health professionals. 
Perhaps more effort should be made into forging links between health care professional 
bodies and the media to educate the public so that issues can be handled more evenly 
and accurately. 
2.2.11 Patients 
A number of patient factors are known to influence prescribing such as their age, 
socio-economic status and how informed they are. These, along with patient demand, 
have been discussed earlier as being important determinants of varying drug 
consumption. 139 Bradley found expectations of patients to be the commonest reason 
cited by GPs for issuing a prescription. 150 
In 1991 , medical sociologists at the 
University of London published the findings of 
a questionnaire study which measured patients' attitudes towards the issue of a 
prescription in general practice and recorded whether or not a prescription was 
issued. 201 The results were not entirely conclusive but they indicated that the attitude 
of the patient influenced the outcome. Patients presenting without appointments were 
associated with a greater tendency to receive a prescription. The proportion of patients 
receiving a prescription (61 %) was found to exceed the proportion of patients expecting 
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a prescription. The researchers also found that doctors were more aware of the pressure 
to prescribe than of the preference for self-care. 
This research was followed three years later by semi-structured interviews with 30 
adult patients from two general practices to describe their ideas and expectations about 
prescribing and their self-reported behaviour in cashing prescriptions. 2 02,2 03 
Interviews revealed that the desire for a prescription can be related to the stage of the 
illness at which a patient consults their doctor but that it is impossible to satisfy all 
patients' expectations. Also, it was found that not all patients either wanted a 
prescription or collected it if they received one. Britten concluded that the 
appropriateness of the outcome of the consultation could beneficially include 
confronting the patient about their expectations in receiving a prescription. 
For those patients receiving an unexpected prescription, it could be that either they 
are disinclined to use their medication or that they are non-concorders with prescribed 
medication. The latter could be as a result of not having the prescription dispensed or 
by not taking the prescribed items as directed. In 1984, Begg carried out an audit of 
patients who received prescriptions in one GP practice and suggested that the number of 
prescriptions not dispensed could be a measure of the quality of doctor-patient 
communication. 204 A study to determine the rate of patients not redeeming their 
prescriptions in primary care was performed by Beardon et al, from the Department of 
Pharmacology and Clinical Pharmacology, Dundee Medical School. 36 Over a three 
month period in one Health Centre in Tayside, 4,854 patients received a total of 20,921 
prescription items and overall 702 (15%) patients failed to have 1072 (5.2%) 
prescriptions dispensed. 36 The authors suggested that prescribing levels may have 
exceeded patients' expectations. Of those who redeemed prescriptions, seventeen per 
cent were not exempt from prescription charges compared with 33% of patients who 
failed to redeem them. 
Other research from the patient perspective has also been carried out on 1,068 
randomly selected Chinese in Hong Kong using telephone interview and questionnaire 
techniques. 205 The study investigated whether the Chinese expect prescribed 
medication when they are ill because doctors are known to prescribe in nearly 100% of 
consultations. A much higher proportion of patients admitted to always expecting a 
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prescription (76%) than reported in the UK201 and half this number thought medicine 
was always necessary. With respect to the medication last prescribed to them, only 48% 
had completed the prescribed course with a significantly higher proportion (72%) of 
those who thought too many drugs had been prescribed not finishing the course. 
Younger patients who had received more education, were less convinced that illnesses 
always needed drug treatment and were less likely to expect a prescription for every 
consultation. 
In Australia in 1997, two behavioural scientists investigated expectations of 336 
patients' and their GPs perceptions of these patients' expectations. 206 Patients who 
expected medication were nearly three times more likely to receive medication and ten 
times more likely to receive medication when the GP thought the patient expected it. 
Overall patients were more likely to receive medication when the practitioner judged the 
patient to want medication than when the practitioner ascribed no medication to the 
patient. 
A similar study by Britten and Ukoumunne a statistician, involved 544 patients who 
had consulted 15 GPs in four practices. 207 These researchers also found that the 
decision to prescribe was closely related to actual and perceived expectations but that 
the latter (doctors') perceptions of patients' expectations) was the more significant 
influence. 
However, the findings of research involving 371 patients in five Oxford general 
practices conducted by three senior house officers208 slightly contradicted the previous 
study by Britten. 207 Ramsden et al found no relation between GPs confidence in the 
pharmacological efficacy of their prescriptions and the patients' expectations for 
prescriptions, concluding that doctors are not pressurised into giving prescriptions they 
do not believe are of benefit. Britten's study directly measured both patients' 
expectations and doctors' perceptions of patients' expectations along with their decision 
to prescribe, whereas the study by Ramsden et al was limited to using the patients' 
expectations as a proxy for doctors feeling pressurised. 
62 
Review of the literature 
2.2.12 Prescriber and working environment 
In 1992, researchers from the Department of Primary Health Care, University 
College London found that the decision making by GPs in the diagnosis and 
management of lower urinary tract symptoms in women revealed extensive differences 
between patients. 209 Of 61 subjects from two group general practices in suburban 
London presenting with symptoms of frequency or dysuria, GPs who knew the patients 
well were found to be four times more likely to make a correct prediction of the test 
result and twelve times less likely to prescribe antibiotics. The GPs were five times 
more likely to make more accurate predictions in patients from social class one and two 
and were six times more likely to prescribe antibiotics for older women in the sample. 
This study was limited in sample size and may not be representative of general practice 
consultations. It might be inferred from this study that in addition to patient factors, 
there are probably a variety of physician characteristics which must be associated with 
the outcome of the consultation. 
In the same year as previously, a paper published by researchers from the Drug 
Utilization Research Unit in Northern Ireland analysed the prescribing of 362 GPs from 
132 practices to establish the relationship between the number of partners and the 
number of drugs prescribed. 210 Not surprisingly, there was found to be a significant 
correlation between the number of different preparations prescribed and the number of 
GPs working in the practice; however, this was the first study to establish this. No 
correlation was found between the number of different drugs prescribed and the mean 
prescribing cost per patient or the mean list size of the doctors in each practice. Of 
some concern was the finding that the number of different drugs prescribed by practices 
claiming to have a practice policy or operate a formulary was not significantly different 
from that among practices with no such formulary. These findings are of importance as 
the greater the number of different drugs prescribed, the greater will be the risk of side 
effects and possibly dangerous interactions. 
Researchers in the Department of General Practice in Edinburgh investigated the 
duration of patient-doctor consultation of 86 GPs to see whether this affected patient 
care. 211 Despite the patient case mixes of the GPs appearing to be similar, the results 
varied greatly. Patients reported greater satisfaction with longer consultations which 
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were associated with dealing: with more of the patients' psychological problems; with 
more long term relevant health problems and with health promotion. With respect to 
prescribing, longer consultations involving a more thorough patient examination could 
reveal problems requiring a prescription and yet the provision of a prescription has also 
been long associated with a method of terminating short consultations. 
In Section 2.2.7.2 the importance of postgraduate education to maintain up-to-date 
drug knowledge for prescribers was discussed. Murray et al, academic GPs from the 
Department of Postgraduate Medicine, University of Glasgow published two studies in 
the early 1990s which analysed the characteristics of GPs attending educational 
meetings212 and a follow up study213 looking at their demographic characteristics. In 
the first study, of 171 GPs who had attended more than 35 half day sessions of 
accredited education,, the high attenders were more likely to be women, to be members 
of the Royal College of General Practitioners and to work in a training practice. 212 The 
majority of doctors had been qualified for between 10 and 30 years and worked in group 
practices of three or more doctors. The second study involved sending a questionnaire 
to identify the demographic characteristics of 1,672 doctors who had attended sufficient 
sessions to claim their postgraduate education allowance. 213 A 93% response rate was 
achieved and there were found to be particular differences in the attendance at different 
styles of meetings, namely, disease management, service management and health 
promotion. GPs older than 55 years attended the highest mean number of educational 
sessions on disease management and the lowest number of the other two styles of 
meeting. GPs in rural areas attended fewer meetings than those in urban areas, 
particularly with respect to disease management. Doctors from smaller practices 
attended significantly fewer sessions on service management than those from larger 
practices and full-time doctors attended more service management sessions than part- 
time doctors. The only difference between sexes was that men attended significantly 
more sessions on service management and women attended more on health promotion. 
Earlier in the 1990s, a number of studies in the UK investigated the differences in 
prescribing between fundholding and non-fundholding practices. Health service 
researchers at the University of Oxford used PACT data to measure various aspects of 
prescribing in a variety of dispensing, non-dispensing, fundholding and non- 
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fundholding practices. 214 In the six months after the NHS reforms, prescribing costs 
increased most among non-fundholders and the increase in average cost per item was 
greatest among this group too. The number of items prescribed increased most in the 
non-dispensing fandholders group but the level of generic prescribing in the dispensing 
fundholders at 34% was nearly 15% below that of the other two groups. Overall, five of 
the eight fundholding practices made savings in their drugs budget at the end of their 
first year compared with none of the seven non-fundholding practices. 
A multi-disciplinary team of researchers from the Department of General Practice, 
Edinburgh compared prescribing patterns between six fundholding practices and six 
non-fundholding practices using the more accurate 'defined daily dose' measure. 215 
Over a two year period the costs rose least in the fundholding practices. 
Pharmacists and clinical pharmacologists in Newcastle upon Tyne examined the 
effects of a financial incentive scheme on prescribing in non-fundholding general 
practices. 89 Of 442 practices, 102 achieved their target savings indicating that the 
prescribing behaviour of non-fundholding general practitioners responded to financial 
incentives in a similar way to that of fundholding practitioners. 
At about the same time health service researchers in Oxford investigated the 
changes in prescribing practice between eight fundholding practices and five non- 
fundholding practices which had similar practice characteristics. 2 16 The results 
indicated that prescribing costs rose by a third or more in all practices irrespective of 
their type. The period of prescribing data investigated was over three years which was 
greater than in the previous two studies and in this study the effectiveness of 
fundholding in curbing prescribing costs was not proven. 
Researchers from the Department of Pharmacology and Therapeutics at the 
University of Liverpool published a study in 1996 which investigated the influence of 
practice characteristics on prescribing in GP practices. 217 With the exception of 
variation in total prescribing costs which was largely accounted for by fundholding, 
differences in prescribing behaviour were better explained by deprivation, training 
status and partnership status. 
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2.2.13 Summary 
This review section has indicated that GPs are exposed to a wide range of factors 
that can potentially influence their prescribing. Many influences are independent of 
national boundaries, others may be peculiarly related to local or national health care 
practice and professional organisations. Although the volume of literature associated 
with prescribing influences is substantial, there appears to be relatively little which 
either investigates the impact of different influences or how GPs perceive their relative 
importance. The next key area of the literature review explores, aspects of quality 
prescribing. 
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2.3 QUALITY PRESCRIBING 
"I do not want two diseases: one made by nature and one made by the doctor)l. 
(Napoleon Bonaparte 1820) 
2.3.1 What is quality? 
Quality of care is an increasingly important criterion in the provision of health- 
related services. Quality assurance covers a wide range of factors incorporating how to 
develop, ensure, improve and manage the quality of patient care218. At the beginning 
of the 1990s, the WONCA European Working Party on Quality in Family Practice 
(EQuiP), a collaboration between professional organisations for family doctors in 17 
European countries carried out a cross-country investigation of quality assurance. 219 
The purpose of this exercise was to exchange experience of activities and offer support 
where necessary in order to speed up developments in different countries. These 
activities include the setting of guidelines for practice through structured methods, 
application of feasible methods for quality assessment and use of new methodologies 
for changing practice performance in order to improve future quality of care as well as 
cost containment. From the findings it appeared that countries where the health care 
system favoured a strong and central position for the GP were more advanced in 
developing quality assurance in general practice. However in all countries, the 
resources available to GPs and practices in order to set up quality activities in their work 
setting were limited. 
Although prescribing is just one aspect of patient care, it is nevertheless an essential 
component representing one of the core functions of the doctor. In the UK, The Royal 
College of General Practitioners began to address quality in general practice in 1983 
with the underlying belief that quality was measurable through such activities as audit 
and hence GP practices were encouraged in this respect. 220 The process continues to 
this day with attempts to link 'better' general practice to 'better' hospital and 
community services in order to offer seamless care to patients. 
218 Quality in general 
practice has been described as the relationship between actual care and the expectations 
of the various parties involved. 
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Since the late 1980s, quality improvement has become a government strategy for 
reforming the management and organisation of public services. 221 The current British 
Government produced a white paper in December 1997 entitled 'The New NHS: 
Modern and Dependable, 53 which introduced the term clinical governance, defined as 
6a ftamework through which NHS organisations are accountable for continuously 
improving the quality of their services and safeguarding high standards of care by 
creating an environment in which excellence in clinical care will flourish. ' A 
subsequent white paper 'A first class service: quality in the new NHS, 222 published in 
July 1998 announced that quality health care would be tackled in three ways: by setting, 
delivering and monitoring standards. 
2.3.2 Quality indicators 
In general, the quality of prescribing cannot be assessed directly as there are no 
routine data available which directly link morbidity to drugs. Even if this were possible, 
the medical history of the patient would ideally also need to be known. Furthermore, 
there are anomalies in that many traditional and generally accepted treatments do not 
entirely follow the principles of evidence-based medicine. 223 Consequently 
performance or quality indicators are proxy tools used to monitor and evaluate 
prescribing by measuring aspects of drug utilization. The EQuiP Working Party has 
defined an indicator as: 'a measurable element ofpractice performance for which there 
is evidence or consensus that it can be used to assess the quality and hence change the 
quality of care provided,. 224 They can be used for three overlapping purposes: to raise 
awareness, to target interventions and to facilitate audit. 225 Medical audit has been 
defined by the NHS executive as the systematic, critical analysis of the quality of 
medical care including the procedures used for diagnosis and treatment, the use of 
resources and the resulting outcome and quality of life for the patient. 218 
A number of principles underlie prescribing indicators226 and include: 
risk benefit - the use of more potent but toxic drugs within a group should be 
restricted to patients with an appropriate risk benefit ratio 
* doctor's knowledge - drugs should be consistently prescribed from a familiar 
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range of drugs which is recognised as good medical practice 
monitoring and management of care - patients with long term pathology 
particularly those receiving active treatment should have their condition and 
treatment (ideally the most cost-effective available) regularly reviewed 
patients' clinical needs - the appropriate quantities of drugs for patients' needs 
should be provided as economically as possible in order to free resources for 
other health needs 
Houghton, an associate advisor in general practice and GP in the West Midlands, 
has proposed that if prescribing performance indicators can identify substandard 
medical performance then they could help form a relatively inexpensive and simple 
system of reaccreditation for doctors, especially GPs. 227 
2.3.3 Measuring quality prescribing 
In this context, quality is not only difficult to define but it is even more difficult 
to measure adequately and satisfactory. In England, prescribing is commonly measured 
by three rates: the number of items prescribed, the cost per item and the cost per patient. 
The rates can be applied both to prescribing overall and to prescribing in specific 
therapeutic groups. Measurement of prescribing is facilitated by the use of prescribing 
analysis and cost (PACT) data which has traditionally been used to set and monitor 
prescribing budgets and is now increasingly used for the purposes of developing 
prescribing indicators. 65 Practices' prescribing rates are compared with the local health 
authority averages (weighted with respect to prescribing units based on the number of 
patients over 65 years of age and those under 65 years) and with national averages. 
None of these measures is entirely meaningful and using health authority averages as 
the standard for comparison is questionable. 223 However, when they are used to 
compare health authorities with each other, some patterns have been found to emerge. 
In poorer, more industrialised areas, the items-per-patient rate tends to be relatively high 
and the cost-per-itern relatively low. In more affluent areas, items-per-patient tends to 
be lower and cost-per-item higher. The cost-per-patient in both cases is determined 
more by the number of items than the cost of each item. Reasons for these trends are 
considered to be in part due to higher unemployment levels in poorer. more 
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industrialised areas with a corresponding higher proportion of people exempt from 
prescription charges being prescribed items which would tend to be purchased over the 
counter in more affluent areas. 228 
2.3.3.1 Units of measurement 
2.3.3.1.1 Volume 
Quantifying drug consumption can be related to simple physical units, such as the 
number of packages or tablets, grams of ointment and the number of prescription 
items. 229 The number of units depends to a considerable extent on the intended 
duration of the prescriptions and thus the number of tablets for the same drug will vary 
from prescription to prescription. However, the number of units is of value in 
evaluating the clinical use of drugs as well as measuring the frequency of prescriptions. 
Simple counting of tablet numbers ignores variations in tablet strengths resulting in 
low strength preparations disproportionately influencing numbers more than high 
strength preparations. Similarly short-acting preparations will tend to contribute more 
than long-acting preparations. 
If consumption is given in terms of grams or active ingredients, drugs with a low 
potency will have a larger fraction of the total than drugs with high potency. Combined 
products may also contain different amounts of active ingredients from single drug 
products which will not be reflected in the figures. 
2.3.3.1.2 Defined daily dose (DDD) 
The basic definition of the defined daily dose (DDD) unit is that it is: the assumed 
average maintenance dose per day for a drug used on its main indication in adults. 
229 
DDDs are a much more meaningful way of measuring volume as they are independent 
of prescription duration though they may not necessarily reflect the recommended or 
actual dose prescribed. The individual dosages used will often differ from the DDD 
because of individual patient characteristics such as age and weight, severity of clinical 
condition and pharmacokinetic considerations. 
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Since many drugs are used at different dosage levels for different indications, this 
needs to be taken into consideration when evaluating drug consumption figures. For 
drugs used in short courses, for example antibiotics, the duration of treatment may differ 
from one drug to another and this is important when comparing the use of the different 
drugs. DDDs have not been established for some types of drugs, for example skin 
preparations and a recommended dosage of a drug may vary between countries, making 
national comparisons difficult. Sales or prescription data monitored and presented in 
DDDs will thus give only a qualified estimate of consumption and not an exact picture 
of actual use. 
Despite its limitations, the defined daily dose is a much improved unit of measuring 
prescribing comparisons which is independent of price differences and different 
preparations. Both national and international long term studies have been carried out 
using DDI)s and comparisons between countries have also been made, notably in 
Scandinavia. 23 0-23 4 
2.3.3.1.3 Prescribed daily dose 
The prescribed daily dose (PDD) can be determined from prescription records and 
patient interviews but it is important to relate it to the diagnosis on which the dosage 
was based. 229 The PDD will give the average daily amount of a drug that is currently 
prescribed. There are occasionally substantial discrepancies between the PDD and the 
DDD for example with antibiotics, PDDs vary according to the severity of the infection 
whereas the DDD for most antibiotics are based on treatment of moderately severe 
infections. In hospital care, much higher doses are frequently used and this must be 
considered when using the DDD as a unit of measurement. Therefore, it is important to 
take this into consideration when evaluating and interpreting drug consumption figures. 
PDDs may well differ from one country to another and so there should be an element of 
caution when international comparisons are made and considered. The PDD can vary 
according to both illness treated and national therapy traditions. 
For drugs where the recommended dosage differs from one indication to anotherg 
for example antipsyc otics, it is important that diagnosis is linked to the prescribed 
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daily dose given. Pharmacoepiderniological information, for example sex, age and 
single/combination therapy is also important in order to interpret a PDD- 
2.3.3.1.4 Cost 
Local cost analysis of drug expenditure is satisfactory provided comparisons are 
being made in the same sector of health care at a similar point in time. However, 
national and international comparisons based on cost parameters are often misleading 
and of limited value in the evaluation of drug use. Price differences between alternative 
preparations and different national cost levels make the evaluation difficult. Long-term 
studies are also difficult due to fluctuations in currency and changes in prices. When 
cost data are used, an increase in the use of cheaper drugs may have little influence on 
the total level, while a shift to more expensive drugs is more readily noticed. 
Cost analyses are applicable for prescription studies of a single substance. As with 
the number of prescription items though, cost is also partly determined by the intended 
duration of the prescription, not just the basic cost of the drug. 
2.3.3.1.5 Patients and population 
Prescribing levels are effected by the level of morbidity in a practice population in 
general practice but currently there is no way of measuring it. 223 The age and sex 
structure of the population also influence prescribing patterns. Different patients require 
different numbers of prescriptions and before reasonable comparisons can be made, a 
practice population needs to be standardised as far as possible. In England, the 
prescribing unit gives some allowance for this by weighting patients of 65 years and 
over three times as heavily as younger patients but the system is crude and inaccurate. 
In an attempt to improve this measurement, a system was developed in 1993 of 
ASTRO-Pus (age, sex and temporary resident originated prescribing units) that weights 
for nine age bands in both sexes and for temporary residents and this is now used in 
determining prescribing budgets. 35 More recently for specific therapeutic groups, 
similar cost weightings called STAR-PUs (specific therapeutic group age/sex related 
prescribing units) have been established which make possible much fairer comparators 
for a practice's prescribing than the system of pUs. 
66 The rationale behind their 
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development is because each therapeutic group has a different age/sex distribution of 
use, for example cardiovascular and gastrointestinal drug costs are particularly high in 
older patients and endocrine drug costs are higher for women than for men. 
2.3.4 Development of quality indicators 
The Delphi approach has often been used in the development of quality indicators 
or markers in an attempt to obtain a consensus opinion. In 1993, Schrijver and Crede, 
two pharmacists working for Barking and Havering Health Authority, drew up a list of 
five prescribing quality statements following wide consultation with experts and 
GPs. 235 These were with respect to the: 
e percentage cost of inhaled prophylaxis to total costs of asthma treatment, 
* level of generic prescribing, 
* percentage of total NSAIDs prescribed from the five most commonly used, 
9 appropriate upper benzodiazepine prescribing level (items per 1000 patients), 
* appropriate percentage of cephalosporin relative to penicillin prescriptions. 2 35 
After presentation at two postgraduate meetings, GPs were asked to attach a value to 
each statement and this process was repeated twice. The first three statements were 
generally considered to be fairly valuable quality markers but there was a low opinion of 
the usefulness of the final two statements. Despite the recognition by the GPs of certain 
quality markers, their prescribing behaviour based on the three accepted statements was 
found to significantly fall short of their rating. 
Academic health service researchers at the University of Manchester published a 
study in 1998 which attempted to develop indicators of appropriateness of long term 
prescribing in general practice. 236 A nominal group composed of nine national key 
personnel in the field of prescribing identified potential prescribing indicators. Of 34 
statements, 13 prescribing indicators suitable for application were identified and rated in 
a two round Delphi study by 100 GPs and 100 community pharmacists. Subsequently 
nine indicators of appropriateness of prescribing were produced suitable for application 
to the medical record of any patient on long-term medication in UK general practice. 
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Roland et al from the National Primary Care Research and Development Centre in 
Manchester, recently undertook a large study into the agreement between GPs and 
health authority managers on what should be counted as a good performance indicator 
for use by health authorities in monitoring general practice. 221 In an initial survey of 
all health authorities in England, they identified a total of 240 relevant indicators that 
were in use for assessing performance. Again the Delphi approach was used, this time 
among 57 GP course organisers and 47 health authority managers. Agreement on what 
is an acceptable indicator of quality was achieved for only a tiny minority of conditions, 
and for many of these, performance data were not routinely available. In the area of 
prescribing, there was a low level of support for prescribing indicators. The most highly 
rated indicators were associated with the organisation of care and training within the 
practice such as prescribing audit and regular prescribing meetings. The most highly 
rated indicator relating to individual drug details was the ratio of co-trimoxazole to 
trimethoprim prescribed. 
Consensus methods such as the Delphi technique have been criticised for the lack 
of a formal decision making structure and for having their outcome influenced by their 
panel composition. 237 Clinical pharmacology and pharmacy researchers in Newcastle 
upon Tyne managed to avoid these issues when developing a range of criteria of 
prescribing quality. 67 This was dealt with firstly by requiring unanimity on the choice 
of criteria and standards within the group which consisted of eight GPs. Secondly, by 
convening a group of practising GPs, decisions on general practice prescribing were 
made by a peer group. In contrast to the former studies discussed, it remains 
questionable whether unanimity with eight GPs would be more meaningful than general 
consensus by larger numbers of Practitioners. 
Where some quality indicators have been developed though, other groups have 
found them unacceptable, which makes it difficult for standards to be confidently 
established. For example the ratio of inhaled steroids to bronchodilators in the 
management of asthma has been used as a quality indicator by many health authorities 
in the UK, mainly since its reference in the Audit Commission Report in 199430 and it 
has subsequently been endorsed by others. 
238 However, when attempting to develop 
consensus indicators, others have found that there is no agreement about how much 
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prescribing meets the needs of asthmatics. 67 Also bronchodilators are of symptomatic 
benefit for many patients with chronic bronchitis or emphysema where steroids are less 
often of value. Thus it may be argued that a high steroid: bronchodilator ratio represents 
poor prescribing in the context of non-asthmatic disease and as an indicator it is 
inappropriate unless there is a link of drug use to morbidity. A study attempting to 
determine appropriateness of this co-prescribing from PACT data alone even concluded 
that a more sophisticated approach was required to assess and improve prescribing 
quality taking into account the many factors which influence prescribing decisions239 
and yet the ratio continues to be used as a prescribing indicator. 
2.3.5 Quality indicators in use 
There have been many types of performance indicators used to assess prescribing 
including the: 
9 appropriateness of drug use240 
" appropriate monitoring of drugs236 
" prevalence of fixed combination drugs use of three or more ingredientS241 
" prevalence of polypharmacy prescribing8 
" generic prescribing rate30 
* adherence to prescribing guidelines/ formularies 132 
prescribing of drugs from a limited range242 
frequency of prescribing i. e. rates and ratios of prescribing243 
9 quality of life outcomes244 
With larger numbers of people living into old age, there has been an increase in the 
number of nursing homes, particularly throughout the 1980s. The availability of 
nursing staff to administer drugs and initial prescription charts has meant that 
monitoring an elderly person's regular pattern of drug consumption is considerably 
more accurate than it would have been in the domestic setting. Associated with this, 
assessment of the quality of prescribing in nursing home residents is one example of 
75 
Review of the literature 
where a number of investigations have been performed. In 1987, benzodiazepines were 
described as drugs to avoid in the elderly. 245 Shortly afterwards, a study was carried 
out in 15 Oxfordshire nursing homes by two community health researchers to examine 
how widely these drugs were prescribed by GPs to patients. 246 In this study, despite 
the limited numbers and similarity of the subjects, there was a forty-fold difference 
found in the average number of benzodiazepine prescriptions per resident. Whilst no 
attempt was made to identify what the cut-off point should be for good and poor quality 
prescribing of benzodiazepines, monitoring their use appeared to be an effective tool for 
highlighting the range of variation in prescribing between nursing homes. 
In 1993,, a team of medical and non-medical researchers from the medical school, 
University of California published a study in which they attempted to relate the quality 
of prescribing in 12 nursing homes in the greater Los Angeles area to the characteristics 
of the physicians who served them. 247 The definitions used to assess quality of 
prescribing were the overall number of prescription drugs per resident and the use of 
medications deemed inappropriate by a panel of experts. The characteristics of the 
doctors having the most inappropriate prescribing included older age, having infrequent 
consultation with psychiatrists and those who worked in smaller practices. The doctors 
associated with the best prescribing were those who held certificates of added 
qualification in geriatrics, those who frequently consulted psychiatrists and female 
doctors. As relatively few doctors were found to have relevant postgraduate 
qualifications and as only 6% of the 221 participants were female, these results must be 
interpreted with caution. Such was the belief that there was a link between 
qualifications and better quality of care by doctors that in 1991, two years prior to this 
study the Medical Insurance Agency in the UK decided to offer annual indemnity 
arrangements at considerably lower rates to doctors who had passed the membership 
examinations of The Royal College of General Practitioners. 24 8 
A research team from the School of Pharmacy, University of Stockholm 
investigated the influence on the quality of psychotropic prescribing from the resident 
and organisational perspective in 33 Swedish nursing homes. 240 A list of 13 drug 
criteria based on published guidelines and recommendations were developed to measure 
appropriateness, in terms of excessive use of psychotropic drugs. Residents diagnosed 
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with a psychiatric disorder and younger residents had more deviations from the criteria 
although resident's clinical and demographic characteristics did not account for 
variations in appropriateness of drug use from one home to another. Facilities with 
better nurse staffing and drug intervention teams had fewer deviations from the criteria 
but only 15-20% of the variation in drug prescribing was explained by these predictors. 
Drawbacks to this study included the documented diagnostic reports which were 
thought to be limited and their accuracy was uncertain. Like most of the 
aforementioned studies, the criteria for measuring quality in this study in terms of 
appropriateness do not take into consideration the clinical condition of individual 
patients. The use of some drugs classed as inappropriate may in fact be appropriate, 
especially where no alternative treatment is available in those cases where some 
residents experience serious psychiatric symptoms. 
2.3.6 Implications for research 
There is no current system which is entirely adequate to evaluate the quality of GP 
prescribing. As systems are developed in the future, they may only be relevant on an 
international level where there are standard accepted guidelines between countries in the 
treatment management of conditions. Currently over- or under- prescribing is often 
selected as a marker, but neither are necessarily accurate indicators of appropriate 
prescribing. 51 Improving some aspects of the quality of prescribing may lead to short- 
term cost savings due to initiatives such as generic prescribing. In other areas, increased 
drug costs may be forecast but with potential reductions in the overall health care bill 
and social consequences especially including the return to work. For example, in 
asthma the use of expensive prophylactic inhaled corticosteroids may reduce emergency 
hospital admissions. 30 Thus, the standardised measures being developed already reveal 
that an apparently high cost practice may in fact be more economical than an apparently 
low cost practice. Drugs that seem initially expensive in general practice may save 
money long term. This is a very under-researched area. 223 
Nevertheless, by indirectly measuring quality, prescribing indicators can alert 
prescribers and point to potential performance issues that may require more intense 
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review within a practice. 249 Quality is a very difficult concept to pursue and 
educational use of performance indicators may be one realistic way forward. 
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Table 2.1 Prescription items and cost of prescribed medicines per head per year in 
EC countries33,250 
Country Rxs per 
head 1980 
Rxs per 
head 1990 
Annual drug costs 
per head (f) 1991 
Annual drug costs 
per head (f) 1995 
France 27.6 38.0 112 202 
Italy 19.9 38.0 107 106 
Spain 14.4 20.1 64 112 
Germany 14.3 14.8 91 154 
UK 6.6 7.6 64 88 
Netherlands 3.9 4.2 53 110 
Table 2.2 A brief history of therapeutic formularies and essential drug lists7l 
1970 to Development and evaluation of hospital formularies in Italy and the US; 
1975 Systematization of the national drugs lists with guidelines in Scandinavia; 
First essential drugs lists in developing countries such as Mozambique and Peru 
1977 Publication of WHO Technical Report Series No. 615 (The selection of 
essential drugs: report of a WHO Expert Committee) 
1978 WHO Declaration of Alma-Ata on Primary Health Care Publication of WHO; 
Regional Office for Europe's first book on drug utilization studies (WHO 
Regional Publications, European Series, No. 8); 
A formulary tailored for general practice 
Creation of WHO Action Programme on Essential Drugs 
1981 Creation of periodic British National Formulary 
1985 After long debate, approval of limited lists of drugs in the UK for use by GPs; 
In the first half of the 1980s, publication of various problem-solving or drug- 
orientated therapeutic formularies for general practice, in for example Belgium, 
Nicaragua, Scandinavia, Spain (starting from Catalonia) 
1988 Fifth edition of the List of Essential Drugs (WHO); 
Clear and growing acceptance of general practice formularies in most developed 
countries; 
Availability of formularies with prescribing guidelines in many of the least 
developed countries such as Burkina Faso, Ghana and Zimbabwe 
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Table 2.3 The types of outcomes that can be measured by clinical trials 
Clinical outcomes Patient outcomes Economic outcomes 
Clinical endpoints Quality of life Cost minimisation 
Signs and symptoms Functional status Cost effectiveness 
Laboratory values General health perception Cost-benefit analysis 
Rate of mortality Satisfaction with care Cost-utility analysis 
Table 2.4 Model specification: source of variation by level of data collection251 
Level of collection 
Sources of 
variation 
Countries Regions GPs 
Morbidity Small Medium Medium 
Population Large Small Small 
Health system 
--- 
Large Medium Small 
rP-rofessional T Small Medium Large 
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Figure 2.1 The stages in the uptake of a new drug by a prescriber152 
awareness -> interest evaluation -> trial adoption 
no further interest rejection 
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CHAPTER THREE 
METHODS 
The research presented in this thesis consists of two distinct parts of the study, 
namely the main prescribing study and the two-stage Delphi prescribing influences 
questionnaire study. The methodology employed is presented separately. 
3.1 INTRODUCTION TO THE PRESCRIBING STUDY 
One outcome of the Bielefeld conference (Section 1.1) was agreement by delegates 
that the development and implementation of a European Formulary for general practice 
might improve the standard of prescribing with the provision of more rational, 
appropriate and safer prescriptions for patients of all European countries. Subsequently, 
a multidisciplinary group of approximately 50 delegates from 17 East and West 
European countries established a European Formulary Group with ten members forming 
the editorial board. Work then began on producing a European Formulary, based on the 
sound principles of clinical pharmacology and therapeutics, selecting drugs with proven 
efficacy, relative safety and where possible which were economic in use. It was agreed 
that the European Formulary should be designed to be presented in two sections: firstly, 
as a rapid consultation Formulary document, listing conditions and appropriate drug 
recommendations together with contra- indications, interactions, dosages, duration of 
action and side effects; and secondly, in the form of a more comprehensive Appendix 
providing referenced justification for the selected drugs. The European Formulary was 
also to include general guidelines on rational prescribing. 
In 1994, after 16 meetings, a draft European Formulary with Appendix had been 
developed. A trial to evaluate the combined effectiveness of the European Formulary in 
association with an educational intervention upon European general practice prescribing 
was granted three years BIOMED funding between May 1994 and May 1997. The 
study was planned to involve 11 European countries, namely Belgium, England, France, 
Ireland, Italy, the Netherlands, Northern Ireland, Norway, Portugal, Scotland and Spain 
and to be centrally co-ordinated from Newcastle upon Tyne. Those individuals who 
were actively involved with the development of the European Formulary agreed to act 
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as national co-ordinators in each of the eleven European countries. Their role included 
the recruitment of local GPs to the study, the collection and translation of data and the 
delivery of the educational intervention. Centres in other European countries originally 
considering participation in the study included Gottingen and Wuppertal in Germany 
but withdrew due to insufficient finance as it was considered that GPs would only 
participate in research if they received adequate remuneration. Nevertheless, German 
representation on the Editorial Board of the European Formulary continued to play an 
active role in its on-going development. Annual weekend meetings for the co- 
ordinators and a research team were planned to take place in the spring each year in 
Newcastle upon Tyne, until termination of the funding in 1997. My input for these 
meetings included discussion of the progress of the study; planning of the content and 
implementation of the educational intervention and feedback on the prescribing data. At 
the meetings, time was set aside for discussing the update of the European Fonnulary. 
3.1.1 Aims 
3.1.1.1 Main aim 
9 To determine the effect of a consensus-based European Formulary as part of 
an educational intervention on the prescribing practices of GPs. 
3.1.1.2 Subsidiary aints 
9 To record and evaluate prescribing in the different European countries and to 
compare and contrast differences in diagnoses and use of drugs with regard to 
the number of prescribed items and types of medication prescribed. 
e To investigate the extent to which the drugs prescribed in the different European 
countries are in agreement with those recommended in the Formulary and the 
extent to which the proportion of presenting patient diagnoses are covered by the 
Fonnulary. 
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e To assess the prescribing patterns using performance indicators after 
implementation of the educational intervention, in order to see in which 
countries prescribing patterns changed in line with the recommendations of the 
European Formulary. 
3.1.2 Prescribing performance Indicators 
Generic indicators measured were whether: 
* the proportion of total new drugs prescribed for a given condition as 
recommended in the European Formulary increased. 
* the range of different drugs being prescribed was reduced. 
* the number of consultations resulting in a prescription reduced where 
diagnosis associated with no prescription reflected European Formulary and 
educational intervention advice. 
More specific indicators measured were whether: 
* prescribing performance improved by investigating the uptake of the 
European Formulary Group's recommendations, in certain therapeutic areas. 
,* additional markers identified from reviewing the relevant prescribing 
literature, could also be explored in order to assess the prescribing 
performance of the GPs in the different countries. 
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3.1.3 Methods 
3.1.3.1 Design 
The study design was a multi-centre controlled trial involving up to 40 participating 
GPs recruited by a co-ordinator in each of the eleven countries listed previously 
(Section 3.1). Within each country, the participating GPs were randomised into two 
groups; one was to receive the European Formulary and educational intervention (the 
study group) while the second (the control group) received neither the Formulary nor 
the intervention. In countries where GPs operate in group practices, randomisation was 
conducted at the practice level to avoid contamination between control and study groups 
which could otherwise have occurred within practices (i. e. no two doctors in the same 
practice were randomised to different groups). 
3.1.3.2 Subject sample 
No finances were available from the research grant to reimburse the GPs' time for 
participation in the trial and so the only incentives were the availability of feedback 
from the project analyses three years later and access to the educational intervention, 
which only half the GPs were programmed to receive within the study period. With this 
in mind, each co-ordinator attempted to recruit 40 GPs to participate in the trial, half of 
whom would form the study group and the other half the control group. For GP 
confidentiality and data management purposes, the co-ordinators numbered each control 
group I to 20 and each intervention group 21 to 40. 
3.1.3.3 Ethical considerations 
Ethical permission for this study was not required since patients' medical care was 
not being adversely affected and the intervention only involved the doctors concerned. 
In addition the information recorded by the GPs was anonymous as each patient was 
identified only by a number. 
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3.1.3.4 Information to GPs 
All the GPs who were recruited to the trial received project guidelines together with 
standardised data recording forms and illustrated examples of completed ones (Annex 2 
and 3). The guidelines were translated into the appropriate language by each national 
co-ordinator and they explained clearly and concisely how the data record forms were to 
be completed. 
). 1.3.4.1 Pilot study 
The data recording forms issued to the GPs and the information provided was based 
on a relatively small scale pilot performed by the co-ordinators who also worked as GPs 
part-time. Co-ordinators kept a record of all patients seen over a two week period and 
the information recorded included the patient's name, age, diagnosis and treatment 
given. 
3.1.3.5 Data recording 
3.1.3.5.1 Phase I 
Each participating GP recorded two sets of data, the first time period (Phase 1) of 
data recording being in the autumn of 1994. The GPs were asked to record information 
from consecutive face-to-face consultations until a total of 200 different patient drug 
prescriptions had been written. Where a drug was prescribed, the doctor recorded the 
name of the drug, whether the drug was a single active entity or part of a combination 
preparation. Also recorded was one of four possible factors which influenced the 
prescribing of that particular drug preparation, identified by a code letter, as follows: 
R where a drug was prescribed as a regular repeated prescription item. 
where a drug was prescribed as directed by a hospital or specialist. 
A where a drug was prescribed and requested by the patient, as a result 
of having been prescribed the drug by another doctor previously. 
N where a drug was prescribed for a patient's new problem uninfluenced 
by any previous prescription the patient had received. 
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Other recorded details included the patient's age (to the nearest whole number), sex 
and diagnosis(es) where appropriate. The GPs were asked to record a diagnosis for 
every drug prescribed, even if there was more than one drug for the same diagnosis and 
in addition they were asked to clearly indicate which drug was associated with which 
diagnosis. Finally, the GPs were also asked to record details of any intervening 
consultations where a prescription had not been issued. 
The diagnostic data were translated into English as necessary by the national co- 
ordinators. Completed data sets were then sent to Newcastle upon Tyne for manual 
coding and computer data entry by the author GJ. Specific drug and diagnosis coding 
frames were developed, which were diverse enough to allow for the variety of 
prescribing practices across Europe and to facilitate the data coding process 
(Section 3.1.3.6) 
3.1.3.5.2 Phase 11 
To measure the effects of the educational intervention, the second time period 
(Phase II) of data collection by the participating GPs was in the autumn of 1995, twelve 
months after the first period. Prior to Phase 11, the GPs who were part of the study 
group received the educational intervention at the beginning of the autumn. The same 
fields of data were required to be recorded in Phase 11, as described above in time 
Phase I (Section 3.1.3.5.1). 
3.1.3.6 Coding Frames 
Both the drug and diagnosis coding systems were specifically developed (by GJ) 
for the study as outlined in detail below. 
3.1.3.6.1 Diagnosis codes 
The diagnosis coding frame consisted of two types of codes: two digit codes for 
those diagnoses covered by the European Formulary and three digit codes for any 
others. Of the latter, several diagnoses were not explicitly mentioned in the European 
Formulary but could be considered to be implicitly referred to in the European 
Formulary. Two examples of these 'half-way house' type diagnoses included; 
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ischaemic heart disease (IHD) and bronchitis. IHD can mean that the patient is being 
treated for either angina pectoris or treatment following a myocardial infarction, or 
possibly both, and many GPs used the label IHD when recording the patient's diagnosis. 
The treatment strategy for both these conditions was discussed separately in the 
European Formulary but as the term IHD was not explicitly stated, it was decided to use 
an additional code where this was recorded. With the second example bronchitis, many 
GPs recorded this only as the patient diagnosis, without specifying whether it was either 
acute or chronic. The European Formulary discusses lower respiratory tract infections 
which includes acute bronchitis only so it was decided to give both bronchitis and 
chronic bronchitis two additional separate diagnoses codes. In total, 173 diagnoses 
codes were utilised, 66 (Annex 4) representing areas covered by the Formulary and 103 
(Annex 5) further codes representing conditions outside the scope of the European 
Formulary. The non-Formulary diagnoses codes were added after referring to the ninth 
version of the International Classification of Diseases. 252 
The layout of the European Formulary was broadly based on the British National 
Formulary (BNF)6 classification system but some therapeutic sections were further 
subdivided; for example, allergy formed a section heading of its own in the European 
Formulary whereas in the BNF, allergy is included within the Respiratory System 
Chapter. Overall, the European Formulary consisted of eighteen clinical therapeutic 
section headings which as previously mentioned differed from the BNF in that its focus 
was specifically concerned with use in primary care only and therefore also included a 
section on drugs held in the 'doctor's bag'. 
3.1.3.6.2 Drug codes 
The drug coding frame was based on the British Read Codes Classification 
system. 253 An up-to-date list of alpha-numeric Read Codes was obtained in February 
1995 and converted into four digit numeric codes falling between 0001 and 9999 as this 
was considered to be the optimum format for manual coding purposes. 
254 For ease of 
reading, the list was sorted into lower case alphabetical generic drug names in clinical 
therapeutic chapters equivalent to the BNF. The drug database had to be diverse enough 
to allow for the wide range of active drug entities prescribed in the participating 
countries and yet practical to use. To make this list more manageable, certain drugs 
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were deleted which would not be expected to be routinely prescribed in primary care for 
example many cytotoxic drugs. Adequate space was left between each of the 
therapeutic chapters to enable additional drug entities to be added as the coding of data 
from the different countries progressed. The European Formulary listed 126 drugs, their 
selection having been based on efficacy, safety, cost and availability in the participating 
countries. As a result, all the recommended drugs were already included within the 
Read Codes Classification. Overall, 1,616 drug codes classified into eighteen 
therapeutic chapters were cited in the study. Chapters I to 15 were synonymous with 
the corresponding BNF chapters. Chapter 16 consisted of miscellaneous supplementary 
drugs, Chapter 17 included appliances, dressings, reagents and borderline substances 
and Chapter 18 included unknown and unidentifiable drugs. In Chapters 16 to 18, 
single codes were given to groups of drugs, for example 9501 represented appliances, 
dressings and reagents. Unknown drugs were ones where the writing was illegible, 
whereas unidentifiable drugs were ones which could not be traced from the information 
sources utilised. This could have been because, firstly, they were herbal or 
homoeopathic derivatives and possibly excluded from more pharmacologically based 
drug manuals; secondly, they may have been recently granted a licence in a country; or 
thirdly, they may have been spelt incorrectly hindering their identification. Unknown 
and unidentifiable drugs represented less than 1% of the total number of drugs recorded 
in this study. 
3.1.3.7 Diagnosis and drug coding procedure 
The process began with (GJ) coding the data from non-English speaking countries 
as it was anticipated that this would present the biggest task which should be tackled at 
an early stage. The data collated in the project were of varying quality both within and 
between countries. Original copies of translated data sets with adequate space left for 
coding purposes, which had either been computer generated, typed or neatly printed, 
were considerably more acceptable than photocopied, untranslated forms written in an 
illegible cramped up style at the other extreme. Examples of where slight variations in 
hand writing caused problems with identification, included adoption of the following 
abbreviated diagnoses terminology by participating GPs: 
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PUO pyrexia of unknown origin 
P UD peptic ulcer disease 
P VD prolapsed vertebral disc 
P VD peripheral vascular disease 
PID pelvic inflammatory disease 
Patient symptoms were frequently recorded by the GPs, rather than specific 
diagnoses, so the coding frame had to be developed to be sufficiently versatile but still 
capable of enabling rapid reference. Where combination drugs were prescribed, 
additional diagnosis codes were matched with each separate active drug entity 
ingredient. Although the GPs were asked to record a diagnosis for every drug 
prescribed, even where there was more than one drug for the same diagnosis this was 
sometimes inadequately done. As a result, clustering of diagnoses and drugs was 
sometimes a problem, leaving one to interpret which drug had been prescribed for which 
diagnosis. In these situations, links between diagnosis and drug were only made where 
this was considered unambiguous. 
Generic prescribing is not widely used around Europe and even in countries where 
it is practicable and encouraged for example in the UK, prescribers may still use 
proprietary drug names. Often co-ordinators translated the commonly occurring 
proprietary drugs on the recording sheets but left the remainder to be identified. All the 
generically named active drug entity ingredients present in combination drugs had to be 
identified and coded, which resulted in a complex investigative exercise to reveal the 
ingredients of unusual proprietary drug compound formulations which are especially 
common in Belgium and the southern European regions. Also generic drugs with added 
proprietary names, for example Salamol (salbutamol) appeared to be particularly 
common in the Republic of Ireland. For this process, a variety of reference documents 
were used to identify the unknown and untranslated drugs as follows: 
a) Martindale Extra Pharmacopoeia, the 30"' and 31" editionS20,255, which 
describe many proprietary preparations available in a wide range of countries, all 
their ingredients (the majority of which have separate entries as monographs) 
and their indications for use; 
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b) the World Health Organisation (WHO) Anatomical Therapeutic Chemical 
(ATC) classification indexes (1995 and 1996), 256 
c) a variety of sources including regional and national formularies available in 
the different countries. 257-259 
The use of these reference documents was essential, not only for identification 
purposes, but also when deciding in which relevant section to classify and code 
additional drugs on the same prescription as some drugs, for example aspirin and 
propranolol, can be used for a variety of indications. For the coding of oral 
contraceptives and hormone replacement therapy (HRT), it was decided to give the 
preparations one standard code each, instead of coding all the separate drug entities as 
follows: 
3617 oestrogen and progestogen combined oral contraception 
3625 progestogen only oral contraception 
3003 conjugated oestrogens with progestogen for HRT 
3083 oestrogens only for HRT 
3059 progestogens only for HRT 
3632 ethinyloestradiol (when combined with 7229 below) 
7229 cyproterone acetate where recorded for the treatment of acne. 
The active ingredients cyproterone acetate combined with ethinyloestradiol which 
when combined together are indicated for the hormonal treatment of acne as well as for 
contraception were separately coded. 
Problems encountered in the coding procedure were successfully dealt with as they 
presented but were instrumental in prolonging the coding procedure. Once all the data 
from Phase I had been coded, a month was devoted to cleaning up the data and editing 
codes where necessary. This cleaning and editing exercise was again repeated on 
completion of the coding from Phase 11. 
91 
Methods 
3.1.3.8 Data Processing Management 
The data management was split into three distinct parts. In order to manage the 
data, various computer programs were written in FONTRM 77 and compiled to run on 
Newcastle University's UNIX machines. 
3.1.33.8.1 Data entry systems 
A menu-driven data entry system was developed by a computer/medical statistician 
advisor and installed on the project computers. The system managed eleven fields of 
information: country; data period Phase I/Phase 11; study/control group GP; GP number; 
patient number; patient age; sex; diagnosis code; drug code; combination drug/non- 
combination drug; and category of prescription. 
1.3.8.2 Data analysis systems 
After data entry, data analysis systems were run on Newcastle University's UNIX 
machines. Access to these was through terminal software running on computers linked 
to the University Main Frame. These analytical systems linked the drug, diagnoses, and 
survey data to allow analysis by country, GP, patient category, drug category and/or 
diagnosis category. 
3.1.3.8.3 Data processing 
Using purpose-written software, a menu-driven data processing program was 
created by the computer/medical statistician advisor. This complemented the data entry 
system and facilitated extraction of selected data to be investigated further. 
3.1.3.9 Statistical analysis 
Statistical analysis was done using the SPSS 7.0 statistical analysis package. For 
the primary response variables (the percentage of drugs used, the range of items 
prescribed and the percentage of patient-doctor consultations for a condition), paired 
differences were calculated for each participating GP and analysed using analysis of 
variance (ANOVA). Results are expressed as means and standard errors of the mean 
(mean ± SEM) where measuring differences between populations and standard 
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deviations are stated where describing the spread within a population. Use of the term 
'study group GPs' in this thesis is synonymous with 'intervention group GPs'. 
When performing the necessary searches in the database before conducting the 
statistical analyses, all the searches involved linking/matching drugs prescribed to their 
diagnosis, except where stated. This matching ensured that additional drugs a patient 
may be receiving for other presenting conditions were excluded from the analysis. A 
search involving no matching of drugs to diagnosis identified all the consultations for a 
condition (whether or not they resulted in a prescription), in order to establish the 
proportion of GP consultations for that condition. On investigating the levels of 
concordance with drugs prescribed in the European Formulary and the range of drug 
items prescribed, the analyses were performed considering those recorded as 'N' drugs 
only (Section 3.1.3.5.1) unless where explained otherwise. It was considered that newly 
prescribed drugs would be a more realistic measurement of the GPs' prescribing 
practice, uninfluenced by hospitals or previous prescriptions as other researchers have 
suggested. 260 In order to assess whether the range of items prescribed would be 
reduced by the educational intervention in certain situations, the absolute range of items 
prescribed was quoted. 
3.1.3.10 Content, development and dissemination of the educational intervention 
The trial sought to evaluate the effect of the European Formulary and the 
intervention exercise in the areas of antibiotics; non-steroidal anti- inflammatory drugs 
(NSAIDs); and the prescribing of drugs of limited proven clinical value. Rational 
prescribing of these three groups of drugs was thus to form the basis of the educational 
intervention and to be delivered to the study group GP participants prior to the data 
recording of Phase 11. 
In 1995, at the annual weekend meeting of the co-ordinators (Section 3.1), time was 
spent finalising the plans for the dissemination of the European Formulary to the GPs 
and discussion also took place on what advice and instruction should be given by co- 
ordinators to the GPs. It was agreed that the co-ordinator in each country would be 
responsible for delivering this educational package and it was recognised that the 
intervention protocol needed to be standardised so that the procedure could be carried 
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out as consistently as possible in each country. Although the content of the educational 
intervention was standardised, the style of its administration would obviously vary from 
co-ordinator to co-ordinator in each country and this could not be controlled. 
It was decided that the European Formulary along with appropriate sections of the 
more detailed Appendix would be disseminated to the doctors in the intervention group 
at the beginning of the autumn of 1995, approximately two weeks before the date of a 
predetermined meeting. The GPs would receive their copies together with some clear 
and concise messages offering guidance on rational prescribing in each of the three 
therapeutic areas being targeted. It was anticipated that the GPs would consider these 
messages and discuss them at the scheduled meeting. It was also felt that this approach 
would increase the doctors' commitment to attend. 
3.1.3.10.1 NSAIDs -main messages261,262 
* Critical assessment of the use of NSAIDs is needed particularly where minor 
or self-limiting ailments present, for example sprains and strains. If drug 
intervention is required, simple analgesics should initially be used. 
* NSAID use in elderly patients with osteoarthritis should be minimised. 
* The duration of NSAID therapy should be limited when possible. 
9 Particular attention should be made to the effects of NSAIDs on elderly 
patients and the lowest effective dose used. 
e NSAIDs with a long half-life, for example the oxicams, tend to be associated 
with more severe side effects and consequently their use should be 
discouraged, especially in the elderly. 
* Special caution is required in prescribing NSAIDs for patients with a history 
of asthma, gastro -intestinal complications especially ulcers, renal problems, 
inflammatory bowel or diverticular disease and with concomitant intake of 
aspirin, diuretics, ACE inhibitors and steroids. 
e Where a topical formulation is required a rubefacient should be used as 
evidence implies that topical NSAIDs are not cost-effective. 
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* GPs should prescribe from a small range of NSAIDs. 
9 The European Formulary Group (EFG) recommends that simple analgesics 
should be used where possible before NSAIDs. Where NSAIDs are indicated 
the EFG recommends: 
first-line - ibuprofen 
second-line - diclofenac or naproxen 
third-line - indomethacin 
These drugs are predominantly the most effective, safe and economical 
NSAIDs as supported by evidence from the Committee of Safety of 
Medicines (CSM) in the UK. 263 
3.1.3.10.2 Antibiotics -main messages261,262 
Antibiotic prescribing covers the treatment of a vast range of infections and so it 
was decided to target the management of urinary tract infections (UTIs) and infections 
associated with the respiratory tract. In all common infections, first line use of third 
generation broad spectrum cephalosporins, fluoroquinolones and the new macrolides 
should be avoided or strictly limited. They are relatively expensive and unjustified use 
increases the likelihood of microbial resistance. 
UrinM tract infections 
* UTIs are more common in women and present as either lower or upper types. 
* Urine cultures should always be taken in men with lower UTIs because of 
possible complications and treatment duration should be 7-10 days. 
e In women with single cases of uncomplicated lower UTIs, culture is not 
usually necessary but care needs to be taken such as urinating after sexual 
intercourse to prevent the ascent of the infection. 
e Upper UTIs may coexist with lower UTIs and if a3 day antibiotic course is 
ineffective then a renal infection should be suspected. 
e In case of the latter, an early start of effective drug therapy is important, 
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especially in children. Hospitalisation and parenteral therapy may be needed. 
* Asymptornatic bacteriuria should be treated in pregnant women and children. 
9 The EFG recommends UTI treatment with: trimethoprim or amoxycillin. 
Where these drugs fail or are contraindicated then norfloxacin or consistent 
prescri ng of an alternative quinolone depending on availability and 
comparative cost per country is recommended. 
Upper respiratory tract related infections 
The upper respiratory tract related conditions covered by the Formulary include 
acute otitis media, acute pharyngitis / tonsillitis and acute sinusitis. For the purposes of 
this thesis we only investigated prescribing for acute pharyngitis / tonsillitis. 
Acute pharyngitis / tonsillitis 
* These conditions are very common, usually viral in origin and can therefore 
normally be treated adequately with paracetamol. 
* Delaying treatment to await the results of culture samples does not increase 
the risk of complications. 
9 When a swab confirms a bacterial infection, phenoxymethylpenicillin 
(penicillin V) is the drug of choice or alternatively erythromycin (beware of 
interactions) for patients allergic to penicillin. 
9 The drugs recommended by the EFG are phenoxymethylpenicillin, erythromycin 
and paracetamol. 
Lower respiratory tract infections 
* Prescribing of antibiotics for acute bronchitis is almost always irrational. 
Prescribing of antibiotics to treat acute exacerbations of chronic bronchitis is 
more acceptable although still controversial. 
Previously well children and adults with pneumonia usually recover well with 
a prescription for a penicillin or erythromycin but beware of interactions with 
96 
Methods 
the latter. 
" Rare pathogens should be suspected in patients at risk from pre-existing 
conditions and hospitalisation may have to be considered. 
" GPs should prescribe from a small range of antibiotics. 
" The four drugs recommended by the EFG are: 
amoxycillin, benzylpenicillin, doxycycline and erythromycin. 
3.1.3.10.3 Limited perceived clinical value drugs - main messages 
This group could potentially include many different drugs; however, this area of 
prescribing is controversial and there are also legal implications of labelling drugs as of 
'little value'. Consequently, for the purposes of the intervention it was agreed that: 
cerebro-active drugs; vitamins; tonics and appetite suppressants would be the drugs 
targeted and discouraged from prescribing. This area of prescribing is not presented or 
discussed in this thesis. 
3.1.3.11 Selection of the prescribing data analysed in the thesis 
The data analysed from the main prescribing study in this thesis are divided into 
three sections. The first section compares general features of the data in terms of the 
numbers of participating GPs in the different countries, patient characteristics, 
prescription details, overall concordance with the European Formulary and the most 
commonly presenting diagnoses and drugs used. The second one investigates the main 
areas of prescribing targeted in the educational intervention namely antibiotics and 
NSAIDs but excludes drugs of limited clinical value. The third section considers 
prescribing patterns for hypertension and asthma, two areas covered by the European 
Formulary but not targeted in the educational intervention. 
Of the drug groups targeted in the educational intervention, the BIOMED study 
analyses fundamentally focused on whether overall prescribing patterns in these areas 
showed changes towards the drugs recommended in the European Formulary. These 
analyses were limited in that there was no linking or matching of drugs prescribed to 
diagnoses and therefore as well as not revealing which drugs were being prescribed for 
which conditions, it could not be inferred whether prescribing of the recommended 
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drugs was appropriate or even necessary For example, prescribing of broad spectrum 
antibiotics such as tetracyclines were discouraged when acute pharyngitis or tonsillitis 
presents but as a result of tetracyclines being recommended in the European Formulary 
for other conditions, their inappropriate use could artificially bias concordance levels 
unless analyses were performed linking drugs to diagnoses. By extracting the 
prescribing data, linking drugs to their appropriate indications in the European 
Formulary, the results presented in this thesis give a more detailed accurate and 
meaningful comparison and evaluation of prescribing patterns. 
Exploring prescribing patterns for conditions included in the European Formulary 
but not targeted by the educational intervention enabled one to determine how 
successful the dissemination of written prescribing recommendations alone were in 
improving prescribing. Hypertension and asthma therefore were primarily selected 
because of their common occurrence in the study; they were the first and sixth most 
frequently occurring diagnoses respectively. As well as it being logical to analyse areas 
where data would be most abundant, hypertension and asthma are distinct diagnoses as 
opposed to those symptoms, although both present with different levels of severity 
which could not be reliably investigated. The results are presented in Chapters 4,5 and 
6. 
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3.2 INTRODUCTION TO THE PRESCRIBING INFLUENCES STUDY 
The prescribing data from the European Formulary project presented in Chapters 3, 
4 and 5 have indicated that there are wide variations in drug utilization by GPs between 
the participating countries. It was postulated that additional knowledge of the factors 
influencing the GP participants prescribing could contribute to a more rigorous 
interpretation of these data. From reviewing the literature of the factors influencing 
prescribing (Section 2.2), no previous study appears to have attempted to ask a pan 
European group of GPs to rate the importance of what they perceive to have influenced 
their individual prescribing. 
3.2.1 AIMS 
3.2.1.1 Main aims 
e To identify what the main factors are that GPs perceive to influence their 
prescribing in the different countries. 
e To compare the demographic profiles and working environment of the sample 
of GPs from the eight European countries. 
3.21.2 Subsidiary aims 
* To enable separation of the reported influences into different categories. 
e To obtain a consensus-based list of influences ranked in order of perceived 
importance. 
9 To consider how enviromnental and personal characteristics could contribute 
to variations in prescribing behaviour. 
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3.2.2 Pilot study 
The questionnaire evolved from one initially designed and piloted in the summer of 
1996 among twenty members of the Department of Primary Health Care in Newcastle 
upon Tyne. The twenty participants had a variety of medical and non-medical 
backgrounds and all were engaged in research at the time. Shortly afterwards in 
November 1996 a revised questionnaire was further piloted among 27 GPs from the 
Newcastle area who had participated in the European Formulary Project. Of the 
Newcastle GPs, 26 responded and feedback from this exercise resulted in further 
amendments being made to the questionnaire. 
No ethical committee approval was felt to be required for this study to proceed. 
3.2.3 Subject sample 
The questionnaires were circulated to 241 GP participants from eight countries who 
had participated in the main controlled trial investigating the effect of a European 
Formulary as part of an educational intervention. This sample differed slightly from the 
236 GPs whose data was utilised in the main prescribing study in that seven additional 
GPs from Belgium (five Flemish speaking and two French speaking) whose earlier 
prescribing data could not be analysed were also included. One English and one 
Spanish GP who dropped out of the study between Phases I and 11 were excluded as 
they changed locations and were not traced. 
3.2.4 Questionnaire number one 
A short questionnaire was developed consisting of 13 questions (Annex 6). Twelve 
were simple 'tick box' or 'one word answer' style questions on demographic details and 
the working environment of the doctor. Question number 13 was in the form of an 
6open' style question. The length of the questionnaire was limited to fit one side of A4 
paper in order to optimise the response rate. The final question was formed to generate 
a staged Delphi study. 
264 The Delphi design technique is an approach in which 
participants respond to open question(s) by generating ideas that are subsequently used 
to form the basis of the questions for later qualitative rounds. 
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Translations of questionnaire stage one into the appropriate languages, namely 
Dutch, French, Italian, Spanish, and Portuguese, were performed by pharmacists or 
doctors independent of the project from each of the non-English speaking countries. In 
addition, a standard letter for distribution with the questionnaire to each of the 
participating GPs (Annex 7) was translated by each of the countries' co-ordinators. 
3.2.5 Questionnaire number two 
After distribution and return of the completed stage one questionnaires, perceived 
influences generated by the GPs in response to question 13, the 'open' style question, 
formed the basis of the second questionnaire (stage two). Prior to the dissemination of 
the second questionnaire (Annex 8), all the responses received from the open ended 
question 13 were separated into different categories or themes of likely influences 
(Annex 9). In this second round, the GPs were presented with a list of all the perceived 
influences of the GP participants under category headings and asked to rank the 
categories in order of decreasing importance which he/she believed to have acted on 
their personal prescribing since the autumn of 1994. As previously, with the help of the 
co-ordinators the necessary translations were obtained as appropriate, including a 
standard letter for distribution with the questionnaire to each of the participating GPs 
(Annex 10). 
3.2.6 Validation process 
In order to validate the questionnaires as part of a quality control procedure, each 
co-ordinator was sent the translation of Questionnaire number one (independently 
obtained) sealed in an envelope with a copy of an English version in a separate 
envelope. Each co-ordinator was asked to back translate the translated questionnaire, 
before comparing this with the English version. The co-ordinators were asked to 
translate the stage two questionnaire which was much simpler; consequently, from the 
experience gained, it was considered that no back-translation was necessary. 
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3.2.7 Mailing schedule 
The addresses of the GP participants in the different countries were requested and 
obtained from the co-ordinators which enabled control of the distribution of the 
questionnaires from Newcastle upon Tyne. This was necessary so that by mailing 
questionnaires to GP participants furthest away from Newcastle in a staggered process, 
this would facilitate their arrival at all destinations on a similar time scale. 
Both Questionnaires numbers one and two were mailed with an International Reply 
Paid Coupon to GPs outside the UK and with Reply Paid Envelopes enclosed to GPs 
within the UK. At the bottom of each questionnaire there was a GP identity number 
which was used to identify the original questionnaire upon its return. With the Delphi 
approach, it is recommended that subsequent rounds of questionnaires need to be sent 
out at fairly precise six weekly intervals. 264 However, due to the geographical distance 
over which the exercise was taking place, extra time had to be allocated for both the 
outward and return postage time as well as for the follow-up reminder questionnaires. 
In order to attempt to achieve a response rate in excess of 60%, one follow-up reminder 
questionnaire to all non-responders was distributed in the first round which resulted in 
an interval of approximately five months between staged Questionnaire number one and 
Questionnaire number two being sent out. In the second round two follow-ups were 
necessary and non-responders to Questionnaire number one were sent both 
questionnaires. 
As an added incentive for the GPs to respond, a six page summary was included 
with Questionnaire number one, based on the final report sent to the BIOMED sponsors 
upon termination of the funding for the European Formulary project. In addition, the 
GPs were offered feedback from the final results of the two-stage Delphi questionnaire 
study upon completion of the research. Finally, it was stressed to all the GPs that the 
contents of their questionnaires would remain anonymous. 
3.2.8 Data entry and analysis 
The data in this questionnaire study was managed in Access for Windows 95 
Version 7.0. Tables called QUESTIONNAIRE I DATA and QUESTIONNAIRE 2 
DATA were created to hold all the information from Questionnaires number one and 
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two upon their return in various fields. All information collected from each returned 
questionnaire was coded prior to entry into the database tables as necessary. All the 
codes were numerical; for example, 'yes' and 'no' were substituted with 'I' and '2' 
respectively. The Access program also enabled address labels to be prepared and by 
creating a 'Returned Questionnaire' field in the database, non-respondents could be 
easily identified in order to send out reminder questionnaires. 
The data, once entered into the database tables were analysed using a series of 
queries (questions about data stored in tables). Once the data were entered into the 
database, 'queries' were designed and run to retrieve certain information for the 
necessary comparisons to be made, for example all GPs from a certain country. 
For Questionnaire number two, each response was weighted such that a category of 
influence positioned in first place (i. e. representing the most influence), received a score 
of seven, a category in second place received a score of six and so on until the category 
of least importance received a score of one. 265 All categories were scored as it is 
assumed that they all have some degree of influence irrespective of whether 
acknowledged by the GP participants from each country. The results are presented in 
Chapter 7. 
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CHAPTER FOUR 
PRESCRIBING STUDY 
GENERAL COMPARATIVE RESULTS 
4.1 NUMBERS OF PARTICIPATING GPs 
In total there were 236 doctors who participated in the prescribing study with 217 
valid matching pairs of GP data sets from Phase I and Phase 11 (Table 4.1). Of these, 
there were 116 study and 10 1 control GP pairs 
only achieved in Italy and Scotland in Phase 1. 
4.2 PATIENT CHARACTERISTICS 
4.2.1 Numbers of patients consulting 
The target of recruiting 40 GPs was 
Data were recorded on 101,544 doctor-patient consultations in this study. 
Statistically significant differences were found between the countries (p <0.001) in the 
number of patients consulting but not between the control and study groups within 
countries (p = 0.80) (Table 4.2). There were found to be no statistically significant 
differences (p = 0.08) between Phases I and 11 in the number of patients who consulted. 
Overall there was an average increase of 6 patients per GP (3.34). After the educational 
intervention, the differences between the control and study groups were not significant 
either (p = 0.67). 
In Belgium, data was not provided on patients who consulted without receiving a 
prescription, therefore only approximately 200 patients were seen on average (Table 
4.2). There were slight variations in the numbers within each of the subgroups (Phase 
1/11 control/intervention groups) though, which was due to factors such as the 
prescription data including patients receiving vaccines during consultations. Many of 
the GP participants recorded patients receiving vaccines as a form of treatment but for 
the purposes of this study they were not included in the coding of the drug data. 
The Portuguese GPs did provide data on patients who consulted without receiving a 
prescription but most GPs there, failed to reach the target of 200 patients who received 
prescriptions. 
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The data from England, Northern Ireland and Scotland showed a similar trend with 
the highest numbers of patients being recorded in these regions. This is indicative of a 
lower prescribing rate in the UK than in the other participating countries. 
4.2.2 Gender profiles of patient consultations 
The differences in the proportion of consultations for male patients between 
countries were found to be highly significant (p <0.001) in both Phase I and 11 but there 
were no significant differences within countries or between Phases (Table 4.3). 
Differences in the proportion of male consultations between the control and study 
groups after the intervention were also not statistically significant (p = 0.66). There 
were highly significant differences in gender between countries (p <0.001) but not 
between control and study groups (p = 0.08). 
In all of the countries, the proportions of males consulting were below the 50% 
level, indicating that the majority of consultations were for females. In Belgium, the 
proportion of consultations for males was much closer to females compared with any 
other country. 
4.2.3 Age profiles of patient consultations 
The average patient age in Phase I was 45.9 years (0.09) compared with 45.1 years 
in Phase 11 (0.11). Although this difference in age only represents approximately 10 
months, this was statistically significant (p = 0.02). The average age of patient in the 
study group overall was 44.9 years (0.1) compared with 46.2 years (0.1) in the control 
group. This difference in age was of borderline statistical significance (p = 0.04). 
4.3 PRESCRIPTION DETAILS 
4.3.1 Proportion of consultations resulting in a prescription 
Highly significant differences were found between the countries (p <0.001) but not 
within countries in the proportion of consultations resulting in a prescription (Table 
4.4). Between Phases I and 11, there were found to be statistically significant differences 
(p = 0.03) in the proportion of patients consulting who received prescriptions with an 
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average decrease of 2% (0.8) per GP. Differences between the control and study groups 
after the intervention were not significant (p = 0.45). 
A higher proportion of patients received prescriptions in all the southern European 
countries compared with the English speaking countries. England was the only country 
where there was a notable increase in the number of consultations resulting in 
prescriptions within the study group after the intervention. Although this was contrary 
to one of the objectives of the intervention exercise, this difference was not statistically 
significant (p = 0.71). 
4.3.2 Categories of prescriptions 
Overall 42% (1) and 41 % (1.1) of prescribing were N drugs in Phase I and Phase 11 
respectively (Table 4.5). Category A prescriptions accounted for 11% (0.7) and 10% 
(0.6) of drug items in Phase I and Phase Il respectively. Drugs prescribed by repeat 
prescription accounted for 37% (1) and 38% (1) of items and hospital/specialist 
prescribed drugs accounted for 9.1% (0.7) and 9.2 % (0.6) of all drugs prescribed for in 
Phase I and Phase 11 respectively. 
There was a high level of consistency in prescribing patterns within the countries 
from Phases I to 11. For category A drugs, the lowest levels were found in the control 
and study groups of Italy and the highest levels were found in England and Scotland for 
both Phases. England, Scotland and Northern Ireland had similarly low patterns of 
hospital/specialist initiated prescribing, in contrast to approximately one in four 
prescriptions in Spain fitting into this category. For newly prescribed items, the highest 
levels were found in Northern Ireland for both Phases and these were double those of 
Spain which consistently had the lowest levels of new prescriptions. Relatively high 
levels of repeat scripts were found in all countries 
4.3.3 Number and range of drug entities prescribed 
There were highly significant differences between countries in both the number and 
the range of drugs prescribed (p <0.001) excluding the Spanish data from the analyses 
(Table 4.6 and Table 4.7). There were also highly significant differences (p <0.001) 
between Phases with respect to both the number and the range of drugs used. Exclusion 
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of the Portuguese data from this analysis removed these statistical differences. After the 
intervention there was an average decrease of 29 drugs in the study group overall 
compared with a decrease of 21 drugs in the control group and this difference was 
statistically significant (p <0.001). With respect to the range, there was an average 
decrease in 12 drugs prescribed by the study group overall compared with only a 
fraction of a decrease by the control group after the intervention and this difference was 
also highly significant (p <0.001). 
The lowest number of drugs were prescribed in England, Scotland and Portugal but 
in the latter there was a lower volume of doctor-patient consultation data recorded and 
so one would expect a lower average number of drug entities prescribed there. The 
smallest ranges of drug entities prescribed were in England, Northern Ireland and 
Scotland. The largest range of drugs were found to be prescribed in Spain and despite 
only half the number of patient consultations being recorded by the Spanish GPs in 
Phase 11, the average range of drugs remained relatively high. 
4.4 FORMULARY CONCORDANCE 
4.4.1 Drug concordance with the European Formulary 
Highly significant (p <0.001) differences were found between countries in the 
variation in percentage of drug concordance with the European Formulary (Table 4.8). 
Overall in Phase I the level of concordance was 47.8% compared with 46.5% in Phase Il 
and this difference was of borderline statistical significance (p = 0.06). 
For all data combined, there was a 2.9% (0.7) increase in the proportion of 
prescribed drugs which were listed in the European Formulary for the study group 
compared to a reduction of 1.3% (0.6) in the control group. This difference was highly 
significant (p <0.001). There appeared to be notable increases in the prescribing of 
Formulary recommended drugs after the intervention in the study groups of Belgium, 
Italy, Northern Ireland and Portugal compared with their corresponding control groups. 
These differences were highly significant (p <0.001) in Italy and Portugal. In general 
the highest levels of Formulary concordance were found in England averaging about 
60% in each of the subsets, followed by Scotland. The lowest level of Formulary 
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concordance was found in Portugal, where approximately one in three drugs prescribed 
was listed within the Formulary. 
4.4.2 Diagnosis concordance with the European Formulary 
Highly significant differences (p <0.001) were found between countries in the 
proportions of diagnosis presentations covered by the European Formulary (Table 4.9). 
No statistically significant differences were found between Phase I and 11 (p = 0.37). 
Overall, the difference between the slightly higher proportion of diagnoses being 
covered by the Formulary in the study group compared with the control group after the 
intervention was not statistically significant (p = 0.26). The greatest increase in 
presenting diagnoses covered by the Formulary in the study group compared with the 
control group was in Belgium but this difference was not statistically significant 
(p = 0.17). In general, the management of presenting patient diagnoses in the 
Mediterranean countries, especially in Portugal, appeared to be covered to a greater 
extent by the European Formulary than in the other countries. 
4.5 MOST COMMON PRESENTING DIAGNOSES AND DRUGS USED 
4.5.1 Top ten Formulary and non-Formulary drugs 
Amoxycillin was the single most commonly prescribed drug overall from the 
prescribing data and the only antibiotic to feature in the top ten Formulary listed drugs 
(Table 4.10). Paracetamol was the second most commonly prescribed single component 
drug but its use in both combination and non-combination form combined would have 
made it the most commonly prescribed drug overall. Of the top ten most commonly 
prescribed Formulary drugs, four were indicated for cardiovascular related conditions 
and three represented pain/anti-inflammatory use. 
Co-amoxiclav was the most commonly prescribed non-Formulary recommended 
drug and one of two antibiotics to feature in the list of the top ten of these. When 
comparing co-amoxiclav and amoxycillin use 
it can be seen that the latter was 
consistently the antibiotic of choice compared with co-amoxiclav 
in all the countries. 
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Three of the top ten non-Formulary recommended agents were combination drugs, 
generally discouraged by the European Formulary. 
Overall the volume in terms of number of prescribed items that the top ten 
Formulary recommended drugs represented was approximately three times the use of 
the top ten non-Formulary agents 
4.5.2 Top ten Formulary and non-Formulary diagnoses 
Hypertension, whose management was covered by the European Formulary was the 
most commonly occurring diagnosis overall and the number one condition in all the 
countries except for England and Northern Ireland (Table 4.11). The top ten most 
commonly presenting diagnoses covered by the Formulary accounted for almost one 
third of the total patient diagnoses. In contrast the top ten most commonly presenting 
patient diagnoses not covered by the Formulary represented approximately 13% of 
conditions. The most commonly presenting non-Formulary diagnosis was low back 
pain. 
4.6 DISCUSSION 
Of the GPs participating in the study, dropouts were only a slight problem in the 
control group of Phase 11. The main reason for this was probably due to the fact that 
these GPs did not have the added incentive of receiving the European Formulary and 
participating in the educational intervention. 
All the data collected from the different countries were comparable with two 
exceptions. Firstly the Belgian GPs did not provide details of consultations not 
resulting in a prescription and the Spanish GPs only agreed to participate in Phase 11 if 
they recorded approximately 50% the number of consultations recorded in Phase 1. 
Therefore where appropriate these two data sets were excluded from certain analyses. 
For the patient characteristics, there was found to be a highly significant difference 
in age between Phases. Whilst this may appear to be problematic with respect to 
potentially interfering with the results in this study, there is no clinically significant 
difference in prescribing for an age of 45.9 years compared with 45.1 years. 
Statistically significant differences are more likely to occur with larger sample sizes 
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associated with large denominators, for example in this analysis there were 52,389 
patients in Phase I and 45,481 patients in Phase 11. Therefore these statistically 
significant differences neither affected the analyses nor the conclusions. 
Comparing the prescribing patterns between countries, it was found that a higher 
proportion of patients received prescriptions in all the southern European countries 
compared with the UK. The proportion of patients receiving prescriptions in Ireland fell 
in the middle. This compares fairly well with international health statistics data which 
found that of the countries participating in this study, that the UK had the lowest 
number of prescription items per person followed by (Belgium), Ireland, Spain, Portugal 
and then Italy. 250 
Category of prescription (N, A, R or H) is problematic in interpretation. While 'N' 
drugs are clearly defined, many drugs which were recorded as repeats would have 
originally been initiated by hospital doctors, for example insulin. Therefore the results 
recorded in this study for hospital/specialist prescriptions do not reflect all hospital 
initiated prescribing and are generally lower than others have reported. 30 Spain 
recorded the highest 'H' prescription rates which may be as a result of the combination 
of short consultations and high referral rates seen in primary care in that country. 266 
However this is conjecture. Also the study recorded lower numbers of 'R' prescriptions 
than others have found30 but this is a reflection of the fact that data were recorded of 
prescriptions issued from face-to-face doctor-patient consultations only. 
The study showed that there was a significant reduction in the range of drugs 
prescribed after the educational intervention. Spain recorded the highest average range 
followed by the other southern European countries and Belgium. This could be due to a 
higher number of drugs available on the market in these regions compared with the UK 
and Ireland, thus allowing more choice. 
16 
Drug concordance with the European Formulary was between 33 and 60% which 
was considerably lower than the aim to cover 90% of the treatment. The drug 
concordance levels are also likely to be artificially high as the analysis did not take into 
account whether the listed drugs were being prescribed appropriately for their 
recommended indications. The proportions of 
diagnoses presentations covered by the 
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European Formulary were also considerably lower than its aim to cover 90% of the 
conditions seen by GPs. Despite this their levels were notably higher than the drug 
concordance levels. 
A comparison of the top ten Formulary and non-Formulary recommended drugs 
indicated that the bulk of prescribing is represented by a small number of drugs and the 
most commonly used drugs were those listed in the European Formulary. Of the top ten 
non-Formulary drugs, a future European Formulary would need to consider whether to 
include the likes of ranitidine, bendrofluazide,, flucloxacillin and betamethasone. 
Although the list of top 10 non-Formulary drugs did include what could be perceived as 
unnecessarily high use of certain ones such as co-proxamol, lorazepam. and piroxicam.. 
For the top ten Formulary diagnoses, it can be seen that they represented the 
majority of diagnosis presentations. Of the top ten non-Formulary diagnoses, six of 
these conditions (low back pain, URTI, ischaemic heart disease, bronchitis, chronic 
bronchitis, and respiratory tract infection) could be described as 'half way house' 
diagnoses (Section 3.1.3.6). These 'half way house' diagnoses were not explicitly listed 
in the Formulary but ones which could be interpreted as implicitly being included under 
the management of related conditions. This also highlights that there were problems in 
the way this information was recorded. For example, the European Formulary discusses 
lower respiratory tract infections which includes acute bronchitis but many GPs just 
recorded a diagnosis of bronchitis without specifying whether this was acute or chronic. 
Inclusion of these half-way house diagnoses to the list of Formulary conditions may 
have increased the proportions of presenting diagnoses covered by the Formulary levels 
to around the 75% mark. 
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Table 4.5 Average percentage (SEM) of all prescriptions by category 
Phase I 
Region Group 
Category of Prescription 
AHRN 
Belgium Study 10(4.4) 8(2.2) 43 (5.3) 39(3.8) 
Control 6(3.8) 5(3.4) 39(6.6) 50(7.4) 
England Study 20(2.3) 3 (0.9) 26(3.2) 51(2.7) 
Control 20(4.7) 2(0.8) 34(4.9) 44(4.7) 
Ireland Study 10(2.9) 5 (1.3) 34(3.4) 52(3.3) 
Control 11 (1.6) 7(2) 42(2) 40(2.1) 
Italy Study 4(l. 1) 9(1.3) 45(2.8) 42(2.2) 
Control 5(l. 4) 11 (1.1) 50(2.7) 35(2.5) 
N. Ireland Study 10(2.2) 3 (1.2) 27(2.6) 59 (3.1) 
Control 14(5.7) 5 (1.3) 31(6.8) 50(2.4) 
Portugal Study 6(l. 1) 16(2.5) 48(2.6) 30(2.8) 
Control 6(2) 9(1.5) 37(3.8) 49(4.8) 
Scotland Study 20(2.4) 3 (0.5) 28(3.3) 49(2.6) 
Control 16(3.3) 2(0.6) 33 (3.8) 50(2.2) 
Spain Study 6(1.1) 31 (2.1) 38(2) 25(l. 6) 
Control 12(1.6) 21 (3.2) 38(4.1) 29(l. 9) 
Phase II 
Region Group 
Category of Prescription 
AHRN 
Belgium Study 10(4.8) 10(3.8) 41 (5.6) 39(2.2) 
Control 9(4.1) 6(3.9) 37(6) 48(6.5) 
England Study 18(2.3) 5 (1.2) 27(2.4) 50(l. 9) 
Control 12(3) 4(l. 1) 39(4) 45 (3.5) 
Ireland Study 9(2.3) 6(l) 29(3.2) 57(2.9) 
Control 9(1.5) 10(2) 36(2.1) 46(2.3) 
Italy Study 5(1.2) 8(l. 3) 49(3.3) 37(2.7) 
Control 5(1.6) 11 (1.2) 49(2.9) 34(3.8) 
N. Ireland Study 13 (2.9) 3 (1.5) 27(2.1) 57(4.4) 
Control 12(3.9) 4(l. 4) 30(4.1) 53 (4.6) 
Portugal Study 8(l. 7) 17(2.7) 45(2.5) 30(3.2) 
Control 6(1.8) 8(l. 4) 41 (2.6) 45(3) 
Scotland Study 16(2.5) 4(0.8) 31 (3.3) 49(2.5) 
Control 15 (3.3) 1 (0.3) 32(3.8) 52(2.4) 
Spain Study 7(1-9) 26(2.8) 44(3.6) 23(2.2) 
Control 8(2.3) 20(3) 49(4.6) 24(2) 
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Effect of the European Formulary and educational intervention 
CHAPTER FIVE 
PRESCRIBING STUDY RESULTS 
EFFECT OF THE EUROPEAN FORMULARY AND 
EDUCATIONAL INTERVENTION 
5.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS 
5.1.1 Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are used by people with both 
acute and chronic musculoskeletal disorders to relieve pain, particularly where 
inflammation is a factor. In the UK, there are currently 25 NSAIDs available in the 
BNF6 in over 90 different formulations indicating a great deal of choice. In 
Martindale's Extra Pharmacopoeia (31"ed)20,124 different NSAIDs are discussed. 
NSAIDs are one of the most frequently prescribed groups of drugs in general practice 
but treatment with them can be associated with a variety of serious side-effects (SEs), 
particularly in the elderly. 263 As a drug class, NSAIDs have been shown to be the most 
frequent cause of reported adverse drug reactions ADRs in various countries, 267 with 
up to 25% in the UK. In England in 1997, almost 20 million prescriptions for NSAIDs 
were dispensed with a net ingredient cost of approximately 160 million pounds29 and 
world-wide it is estimated that in excess of 30 million people take NSAIDs daily268, 
40% of whom are older than 60 years of age269. 
5.1.2 Rational prescribing of NSAIDs 
When prescribing for patients with musculoskeletal and joint diseases, many factors 
have to be taken into consideration before deciding which drug to prescribe. Initially, 
the prescriber will have to decide whether an NSAID is really needed as the majority of 
musculoskeletal conditions will respond to simple analgesics or a topical rubefacient 
may suffice. It has been found that up to 50% patients with osteoarthritis can be 
managed by paracetamol alone. 
270 Taking single one-off doses of an NSAID will only 
combat pain, which may be appropriate in osteoarthritis, but if a full anti-inflammatory 
effect is required, such as in rheumatoid arthritis, regular dosing is essential. 
270 Once 
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an NSAID is considered necessary, awareness of the marketing authorisations for 
different NSAIDs is important before selection for a condition. 191 
The balance between the benefits and risks of NSAIDs requires careful 
consideration, particularly in the elderly. 6 The majority of NSAIDs appear to have 
similar efficacy but variations exist in patient response to NSAIDs which may be related 
to drug pharmacokinetics associated with differences in chemical structure. Safety 
profiles of NSAIDs appear to differ considerably and so this should play a large part in 
drug selection for a particular indication. Dosages for the elderly should be tailored to 
the individual because with increasing age there is a reduction of renal clearance as well 
as drug distribution and metabolism being significantly altered. Consequently the 
clearance of some NSAIDs, including naproxen, ketoprofen and ibuprofen, has been 
found to be reduced in the elderly. 271 
The severity of side-effects is thought to be linked to drug plasma half-lives. 272 
NSAIDs are generally divided into two groups, those with short half-lives (less than six 
hours) including ibuprofen, flurbiprofen, ketoprofen and diclofenac and those with long 
half-lives (more than twelve hours) including piroxicam, tenoxicam and fenbufen. 
Drugs with longer half-lives take longer to achieve maximal clinical effects. 273 The 
Committee on Safety of Medicines (CSM) data263 in the UK have supported evidence 
that long half-lives are associated with a greater number of side-effects and have 
attempted to rank NSAIDs in terms of their relative safety. 
Side-effects of NSAIDs include gastro-intestinal (GI) complications, 
hypersensitivity reactions and nephrotoxicity. 6 The majority of the intestinal problems 
occurring in patients with arthritis are the result of NSAIDs. The elderly are particularly 
at risk of NSAID-induced peptic ulcer disease which can lead to perforation, bleeding 
and ultimately to death. For elderly people with a previous history of peptic ulcer 
disease where no other pharmacological or non-pharmacological methods other than 
treatment with an NSAID is possible, co-prescribing of misoprostol or an H2 antagonist 
prophylactically with an NSAID should be considered. However, if all prescriptions for 
NSAIDs in England, for example, were prescribed with misoprostol or ranitidine then 
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the annual additional cost of co-prescribing based on 1995 data would be approximately 
E200m and f 600m respectively. 2 74 
The criteria upon which rational prescribing of NSAIDs should be based include 
that: 
they should be used when licensed and necessary for the presenting diagnosis, 
2. patient history should be checked for concomitant diseases, e. g. GI disorders, 
"I 3. concomitant prescribed and OTC drugs should be checked for interactions, 
4. the use should be avoided in the elderly where possible, 
those with the lowest risk of side-effects (shortest half-life) are preferential, 
6. treatment should begin with lowest recommended dose and increased against 
symptom relief, 
7. a small range should be used (60% of patients will respond to any NSAID), 
8. no patient should be co-prescribed more than one NSAID at a time, 
9. topical NSAIDs have limited proven clinical value. 
5.1.2.1 NSAIDs by injection, suppository or topical application 
NSAID administration by injection is seldom the preferred route, although 
diclofenac for example is often given by injection formulation for the relief of pain 
when ureteric colic presents. Some NSAIDs such as diclofenac and indomethacin have 
been formulated as suppositories, which can be used to relieve night pain and early 
morning stiffness. Drugs are generally absorbed more slowly through the rectal mucosa 
than after oral administration but prescription of a longer acting oral NSAID can 
achieve the same benefit. 
272 An advantage of NSAID suppositories is that they avoid 
the GI complications but one negative aspect of them is that they have the potential to 
cause rectal irritation or proctitis. 
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Topical NSAIDs are widely prescribed and purchased over the counter for soft 
tissue, musculoskeletal and joint conditions. There is little or no published evidence on 
topical NSAIDs either in comparison to, or in combination with, standard treatments 
such as paracetamol, rubefacients or oral NSAIDs. 275 The efficacy of topical NSAIDs 
has been discussed in a few clinical papers with different outcomes. One systematic 
review has found that the majority indicate a large placebo effect but others reveal that 
topical NSAIDs are significantly more effective than placebo in terms of pain 
reduction. 276 It is generally considered that the warmth and rubbing sensation 
associated with the application of topical NSAIDs might be equal to that of 
conventional rubefacients or embrocations which are much cheaper and do not require a 
prescription. 277 Many topical NSAIDs have been marketed in the hope that their local 
application will overcome the adverse effects associated with oral NSAIDs and at the 
same time have an enhanced therapeutic action. Following the application of topical 
NSAIDs, the drug plasma levels are many times lower than after dosing with equivalent 
oral NSAIDs272 and so they are well tolerated and seem relatively safe. However, 
topical NSAIDs do have a degree of systemic absorption and therefore it is possible for 
side-effects to occur in the same way as with oral NSAIDs. 
In general, topical NSAIDs are relatively expensive compared with oral NSAIDs 
and there is insufficient evidence available to allow ranking of these preparations in 
terms of efficacy and relative systemic safety. Clinical trials to date only offer some 
support in the use of these preparations for acute, self-limiting, soft tissue injuries. 278 
5.1.2.2 European Formulary recommendations 
Four NSAIDs were recommended in the European Formulary, namely ibuprofen, 
diclofenac, naproxen and indomethacin and all were selected on the basis of efficacy, 
safety and cost. Although aspirin is chemically classed as a salicylate NSAID20,256' it 
is important to note that aspirin is recommended for use as a simple analgesic in the 
Formulary rather than for its anti-inflammatory effect. Of the disorders covered by the 
European Formulary, NSAIDs were included in the symptomatic drug management of 
the following conditions: 
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e pain 
o migraine 
4D cholecystitis/gallstones 
9 renal colic/calcinosis 
o pre-menstrual syndrome/clysmenorrhoea 
e arthropathies 
o gout and hyperuricaernia 
* terminal care 
The European Formulary Group (EFG) recommendations associated with NSAID 
prescribing included that: 
* aspirin (salicylates) should not be given to children under the age of 12 years 
because of the risk of Reye's syndrome, 
e simple analgesics should be tried first-line, before NSAIDs 
9 NSAIDs are appropriate for bone pain and where an anti-inflammatory action 
is required, 
* NSAID use should be minimised in elderly patients (particularly those with 
osteoarthritis which is a degenerative condition, not anti-inflammatory), 
because of the risk of GI problems, 
e routine prophylactic prescription of misoprostol to counteract possible GI 
ulceration should be considered only in the frail elderly and in those with 
previously documented chronic peptic ulcer, 
* the duration of NSAID treatment should be limited where possible, 
9 the lowest effective NSAID dose should be used, particularly in the elderly, 
e prescribing of NSAIDs needs special caution in patients with a history of 
asthma, inflammatory bowel, diverticular or renal disease!, and with 
concomitant intake of aspirin, diuretics, ACE inhibitors and steroids. 
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5.1.2.3 Proposed prescribing performance indicators 
There are many criteria which can be used in the assessment of rational prescribing 
of NSAIDs, several of these were referred to in Sections 5.1.2,5.1.2.1 and 5.1.2.2. Due 
to the method of data collation in this study, some criteria, including the drug 
formulation and prescribed dosage cannot be investigated in this results section. 
Consequently, the following hypotheses were drawn up based on quality indicators 
which could be adapted to critically explore the NSAID prescribing data in the different 
countries. The hypotheses were that: 
9 the proportion of newly prescribed NSAIDs which were listed within the 
European Formulary increased following the educational intervention and 
istri ution ote Formulary, 
* over 90% of patients in whom NSAIDs are indicated should be adequately 
treated with the four Formulary recommended NSAIDs, 
the NSAID of choice in each country was used in approximately 60% of 
cases as 60% of people respond to any NSAID, 
the range of newly prescribed NSAIDs would be reduced following the 
educational intervention and distribution of the Formulary, 
9 the proportion of new prescriptions for simple analgesics (recommended in 
the European Formulary) which were prescribed for the conditions listed in 
Section 5.1.2.2 increased following the educational intervention, 
9 the proportion of consultations for conditions listed in Section 5.1.2.2 resulting 
in a new analgesic prescription increased following the educational 
intervention and distribution of the European Formulary. 
5.1.2.4 Data manipulationlmethodology 
For the purposes of the NSAID analyses in this thesis, it has been assumed that 
aspirin is predominantly prescribed for either its analgesic or for its antiplatelet effect 
and therefore it has not been classed as an NSAID. To produce an anti-inflammatory 
effect, high regular dosage of aspirin is required but no dosage information was 
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recorded in the prescribing data obtained, which would be essential in order to establish 
this use. In order to critically evaluate the NSAID prescribing by the GP participants in 
the different countries, all the searches except where specified involved drugs matched 
to diagnoses. The following searches were performed within the database: 
* all Phase I prescribing of new NSAIDs, 
9 all Phase 11 prescribing of new NSAIDs, 
9 all Phase I study group prescribing of new NSAIDs, 
* all Phase 11 study group prescribing of new NSAIDs, 
e prescribing of new NSAIDs for both Phases combined, 
9 all Phase I prescribing of new NSAIDs and simple analgesics for conditions 
listed in Section 5.1.2.2 , no matching of drugs to diagnoses, 
* all Phase 11 prescribing of new NSAIDs and simple analgesics for conditions 
listed in Section 5.1.2.2, no matching of drugs to diagnoses, 
e NSAID prescribing for both Phases combined, 
* NSAID prescribing for both Phases combined in patients under 60 years, 
* all NSAID prescribing for both Phases combined in patients over 60 years. 
For the country by country comparative prescribing results section, it was decided 
to combine the data from Phase I and Phase 11 which is likely to provide a more 
meaningful illustration of the overall prescribing pattern compared with looking at the 
trends in each of the Phases separately. 
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In the results tables, the data were presented in order of prescribing volume in terms 
of the number of items prescribed. The NSAID data were sorted based on the following 
classification: 
1. Acetic acid derivatives 
2. Proprionic acid derivatives 
3. Oxicam derivatives 
4. Selective cox-2 NSAIDs 
5. Anthranilic acid derivatives 
6. Miscellaneous NSAIDs 
7. Salicylic acid derivatives 
8. Topical preparations. 
5.1.3 Results 
5.1.3.1 Prevalence patterns 
NSAID prescribing accounted for 9% (0.6) of all prescribing in Phase I and 7.5% 
(0.2) in Phase 11 and a more detailed breakdown of Prescribing can be seen in Table 
5.12. There were significant differences between the control and study groups 
(p = 0.02) and highly significant differences between countries (p <0.001) and a highly 
significant country by group (p <0.001) interaction (i. e. the size of the control vs. study 
effect depended upon country). Overall Portugal and Italy showed the highest NSAID 
prescribing, with 26% of the total number of drugs prescribed being NSAIDs by the 
Portuguese control group in Phase 1. Exclusion of the Portuguese data from the analysis 
removed the last two statistical differences above and the difference between the control 
and study groups became of borderline significance (p = 0.05) suggesting that Portugal 
was an outlier, disproportionately skewing the data. 
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5.1.3.2 Prescribing performance indicators before and after the intervention 
5. L. 3.2.1 Concordance with NSAIDs recommended in the European Formulary 
The level of prescribing concordance with the NSAIDs recommended in the 
European Formulary i. e. ibuprofen, diclofenac, naproxen and indomethacin, for new 
prescriptions can be seen in Table 5.13. There was a trend towards Formulary 
recommended NSAIDs with the intervention group increasing on average by 7.9% (2-6) 
compared to the control group which increased by 0.7% (2.7). This difference was of 
borderline statistical significance (p = 0.05). There was no significant difference 
(p = 0.26) found between countries. The larger differences between movement towards 
the Formulary by the intervention group and movement away by the control group were 
observed in England, Italy, Northern Ireland and Portugal. In England, this difference 
was of borderline significance (p = 0.05). Overall, the greatest concordance with the EF 
can be seen in the UK where more than four out of five new NSAID prescriptions were 
for those recommended in the Formulary. This compares with the prescribing by GPs in 
Italy and Portugal where just over one in three new NSAID prescriptions were those that 
were recommended. 
The total overall prescribing levels of the four recommended NSAIDs increased by 
approximately 12% in the intervention group from Phases I to 11 (Table 5.14). Within 
the intervention groups of the individual countries, the total prescribing levels increased 
by a minimum of 10% in Ireland, Italy, Portugal and Spain. Depending on the country, 
either diclofenac or ibuprofen was the NSAID of choice, other than Belgium where 
naproxen was the most commonly prescribed NSAID. The largest increases of 
individual NSAID prescribing from Phase I to Phase 11 were for ibuProfen in Italy, 
Northern Ireland and Spain. 
For information, Table 5.15 indicates how prescribing of the most commonly used 
NSAIDs outside the Formulary by the study group GPs of Phases I and II, compares 
with use of NSAIDs recommended in the European Formulary (Table 5.14). The four 
most commonly used non-Formulary NSAIDs were nimesulide, piroxicam, mefenamic 
acid and ketoprofen. 
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5.1.3.2.2 Proportion of new prescribing covered by the four Formulary MAIDS 
The 90% prescribing target was not achieved by any of the countries in Phase I 
although the four Formulary NSAIDs covered in excess of 80% of the prescribing in 
England, Northern Ireland and Scotland (Table 5.14). In Phase II, prescribing of the 
four NSAIDs combined increased considerably in all the countries except for Belgium. 
Prescribing in England and Scotland was over the 90% mark. 
5.1.3.2.3 Proportion of new prescribing covered by the NSAID of choice 
The NSAID of choice varied from country to country but it was always a European 
Formulary recommended NSAID (Table 5.14 and Table 5.16). In Phase 1, no individual 
NSAID in any of the countries reached the 60% target. In England and Northern 
Ireland, prescribing of ibuprofen was the closest being just under the 50% mark and in 
Scotland 47% of NSAID prescriptions were for diclofenac. In Phase 11, the 60% mark 
was achieved in Northern Ireland by the prescribing of ibuprofen. 
5.1.3.2.4 The range of drugs prescribed 
There was no significant difference in the range of NSAIDs prescribed as new 
drugs from Phase I to Phase 11 either between countries (p = 0.3 1) or between the 
control and study groups (p = 0.53) (Table 5.17). There was a trend towards a reduced 
range of NSAIDs prescribed in the intervention groups of Belgium, Ireland and 
Northern Ireland compared with their control groups, but none of these changes was 
statistically significant. The largest ranges of NSAIDs were prescribed in Italy and 
Portugal and the smallest ranges were found to be prescribed by the UK GP participants. 
5.1.3.2.5 Proportion of simple analgesics prescribed compared with NSAIDs 
The intervention group as a whole increased its proportion of simple analgesic 
prescribing from Phase I to II by 5.4% (2) compared with a decrease in the control 
group by 5.6% (2.6) and the difference was found to be statistically significant 
(p 0.001) (Table 5.18). There was no significant difference found between countries 
(p 0.07). Within individual countries, trends towards an increase in prescribing of 
analgesics by intervention groups compared with control groups can be seen in England, 
Ireland, Italy, Northern Ireland and Scotland. The largest difference in prescribing of 
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simple analgesics between control and intervention groups was in Italy and this was 
highly significant (p <0.001). A statistically significant statistical difference was also 
found between the control and study groups in Spain (p = 0.03), but in Table 5.18 this 
can be seen to be due to the large decrease in the proportion of simple analgesics 
prescribed by the control group with the level in the intervention group remaining 
constant. 
5.1.. ' 3.2.6 Proportion of consultations resulting in a simple analgesic 
The proportion of consultations for conditions listed in Section 5.1.2.2, resulting in 
the prescription of a simple analgesic increased by 1.9% (0.7) in the intervention group 
compared with a decrease of -1.2% (0.5) in the control group and this was of 
statistically high significance (p <0.001) (Table 5.19). No significant difference was 
found between countries (p = 0.12). Belgium was excluded from this analysis as no 
data were provided on consultations without a prescription. An increased trend towards 
new prescribing of simple analgesics can be seen in the intervention groups of all 
countries,, except for Portugal where the trend towards prescribing simple analgesics 
was greater in the control group. The largest increase in consultations resulting in the 
prescribing of a simple analgesic was found in Italy and this was statistically significant 
(p = 0.002). 
5.1.3.3 Comparisons ofNSAID prescribing 
A total of 10,799 NSAID prescription items was recorded in all countries, both 
Phases combined (Table 5.20). The majority of these, 5,850 (54%), were new 
prescriptions varying from 36% in Spain to 65% in Italy (mean 55%, SD 9.2). From the 
remainder, 2,738 (25%) were regular repeat prescriptions, 1,311 (12%) were prescribed 
upon request of the patient as a result of having been prescribed on a previous occasion, 
759 (7%) were hospital/specialist initiated prescriptions and 141 (1.3%) NSAIDs were 
not categorised. 
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5.1-3.3.1 Acetic acid derivatives 
The acetic acid derivatives with relatively short half-lives were the most commonly 
prescribed class of NSAIDs accounting for 37% of those prescribed from all the drug 
classes collectively (Table 5.20). Prescribing of acetic acid derivatives varied from 27% 
in Italy to 58% in Spain (mean 37%, SD 9.5). Diclofenac was the acetic acid derivative 
of choice in all countries accounting for over 75% of the prescribing from within this 
group. For all drug categories combined, diclofenac prescribing varied from 19% in 
Italy to 40% in Ireland (mean 30%, SD 7.7) and prescribing of indomethacin, the second 
most commonly prescribed drug in this group varied from 1.4% in Northern Ireland to 
7.7% in England (mean 4.5%, SD 2.2). For new NSAID prescriptions only (Table 
5.16), diclofenac use varied from 20% in England to 44% in Ireland (mean 29%, 
SD 9.3), and new prescribing of indomethacin varied from 0.4% in Northern Ireland to 
6.1 % in Spain (mean 3.1 %, SD 2.1). 
Within this NSAID class, aceclofenac use in Spain accounted for 10% of the 
prescribing overall. In Northern Ireland, two and a half times as much acematacin than 
indomethacin was prescribed and almost an equal amount of ketorolac as indomethacin 
was used in Italy. 
5.1.3.3.2 Proprionic acid derivatives 
Proprionic acid derivatives were the second most commonly prescribed class of 
NSAIDs accounting for 30% of those prescribed overall, varying from 15% in Spain to 
60% in England (mean 37%, SD 17) (Table 5.20). The majority of proprionic acid 
derivatives tend to also have short half-lives (similar to the acetic acid derivatives). 
lbuprofen was the most commonly prescribed NSAID in this group, representing just 
under 16% of the total number of NSAID prescriptions overall. Twice as much 
ibuprofen was prescribed as naproxen, the second most commonly prescribed proprionic 
acid derivative, and four times as much ibuprofen was prescribed as ketoprofen, the 
third most commonly prescribed NSAID. For all categories combined, ibuprofen use 
varied from 5.8% in Spain to 43 % in Northern Ireland (mean 21%, SD 16) and for new 
NSAIDs only (Table 5.16) ibuprofen varied from 5.1% in Belgium to 50% in Northern 
Ireland (mean 24%, SD 18). Prescribing of naproxen varied from 4.6% in Portugal to 
28% in Belgium (mean 11%, SD 8.5) for all prescription categories combined and new 
134 
Effect of the European Formulary and educational intervention 
naproxen prescriptions (Table 5.16) varied from 3.7% in Ireland to 29% in Belgium 
(mean I I%, SID 9.1). 
In Italy, ketoprofen was the proprionic acid derivative of choice accounting for 
almost 10% of the NSAID prescriptions overall and in Spain piketoprofen was the 
proprionic acid derivative of choice there. Piketoprofen is only available in a topical 
formulation and so for the purposes of NSAID classification was grouped with the 
topical NSAIDs in Table 5.20. 
5.1.3.3.3 " Oxicam derivatives 
The oxicarn derivatives were the third most common group of NSAIDs prescribed 
(Table 5.20) varying from 1.6% in Ireland to 18% in Italy (mean 7.8%, SD 5.7). The 
oxicams have been reported as having the longest half-lives of all the different classes of 
NSAIDs. Piroxicam was the oxicam of choice in all the countries and its use varied 
from 1.1% in Ireland to 16% in Italy (mean 6.5%, SD 4.6) for all prescription categories 
combined. For newly prescribed NSAIDs (Table 5.16) only, piroxicam use varied from 
0.7% in Ireland to 16% in Italy (mean 5.3%, SD 4.7). 
5.1.3.3.4 Selective cox-2 NSAIDs 
Of the NSAIDs prescribed in this study, nimesulide was the only one classed as 
selective inhibitor of cyclo-oxygenase-2 (Cox-2) at the time of data collection. It was a 
particularly popular choice of NSAID in Italy and Portugal, representing 19% and 16% 
of the NSAID items prescribed respectively in each of those two countries (Table 5.20). 
Of the remaining countries it was also available on prescription (at the time of data 
collection) in Belgium and Ireland. In Italy, for all categories of NSAIDs prescribed, 
nimesulide use was actually on a par with diclofenac use. In Portugal, nimesulide was 
comfortably the second most popular NSAID prescribed overall with almost as much 
being used as for the whole category of proprionic acid derivatives in that country. For 
newly prescribed NSAIDs, nimesulide was the third most commonly prescribed NSAID 
overall, representing 10% of the total number of NSAID prescription items (Table 5.16). 
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5.1.3.3.5 Anthranilic acid derivatives 
This group accounted for less than 5% of the total of NSAIDs prescribed from all 
prescription categories combined, varying from 0% in Belgium to 20% in Ireland 
(mean 4.9%, SD 6.8) (Table 5.20). Mefenamic acid was the most commonly prescribed 
NSAID in this group, varying from 0% in Belgium and SPain to 20% in Ireland 
(mean 4.7%, SD 6.9) for all categories combined and for new NSAIDs (Table 5.16) its 
use varied from 0% in Belgium, Portugal and Spain to 19% in Ireland (mean 4.6%, 
SD 6.5). 
5.1.3.3.6 Miscellaneous NSAIDs 
Prescribing of miscellaneous NSAIDs accounted for 4.3% of NSAID prescriptions 
for all prescription categories combined (Table 5.20). Their use varied from I% in 
England and Ireland to 7.9% in Italy (mean 3.3%, SD 2.6%). Within this group in Italy, 
morniflumate accounted for 3.8% of NSAIDs prescribed and feprazone 1.8%. Of the 
NSAID prescriptions in Portugal, clonixin accounted for 1.9% and nabumetone 1.6%; in 
Spain, nabumetone represented 1.7% of the NSAIDs prescribed there. 
5.1.3.3.7 Salicylic acid derivatives 
Salicylic acid derivative use (Table 5.20) varied from 0% in Northern Ireland to 
10% in Portugal (mean 2.1%, SD 3.6). Lysine aspirin (a chemical derivative of aspirin) 
was the most commonly prescribed salicylate, accounting for over 10% of the NSAIDs 
prescribed in Portugal and 4.3% of those prescribed in Belgium. As previously stated 
aspirin was excluded from this analysis as no dosage information was recorded by 
prescribers to indicate if prescribed for its anti-inflammatory effect. 
5.1.3.3.8 Topical NSAIDs 
As previously explained, no proper analysis could be performed categorising 
topical NSAIDs. However at the time of data collection in this study, some NSAIDs 
were only available as topical formulations and included etofenamate, niflumic acid, 
piketoprofen and bendazac. These drugs were prescribed in Belgium and the southern 
European countries only, etofenamate and bendazac being available in all four countries 
(Table 5.20). Bendazac was prescribed in only Italy and Portugal and piketoprofen was 
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only prescribed in Spain. In Spain, etofenamate represented 6.4% of the NSAIDs 
prescribed and piketoprofen accounted for 7.7%. None of these four topical NSAIDs 
were prescribed in English speaking countries as they were not licensed and therefore 
unavailable. 
5.1.3.4 Prescribing in different age groups 
5.1.3.4.1 NSAID use in patients under 60 years 
The bulk of NSAID prescribing in patients under 60 years of age for all drug 
categories in Phases I and 11 data combined can be seen in Table 5.2 1. The drugs 
recommended in the European Formulary were the mainstay of treatment in all the 
countries except for in Italy and Portugal. These findings were similar to the results 
presented in Table 5.1 for new NSAID prescribing only. It can be seen in Table 5.21 
that a broader range of NSAIDs were required in Belgium, Italy, Portugal and Spain in 
order to cover 90% of the prescribing volume. Several of the NSAIDs listed were only 
prescribed in certain countries such as nimesulide (Section 5.1.3.3.4). Despite being 
only prescribed in considerable amounts in Italy and Portugal, nimesulide was the third 
most commonly prescribed NSAID overall. Whilst selective cox-2 NSAIDs have the 
potential to improve patient care, they may be most appropriate in patients over 60 years 
of age who are more susceptible to GI side effects from NSAIDs. Other NSAIDs which 
were also commonly used in patients under 60 years of age included piroxicam, 
particularly in Belgium and the Mediterranean countries and mefenamic acid, a popular 
choice in the English speaking countries especially Ireland. 
5.1.3.4.2 NSAID use in patients 60 years and over 
Levels of Fon-nulary recommended NSAIDs were notably greater in patients of 60 
years and over in Belgium, Italy, and Portugal, than in those who were younger than 60 
(Table 5.22). Formulary concordance was however below 50% in the latter two 
countries. In contrast, concordance with Formulary recommended NSAIDs prescribed 
for Spanish patients over 60 years of age was lower than the level in younger patients. 
Again, a much narrower range of drugs was prescribed in the English speaking countries 
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than in the southern European regions in order to achieve a 90% level of prescribing 
volume. 
The aggregate levels of nimesulide and piroxicam were reversed in patients under 
60 when compared with patients over 60. In Italy and Portugal, nimesulide use dropped 
from the third most commonly prescribed NSAID for patients under 60 to the sixth most 
commonly prescribed for patients over 60. In contrast, piroxicam levels overall almost 
doubled in use from patients under 60 years to patients over 60 years, especially in Italy 
where one in five NSAID prescription items was for piroxicam. Piroxicam was the 
third most commonly used NSAID in patients over 60 years, marginally lower than the 
level of ibuprofen. Table 5.22 also shows the relatively high prescribing of tenoxicam 
in Belgium and higher prescribing levels of those NSAIDs only available in a topical 
formulation for patients over 60 years, notably in Spain. In Ireland, 14% of NSAID 
prescription items were for mefenamic acid, where it was the third most common 
choice. 
5.1.3.4.3 Diagnoses where NSAIDs were prescribed in patients under 60 years 
Pain and arthropathies (both disorders where NSAIDs were recommended in the 
European Formulary) were the two most commonly occurring conditions for which 
NSAIDs were prescribed in patients under 60 years (Table 5.23). NSAIDs were also 
commonly prescribed for musculoskeletal disorders not covered by the Formulary, such 
as low back pain. NSAIDs were also prescribed for some conditions listed within the 
Formulary such as throat infections, for which their use was not recommended. Such 
prescribing occurred particularly in Italy where 14% of the NSAIDs prescribed there 
were for throat infections. In addition,, there appears to be a relatively high level of 
NSAID prescribing for pre-menstrual syndrome and/or dysmenorrhoea in Scotland. 
This could be associated with high levels of mefenamic acid prescribing there (Table 
5.21), especially as this drug is licensed for this condition and has been promoted 
accordingly. 
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5.1.33.4.4 Diagnoses where NSAIDs were prescribed in patients 60 years and over 
The range of diagnoses for which NSAIDs were prescribed for patients 60 years 
and over is considerably reduced compared with their use in patients under 60 (Table 
5.24). The disorders being treated in Table 5.24 were notably those characteristic of an 
elderly population. The top two diagnoses were arthropathies and pain, similar to Table 
5.23 but the positions were reversed. The prevalence level of arthropathies for which 
NSAIDs were prescribed trebled overall in patients 60 years and over compared with 
patients under 60. Again, there was NSAID prescribing for musculoskeletal conditions 
not included in the European Formulary such as low back pain and NSAID use for 
conditions listed in the Formulary but which did not include NSAIDs as part of the 
recommended drug management, such as neuralgia. 
5.1.4 Discussion 
In this study, NSAID prescribing represented almost 10% of the total prescribed 
items overall - confirming that they were a key area for intervention in attempting to 
educate prescribers and consequently promote more rational prescribing. The majority 
of drug entities prescribed were for newly prescribed items and although the level was 
relatively lower than that for antibiotics, this was offset by the large volume of NSAID 
data available for analyses. 
Where an NSAID prescription is considered necessary, patient response will tend to 
determine the most appropriate one. However, it is preferable for prescribers to 
prescribe from a small range, selecting NSAIDs that have been marketed for some time 
and that have a better-than-average safety margin. Using this convention, drug 
formularies49,78,81,84 and prescribing guidelines279 tend to be fairly consistent in 
selecting ibuprofen as the first-line NSAID of choice, followed by naproxen, diclofenac 
and indomethacin. It is generally accepted that NSAIDs with shorter half-lives have 
fewer side-effects than those with longer half-lives272 although one report280 of 
comparative toxicity found fenoprofen with a half-life of three hours to have a greater 
incidence of serious GI effects than piroxicam with a half-life of 45 hours. Even though 
this information is widely available to prescribers, keeping up-to-date with newly 
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published research reporting changes in the relative toxicity of one NSAID compared 
with another281,280 is an ongoing and time consuming task for any prescriber. 
The three most successful outcomes of the study were: 
1. that the difference between the increase by the intervention group compared 
with the control group in concordance with the Formulary between Phase I 
and 11 was of borderline statistical significance. 
2. for the simple analgesic and NSAID data combined, there was a highly 
significant increase in the proportion of simple analgesics prescribed from 
Phase I to II indicating that to an extent the former were displacing NSAIDs. 
3. there was a highly significant increase in the proportion of consultations for 
conditions within the Formulary for which both simple analgesics and NSAIDs 
were used. 
All these findings suggest that the intervention may have had some impact, 
especially in England, Italy, Northern Ireland and Portugal where the most positive 
trends were found. However, the relatively high level of oxicam prescribing and in 
particular the greater use of piroxicam in all the countries in patients over 60 years of 
age compared with those under 60, suggests that some advice was ignored. 
In this results section, a blanket analysis was performed on general concordance 
with European Formulary recommended NSAIDs, irrespective of what disorders they 
were being prescribed for. Should this analysis have been based on concordance with 
prescribing for the conditions within the Formulary then the volume of NSAID data 
available would have been considerably reduced, especially that relating to prescribing 
for patients below 60 years of age. The reason for this is because not only were patients 
with conditions being prescribed NSAIDs where they were not recommended but many 
of the musculoskeletal conditions for which NSAIDs were being used for were not 
included in the European Formulary and Appendix. Therefore the document appeared 
limited in its coverage. Additionally, sophisticated analyses, comparing differences in 
NSAID prescribing between osteoarthritis and rheumatoid arthritis for example, would 
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have been problematic as the majority of GPs tended to record the diagnosis as arthritis 
only, omitting to specify the type. 
There were marked differences in the pattern of NSAID prescribing between 
countries - for example in Italy, nimesulide was the most commonly prescribed drug, 
whereas in all other countries diclofenac or ibuprofen were the NSAIDs of choice. 
Nimesulide, a cox-2 derivative, was an example of an NSAID only available and 
established in certain countries thus contributing to variations in prescribing patterns 
between countries. Of the most commonly used NSAIDs, many were actually available 
in all the countries but there were notable differences in the order of their preference. 
Possible reasons for the failure of ibuprofen to be the most commonly prescribed 
NSAID in the study could include: firstly, that it may be cheaper to purchase over the 
counter compared with the cost Payment for a prescription and secondly, as a 
consequence of its wide availability OTC, some patients may have already 
experimented with it first, before requiring an alternative. 
An aspect of the prescribing that appeared somewhat contradictory was that in Italy 
and Portugal, for patients under 60 years, nimesulide prescribing was greater than 
piroxicam and yet the reverse occurred for patients over the age of 60. It would have 
been expected that the cox-2 NSAID would have been prescribed more for the elderly, 
to protect against the increased likelihood of side-effects, and piroxicarn with its 
relatively poor safety profile to be prescribed less for the elderly. Three years after the 
data were collected for this study, Italian epidemiological researchers in Rome have 
reported that despite being confirmed to be among the most gastrotoxic NSAIDs, 
piroxicam. is still one of the most commonly prescribed. 
282 Consequently, they 
concluded that piroxicam use potentially represents a great public health concern. At 
the same time in Portugal, because of piroxicam being one of the most commonly 
prescribed NSAIDs, high levels of reported photosensitivity adverse effects has resulted 
in dermatological researchers from Porto proposing that piroxicam prescription should 
be avoided. 283 Drug utilization research in the province of Seville, Spain, has also 
found piroxicarn to be one of the two most commonly prescribed NSAIDS284, although 
these findings were not reflected in the Spanish data in this study. 
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Interventions with respect to NSAID have been found to be successful in both 
primary and secondary care. The effect of regular audit sessions between prescribers, 
specialist clinicians and pharmacists resulted in a 40% reduction in NSAID prescribing 
in the accident and emergency department of a London hospital. 285 In general practice, 
prescribing formularies have been shown to reduce the range of NSAID prescribing286 
but in this study, there was found to be limited and no significant reduction in the ranges 
that were prescribed. The smallest ranges of NSAIDs were found in the UK in both 
patients below and above 60 years of age. Coupled with the high Formulary 
concordance levels there, this indicates that prescribing was both more consistent as 
well as more in line with the recommendations than elsewhere. In England, ibuprofen 
was the most commonly prescribed NSAID followed by diclofenac and then naproxen 
which compares reasonably well with Department of Health reports of little difference 
in the number of prescription items for ibuprofen and diclofenac with naproxen falling 
in to third place. 29 This trend towards consistent prescribing of a relatively small range 
of NSAIDs therefore seems to be largely mirrored across the whole country. 
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5.2 URINARY TRACT INFECTIONS 
5.2.1 Introduction 
In the UK, UTIs account for approximately 2% of GPs' consultations. 287 Urinary 
tract infection (UTI) is a common condition especially affecting many women at 
sometime in their lives. Each year around 5% of women present to their GPs with 
dysuria and frequency. 288 Of these, about half have a urinary tract infection as 
confirmed by the presence of a threshold number of bacteria in their urine. In males, 
UTI is uncommon in youth and middle age but the problem becomes more prevalent 
with increasing age, frequently being associated with an underlying abnormality of the 
renal tract. 
In this results section,, a comparison of prescribing patterns between countries for 
UTIs in women 16 years and over and in males and females overall will be made. UTI 
management is complicated in men due to the underlying pathology and low 
prevalences of UTIs in men and limited data from children are unlikely to enable valid 
comparisons of these groups alone from the database. 
5.2.2 Clinical presentation 
Anatomically, UTIs may be classed as either lower, the site of infection being the 
bladder and/or urethra, or upper, occurring in the kidneys and/or ureters. 289 
Alternatively, they can be classed according to the likely response of therapy into those 
that are uncomplicated (the majority) and those that are complicated. Lower UTIs 
(simple or uncomplicated) are generally ascending bacterial infections from a patient's 
own gut flora into the bladder via the urethra. Upper UTIs (complicated) involve 
inflammation of the kidney tissue and response to therapy depends on the presence of 
certain risk factors including diabetes mellitus, immunosuppressant drugs and 
pregnancy. 6 An infection is also considered to be complicated, and may have serious 
consequences, if it affects pregnant women, children, men or the elderly. Recurrent 
infections are more serious and may be due to relapse but are more often as a result of 
re-infection. Recurrent episodes are an indication for radiological investigation 
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especially in children in whom untreated pyelonephritis may lead to permanent kidney 
damage. 290 
Infection generally presents as either cystitis or acute pyelonephritis. Typical 
symptoms of cystitis include dysuria, nocturia, frequency and urgency of urination. 
Suprapubic pain, cloudy or foul-smelling urine, haernaturia, or, in elderly patients, 
confusion may also occur. 288 Acute pyelonephritis typically causes flank pain and 
fever, often with nausea,, vomiting, malaise and/or symptoms of cystitis. 
Asymptornatic bacteriuria (significant bacteriuria without symptoms of urinary 
infection) is found in 15-20% of women aged 65-70 years and does not seem to impair 
renal function or shorten life. 288 Asymptomatic bacteriuria also occurs in 4-7% of 
pregnant women but is then associated with premature delivery and low birthweight. 
291 
5.2.3 Diagnosing UTIs 
In women presenting with uncomplicated cystitis, diagnosis can be based on the 
history and clinical signs, together with results of urine dipstick testing for nitrites 
and/or leucocyte esterase. 288 if the nitrite test is positive, it is reasonable to start 
appropriate antibiotic therapy without accompanying culture of the urine. However, if 
both tests are negative, urine should be sent for culture. Uncomplicated UTIs are 
usually caused by single organisms and so culture of urine is not usually necessary 
although microscopic examination may provide helpful clues. 
Urine culture is essential in the management of certain situations including 
complicated infections, in those who are pregnant and where empirical antibiotic 
treatment fails. In these circumstances, treatment can be started with the 'best guess' 
antibiotic before results are available but it may need to be modified after subsequent 
culture findings. 
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5.2.4 Rational prescribing for UTIs 
The goal of antibiotic therapy is simply to provide resolution of symptoms in the 
shortest possible time with the minimum of adverse effects, as economically as 
possible. 292 
5.2.4.1 Current recommendations 
Trimethoprim is usually first-line recommended therapy in uncomplicated lower 
UTIS6. effective against approximately 70% of urinary pathogens. 293 Nitrofurantoin 
and oral cephalosporins may be alternative first-line drugs. 6 Resistance of urinary 
pathogens to older antibiotics is increasing and it has been calculated that around 50% 
of urinary pathogens are now amoxycillin and ampicillin resistant which makes them 
both unsuitable for empirical therapy. 293 Up to 90% of urinary pathogens are sensitive 
to co-amoxiclav, an alternative for infections caused by bacteria resistant to 
trimethoprim. 293 The fluoroquinolones are effective in uncomplicated cystitis because 
only 5% of pathogens are resistant29_3, although resistance will increase the more these 
drugs are prescribed. Five-day and seven-day treatment regimens are usually 
recommended for the treatment of uncomplicated UTls19I but three days has been 
found to be adequate. 288 
In a woman who has recurrent infection with a proven microbial cause and in 
whom imaging investigation has proved negative, prophylactic trimethoprim, 
cephalexin, nitrofurantoin or norfloxacin therapy can reduce the likelihood of further 
attacks. 294 Prophylaxis should be started after successful treatment of infection and 
continued for 3-6 months. 
Patients with acute pyleonephritis should be admitted to hospital if accompanied by 
vomiting or requiring intravenous antibiotic therapy or rehydration. Treatment should 
be started blind with trimethoprim, a 'second or third generation' cephalosporin, a 
fluoroquinolone or an aminoglycoside while waiting for culture results, then changed as 
necessary but continued for 10-14 days. 
288 Severely ill patients are likely to have an 
underlying complication and should be referred. 
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Approximately 30% of pregnant women with untreated asymptornatic bacteriuria 
NN, 'ill develop acute pyelonephritis during the pregnancy. 291 If infection is found and if 
the causative organism is known to be susceptible, amoxycillin, an oral cephalosporin or 
nitrofurantoin is the preferred antibiotic for a minimum of 7 days treatment. 295 In the 
case of a relapse, urine should be cultured 1-2 weeks after stopping treatment. 
5.2.4.2 European Formulary recommendations 
The following drug treatment strategy was recommended in the European 
Formulary: 
1. Lower UTIs and asymptornatic bacteriuria - trimethoprim, amoxycillin 
2. Upper UTIs, initial treatment - trimethoprim, amoxycillin 
3. If treatment with first-line drugs fails or when these drugs are contraindicated 
(after relevant microbiological diagnosis) - norfloxacin or consistent 
prescribing of an alternative fluoroquinolone depending on availability and 
comparative cost per country. 
The European Formulary Group recommendations in the Appendix included that: 
* short courses of trimethoprim and aminopenicillins are first-line treatment for 
uncomplicated UTIs, 
9 longer regimens of these drugs are required where renal infections present, 
e the newer drugs (cephalosporins and fluoroquinolones) should be used for 
treatment failure after relevant microbiological diagnostics or when the first- 
line drugs are contraindicated, 
aminoglycosides should never be used outside hospitals, 
asymptomatic bacteriuria should be treated only in pregnant women and 
children. 
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5.2.4.3 Proposed prescribing performance indicators 
The following hypotheses were drawn up based on quality indicators which could 
be adapted to critically explore the UTI prescribing data in the different countries. The 
hypotheses for UTIs were that: 
,* low prevalences of UTIs in men and children as well as complications in their 
underlying pathology indicate that the analysis should focus primarily on 
prescribing patterns in females of 16 years and above to enable valid 
comparisons from the database, 
e the proportion of antibiotics prescribed which were listed within the European 
Formulary increased following the educational intervention and the 
distribution of the Formulary, 
e the range of newly prescribed antibiotics would be reduced following the 
educational intervention and the distribution of the Formulary 
o trimethoprim being the established first-line drug treatment for UTIs and 
effective against approximately 70% of urinary pathogens should thus be 
found to be prescribed for approximately 70% of UTIs in each country, 
o the use of co-trimoxazole should be justified and limited due to its reported 
adverse toxicity, 
9 the prescribing of the newer second and third generation cephalosporins 
(e. g. cefuroxime, cefixime, ceftibuten and cefpodoxime) and the use of 
fluoroquinolones (e. g. ciprofloxacin) should be based on pharmacoeconornics 
and reserved for cases where specific sensitivity has been demonstrated, 
* the use of combination antibiotic preparations should be limited as they do 
not allow for flexible dosing and their cost usually exceeds that of the 
combined cost of the individual entities if they were prescribed separately, 
9 aminoglycoside antibiotics should not be prescribed outside hospitals. 
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5.2.5 Data manipulation/methodology 
In order to critically evaluate the UTI prescribing by the GP participants in the 
different countries, all the searches with the exception where specified involved drugs 
matched to a UTI diagnosis. The following searches were performed within the 
database: 
* UTIs in both sexes all ages combined, no matching of drugs to diagnosis for 
both Phases combined, 
* UTIs in both sexes all ages combined, for both Phases combined, 
* UTIs in children less than 16 years of age, for both Phases combined, 
UTIs in women 16 years upwards, no matching of drugs to diagnosis for both 
Phases combined 
UTIs in women 16 years upwards, for both Phases combined, 
* all Phase I new prescriptions for UTIs in women 16 years upwards antibiotic 
selection only, 
e all Phase 11 new prescriptions for UTIs in women 16 years upwards antibiotic 
selection only, 
9 all Phase I new prescriptions for UTIs in all males and females combined, 
antibiotic selection only, 
e all Phase 11 new prescriptions for UTIs in all males and females combined, 
antibiotic selection only. 
In order to analyse whether there had been any move towards increased 
concordance with the European Formulary following the educational intervention, 
searches were performed on 'new' prescribing for UTIs in women from both Phases. 
New prescribed items were selected, firstly as it was considered that this would be a 
more realistic measurement of the GPs' prescribing practice, uninfluenced by hospitals 
or previous prescriptions. Secondly, antibiotics should be seldom given as repeat 
prescriptions. 
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For the country by country comparative results section, it was decided to combine 
all the data from Phases I and 11 as this is likely to provide a more meaningful 
illustration of the overall prescribing pattern compared with looking at the trends in 
each of the Phases separately. 
In the results tables, the data were presented in order of prescribing volume in terms 
of the number of items prescribed. The UTI antibiotic drug data were sorted based on 
the following classification: 4: 1 
I Penicillins including: 
- amoxycillin combined with clavulanic acid (betalactamase inhibitor) 
2 Cephalosporins 
Tetracyclines 
4 Aminoglycosides 
5 Macrolides 
6 Sulphonamides and trimethoprim 
7 Fluoroquinolones 
8 Other miscellaneous antibiotic groups combined including: 
- bactericidals, lincosamides,, nitrofurans and steroidals 
9 Other drug entities (not antibiotics) prescribed by the GPs for UTIs 
5.2.6 Results 
5.2.6.1 Morbiditylprevalence patterns 
Urinary tract infections were the fourteenth most commonly occurring diagnosis 
and accounted for 2.1% of the total number of general practice consultations (Table 
5.25). The proportion of UTI consultations varied between 1.5% in Northern Ireland to 
2.6% in Ireland (mean 2%, SD 0.36). The majority of these consultations were for 
females of 16 years and over, varying from 1.1% in Northern Ireland to 1.8% in 
Portugal (mean 1.4%, SD 0.24). The proportion of patients presenting with a UTI who 
received treatment varied from 86% in England and Scotland to 96% in Portugal (mean 
90%, SD 3.7) and in females of 16 years and over, varied from 89% in England to 96% 
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in Ireland and Portugal (mean 92%, SD 3.2). Of a total of 2,061 patients in this study 
presenting with a UTI, 1,825 required a prescription of one or more drug entities and of 
those requiring treatment 1,339 (73%) were women 16 years and above. 
5.2.6.2 Proportion of new antibioticsfrom all antibiotic categories 
Results are detailed in Table 5.26 for new antibiotic drugs only, indicating that 
antibiotics are seldom prescribed from either of the 'R', 'A' or 'H' categories 
(Section 3.1.3.5). The intervention group prescribed on average 82% (2.6) of antibiotics 
as new antibiotics for UTIs in Phase I and 75% (3.1) in Phase 11 compared to the control 
group of 77% (2.7) and 74% (3.3) in Phase I and 11 respectively. There was no 
significant difference in the proportion of new antibiotics items prescribed between the 
control and study groups, neither on average (p = 0.41) nor between countries 
(p = 0.84). 
5.2.6.3 Prescribing performance indicators before and after the intervention 
5.2.6.3.1 Concordance before and after dissemination of the European Formulary 
The level of prescribing concordance with the first-line drugs in the European 
Formulary recommended for UTI i. e. amoxycillin and trimethoprim can be seen in 
Table 5.27. Despite an increase of 5.5% (5.4) in the intervention group as opposed to an 
increase of only 1.3% (4.9) in the control group, this difference was not significant 
(p = 0.24). Between countries the difference was of borderline significance (P = 0.05) 
though. Within Belgium, Ireland, Italy and Portugal, there appeared to be a trend 
towards use of Formulary recommended drugs. In Ireland, the difference between the 
intervention group from Phase I to Phase 11 was of borderline significance (p = 0.05), 
but the difference between the control and intervention groups was not significant 
(p = 0.82) as there was increased concordance with the Formulary in the control group 
too. 
Overall, prescribing by the GPs in Northern Ireland demonstrated the greatest 
concordance with the European Formulary, followed closely by England, Scotland and 
Ireland. Concordance levels in the remaining countries indicated that European 
Formulary first-line recommended drugs were seldom prescribed. 
150 
Effect of the European Formulary and educational intervention 
Of the two first-line antibiotics recommended in the Formulary for UTIs, 
trimethoprim was the more commonly prescribed (Table 5.28) and was prescribed in 
preference to amoxycillin in all countries except for Portugal. From study group Phases 
I to 11, there were considerable increases in trimethoprim use in Ireland and Scotland 
although in the Spanish Phases I and 11 study groups, neither trimethoprim nor 
amoxycillin were prescribed. 
5.2.6.3.2 Range of antibiotics 
There was a slight decrease in the range of newly prescribed antibiotic items for 
UTIs in both males and females from Phases I to 11 in both the study and control groups 
but this difference was not significant (p = 0.29) (Table 5.29). The Spanish data were 
excluded from this analysis due to the number of recorded consultations in Phase 11 
being halved. A borderline significant difference was found between countries 
(p = 0.06). The analysis was repeated for the range of new antibiotics prescribed for 
females of 16 years and above. The results were similar and again there was found to be 
no significant difference either between the study and control groups (p = 0.42), or 
between countries (p = 0.06). The largest decrease in the range from Phase I to Phase 11 
between the control and study groups occurred in Ireland but this difference was also 
not significant (p = 0.17). 
5.2.6.3.3 Prescribing of trimethoprim 
The highest use of trimethoprim was in the Phase I study group of Northern Ireland 
(Table 5.28) where it represented 67% of the antibiotics prescribed for UTIs in females 
of 16 years and over, compared with 0% in Belgium, Portugal and Spain. Trimethoprim 
was the single most commonly prescribed new antibiotic for UTIs in females of 16 
years and above (Table 5.30) as well as for all prescription categories combined (Table 
5.32). For UTI prescribing overall in males and females, all prescription categories 
combined (Table 5.33), trimethoprim use varied from 0% in Spain to 58% in England 
(mean 24%, SID 24). The level of Prescribing of trimethoprim therefore generally fell 
considerably below the proposed 70% mark. 
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5.2.6.3.4 Prescribing of co-trimoxazole 
Co-trimoxazole was the fifth most commonly prescribed new antibiotic overall for 
UTIs (Table 5.30). In Ireland and Portugal, co-trimoxazole was the second most 
commonly prescribed antibiotic and relatively high levels of its use were also found in 
Belgium and Italy. 
Between study group Phases I to 11, the overall level of co-trimoxazole prescribing 
almost halved (Table 5.31) with a particularly large decrease in Belgium and Ireland. 
The level in Italy however remained consistent between Phases and there was a three- 
fold increase in its use from the Phase I study group to Phase 11 in Portugal. 
5.2.6.3.5 Prescribing of cephalosporins 
Second and third generation cephalosporins did not feature among the more 
commonly prescribed new antibiotic items for UTIs (Table 5.3 0 and Table 5.3 1). 
For UTI prescribing in females of all prescription categories combined (Table 5.32) 
and overall in both males and females (Table 5.33), the levels of second and third 
generation cephalosporins were relatively low. Of particular note was that in Italy and 
Spain the cephalosporins prescribed were not first generation. 
5.2.6.3'. 6 Prescribing of fluoroquinolones 
From Table 5.30 it can be seen that of the top 15 newly prescribed antibiotic items 
for UTIs, nearly half were fluoroquinol ones. Of the fluoroquinolones represented in 
Table 5.30, their use varied from 2.2% in Northern Ireland to 84% in Spain (mean 35%, 
SD 32). In Northern Ireland, only one fluoroquinolone was used compared with seven 
in Italy. In Belgium and Portugal, norfloxacin was the drug of choice for UTIs in 
females of 16 years and over, and in Italy and Spain pipernidic acid was the drug of 
choice followed by norfloxacin in both countries. From study group Phases I to 11 
(Table 5.3 1), with the exception of slight changes in preference of fluoroquinolone such 
as the increased use of nalidixic acid in England, overall use of fluoroquinolones was 
fairly similar. 
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5.2.6.3.7 Prescribing of combination antibiotics 
Only 239 (18%) of the 1,319 antibiotic drug entities prescribed overall in females 
of 16 years and over for UTIs belonged to combination antibiotics and of these 214 
entities represented co-amoxiclav and co-trimoxazole. In males and females combined, 
there were 1,783 antibiotic drug entities prescribed for UTIs of which 361 (20%) were 
part of combination antibiotics and 328 of the 361 entities represented co-amoxiclav and 
co-trimoxazole (all but 2%). Co-amoxiclav was the most commonly used combination 
antibiotic varying from 0% in Belgium to 17% in Scotland in females of 16 years and 
above (mean 7.2%, SD 6.1) and from 0.6% in Italy to 21% in Ireland (mean 8.2%, 
SD 7.5) in males and females combined. Collectively in the treatment of UTIs, co- 
amoxiclav was prescribed twice as much as amoxycillin. 
5.2.6.3.8 Prescribing of aminoglycosides 
Of the 1,, 042 newly prescribed antibiotic items for UTIs in females of 16 years and 
above, only six were for aminoglyco sides. There were three prescriptions for netilmicin 
in Portugal and two in Italy, in addition there was one prescription for gentamicin in 
Italy. 
5.2.6.4 Comparisons of antibiotic prescribing 
5.2.6.4.1 Sulphonamides and trimethoprim 
Prescribing of this group of antibiotics for UTIs in females of 16 years and over 
varied from 1.7% in Spain to 56% in England (mean 32%, SD 23) (Table 5.32). In both 
males and females for all ages and categories of prescription combined, their use varied 
from 2.6% in Spain to 58% in England (mean 33%, SD 21) (Table 5.33). Trimethoprim 
represented the bulk of prescribed items in this group of antibiotics, although higher 
levels of co-trimoxazole were prescribed in Belgium, Italy, Portugal and Spain than 
trimethoprim. Thus, there was a greater use of trimethoprim in combination, in all of 
the non-English speaking countries. 
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5.2.6.4.2 Fluoroquinolones 
The overall level of fluoroquinolone prescribing for UTIs was marginally below 
that of sulphonamides and trimethoprim. In females of 16 years and over, 
fluoroquinolone use varied from 3% in Northern Ireland to 81% of the items prescribed 
for UTIs in Spain (mean 34%, SD 31) (Table 5.32). In males and females, their use 
varied from 3.5% in Northern Ireland to 82% in Spain (mean 33%, SD 3 1) (Table 5.33). 
The results indicate that in England, Ireland, Northern Ireland and Scotland, 
fluoroquinolone use was below 10%, whereas in Belgium, Italy and Portugal 
fluoroquinolones were prescribed for between a third and two thirds of UTIs, and in 
Spain for over 80% of UTIs. Norfloxacin was the most commonly prescribed 
fluoroquinolone overall and was the drug of choice in Belgium. In Italy and Spain, 
norfloxacin and pipemidic acid were of roughly equal first choice and in Portugal 
norfloxacin and ofloxacin were of roughly equal first choice. 
5.2.6.4.3 Penicillins 
Penicillins were the third most commonly prescribed group of antibiotics for UTIs 
varying from 2.1 % in Italy to 33% in Northern Ireland (mean 16%, SD 9.5) in females 
of 16 years and over (Table 5.32). For UTIs overall in all males and females, their use 
varied from 3% in Italy to 34% in Northern Ireland (mean 17%, SD 11) (Table 5.33). In 
this group, co-amoxiclav was most commonly prescribed, being the drug of choice in 
Ireland, Portugal, Scotland and Spain. In the remaining four countries, amoxycillin was 
the penicillin of choice. 
5.2.6.4.4 Miscellaneous antibiotics 
This group comprised four drugs, namely: nitrofurantoin, fosfomycin, fusidic acid 
and clindamycin. Combined, they represented the fourth most commonly prescribed 
class of antibiotics in females of 16 years and over (Table 5.32) and the fifth most 
common for UTIs overall, in all males and females combined (Table 5.33). In females 
of 16 years and over, their use varied from 0.7% in Scotland to 31% in Belgium 
(mean 9.2%, SD 8.7) and in males and females combined from 0.6% in Scotland to 25% 
in Belgium (1 M SD 11). Nitrofurantoin was the most commonly prescribed drug in 
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this antibiotic group in five of the eight countries, with the exception of Italy, Northern 
Ireland and Spain where fosfomycin was more prevalent. 
5.2.6.4.5 Cephalosporins 
The level of cephalosporin use was fairly similar to the miscellaneous antibiotic 
usage. Cephalosporins were the fifth most commonly prescribed antibiotic group for 
UTIs in females of 16 years and over but (Table 5.32) the fourth most common group 
for UTIs in all males and females combined (Table 5.33). Prescribing of cephalosporins 
varied from 0% in Belgium to 26% in Scotland (mean 6.9%, SD 8.5) in females of 16 
years and above and in all males and females combined from 0% in Belgium to 25% in 
Scotland (mean 7.5%, SD 8.1). 
5.2.6.4.6 Aminoglycosides 
In females of 16 years and above (Table 5.32), aminoglycosides were used in only 
Italy (1.7%) and Portugal (1.7%). For all prescribing data in males and females 
combined (Table 5.33), aminoglycoside prescribing for UTIs was only found in Italy 
(2.1%), Portugal (1.6%) and Spain (0.7%). 
5.2.6.4.7 Tetracyclines and Macrolides 
In females of 16 years and over (Table 5.32), together they represented 0.6% of 
antibiotics prescribed and for all males and females in all prescription categories, they 
accounted for 0.5% of antibiotic use (Table 5.33). 
5.2.7 Discussion 
Receipt of the European Formulary and participation in the educational intervention 
appeared to have little impact on antibiotic prescribing for UTIs. There was a slight 
trend towards greater concordance with first-line recommended drugs in the overall 
study group compared with the control group but no decrease in the range of newly 
prescribed antibiotics was found. 
In the study, the proportion of consultations varied between 1.5% in Northern 
Ireland to 2.6% in Ireland and a similar range of UTI prevalence has been reported 
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within the UK. 287 Over 70% of patients who presented with a UTI were female of 16 
vears and above and considerably more than 70% of the prescriptions for UTIs were for 
newly prescribed items. These results are not surprising as UTIs are more common in 
NN-omen. 296 Nevertheless the findings were important as the volume of UTI prescribing 
data available for analyses in this study was considerably less than that for the two areas 
of respiratory tract infections for which antibiotic use was also investigated. 
The concordance levels for UTI prescribing were disappointing, although the 
results presented were for first-line Formulary recommended drugs only. If the 
concordance with the Formulary had additionally taken into account the use of 
fluoroquinolones (recommended in the Formulary for use where first-line drugs had 
failed or were contraindicated), then the concordance levels would have undoubtedly 
been greater. Summation of fluoroquinolone prescribing from Table 5.31 to 
trimethoprim and amoxycillin use within each of the countries would have still given 
concordance levels that were disappointing. Despite the Formulary allowing flexibility 
from country to country with respect to the fluoroquinolone of choice, there was 
inconsistent fluoroquinolone prescribing in southern Europe with wider ranges used 
than elsewhere. Overall, there was a notable contrast in the use of fluoroquinolones for 
UTIs varying from less than 10% of the antibiotics used in the UK to more than 80% of 
the newly prescribed antibiotic items in Spain. High levels of fluoroquinolone use in 
Spain have been reported by others297 and more recently the level of resistance to 
fluoroquinolones has been found to be considerable in some parts of Spain. 298 Despite 
there being differences in culture and sensitivity patterns both within and between 
countries, there appears to be little rationale in the excessive use of fluoroquinolones 
prescribed for UTIs in southern Europe. 
Trimethoprim use was highest in the UK regions and was the drug of choice for 
UTIs there but the level of prescribing generally fell well below the proposed target 
figure of 70% in all the countries. One positive outcome is that the intervention may 
have helped demote the use of co-trimoxazole, particularly in Belgium and Ireland and 
in both their study groups, there was a corresponding increase in the level of 
trimethoprim prescribing from Phases I to 11. It has been shown that trimethoprim alone 
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is as good as co-trimoxazole for simple UTIs in general practice and has potentially 
fewer side-effects. 299 
There are some limitations in investigating the area of antibiotic prescribing for 
UTIs in this study. Firstly UTIs may present as either simple or complicated infections 
which are managed in different ways and there is no way of separating the two types in 
this data set,, nevertheless the majority of presentations are of the former type. 
Secondly, it is not known where urine culture has been carried out with appropriate 
tailoring of treatment, compared with where a 'best guess' treatment strategy has been 
selected. Thirdly, as already mentioned culture and sensitivity patterns differ from 
region to region and this will be partially responsible for some variations in antibiotic 
prescribing patterns. Fourthly, no data were available comparing the duration of 
antibiotic treatment regimens which are known to vary. 288 There are also some 
limitations with respect to recommendations for UTI treatment within the European 
Formulary. Amoxycillin has been reported to be unsuitable for empirical therapy 
because of its association with a high failure rate as a result of high levels of 
resistance289293 but it was recommended as first-line treatment in the European 
Formulary. Secondly, the European Formulary appeared to be limited in its range of 
treatment options. Nitrofurantoin and an oral first generation cephalosporin (except for 
cephalexin) which have been recommended elsewhere as alternative first-line 
drugs288,289, were excluded. 
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5.3 RESPIRATORY TRACT INFECTIONS 
5.3.1 Introduction 
The prescribing of antibiotics for respiratory tract infections (RTIs) has long been 
and continues to be an area of controversy. 00 Davey et al, a general practice research 
group from Dundee, analysed PACT and SPA data from 1980 to 1991 which revealed 
that there was an average increase of 5% per year for all antibacterial items prescribed in 
the community in England and Scotland. 301 The authors speculated that the changes 
represented an increased tendency to prescribe for respiratory conditions. Despite this 
increase being of concern, even larger increases in antibiotic prescribing were found 
over the same time period in other countries (Table 5.34). 
Increased prescribing of antibiotic items has major implications for increased cost 
burdens on different health care systems. In the UK, the Audit Commission in 1994 
estimated that f295m could be saved from the NHS drug bill if overprescribing was 
reduced. 30 Of this, approximately f 80m was attributed to antibiotics which at the time 
represented 45% of the total cost of antibiotic prescribing. Antibiotics are frequently 
prescribed for viral infections against which they are ineffective; even when they are 
indicated, the duration of treatment is often unnecessarily long. In addition, research by 
GPs in II general practices in Southampton showed that antibiotic prescribing increases 
patients' belief in antibiotics and their intention to reconsult, compared with either not 
prescribing or offering a delayed prescription. 302 Currently the cost of oral antibiotics 
in England and Wales is f 175m. 29 
Unnecessary overprescribing of antibiotics is also a major public health concern as 
it promotes the building up of resistance and disturbs the balance of micro-organisms in 
the body which may permit more severe infections to develop. Research between 1991 
to 1996 which involved taking samples from patients in England and Wales with 
meningitis or septicaemia has found that the percentage of Staphylococcus aureus 
samples resistant to beta-lactam antibiotics has increased from 1.5% to nearly 22%. 
303 
In September 1998, the UK Standing Medical Advisory Committee (SMAC) published 
a report called the 'Path of Least Resistance' which identified four areas that could 
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make a significant impact on the volume of antimicrobials prescribed. 304 The report 
included the following key recommendations that: 
9 antibiotics should not be prescribed for simple coughs and colds, 
* antibiotics should not be prescribed for viral sore throats, 
e specia consideration should be made when determining the appropriate 
duration of treatment, 
e anti iotic prescribing over the telephone should be limited to exceptional 
cases. 
There is no single antibiotic which is effective against all bacteria. Some 
antibiotics such as penicillin have a relatively narrow spectrum of activity, while others 
have a much broader spectrum of activity. It is prescribing of the latter that has been 
shown to promote most drug resistance. The main problem in prescribing of antibiotics 
in general practice is that Prescribers rarely know the precise organism involved, nor 
consequently the best drug to use. In spite of widespread use of antibiotics over the last 
40 years, many bacterial infections in general practice remain sensitive to the well tried 
and tested older antibiotics which provides a strong argument against the prescribing of 
newer antibiotics unless there is a specific indication for their use. 
The frequency with which patients with acute respiratory problems present to their 
GP accounts for 17% of all 'acute' consultations as recorded in one study148 though 
antibiotic prescribing for RTIs covers a vast range of presenting diagnoses and 
symptoms. Respiratory infections have also been reported to be the most frequent 
reason for primary health care consultation in Spain. 305 For the purposes of this thesis 
in order to determine any effect of the intervention as well as to compare and contrast 
differences between the countries, it was decided to group together some of the 
diagnostic codes as follows: 
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* Throat Infections 
- acute pharyngitis/tonsillitis and sore throat/throat infection 
* Lower Respiratory Tract Infections 
- acute bronchitis, bronchitis, chronic bronchitis and pneumonia 
5.3.2 Throat infections 
5.3.2.1 Diagnosing Throat Infections 
The sore throat syndrome is one of the commonest presenting conditions in general 
practice and there is strong evidence that the majority are caused by viruses for which 
the prescription of an antibiotic is inappropriate. Streptococcal sore throat/pharyngitis is 
difficult to diagnose on clinical grounds alone as it is usually indistinguishable clinically 
from viral infections. Culture of a throat swab is used conventionally to make a 
definitive diagnosis. Using throat-swab culture as a method of determining the cause of 
sore throat has several limitations including errors that can arise when the swab is 
positive because of carriage rather then streptococcal infection. 306 In addition, the cost 
of swabbing all acute sore throats routinely in UK general practice would be 
approximately f-40 million annually. The difficulties in establishing the causative 
agents and the uncertain contribution this information provides in deciding on treatment 
as well as the time delay makes the choice of treatment controversial. 3 07 For practical 
reasons an empirical, epidemiologically based approach is often used by doctors and 
may be accepted in many cases. Although this approach is inexpensive, using clinical 
scorecards or symptom clusters to identify individuals who would benefit from 
treatment is insensitive with low predictive value and therefore this method is not 
entirely rational. 308 
5.3.2.2 Rational prescribingfor Throat Infections 
The aim of treatment is to relieve symptoms, prevent complications and limit the 
spread of the illness by eradicating the infecting strain of streptococcus (if present) from 
the upper respiratory tract. 
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A streptococcal throat infection is usually self-limiting and symptoms can be 
relieved with simple analgesics, though symptoms may resolve more quickly when 
penicillin is given. Traditionally, bacterial pharyngitis has been treated with antibiotics 
to prevent serious complications like acute rheumatic fever or acute 
glomerulonephritis. 306 The rarity of these complications in industrialised countries has 
led to controversies about the value and cost-effectiveness of treating streptococcal sore 
throat with antibiotics. 300 Nevertheless,, relatively recent outbreaks of rheumatic fever 
in the US suggest that some streptococcal micro-organisms may still be potentially 
dangerous for a minority of patients. 309 Immediate treatment may therefore be 
indicated in patients with severe pharyngitis, with or without exudate but with 
pronounced systemic features and in those with scarlet fever. Delaying treatment to 
await the results of culture does not increase the risk of complications but if time is 
taken to obtain bacteriological results, antibiotics are not necessarily going to shorten 
the course of the illness. 
5.3.2.3 European Formulary recommendations 
The following drug treatment strategy was recommended in the EF: 
1. Symptomatic - simple analgesics (e. g. aspirin and paracetamol) 
2. Antibiotics - phenoxymethylpenicillin or erythromycin 
The European Formulary Group (EFG) recommendations in the Appendix included 
that: 
o pharyngitis/tonsillitis can usually be treated with a simple analgesic, 
e when a swab confirms a bacterial infection, phenoxymethylpenicillin is the drug 
of choice or alternatively erythromycin for patients allergic to penicillin, 
* prescribing of amoxycillin or cephalosporins (effective broad spectrum drugs) 
for this condition may favour the emergence of resistant Haemophilus 
in uenzae resistant strains in the community. Ifl 
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5.3.2.4 Proposed prescribing performance indicators 
The following hypotheses were drawn up based on performance indicators which 
could be adapted to critically explore the prescribing data for pharyngitis/throat related 
disorders in the different countries. The hypotheses were that for pharyngitis/throat 
related disorders:: 
* the proportion of newly prescribed antibiotics which were listed within the 
European Formulary would increase following the educational intervention 
and the distribution of the Formulary, 
the proportion of consultations resulting in an antibiotic prescription would 
reduce following the intervention and distribution of the Formulary, 
the range of new drugs prescribed would reduce following the educational 
intervention and the distribution of the Formulary, 
e the prescribing of broad spectrum antibiotics would be limited following the 
educational intervention and distribution of the Formulary as they promote a 
build up of drug resistance, 
* the prescribing of new macrolides e. g. clarithromycin would reduce following 
the intervention and distribution of the Formulary as they are expensive and 
should only be used for resistant strains compared with erythromycin which is a 
reasonable alternative for patients allergic to penicillin, 
* the proportion of simple analgesics prescribed which were listed within the 
European Formulary would increase following the educational intervention 
and the distribution of the Formulary, 
the proportion of consultations resulting in an analgesic prescription would 
increase following the intervention and distribution of the Formulary. 
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5.3.2.5 Data man ip ulationlineth odology 
In order to critically evaluate the prescribing for throat infections by the GPs in the 
different countries, all the searches except where indicated involved a matching of drugs 
to diagnoses. The following searches were performed in the database: 
9 all antibiotic prescriptions for throat infections for both Phases combined, no 
matching of drugs to diagnoses, 
* all consultations for throat infections for both Phases combined, no matching 
of drugs to diagnoses, 
e new antibiotic prescriptions for throat infections, Phase I only, 
e new antibiotic prescriptions for throat infections, Phase 11 only, 
* new antibiotic prescriptions for throat infections for both Phases combined, 
9 new analgesic and NSAID prescriptions for throat infections, Phase I only, 
9 new analgesic and NSAID prescriptions for throat infections, Phase 11 only, 
* new analgesic and NSAID prescriptions for throat infections, both Phases 
combined,, 
" all drug prescribing for throat infections for both Phases combined, 
" new drug prescribing for throat infections, both Phases combined, 
" all study group Phase I new drug prescribing for throat infections, 
" all study group Phase 11 new drug prescribing for throat infections, 
* new antibiotic prescriptions for throat infections, no matching of drugs to 
diagnoses Phase I only, 
9 new antibiotic prescriptions for throat infections, no matching of drugs to 
diagnoses Phase 11 only, 
e new analgesic and NSAID prescriptions for throat infections, no matching of 
drugs to diagnoses Phase I only, 
e new analgesic and NSAID prescriptions 
for throat infections, no matching of 
drugs to diagnoses Phase 11 only. 
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For the country by country comparative prescribing results section, it was decided 
to combine the data from Phase I and Il which is likely to provide a more meaningful 
illustration of the overall prescribing pattern compared with looking at the trends in each 
of the Phases separately. 
In the results tables, the data were presented in order of prescribing volume in terms 
of the number of items prescribed. The drug data for throat infections were sorted based 
on the following classification: 
I Penicillins including: 
- amoxycillin combined with clavulanic acid (betalactamase inhibitor) 
2 Cephalosporins 
Tetracyclines 
Aminoglycosides 
Macrolides 
Sulphonamides and trimethoprim 
7 Fluoroquinolones 
8 Other miscellaneous antibiotic groups combined including: 
- bacterio statics, lincosamides and other individual antibiotics 
9 Analgesics and NSAIDs 
10 Other drug entities (neither antibiotics nor analgesics) prescribed by the GPs 
for throat infections 
5.3.2.6 Results 
5.3.2.6.1 Morbidity/prevalence patterns 
The different throat infection diagnostic codes when consolidated represented the 
fifth most commonly occurring diagnosis and accounted for 3.7% of the total number of 
general practice consultations. From Table 5.35 it can be seen that the proportion of 
consultations for throat infections varied between 2.1 % in Spain to 5.4% in Belgium 
(mean 3.9%, SD 1.2). The proportion of patients presenting with a throat disorder who 
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received treatment varied from 79% in England to 99.8% in Portugal (mean 90%, 
SD 6.3). Of a total of 3,830 patients presenting with a throat disorder, 3,430 were 
prescribed 4,235 drug entities of which 3,588 (85%) were new prescriptions and 3,863 
(91 %) were single non-combination drugs. 
5.3 3.2.6.2 Prescribing performance indicators before and after the intervention 
5.3.2.6.2.1 Concordance with antibiotics recommended in the European Formulary 
For newly prescribed antibiotic items, both the intervention and control groups 
moved away by -1.8% (4.1) and -6.7% (4.9) respectively from the Formulary 
recommendations (Table 5.36). Despite there being a larger movement away by the 
control group, the difference was not significant (p = 0.43). Significant differences were 
found between the countries (p = 0.002) but there was no significant (p = 0.42) country- 
by-group interaction. 
In Ireland, there appeared to be some positive movement towards increased 
prescribing of the Formulary recommended drugs - the difference between the 
intervention group from Phase I to 11 was significant (p = 0.009) and the difference 
between the control and intervention groups from Phases I to 11 was of borderline 
significance (p = 0.04). There was also some positive movement towards the Formulary 
recommended drugs in Italy, Northern Ireland and Portugal (Table 5.36) but the 
differences were not statistically significant. Overall, the greatest concordance with the 
Formulary can be seen to occur in the English speaking countries with little prescribing 
of the two Formulary recommended antibiotics in Belgium, Italy, Portugal and Spain. 
Phenoxymethylpenicillin was markedly the more commonly prescribed antibiotic, 
of the two recommended in the European Formulary. In both Ireland and Northern 
Ireland prescribing levels of phenoxymethylpenicillin increased by nearly 15% from 
study group Phase I to study group Phase 11. In contrast there was no prescribing of this 
drug in Italy, Portugal and Spain (Table 5.37). Erythromycin levels fluctuated between 
the study groups in the two time periods with increases in all countries except for 
England and Spain. Of particular note was the increase in prescribing of erythromycin 
in Portugal from 4.6% to 14%. 
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5.3-2.6-2.2 Proportion of consultations resulting in a 'new'antibiotic prescription 
Overall there was no significant difference in the proportion of patients receiving 
new antibiotics for throat infections between Phase I and Phase 11 (p = 0.18). Belgium 
was excluded from the analysis as no data were provided on consultations without 
prescriptions. The average proportion of consultations resulting in a prescription 
marginally decreased in the intervention group by 1.2% (3.4) but on average decreased 
even more in the control group by 8% (). 8) between Phases I and 11 (Table 5.38). The 
proportion of consultations resulting in a prescription decreased in the intervention 
groups of all the countries except for Portugal and Scotland but even greater reductions 
were seen in all the control groups except for England and Italy. In none of the 
countries did any of the differences prove to be statistically significant. Overall in Spain 
approximately one in three consultations for a throat infection resulted in a new 
antibiotic prescription whereas in Ireland, over 70% of these consultations resulted in a 
script for a new antibiotic. 
5.3.2.6.2.3 Range of new drugs prescribed 
There was a very slight decrease in the range of new drugs prescribed in both the 
intervention and control groups (Table 5.39). Spain was excluded from the statistical 
analysis due to half the number of consultations having been recorded in Phase 11. 
There was a similar reduction in range between the intervention and control groups and 
so no significant difference were found between them (p = 0.16) but significant 
differences were found between countries (p = 0.02). The largest reduction in the range 
between the intervention and control groups occurred in Belgium and the difference 
there was found to be of borderline significance (p = 0.04). The range of new drugs 
prescribed by the Belgian intervention group appeared to be unusually high though 
compared with the corresponding control group there. Other slight decreases in the 
range were found in Ireland and Northern Ireland compared with their control groups, 
but neither of these was found to be statistically significant. 
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In general, the range of new drugs prescribed for throat infections was lowest in 
England and Scotland averaging approximately 2.5 drugs per GP compared with Italy 
and Portugal where the ranges prescribed were more than double this number. 
5.3.2.6.2.4 Broad spectrum antibiotic prescribing 
The prescribing of arnoxycillin for throat infections was 26% overall which was 
almost equivalent to that of phenoxymethylpenicillin (Table 5.40). Levels of 
amoxycillin prescribing increased substantially in the intervention groups of Italy, 
Portugal and Scotland from Phase I to Phase 11 (Table 5.41) despite the educational 
intervention discouraging the prescribing of broad spectrum penicillins for sore throat. 
The greatest drop in amoxycillin prescribing occurred in the intervention group of 
Northern Ireland from 19% to 12 % (Table 5.41) but levels of arnpicillin (another broad 
spectrum penicillin) remained high there. The level of ampicillin prescribing decreased 
in the overall study group from Phase I to Phase 11 which was predominantly due to a 
decrease in Ireland from I I% to 2.2%. However in Ireland the relative proportion of 
prescribing of co-amoxiclav nearly doubled from 4.6% to 8.7% from Phase I to 
Phase 11. 
Cephalosporins are also broad spectrum antibiotics and are thus discouraged from 
being prescribed for throat infections. From the intervention groups in Table 5.41 it can 
be seen that no individual cephalosporin represented more than I% of the prescribing in 
England, Scotland and Spain. The level of cefaclor reduced overall from Phase I to 
Phase 11 to represent less than 1% of prescribing for throat infections and prescribing 
levels of cephalexin decreased between time periods in the study groups of the three 
countries where it was prescribed namely, Ireland, Italy and Northern Ireland. 
5.3.2.6.2.5 Prescribing of new macrolides 
With Phase I and 11 new antibiotic data combined, erythromycin prescribing overall 
was more than double that of clarithromycin, the second most commonly prescribed 
macrolide antibiotic (Table 5.40). However, in the study groups of Phase I (Table 5.37 
and Table 5.41), prescribing of clarithromycin was overall more than erythromycin 
for 
all drug categories combined and clarithromycin was the macrolide of choice 
in Ireland, 
Italy, and Portugal and of equal choice with erythromycin in Scotland. Between Phase I 
and 11 the overall prescribing of clarithromycin 
in the study groups decreased by a third. 
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At the same time, the prescribing of erythromycin doubled resulting in it becoming the 
macrolide of choice in all countries except for Belgium where the level of 
clarithromycin was five times that of erythromycin (Table 5.40). In Spain, neither 
erythromycin or clarithromycin were prescribed. Some of these changes in prescribing 
may have been prompted by the intervention and dissemination of the Formulary. 
5.3.2.6.2.6 Concordance with analgesics recommended in the European Formulary 
For symptomatic treatment of throat infections, the intervention group appeared to 
move towards prescribing the European Formulary recommended drugs by 15% (7.5) 
compared with the movement away by the control group -6.7% (7.3) (Table 5.42). This 
difference between the control and study groups was found to be highly significant 
(p = 0.002) and there were also found to be significant differences between countries 
(p = 0.03) but no significant country by group interaction (p = 0.13). From Table 5.42 it 
can be seen that there was no new simple analgesic prescribing in the control groups of 
England and Ireland but even with exclusion of these two countries from the analysis 
the differences were still statistically significant both between the control and 
intervention groups (p = 0.002) and between countries (p = 0.02). The greatest 
movement towards the prescribing of European Formulary recommended drugs can be 
seen to occur in Belgium, Northern Ireland and Portugal. 
Of all the drugs prescribed for throat infections, paracetamol accounted for 9.3% of 
the prescribing overall and was the most commonly prescribed analgesic. The 
prescribing levels of paracetamol increased in the intervention groups from Phases I to 
11 in all the countries except for England and Ireland (Table 5.37). The largest increase 
in paracetamol prescribing was found in Portugal where levels increased from 3.1 % to 
19%. There were marginal increases in the prescribing of aspirin in the intervention 
groups of England, Ireland and Portugal but for the intervention groups combined, 
aspirin prescribing decreased between Phase I to 11. 
The most commonly prescribed analgesics for throat infections which were outside 
the Formulary recommendations can be seen in Table 5.43. 
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5.3.2.6.2.7 Proportion of consultations resulting in a 'new'analgesic prescription 
The combined effect of the European Formulary and educational intervention did 
not increase the proportion of consultations for throat infections resulting in the 
prescription of a new analgesic (p = 0.75) (Table 5.44). Significant differences in the 
proportion of consultations resulting in an analgesic prescription were however found 
between countries (p = 0.004). The largest difference between control and intervention 
groups in the prescribing of analgesics was found in Northern Ireland (Table 5.44) but 
this difference was not significant (p = 0.08). An increase in the prescribing of 
analgesics was also seen in Italy and Portugal but again neither of these positive trends 
was statistically significant. 
5.3.2.6.3 ) Comparisons of antibiotic prescribing 
5.3.2.6.3.1 Penicillins 
Of the antibiotics and analgesics prescribed for throat infections, the penicillins 
were the most popular group used accounting for 56% of the drugs prescribed from all 
the drug categories collectively (Table 5.45). Penicillin group prescribing varied from 
28% in Belgium and Italy to 80% in Scotland (mean 54%, SD 23). 
Phenoxymethylpenicillin and amoxycillin were the penicillins of choice depending on 
the country and together they accounted for approximately 75% of the penicillin 
prescriptions. For all drug categories combined, phenoxymethylpenicillin use varied 
from 0% in Italy and Portugal to 43% in Scotland (mean 20%, SD 21) and amoxycillin 
use varied from 6.7% in England to 29% in Ireland and Spain (mean 19%, SD 7.7). For 
new antibiotics only (Table 5.40), phenoxymethylpenicillin use varied from 0% in Italy 
and Portugal to 51% in England (mean 23%, SD. 23) and amoxycillin use varied from 
7.6% in England to 57% in Spain (mean 29%, SD 15). 
5.3.2.6.3.2 Macrolides 
Macrolides were the second most common group of drugs prescribed from all drug 
categories combined for throat infections, accounting for 12% of the drugs prescribed 
(Table 5.45). Macrolide use varied from 6.1 % in Northern Ireland to 18% in Portugal 
(mean 9.5%, SD 3.7). Erythromycin was the most commonly prescribed macrolide, 
varying from 2.1 % in Belgium to 13% in England (mean 6%, SD 3.2). As a proportion 
169 
Effect of the European Formulary and educational intervention 
of 'N' antibiotic prescribing, erythromycin prescribing levels varied from 2.5% in 
Belgium to 14% in England (mean 8%, SD 3 ). 6) (Table 5.40). 
From Table 5.40, it can be seen that in all English speaking countries erythromycin 
was the macrolide of choice but in the other four countries there was a trend to prescribe 
the newer antibiotics. In Belgium, clarithromycin was the macrolide of choice being 
prescribed eight times more frequently than erythromycin. In Italy, seven different 
macrolides were prescribed. Azithromycin was the macrolide of choice followed by 
clarithromycin, erythromycin and roxithromycin. Whilst erythromycin was the 
macrolide of choice in Portugal and Spain, summation of the newer macrolides 
prescribed in both countries exceeded erythromycin alone. 
5.3.2.6.3.3 Cephalosporins 
Cephalosporins were the third most common group of antibiotics prescribed 
varying from 0.5% in Spain to 6.9% in Belgium and Ireland (mean 3.5%, SD 2.6) 
(Table 5.45). Cephalexin was the most commonly prescribed cephalosporin both from 
the new antibiotics and from all the drug classes combined (Table 5.40). Despite this, 
the bulk of the cephalosporin prescribing came from the prescribing of cefaclor, 
cefaroxime and cefixime,, all of which are second generation cephalosporins. 
Prescribing of these three drugs was found to be most common in Ireland, Italy and 
Portugal. 
5.3.2.6.3.4 Sulphonamides and trimethoprim 
Sulphonamides and trimethoprim represented 1.9% of the antibiotics and analgesics 
prescribed for throat infections, their use varying from 0% in Spain to 4.3% in Belgium 
(mean 1.6%, SD 1.8) (Table 5.45). Co-trimoxazole accounted for two-thirds of the 
prescribing in this antibiotic group and was the most commonly prescribed in Ireland 
and Italy. For new drugs in Ireland and Italy (Table 5.40), co-trimoxazole accounted for 
3.6% and 3.9% respectively and for all prescription categories combined it accounted 
for 3.3% and 2.2%. 
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5.3-2.6.3.5 Miscellaneous antibiotics 
The miscellaneous antibiotics accounted for 1.5% of the drugs prescribed for throat 
infections. The most commonly prescribed antibiotic in this category was fusafungine 
which varied from 0% in England, Scotland and Spain to 3.5% in Portugal (mean 0.8%, 
SD 1.2) (Table 5.45). Fusafungine is active against both some Gram-positive and some 
Gram-negative organisms and possibly has some anti-inflammatory action. It is used in 
the form of an aerosol spray in the treatment of throat infections. 
5.3.2.6.3.6 Tetracyclines, Fluoroquinolones and Aminoglycosides 
When combined, these three groups of antibiotics accounted for only 1.1% of the 
drugs prescribed for throat infections. From Table 5.45 it can be seen that tetracyclines 
were most commonly prescribed in Belgium (1.1%) and Ireland (1.4%) 
fluoroquinolones were most commonly prescribed in Italy (1.3%) and arninoglycosides 
in Belgium (1.6%). 
5.3.2.6.4 Comparisons of analgesic including NSAID prescribing 
This drugs category represented just under a quarter of those prescribed for throat 
infections from all drug categories combined. Their use varied from 4.5% in Ireland to 
52% in Spain (mean 28%, SD 19) (Table 5.45). 
5.3.2.6.4.1 Analgesics 
Analgesic prescribing, excluding NSAIDs varied from 2.7% in Ireland to 45% in 
Spain (mean 16%, SD 14). Paracetamol was universally the analgesic of choice 
accounting for over 80% of the analgesic prescribing varying from 1.8% in Ireland to 
31% in Spain (mean 13%, SD 9.9) (Table 5.45). Co-codamol was generally the second 
analgesic of choice depending on the country. From Table 5.43 it can be seen that in the 
intervention groups from Phases I to II, co-codamol use decreased from 1.9% to less 
than M 
5.3.2.6.4.2 NSA IDs 
NSAIDs represented nearly 14% of the total prescribing of antibiotics, analgesics 
and anti-inflammatories prescribed for throat infections. Their use varied from 0.7% in 
Scotland to 35% in Italy (mean 11%, SD 13) (Table 5.45). Nimesulide (a cox-2 
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NSAID) was the most commonly prescribed NSAID despite its prescribing being 
restricted to Italy and Portugal only. From Table 5.43 it can be seen that prescribing of 
this drug decreased considerably in the intervention group of Portugal from Phase I to 
Phase 11. 
5.3.2.7 Discussion 
The difference in prescribing patterns between Phases I and 11 suggest that the 
educational intervention may have had some positive effects in improving the 
management of throat infections as has been found with other similar interventions in 
primary care. 310-312 The three most successful outcomes of the study were that: 
1. there was a highly significant increase in concordance by the intervention group 
overall compared with the control group, towards EF recommended simple 
analgesics and within countries the greatest increases were seen in Belgium, 
Northern Ireland and in Portugal. 
2. for antibiotic prescribing, the increase in concordance with the EF by the Irish 
intervention GPs compared with the control group was statistically significant. 
3. there was a significant reduction in the range of new drugs prescribed for throat 
infections between the control and intervention groups in Belgium. 
Throat infections are an example of an acutely presenting condition in primary care 
and hence 85% of the drug entities prescribed for it in this study were found to be for a 
newly prescribed item. A combination of such a high proportion of prescriptions 
belonging to this category and the fact that throat infections represented the fifth most 
common diagnosis, meant that any effect of the educational intervention would be 
expected to be more apparent. 
Antibiotic concordance with the Formulary in general was disappointing, especially 
in the non-English speaking countries where the average levels were well below 50%. 
In these countries, concordance levels with the Formulary recommended simple 
analgesics were better than those for antibiotics but still lower than concordance levels 
in the English speaking countries. Patients presenting with throat infections in southern 
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European countries were found to be more likely to receive a related prescription than 
elsewhere. However one positive feature of the prescribing patterns for throat infections 
in Belgium and the southern European countries was that, between one third and half 
the number of prescriptions issued were for analgesic s/anti-inflammatories which was a 
notably higher proportion than in English speaking countries. It is possible though that 
patients in the UK may be encouraged to purchase OTC analgesics which are relatively 
cheap. 
Of the antibiotics recommended by the Formulary, phenoxymethylpenicillin 
prescriptions increased between Phases I and 11, from 21% to 36% and from 31% to 
44% of all new drugs used in the intervention groups of Ireland and Northern Ireland 
respectively. Erythromycin prescriptions increased from 4.6% to 14% in Portugal 
replacing clarithromycin as the main macrolide there. Prescribing of erythromycin also 
increased after the intervention in the study groups of Ireland, Italy and Scotland to 
replace clarithromycin as the macrolide of choice there. However with the data for 
control and intervention groups in both Phases combined, it was noted that seven 
different macrolides were prescribed by the Italian GPs with azithromycin being the 
macrolide of choice, followed by clarithromycin. While this is indicative of irrational 
prescribing, these patterns may be partially explained by the finding of a sharp rise in 
erythromycin resistant rates in the mid-1990s in North Italy. 313 Common prescribing 
of macrolides for acute URTIs in primary care has been reported by other Italian 
researchers. 314 In Portugal and Spain, summation of the newer macrolides prescribed 
collectively also exceeded the number of erythromycin prescriptions there. 
In the study, amoxycillin was both the antibiotic of choice in Belgium, Italy, 
Portugal and Spain and the level of amoxycillin prescribing overall was almost as high 
as that of phenoxymethylpenicillin. Although amoxycillin has been found to be as 
effective as phenoxymethylpenicillin in treating throat infections315, sore throats 
should be regarded as potentially indicative of glandular fever and thus broad spectrum 
antibiotics such as amoxycillin should not be used for 'blind' treatment of a sore 
throat. 6 There is also little justification for using amoxycillin for throat infections in 
countries where its cost is greater than that of phenoxymethylpenicillin, such as in the 
UK where it is almost double the price. 
279 Of the other broad spectrum antibiotics 
173 
Effect of the European Formulary and educational intervention 
discouraged from being prescribed for throat infections, cephalosporin levels were 
minimal except for being prescribed by some GPs in Ireland and Northern Ireland. 
There are several limitations in investigating the area of antibiotic prescribing for 
throat infections. Firstly the terminology used by GPs to classify and label the 
presenting complaint is inconsistent in-part due to the difficulty in making a clinical 
diagnosis. While it was considered acceptable to clump together codes for acute 
pharyngitis/tonsillitis and sore throat/throat infections in this analysis, the codes for 
respiratory tract infections and URTIs were not included. A 'respiratory tract infection' 
label does not indicate whether the condition was upper or lower and in any case URTIs 
incorporate acute otitis media and acute sinusitis, for which the recommended 
antibiotics where necessary, are slightly different. Research has shown that the use of a 
diagnostic label 'tonsillitis' is more likely to result in a prescription for penicillin than if 
the diagnosis were 'URTF which would be more likely to result in symptomatic 
treatment316 but it was not possible to investigate this further in this research. A 
second limitation is that it was not known whether patients were reattending, having 
experienced side-effects to previous treatment or because it may have failed. This may 
have accounted for only a relatively small number of antibiotic prescriptions though as 
one study in Southampton found reattendance rates to be low302 and another study in 
Scotland found that of nearly 1000 patients who received at least one prescription for an 
antibiotic, only 14% of the infections required more than one antibiotic prescription to 
achieve a successful outcome. 317 Thirdly culture and sensitivity patterns vary both 
between318,319 and within countries320 and this will be partially responsible for 
variations in prescribing, as with the UTI prescribing patterns. 
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5.3.3 Lower respiratory tract infections 
5.3.3.1 Diagnosing Lower Respiratory Tract Infections 
There is considerable variation in the diagnosis classification by which GPs group 
the different presentations of lower respiratory tract infections (LRTIs). LRTIs overlap 
with and include many illnesses such as acute bronchitis, infectious exacerbation of 
chronic bronchitis and pneumonia. 149 LRTIs are frequent community-acquired 
infections affecting both the paediatric and adult population and are one of the 
commonest respiratory illnesses observed in daily medical practice. 
Acute bronchitis implies acute inflammation of the bronchial tree and it is often 
associated with a preceding viral nasopharyngitis (common cold). The most common 
organisms responsible for secondary bacterial infection are Streptococcus pneumoniae 
and Haemophilus influenzae but the frequency with which they occur is unclear. 321 
Whilst many LRTIs seen by GPs are self-limiting conditions, between 5% - 10% 
are pneumonias. 322 In patients with suspected LRTI, there are no firmly established 
clinical criteria that absolutely exclude pneumonia and prospective studies show that no 
individual clinical findings or combination of findings will definitely confirm a 
diagnosis of pneumonia. Again the main organisms responsible are Streptococcus 
pneumoniae, Haemophilus influenzae and viruses. 
321 
Many acute exacerbations of chronic obstructive pulmonary disease/airways disease 
(COPD/COAD) are associated with viral infection and the other organisms identified as 
the most common causes of secondary bacterial infection are Streptococcus 
pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. 
323 
In general practice, the diagnosis of LRTI will nearly always be made on clinical 
grounds alone and the infecting organism is rarely identified. Clinical 
features such as 
older patients with more underlying disease ('typical') and younger patients with more 
upper respiratory tract findings and less underlying 
disease (atypical') are the factors 
which usually determine the practitioners' strategy 
despite the unreliability of predicting 
the causative pathogen. 
324 
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Blood tests,, sputum examination and culture are not usually done in the UK 
because it is generally considered that test results take too long to influence 
management. Chest x-rays are also seldom routinely done despite being indicated in 
certain patients, particularly smokers who are slow to recover or who have a recurrent 
LRTI. One study found that, even in patients already on an antibiotic, sputum culture 
results could often guide clinical decisions, such as in patients with chronic lung disease 
or in whom an antibiotic had failed. 325 
5.3.3.2 Rational prescribingfor LR TIs 
In the UK, approximately 75% of patients consulting their GP with an acute LRTI 
receive an antibiotic. 326 The same respiratory medical research team at Nottingham 
found that between 20-25% seek a second consultation often within a fortnight, usually 
because of persisting symptoms. 149 A follow up study revealed that nearly two thirds 
are prescribed a further course of antibiotic but investigation showed that few of these 
had infections that required such treatment. 327 
There have been several trials comparing a range of antibiotic treatment strategies 
with that of placebo for different LRTIs but, because of variations in inclusion and 
exclusion criteria, few studies can be statistically compared, leaving the evidence 
somewhat inconclusive. Even when a meta-analysis was performed comparing 
antibiotics used in COM, the main outcomes measured differed from trial to trial 
making the analysis diffcult. 328 Despite the results being statistically significant, only 
a small improvement was shown in patients receiving antibiotic therapy for acute 
exacerbations of COPD. 
The majority of healthy adults with few symptoms are unlikely to benefit from 
antibiotic therapy. In clinical trials involving previously healthy patients with acute 
bronchitis, 19-36% developed unwanted effects from the antibiotic. 145,329 Resistance 
to antibiotics is becoming increasingly common in respiratory pathogens and any 
irrational antibiotic prescribing is likely to potentiate this problem. 
330 Initial receipt of 
an antibiotic prescription for a respiratory infection may also influence patient 
expectations for future occasions. 
331 
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At the other end of the spectrum, antibiotic treatment should not be delayed in 
either adults or in children if pneumonia is suspected. 332 Epidemiological evidence 
shows that while many episodes of LRTI are due to viruses, bacterial infection, 
especially pneurnococcal infection is more common in those over 60 years old and in 
those with other underlying medical disorders. 149 If antibiotics are necessary, then the 
aim of treatment is to treat as specifically as possible while ensuring that the most likely 
organisms are affected. 
5.3.3.3 European Formulary recommendations 
The following antibiotic drug treatment strategy based on efficacy, safety, 
convenience and cost was recommended in the European Formulary: 
- amoxycillin 
- benzylpenicillin 
- doxycycline 
- erythromycin 
The European Formulary Group (EFG) recommendations in the Appendix included 
that: 
9 prescribing of antibiotics for acute bronchitis is almost always unnecessary, 
treating acute exacerbations of chronic bronchitis with antibiotics is 
controversial, 
previously well children and adults with pneumonia usually recover well with 
a prescription for a penicillin or erythromycin, 
* rare pathogens should be suspected in patients at risk from pre-existing 
conditions and hospitalisation may have to be considered, 
e GPs should prescribe from a small range of antibiotics, 
9 third generation cephalosporins, fluoroquinolones and new macrolides are 
relatively expensive and their use should be restricted to selected patients. 
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5.3-3.4 Proposed prescribing performance indicators 
The following hypotheses were drawn up based on quality indicators which could 
be adapted to critically explore the prescribing data for LRTIs in the different countries. 
The hypotheses for LRTIs were that: 
the proportion of antibiotics prescribed which were listed within the European 
Formulary increased following the educational intervention and the 
distribution of the Formulary, 
* the proportion of consultations resulting in an antibiotic prescription reduced 
following the educational intervention and distribution of the Formulary, 
the range of newly prescribed antibiotics would be reduced following the 
educational intervention and the distribution of the Formulary 
the prescribing of new macrolides such as clarithromycin would be reduced 
following the educational intervention and distribution of the Formulary as 
they are expensive and should only be used for resistant strains, 
9 the prescribing of fluoroquinolones would be reduced following the 
educational intervention and distribution of the Formulary for the same 
reasons as they are also expensive and should only be used for resistant strains. 
5.3.3.5 Data man ipulationlineth odology 
In order to critically evaluate the prescribing for LRTIs by the GP participants in 
the different countries the following searches (both sexes and all ages combined) were 
performed within the database and except where indicated involved a matching of drugs 
to diagnoses: 
* all LRTI consultations, no matching of drugs to diagnoses for both Phases 
combined, 
* all Phase I new antibiotics prescriptions for LRTls, 
all Phase 11 new antibiotic prescriptions for LRTls, 
e all new antibiotic prescribing for LRTIs for both Phases combined, 
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e all drug prescribing for LRTIs for both Phases combined, 
all Phase I study group new drug prescriptions for LRTIs, 
all Phase II study group new drug prescriptions for LRTIs, 
* all Phase I new antibiotics for LRTIs, no matching of drugs to diagnoses, 
* all Phase 11 new antibiotics for LRTIs, no matching of drugs to diagnoses. 
For the country by country comparative prescribing results section, it was decided 
to combine the data from Phase I and 11 as this is likely to provide a more meaningful 
illustration of the overall prescribing pattern compared with looking at the trends in each 
of the Phases separately. 
In the results tables, the data were presented in order of prescribing volume in terms 
of the number of items prescribed. The antibiotic drug data for LRTIs were sorted 
based on the following classification: 
I Penicillins including: 
- amoxycillin combined with clavulanic acid (betalactamase inhibitor) 
2 Cephalosporins 
Tetracyclines 
Aminoglycosides 
5 Macrolides 
6 Sulphonamides and trimethoprim 
7 Fluoroquinolones 
Other miscellaneous antibiotic groups combined including: 
- lincosamides as well as other individual antibiotics 
9 Other drug entities (not antibiotics) prescribed by the GPs for LRTIs. 
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5.3.3.6 Results 
5.3-3.6.1 Morbidity/prevalence patterns 
The four lower respiratory tract diagnoses codes when combined represent the 
second most commonly occurring area of diagnosis overall accounting for 5.1 % of the 
total number of general practice consultations. The proportion of consultations for 
LRTIs varied from 2.8% in Portugal to 9.5% in Belgium (mean 5.6%, SD 2) (Table 
5.46). The proportion of patients presenting with a LRTI who received treatment varied 
from 89% in Scotland to 97% in Ireland (mean 94%, SD 3). Of a total of 5,190 patients 
with a LRTI,, 4,817 were prescribed 6,773 drug entities of which 3,966 (59%) were new 
prescriptions and 6,163 (91%) were single non-combination drugs. 
5. 
-'). -")'. 
6.2 Prescribing performance indicators before and after the intervention 
5.3.3.6.2.1 Concordance with antibiotics recommended in the European Formulary 
The level of prescribing concordance with the antibiotics recommended in the 
European Formulary for LRTIs i. e. amoxycillin, benzylpenicillin, erythromycin and 
doxycycline can be seen in Table 5.47. The intervention and control groups increased 
their prescribing concordance with the Formulary drugs from Phase I to Phase 11, the 
former moved towards the Formulary by 6.7% (4.4) compared with the latter by 
1.4% (3.9). Although the trend of the intervention group towards using the Formulary 
drugs was greater, this difference was not statistically significant (p = 0.37). There were 
no significant differences found between countries (p = 0.87), nor was there any 
significant country-by-group interaction (p = 0.54). 
The greatest difference between the control and intervention groups from Phase I to 
Phase 11 in the trend towards the use of European Formulary recommended drugs was 
found in Portugal but this was not significant (p = 0.12). There also appeared to be 
some positive movement towards the European Formulary recommended drugs in 
Belgium, Ireland and Italy but again none of these changes proved to be statistically 
significant. 
Overall, the greatest concordance with the European Formulary can be seen to 
occur in England with almost 80% concordance in each of the control and intervention 
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groups. High levels of concordance were also found in Scotland,, Spain and Northern 
Ireland. The lowest level of Formulary concordance can be found in Italy where less 
than one third of the new antibiotic drugs prescribed for LRTIs were those 
recommended in the European Formulary. 
Of the four antibiotics recommended in the Formulary, amoxycillin was the most 
commonly prescribed antibiotic (Table 5.48). From study group Phase I to study group 
Phase 11, there were considerable increases in amoxycillin prescribing with the levels in 
Belgium, Italy and Portugal more than doubling, compared with doxycycline 
prescription levels which more than halved in Belgium and Portugal at the same time. 
Doxycycline was actually preferred to amoxycillin in the Belgian and Portuguese Phase 
I study groups. It can be seen from Table 5.48 that despite being recommended in the 
European Formulary, there was found to be no prescribing of benzy1penicillin which is 
probably because it is commonly administered as an in ection and therefore only used in 
special circumstances. 
5.3.3.6.2.2 Proportion of consultations resulting in a new antibiotic prescription 
The average number of consultations resulting in a prescription (Table 5.49) did 
slightly decrease in both the control and intervention groups by 1.6% (3.2) and 2.1% 
(2.8) respectively (excluding Belgium from the analysis as no data were provided on 
consultations without prescriptions). However, there was found to be no significant 
difference in the proportion of patients receiving new antibiotics for LRTIs between 
Phase I and Phase 11 (p = 0.35). There was a considerable decrease in the proportion of 
LRTI consultations resulting in a prescription in the intervention group in Northern 
Ireland compared with a large contrasting increase in the control group but the 
difference was not significant (p = 0.23). The mean number of consultations resulting 
in a prescription also appeared to decrease in the intervention groups of Scotland and 
Spain compared with their respective control groups but none of these differences 
proved to be statistically significant. Overall in England, Ireland, Northern Ireland and 
Scotland, approximately two thirds of consultations for LRTIs resulted in a new 
antibiotic prescription whereas in Spain only a third of these consultations resulted in a 
new antibiotic prescription. 
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5.3-3.6-2.3 Range of antibiotics prescribed 
From Table 5.50, the range of antibiotics prescribed only marginally decreased in 
both the intervention and control groups and there was no significant difference either 
between them (p = 0.39), or between countries (p = 0.79). The Spanish data were 
excluded from the statistical analysis due to the reduction in the number of patient- 
doctor consultations recorded in Phase 11. Belgium was the only country where the 
decrease in the range from Phase I to 11 was greater than the corresponding control 
group and this difference was not significant. In England, a significant increase in the 
range actually occurred in the intervention group compared with the control group 
(p = 0.04). 
in general, the range of newly prescribed antibiotics for LRTIs was lowest in 
Portugal, averaging approximately 2 per GP compared with Ireland and Northern 
Ireland where the ranges prescribed were double this number. 
5.3.3.6.2.4 Prescribing of macrolides 
With Phase I and 11 new antibiotic data combined (Table 5.5 1), erythromycin was 
the third most commonly prescribed antibiotic and clarithromycin the fourth, although 
the prescribing volume of erythromycin was half as much again as that of 
clarithromycin. In the study groups of Phase I and Phase 11 for all drug categories 
combined (Table 5.52), erythromycin was again the most commonly prescribed 
macrolide overall. However, in the Phase I study groups of Belgium and Italy and the 
Phase 11 study groups of Belgium, Italy, Portugal and Spain clarithromycin was the 
macrolide of choice. In Italy both roxithromycin and azithromycin were prescribed in 
preference to erythromycin (Table 5.5 1). While clarithromycin and azithromycin levels 
increased in the study group overall from Phase I to Phase 11 (Table 5.52), this was not 
as great as the increase in prescribing of erythromycin which became the macrolide of 
choice overall (Table 5.48). In addition, the overall level of roxithromycin decreased 
from 1.2% to less than 1%. 
5.3.3.6.2.5 Prescribing of fluoroquinolones 
Ciprofloxacin was the eleventh most commonly prescribed new antibiotic, and the 
only fluoroquinolone to appear among the 17 antibiotics which represented 1% or more 
of the antibiotics prescribed for LRTIs (Table 5.51). The level of ciprofloxacin 
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prescribing was fairly low in all countries except for Italy (7%) and to a lesser extent in 
Portugal (3.1 %). In the study group of Phase I (Table 5.52), ciprofloxacin went from 
being the seventh most commonly prescribed new antibiotic accounting for 2% of 
prescribing for all countries combined to less than 1% of prescribing in the study group 
of Phase 11 post intervention. 
5.3.3.6.3 Comparisons of antibiotic prescribing 
5.3.3.6.3.1 Penicillins 
Of the antibiotics prescribed for LRTls, the penicillins were the most popular group 
overall for throat infections accounting for 62% of the drugs prescribed from all drug 
categories. Penicillin group prescribing (Table 5.53) varied from 29% in Italy to 77% in 
England (mean 59%, SD 17). Amoxycillin was by far the most commonly prescribed 
penicillin for LRTIs and was the penicillin of choice in all countries. For all drug 
categories combined, amoxycillin use varied from 17% in Italy to 67% in England 
(mean 42%, SD 16) and for the category of new drugs only (Table 5.51), amoxycillin 
use varied from 17% in Italy to 71% in England (mean 44%, SD 17). Overall, co- 
amoxiclav was the second most commonly prescribed drug from this antibiotic class. 
For all drug classes combined, co-amoxiclav use varied from 4.9% in England to 20% 
in Belgium and Spain (mean 13%, SD 5.7) and for new antibiotics only (Table 5.5 1), its 
use varied from 3.8% in England to 19% in Belgium and Scotland (mean 13%, SD 5.6). 
5.3.3.6.3.2 Macrolides 
Macrolides were the second most common group of drugs prescribed from all drug 
classes for LRTIs accounting for 16% of the antibiotics prescribed. Macrolide use 
(Table 5.5 3) varied from I I% in Ireland, Northern Ireland and Portugal to 35% in Italy 
(mean 16%, SD 8.4). Erythromycin was the most commonly prescribed macrolide 
overall varying from 0.5% in Belgium to 11% in England, Scotland and Spain (mean 
7.41 SD 4.2). As a proportion of new antibiotic prescribing (Table 5.5 1), erythromycin 
prescribing levels varied from 0.6% in Belgium to I I% in Spain (mean 7%, SD 4). 
Clarithromycin was the macrolide of choice in Belgium, Italy and Portugal whereas 
in all the English speaking countries and in Spain, erythromycin was the macrolide of 
choice (Table 5.5 1). In the non-English speaking countries there was also an increased 
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tendency to prescribe a broader range of the newer macrolide antibiotics. For all drug 
categories combined, clarithromycin use varied from 0.4% in England to 14% in Italy 
(mean 5.9%, SD 5.1) and as a proportion of new antibiotic prescribing only (Table 5.5 1) 
its use varied from 0.4% in England to 14% in Belgium and Italy (mean 6.3%, SD 5-5). 
5.3-3.6-3.3 Cephalosporins 
Cephalosporins were the third most common group of antibiotics prescribed 
varying from 4% in England to 19% in Portugal (mean 9.9%, SD 5.1). Cephalexin was 
the most commonly prescribed cephalosporin both from all the drug categories 
combined and from the category of new antibiotics only (Table 5.51). For all drug 
categories combined, cephalexin use varied from 0% in Portugal and Spain to 5.9% in 
Scotland (mean 2.1 %, SD 2.2) and for new drugs (Table 5.5 1) from 0% in Portugal and 
Spain to 5.4% in Scotland. The bulk of cephalosporin prescribing for LRTIs was made 
up by second generation cephalosporins, namely: cefaclor, cefuroxime and cefixime, 
which mirrored the prescribing for throat infections. 
5.3.3.6.3.4 Tetracyclines 
Tetracyclines were the fourth most commonly prescribed class of antibiotics for 
LRTIs varying in use from 1.2% in Spain to 21% in Portugal (mean 8.6%, SD 7.3). In 
Belgium, Italy, Northern Ireland, Portugal and Spain, the tetracycline of choice was 
doxycycline whereas in England and Scotland it was oxytetracycline and in Ireland, 
tetracycline. Doxycycline was the joint fifth most commonly prescribed new antibiotic, 
together with ampicillin, for LRTIs (Table 5.5 1). 
5.3.3.6.3.5 Sulphonamides and trimethoprim 
Sulphonamides and trimethoprim represented 3.5% of the antibiotics prescribed 
overall for LRTIs. Their use varied from 0% in Spain to 7.4% in Belgium (mean 3%, 
SD 2.8). Co-trimoxazole was predominantly the most commonly prescribed drug in this 
group varying from 0% in England and Spain to 5.9% in Belgium (mean 1.9%, SD 2.4). 
Of the new drugs prescribed co-trimoxazole use varied from 0% in England and Spain 
to 6.2% in Belgium being most commonly prescribed in Belgium and Ireland (Table 
5.51). In the study group Phase 1, co-trimoxazole was the seventh most commonly 
prescribed antibiotic for LRTIs representing 3.1% of the new antibiotics prescribed but 
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after the intervention prescribing of co-trimoxazole represented less than 1% of the new 
antibiotics prescribed. 
5.3-3-6.3.6 Fluoroquinolones 
Prescribing of fluoroquinolones was minimal in all countries except for Italy and 
Portugal where levels accounted for 10% and 5% respectively of the antibiotic 
prescribing for LRTIs (Table 5.53). As a group they represented 2.3% of the antibiotics 
prescribed overall for LRTIs, their use varying from 0% in Belgium to 10% in Italy 
(mean 2.7%, SD 3.4). Ciprofloxacin accounted for over three quarters of the 
fluoroquinolone prescribing and where they were prescribed, ciproflxoxacin was the 
preferred fluoroquinolone in all countries except for Ireland. 
5.3.3.6.3.7 Aminoglycosides and Miscellaneous antibiotics 
When combined these drug groups accounted for only 0.5% of the antibiotics 
prescribed for LRTIs. From Table 5.51 and Table 5.53, no individual drug from either 
of these two groups was regularly prescribed. 
5.3.3.7 Discussion 
The results indicate that there were some notable improvements in certain aspects 
of prescribing for LRTIs in some countries but none of the changes towards the 
recommendations of the European Formulary and educational intervention was 
statistically significant. There was a positive trend in the concordance level with the 
Formulary in the prescribing of new antibiotic prescriptions by the intervention group 
compared with the control group overall, with notable improvements seen in Ireland, 
Italy, Belgium and Portugal. Concordance with the Formulary varied from 
approximately 30% in Italy to nearly 80% in England indicating that there was less 
scope for GPs to improve prescribing practices in the latter. 
Of individual antibiotics prescribed for LRTIs, Formulary recommended 
arnoxycillin was the penicillin and antibiotic of choice in all the countries, although the 
difference between its high use in England and relatively low use in Italy was almost 
four-fold. Co-amoxiclav was the second most commonly prescribed antibiotic. Similar 
findings were reported in a questionnaire study of GPs in five European countries. 333 
In the Phase I intervention groups of Belgium, Italy and Portugal doxycycline was 
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actually the antibiotic of choice. From Phase I to Phase 11, amoxycillin prescription 
levels more than doubled in the intervention groups of Belgium, Italy and Portugal. 
While these differences suggest that the intervention may have had a positive impact, 
there were equally large decreases in the reduction of Formulary recommended 
doxycycline prescribing from Phases I to 11 in the intervention groups of Belgium and 
Portugal. 
Patient consultations for LRTIs were less likely to result in a prescription in the UK 
than elsewhere, although high prescribing rates were found in all countries. Patient 
expectations are known to be a considerable influence in the prescribing of antibiotics 
for lower respiratory tract illness. One study involving over 1,000 patients in 
Nottingham found that non-clinical factors influenced the decision to prescribe 
antibiotics in nearly half of those patients receiving a prescription. 331A survey of GPs 
from several European countries reported slightly lower prescribing rates334 than found 
in this study but this can probably be attributed to the fact that this data set collated 
details from face-to-face doctor-patient encounters. Considering the proportion of 
consultations for LRTIs which resulted in a newly prescribed antibiotic, there were 
decreases between Phases in the intervention groups of Northern Ireland, Scotland and 
Spain with increases in all of the corresponding control groups. Thus the educational 
intervention may have also had some impact here. 
Erythromycin prescription levels increased in the intervention groups of all the 
English speaking countries from Phase I to 11 in line with the Formulary 
recommendations. While the overall level of erythromycin prescribed for LRTIs was 
double that of clarithromycin, clarithromycin was the macrolide of choice in the 
intervention groups of Belgium and Italy in Phase I and in Belgium, Italy, Portugal and 
Spain in Phase 11. In Italy, as with the prescribing for throat infections, a particularly 
large range of macrolides were prescribed by GPs there. 
Of the fluoroquinolones prescribed for LRTIs, ciprofloxacin was the only one to 
feature in the top 17 new antibiotics used in all the study data combined. A 
disproportionately high level of ciprofloxacin use was seen in Italy and to a lesser extent 
in Portugal but its use decreased from Phase I to 11. 
For all prescription categories combined for the treatment of LRTls, penicillins 
were the most commonly used group of antibiotics in all the countries except for Italy 
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where macrolides were the most common class. Other researchers have found high 
macrolide prescription levels in Mediterranean countries. 333 One other observation 
was that cephalosporins (not recommended in the intervention for LRTIs) were the 
second most commonly prescribed antibiotic class for LRTIs in Ireland and Portugal. 
Limitations with analysing LRTIs include firstly, that there are inaccuracies in 
labelling whether the presenting complaint is of mild severity or otherwise. 321 In the 
analyses in this study, four different diagnoses codes associated with LRTIs were 
clumped together. A wide variation in the terms used by GPs to describe the illness has 
been found by others too. 326 After combining the diagnoses codes for LRTIs, the 
prevalence of LRTI varied from 2.8% in Portugal to 9.5% in Belgium. Marked 
differences in the diagnostic tests used for LRTIs and the frequency of their use has 
been reported from a questionnaire study of GPs across Europe335 and these are 
inevitable confounding factors. A second limitation in this study was that no data were 
available on frequency of patient reconsultations and consequently the initial prescribing 
of the first-line antibiotic was not known. It has been suggested that approximately one 
in four patients reconsult within a few weeks of initial management of LRT1048,149, 
which may partially explain why the proportion of drug entities which represented 
newly prescribed items was lower (59%) compared with the previous two areas of 
antibiotics investigated in this thesis. Thirdly the analysis has not investigated the 
management and prevalence of LRTI in different age groups which can be important as 
there is an increased likelihood of associated co-morbidity. 321 Fourthly, as previously 
mentioned, there are differences in culture and sensitivity patterns which will account 
for some of the differences in prescribing practices. 
336 
At the time of the study, despite guidelines for the management of lower respiratory 
tract infections having been published in several European countries337, wide variations 
were found in antibiotic prescription by GPs in the different participating countries. 
This research confirms the findings of Dorca and Torres two Spanish hospital 
respiratory physicians, that in order to rationalise future prescribing for LRTIs, 
infections which are most likely to benefit from antibiotic treatment need to be defined 
and internationally accepted. 
338 In addition, the criteria for establishing a specific 
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diagnosis of pneumonia needs to be identified, the use of newer antibiotics needs to be 
restricted and general populations need to be better educated. 338 
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CHAPTER SIX 
PRESCRIBING STUDY RESULTS 
EFFECT OF THE EUROPEAN FORMULARY IN ISOLATION 
6.1 HYPERTENSION 
6.1.1 Introduction 
It is estimated that there are around 691 million patients with hypertension world- 
wide339 and many patients with hypertension already have established cardiovascular 
disease. Cardiovascular disease is one of the commonest causes of morbidity and death 
in both developed and developing countries. It is the main cause of death in the United 
Kingdom, accounting for nearly 300,000 deaths per annum (equivalent to one death in 
two) of which half are from coronary heart disease. 340 In the last decade, some 
progress has been made against coronary heart disease for which hypertension is a major 
treatable risk factor. The ability of antihypertensive therapy to reduce stroke mortality 
among hypertensive patients remains the most impressive benefit, although stroke is 
responsible for only one-third as many deaths as coronary heart disease. 339 In England 
in 1997, cardiovascular drug use represented the largest share of prescription volume 
and of net ingredient cost. Prescription items increased from 91 million prescription 
items in 1996 to 97 million in 1997 and net ingredient cost was to f 826 million in 1997, 
an increase of 12% from 1996.29 
6.1.1.1 Diagnosing hypertension 
In recent years, several national and international guidelines on the management of 
hypertension have been published. 341-346 They provide guidance on the identification 
and treatment of those at risk and in so doing attempt to promote a reduction in adverse 
events, particularly increased risk of stroke and coronary heart disease to which 
hypertensive patients are predisposed. The continuous relationship between the level of 
blood pressure and the risk of cardiovascular events and the arbitrary nature of the 
definition of hypertension have contributed to the variation in the definitions issued by 
various national and international parties. The most recent World Health Organisation - 
International Society of Hypertension Guidelines (WHO-ISH) for the management of 
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hypertension346 attempt to provide more consistent advice to clinicians around the 
world in order to reduce confusion. The WHO guidelines define hypertension as a 
systolic blood pressure of 140mmHg or greater and/or a diastolic blood pressure of 
90mmHg or greater in subjects who are not taking antihypertensive medication. 
Guidelines for the treatment of hypertension generally base their recommendations for 
treatment on cut-off blood pressure levels, although to some extent they all take into 
account concomitant risk factors. 347 
6.1.2 Rational prescribing for hypertension 
The primary goal of treatment of the patient with high blood pressure is to achieve 
the maximum reduction in the total risk of cardiovascular morbidity and mortality. 346 
The decision to treat a patient should be based on an assessment of the patient's overall 
risk. In patients with additional risk factors for cardiovascular disease, it is sensible to 
intervene at lower blood pressures than in those with none. 347 Ma or risk factors i 
include previous cardiovascular disease and end organ damage, for example renal 
impairment and familial hyperlipidaernia. Other important risk factors include 
increasing age, cigarette smoking, high blood cholesterol levels, diabetes mellitus and of 
male sex. 347 All hypertensive patients should be encouraged to adopt lifestyle 
modifications such as weight loss, smoking cessation, increased exercise and reduction 
in alcohol and salt intake. 348 These non-pharmacological measures can reduce blood 
pressure and improve other cardiovascular risk factors. 
The six main drug classes used world-wide for treating hypertension are diuretics, 
P-blockers, calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin 11 antagonists and cc-adrenoceptor blockers. 346 Of these drug groups, 
diuretics and beta-adrenoceptor blocking drugs (P-blockers) are the only ones for which 
long term effects on morbidity and mortality have been demonstrated and consequently 
guidelines usually state that they are the preferred drugs of choice. 
347 Several studies 
suggest that these two well established drug groups are as well tolerated as newer drugs 
and where diuretics and P-blockers induce metabolic changes in individual patients, the 
treatment strategy can be tailored accordingly. 347 Trials have provided evidence that 
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ACE inhibitors are preferable in hypertensive patients with diabetes and therefore can 
be considered as drugs of first choice here. 349 
Not all drugs indicated for hypertension work well in everyone -a German study 
found that both hydrochlorothiazide (a thiazide diuretic) and nitrendipine (a calcium 
channel blocker) worked better in older patients than younger ones. 348 When selecting 
an antihypertensive, co-existing diseases should also be considered as some drugs are 
contra-indicated in certain conditions such as P-blockers in asthma, while others may 
treat a concomitant cardiovascular condition as well as the hypertension,, thus 
simplifying therapy and reducing prescribing costs. 
In the elderly, low dose thiazide diuretics are the first-line treatment of choice with 
P-blockers as a good second choice. 350 Ten trials involving 16,164 patients found that 
P-blocker therapy only reduced the odds for cerebrovascular events, whereas diuretic 
therapy was superior and effective in preventing cerebrovascular events, fatal stroke, 
coronary heart disease, cardiovascular mortality and all-cause mortality. 351 Meta- 
analyses have indicated that the benefits of hypertension treatment in the elderly may 
actually be greater than those in younger persons352, and more recently it has been 
suggested that antihypertensive drugs may be particularly beneficial in patients over 80 
years old. 353 
Selection of the most suitable drug to prescribe should be based on published 
scientific evidence for the efficacy of lowering blood pressure in preventing stroke and 
coronary heart disease. There are also important differences in the side-effect profiles 
between drug classes. Without adequate evidence that newer antihypertensive drugs 
significantly alter outcomes, it is difficult to justify the greatly increased cost of their 
more widespread use. Ultimately however, the choice of drug should be tailored to the 
individual patient. 
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6.1.2.1 European Formulary recommendations 
The Formulary recommended that non-drug treatment should be initially 
considered in the management of hypertension. Drug treatment may be added in a 
stepwise fashion until the necessary control has been achieved. The drug treatment 
strategy recommended in the European Formulary was based on efficacy, safety, cost 
and availability as follows: 
1. Initial treatment 
If not effective or if side-effects 
hydrochlorothiazide, atenolol 
hydrochlorothiazide + atenolol 
If no effect, if side-effects or if contraindicated verapamil, nifedipine or enalapril 
In special situations, the European Formulary endorsed prescribing of the following: 
o hypokalaemia hydrochlorothiazide + amiloride/triamterene 
o elderly hydrochlorothiazide, verapamil/nifedipine/enalapril 
9 pregnancy oral methyldopa, or atenolol (from third trimester) 
e hypertensive crisis oral nifedipine or sodium nitroprusside infusion 
The European Formulary Group (EFG) recommendations in the Appendix included 
that: 
9 thiazide diuretics are considered to be the best initial therapy especially in 
elderly patients, 
e the optimal dose is the lowest possible one, 
9 potassium sparing diuretics are unnecessary unless hypokalaernia develops, 
* P-blockers can be used as first-line treatment or together with a thiazide if the 
latter is not effective alone, 
* calcium antagonists and ACE inhibitors should only be considered when 
thiazides or P-blockers fail, or are poorly tolerated, or for co-existing 
indications, 
* vasodilators, ot- blockers and centrally acting drugs should be reserved for 
patients whose blood pressure is not controlled by, or who have contra- 
indications to diuretics, P-blockers, calcium antagonists and ACE inhibitors. 
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6.1.2.2 Proposed prescribing performance indicators 
The following hypotheses were drawn up based on quality indicators which could 
be adapted to critically explore the prescribing data for hypertension in the different 
countries. The hypotheses were that: 
the proportion of antihypertensives prescribed which were listed within the 
European Formulary increased following its distribution, 
the range of drugs prescribed for hypertension would be reduced following 
the distribution of the Formulary, 
* diuretics (thiazide) and P-blockers represented the majority of antihypertensives 
prescribed, 
e calcium channel blockers and ACE inhibitors represented the third and fourth 
largest groups of antihypertensives Prescribed, 
e use of vasodilators, (x-blockers and centrally acting drugs should be limited, 
potassium sparing diuretics as a proportion of overall diuretic prescribing 
should be minimal, 
the use of combination antihypertensive drugs should be limited. 
6.1.23 Data manipulationlmethodology 
In order to critically evaluate the prescribing data for antihypertensive drugs, all the 
searches except the first involved drugs matched to a diagnosis code of hypertension. 
The following searches involving both sexes and all ages combined were performed 
within the database: 
e all hypertension consultations for both Phases combined, no matching of 
drugs to diagnosis, 
9 all hypertension consultations for both Phases combined!, 
9 hypertension consultations, selection of single component drugs only, 
hypertension consultations, selection of single component drugs Phase I only, 
hypertension consultations, selection of single component drugs Phase 11 only, 
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" hypertension consultations, selection of all drug entities Phase I only, 
" hypertension consultations, selection of all drug entities Phase 11 only. 
In the results tables, the data are presented in order of prescribing volume in terms 
of the number of items prescribed. The antihypertensive drug data were sorted based on 
the following classification: 
1. Diuretics (thiazides, loop and potassium-sparing) 
2. P-blockers (cardio selective and non-cardio selective) 
3. Calcium channel blockers (CCBs) 
4. Angiotensin-converting enzyme (ACE) inhibitors 
5. cc-blockers 
6. Centrally acting antihypertensives 
7. Vasodilator antihyprtensives 
8. Other antihypertensive drugs (serotonin antagonists, ganglion blockers, 
adrenergic neurone blockers) 
9. Potassium supplements 
10. Other cardiovascular drugs 
6.1.3 RESULTS 
6.1.3.1 Morbiditylprevalence patterns 
Hypertension was the most commonly occurring diagnosis overall accounting for 
9.4% of the total number of general practice consultations. The proportion of 
consultations (Table 6.54) varied between 4.4% in England to 16% in Portugal 
(mean 9.8%, SD 5-4). Of a total of 9,514 patients with hypertension, 8,955 were 
prescribed 12,841 drug entities. The majority of these, 10,297 (80%), were repeat 
prescriptions. From the remainder, 1,007 (7.8%) were newly prescribed items, 804 
(6.3%) were hospital-initiated prescriptions and 534 (4.2%) were prescribed upon 
request of the patient as a result of having been prescribed on a previous occasion. Of 
the drug entities Prescribed, 91,697 (76%) were single non-combination drugs (Table 
6.54). 
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6.1.3.2 Prescribing performance indicators 
6.1.3.2.1 Concordance before and after dissemination of the European Formulary 
As hypertension is an example of a chronic disorder involving long term 
medication, reflected by less than 8% of the drug entities being new prescriptions for it, 
in this study (section 6.1.3.1), concordance levels were measured using all prescription 
categories combined. To assess the concordance with the Formulary, two analyses were 
performed. Firstly, the level of concordance with both single component and 
combination drugs was measured; and then secondly, an analysis was performed on 
single component drugs only. The reason for this was because some antihypertensive 
drugs, for example hydrochlorothiazide, occur in both single component and 
combination drug formulations, of which only the former was recommended in the 
European Formulary. Consequently, concordance with the European Formulary cannot 
purely be based on analysis of all drug entities together as this does not separate the 
prescribing of combination drug entities from non-combination drug entities. In 
comparison however, measuring the level of concordance with the European Formulary 
on antihypertensive prescribing of single component drugs only is likely to give 
artificially higher concordance levels because of the total number of drug entities being 
lower. 
For both combination and single component drugs, with all prescription categories 
combined, no significant differences were found either in the concordance with drugs 
recommended in the EF (Table 6.55) between intervention and control groups from 
Phases I to 11 (p = 0.21) or between countries (p = 0.91). In Belgium, there appeared to 
be considerable movement towards use of the Formulary drugs by the intervention 
group and movement away from the Formulary recommendations by the control group 
but this difference was not statistically significant (p = 0.28). Prescribing by the GPs in 
Spain demonstrated the greatest concordance with the European Formulary averaging 
approximately 60% in each of the subgroups compared with Ireland at the other extreme 
which averaged approximately 25% concordance in each of its subgroups. 
For single component drugs only, with all prescription categories combined, again 
there was found to be no statistically significant movement towards the use of European 
Formulary (Table 6.56) recommended antihypertensive drugs in control and 
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intervention groups from Phases I to 11 (p = 0.19). No statistically significant difference 
was found between countries either (p = 0.94). The sub-groups of Spain had the 
greatest concordance with the Formulary and those in Ireland demonstrated the least 
concordance with the Formulary, similarly to Table 6.55. 
The change in n values between Table 6.55 and Table 6.56 indicates the difference 
in prescribing of single drug components compared with combination drug entities and 
particular differences were seen in Ireland, Italy and Portugal. In Italy and Portugal, the 
subgroups displayed notably higher levels of Formulary concordance in Table 6.55, 
compared with Table 6.56. From this one can infer that Formulary recommended 
hydrochlorothiazide was being prescribed in combination form in both countries, thus 
artificially increasing the levels of concordance observed in Table 6.55. 
6.1.3 3.2.2 Range of drugs prescribed 
For both combination and single component drugs, with all prescription categories 
combined, there was no significant difference (p = 0.61) in the range of drugs prescribed 
for hypertension from Phase I to Phase II between control and study groups (Table 
6.57). The difference between countries was of high statistical significance (p <0.001). 
Within countries, there was no statistically significant difference between control and 
intervention groups in changes in the range of drugs prescribed. The largest range of 
drugs prescribed for hypertension was in Italy which was nearly three times greater than 
the ranges used in England, Northern Ireland and Scotland. 
For single component drugs only (Table 6.58), the results largely mirrored those of 
all drug entities in Table 6.57. There was no significant difference (p = 0.53) in the 
range of drugs prescribed for hypertension between control and study groups from 
Phases I to 11 and no significant difference between countries (p = 0.31). Within 
countries, the greatest difference between study and control groups after dissemination 
of the Formulary occurred in Belgium but the difference was not statistically significant 
(p = 0.42). Again the largest range of drugs prescribed for hypertension occurred in 
Italy, three times greater than the ranges used by the UK cohort of GPs. 
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6.1.3-2.3 Prescribing of diuretics and P-blockers 
Of the drugs prescribed for hypertension, the diuretics were marginally the most 
popular group overall, accounting for 31% of prescribed items (Table 6-59). P- 
blockers were the fourth most commonly prescribed class of antihypertensives 
representing 15% of the drugs used (Table 6.59). Within countries, diuretics were the 
main antihypertensive drug class used in the four English speaking countries and Spain. 
They were the second most popular in Italy and Portugal. In contrast, P-blockers were 
the main drug class used in Belgium and the second most common in each of the four 
English speaking countries. 
6.1.3.2.4 Prescribing of CCBs and ACE inhibitors 
CCBs were the third most popular group of antihypertensives representing 16% of 
the drugs used (Table 6.59). In the three southern European countries, they were the 
third most commonly used group there and in the remaining five countries they were the 
fourth most commonly used antihypertensive group. In contrast, the ACE inhibitors 
were the second most abundant group of drugs prescribed for hypertension accounting 
for 31% of the drugs prescribed, fractionally less than the proportion of diuretics (Table 
6.59). They were the third most commonly prescribed class of antihypertensives in 
England, Ireland, Northern Ireland and Scotland and were even more popular in all the 
other countries. 
6.1.3.2.5 Prescribing of vasodilators, a-blockers and centrally acting drugs 
Together, these groups combined represented less than 3% of the antihypertensive 
drugs used overall. Of the three groups, a-blockers were the most commonly prescribed 
and in Spain they accounted for 4% of prescribing for hypertension (Table 6.59). 
Prescribing of centrally acting antihypertensives was greatest in Belgium where they 
accounted for 3.7% of the drugs used there. Use of vasodilator antihypertensives was 
minimal in all countries. 
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6.1.33.2.6 Prescribing of potassium sparing diuretics 
Overall, potassium- sparing diuretics represented almost 18% of the total diuretic 
prescribing. In general the levels of potassium- sparing diuretics were low in England 
and Scotland and relatively high in Belgium, Italy and Portugal (Table 6.59). The 
proportion that potassium-sparing diuretics represented of the total diuretic prescribing 
varied from 4.1 % in Scotland to 31% in Belgium (mean 16%, SD 9.5). 
6.1.3.2.7 Prescribing of combination antihypertensives 
Of the 12,, 841 drug entities prescribed for hypertension in the study, 3,144 (24%) 
were part of combination drugs (Table 6.54). This varied from 5.6% of the 
antihypertensives prescribed in England to 37% of those prescribed in Ireland 
(mean 20%, SD 11). Relatively high levels of combination drugs for hypertension were 
also prescribed in Italy and Portugal. 
6.1.3.3 Comparisons of antihypertensive drug classes prescribed 
6.1.3.3.1 Diuretics 
Diuretic group prescribing (Table 6.59) varied from 17% in Belgium to 34% in 
Spain (mean 30%, SD 5.5). This class of antihypertensive drugs were the most 
commonly prescribed in England, Ireland, Northern Ireland, Scotland and Spain. Of the 
diuretics, thiazides were the most commonly prescribed subgroup varying from 11% in 
Belgium to 29% in England (mean 24%, SD 6). Hydrochlorothiazide was the most 
popular diuretic accounting for 12% of the overall prescribing, however bendrofluazide 
which was only found to be prescribed in each of the four English speaking countries 
was predominantly the diuretic of choice there (Table 6.60 and Table 6.61). 
hydrochlorothiazide prescribing varied from 1% in Scotland to 24% in Spain 
(mean 8.3%, SD 8-2). Potassium-sparing diuretics were the second most popular sub- 
group of diuretics representing 5.5% of the drug prescribing for hypertension, varying 
from 1.3% in Scotland to 7.8 % in Portugal (mean 4.6%, SD 2.2). Amiloride was the 
most commonly prescribed potassium- sparing diuretic and was nearly always prescribed 
as part of a combination. Amiloride prescribing (Table 6.60 and Table 6.61) varied 
from 0.7% in Scotland to 5.6% in Italy (mean 2.9%, SD 1.9). Frusemide accounted for 
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nearly all loop diuretic prescribing (Table 6.60 and Table 6.6 1), its use varied from 
1.1% in Belgium to 2.7% in Italy (mean 1.8%, SD 0.5). 
6.1.3-3.2 ACE inhibitors 
This class of drugs was the most commonly prescribed in Italy and Portugal (Table 
6.59). ACE inhibitor use varied from 18% in England to 38% in Italy (mean 27%, SD 
8). Enalapril was the most commonly used one (Table 6.60 and Table 6.61) 
representing 9.7% of the drugs prescribed and its use varied from 0.9% in Ireland to 
16% in Spain (mean 7.7%, SD 5.2). Captopril accounted for 8.2% of the 
antihypertensive drug prescriptions and it was clearly the ACE inhibitor of choice in 
Ireland and Portugal. Lisinopril was the third most commonly used ACE inhibitor and 
it appeared to be the one of choice in Belgium and Northern Ireland. 
6.1.3.3.3 CCBs 
Their use varied (Table 6.59) from 9.4% in Ireland to 20% in Spain (mean 16%, 
SD 3.4). Nifedipine was the CCB of choice and was markedly the one most commonly 
prescribed in all the countries (Table 6.60 and Table 6.61). Nifedipine use accounted 
for nearly 10% of the prescriptions for hypertension, its use varied from 6.4% in Ireland 
to 13 % in Northern Ireland (mean 10%, SD 2.7). Amlodipine, diltiazem and verapamil 
were the second, third and fourth most commonly used calcium channel blockers 
respectively, but even when combined their use was lower than the level of nifedipine 
use (Table 6.60 and Table 6.61). 
6.1.3.3.4 P-blockers 
Their use varied (Table 6.59) from 6.8% in Spain to 36% in Belgium (mean 21%, 
SD 11). P-blockers were the most popular class of antihypertensives in Belgium only. 
Over 80% of the P-blockers prescribed were cardioselective of which atenolol was 
predominantly prescribed (Table 6.60 and Table 6.61). Atenolol use varied from 5.4% 
in Portugal to 24% in England (mean 15%, SD 8.8) and it was the one of only two P- 
blockers to feature in the top drugs prescribed for hypertension (Table 6.61). 
Propranolol was the most commonly prescribed non-cardio selective P-blocker, however 
its use represented less than 1% of the antihypertensives prescribed. 
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6.1.3-3.5 a-blockers 
a-blockers represented 1.6% of the drugs prescribed for hypertension (Table 6.59) 
and their use varied from 0.1% in Portugal to 4% in Spain (mean 1.7%, SD 1.1). 
Doxazosin accounted for over three quarters of the a-blocker prescriptions and it was 
the fifteenth most commonly prescribed antihypertensive drug used overall, although it 
was neither prescribed in Belgium, nor Portugal (Table 6.60 and Table 6.61). 
6.1.3.3.6 Potassium supplements 
Potassium supplements were used in combination with diuretics and they were 
predominantly prescribed in Ireland where they represented 8.4% of the drug entities 
prescribed for hypertension (Table 6.59). Their use elsewhere was found to be minimal. 
6.1.3.3.7 Centrally acting drugs, vasodilators and other antihypertensives 
When combined, these drug groups accounted for less than 1.5% of the drug 
entities prescribed for hypertension (Table 6.59). Their use varied from 0% in Northern 
Ireland to 4.3% in Belgium (mean 1.5%, SD 1.3). 
6.1.3.3.8 Other cardiovascular drugs 
These cardiovascular drugs represented 2.5% of the drugs associated with 
hypertension (Table 6.59), their prevalence varied from 1% in Scotland to 3.5% in 
Ireland (mean 2.5%, SD 1). These cardiovascular drugs were ones not officially 
indicated for hypertension but were nevertheless linked up to a diagnosis of 
hypertension in the prescribing data. It can therefore be inferred that they were being 
prescribed for related co-morbid conditions. 
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6.1.4 Discussion 
In this data set, hypertension was the most commonly occurring diagnosis overall. 
High prevalence levels of hypertension have been found in studies from many European 
countries354-361 and the cardiovascular system has been found to be the main 
therapeutic area in terms of number of prescription items in England. 29 These findings 
together with the fact that hypertension is almost exclusively managed by general 
practitioners made antihypertensive drug utilization patterns an ideal area to investigate. 
Interpretation of these data is however particularly complex for several reasons. 
Firstly, due to the chronic nature of the disease,, drugs are prescribed for use in the long 
term and therefore the numbers of newly prescribed drugs were relatively small. Thus 
when investigating any possible effects of the Formulary dissemination it was not 
realistic to investigate the potentially more meaningful cohort of new prescriptions in 
isolation. Secondly, the therapeutic management of hypertension varies with its severity 
but it was not possible to analyse this in any more detail. The diagnostic coding frame 
used did not include a breakdown of different levels of hypertension severity and in any 
case the majority of GPs were found to record a diagnosis of hypertension only. 
Thirdly, there are a number of recognised risk factors associated with cardiovascular 
diseases such as ethnicity346 which can effect treatment management but this collation 
of data does not permit such investigation. Fourthly, the analyses did not consider in 
detail the area of concomitant use of two or more antihypertensives by patients and 
whether prescribing practices were tailored in patients with co-morbidities. Fifthly, it 
was not possible to identify which drugs (if any) had been tried previously on some 
patients as well as the variations in dosage, formulation and strength of medications 
prescribed, something which was problematic in all areas investigated in this thesis. 
In this study, there was found to be no significant differences either in concordance 
with the Formulary or in the range of antihypertensives prescribed between the 
intervention and control groups from Phases I to 11 following dissemination of the 
European Formulary. The only country where there appeared to be any slight trend 
towards a positive change in prescribing was in Belgium. Formulary concordance was 
below the 50% level in all countries, with the exception of prescribing by the Spanish 
GPs. Relatively large ranges of drugs were prescribed by GPs in all countries, except 
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for the cohort of GPs from the UK. Therefore, one can conclude that dissemination of 
the Formulary and thus receipt of written material alone appeared to have virtually no 
impact on the prescribing for hypertension within the frame of this project. 
On observing the prescribing for hypertension in the different countries, more 
consistent prescribing of different antihypertensive drug classes between the different 
countries can be seen compared with individual drug use. For example, diuretics were 
the main antihypertensive drug class in five countries and the second in two others. 
Also CCBs were the third most commonly used group in the three southern European 
countries and the fourth, in the remaining five other countries. The relative prescribing 
of these two important antihypertensive drug classes could be said to reflect fairly 
rational prescribing and consequently prescribing patterns may actually reflect higher 
levels of concordance with national guidelines within countries than with a 
multinational consensus based European Formulary. Different national guidelines for 
the treatment of hypertension exist and many have been available for about 25 years 
having undergone periodic updating. 362 Whilst the general principles of the European 
Formulary management of hypertension were sound, the individual drugs recommended 
may have been too rigid and inflexible for the diversity of antihypertensive drugs 
available. For example bendrofluazide is the most cost-effective thiazide diuretic in the 
UK and lreland and was the diuretic of choice there but was excluded from the 
Formulary. In contrast though, Formulary recommended atenolol and nifedipine were 
the P-blocker and CCB of choice most distinctly in all the countries. Levels of P- 
blocker prescribing were notably low though in southern European countries and ACE 
inhibitors appeared to be overprescribed in their place. The prescribing of these drug 
classes support what others have reported in Spain. 363,364 
Patterns of prescribing for hypertension do vary from country to country especially 
with respect to individual drug use. Within countries, ideally there should be more 
standardisation of prescribing within the different antihypertensive drug classes and a 
consequent reduction in the range of drugs used. Combination antihypertensive drugs 
which were found to be prescribed particularly in Ireland, Italy and Portugal should be 
minimised as they do not allow for flexible dosing. Also the level of P-blocker use 
should be increased in southern European countries as these drugs together with 
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diuretics are currently the only ones for which long term effects on morbidity and 
mortality have been consistently demonstrated. 
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6.2 ASTHMA 
6.2.1 Introduction 
Asthma is a common inflammatory condition of the airways which may present as 
acute attacks or as a chronic disorder with exacerbations. It continues to be the 
commonest chronic condition of any sort in children and the commonest chronic 
respiratory problem at all ages. Persistently high levels of asthma morbidity and 
mortality have been shown in studies from many countries. 365-372 Recent evidence 
has shown that the prevalence of symptoms of asthma in children varies widely, to a 
twenty fold extent, between countries - from 1.6% in Indonesia to 36.8% in the UK. 
373 
Many of these children have not been diagnosed formally as having asthma by doctors 
and thus many do not receive the appropriate treatment they need. Even amongst those 
who have been diagnosed, undertreatment remains a particular problem in several 
European countries (Dem-nark, Finland, France, Italy, Netherlands, Switzerland and the 
UK)374-380 and beyond371,381-383 Suboptimal treatment in the community, where 
the vast majority of asthma care is delivered, is likely to result in greater use of 
emergency facilities. In the UK, asthma morbidity and mortality data has not improved 
in the past 25 years and it features in the top 20 medical lead causes of death. 384 Of 
those that die, studies have indicated that 80% or more of these could be 
preventable. 38 53 86 Ironically non-concordance with recommended standards is 
probably a major cause of avoidable deaths from asthma. 
Despite underdiagnosis and undertreatment, the requirement for prescriptions in 
asthma care is massive - in the UK for example about 7% of all NHS prescriptions are 
for asthma. 387 The total annual costs of asthma in the UK were estimated to be 
between E322M and E686M in 1990388, of which 20-25% of the direct costs are due to 
hospitalisation. The costs due to asthma in France, in 1995 were approximately 1% of 
direct and indirect health care costs combined, equivalent to 7 thousand million French 
francs (approximately f 700M)3 89 and in the USA at the beginning of this decade they 
accounted for 5.5 billion dollars (approximately f 3,440M). 
390 
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Since consensus statements on asthma management have emerged in various 
countries and international agreement on treatment has been possible, 391 it is 
reasonable to hope that prescribing in the community should be in line with recognised 
guidelines in order to minimise the impact of asthma on both the people who suffer its 
consequences and the health services who serve them. As the majority of asthma is 
diagnosed and treated solely in primary care it was rational for the condition to be 
included in the European Formulary and Appendix. The two documents contained 
discussion about both non-drug treatment and drug treatment. 
In this results section, an investigation of asthma drug utilisation will indicate 
whether the dissemination of written prescribing recommendations alone can improve 
prescribing. In addition, prescribing patterns between countries for children 0- 15 years 
of age and adults 16 years and over will be compared. 
6.2.2 Rational prescribing for asthma 
, nationa139" and 
international To improve asthma management, regiona1392 I 
guidelines have been introduced. 391 The aim of asthma management is to reduce the 
symptoms and restore normal long term function of the airways and reduce as far as 
possible the risk of severe attacks. 262 In the most recent British Thoracic Society 
(BTS) guidelines published in 1997, the most significant change was the urging of 
prescribers to begin management of asthmatic patients with high dose inhaled steroids, 
stepping down the dose once asthma control is established. 3 933 94 The BTS guidelines 
recommend a stepped pharmacological approach to asthma therapy. 
6.2.2.1 European Formulary Recommendations 
Asthma management guidance in the European Formulary reinforced the BTS 
stepwise approach and the following drug treatment strategy was recommended: 
- salbutamol or any alternative short acting 
P, agonist 
- ipratropium bromide 
- beclomethasone 
- prednisolone 
- sodium cromoglycate 
246 
Effect of the European Formulary in isolation 
6.2.2.2 Proposed quality indicators 
The following hypotheses were drawn up based on quality indicators which could 
be adopted to critically explore the prescribing data for asthma in the different countries. 
The hypotheses for asthma prescribing were that: 
* the proportion of drugs prescribed for asthma which were listed within the 
European Formulary increased following the distribution of the Formulary, 
* the range of drugs prescribed for asthma would be reduced following the 
distribution of the Formulary, 
9 the level of use of inhaled corticosteroids increased following the distribution 
of the Formulary, 
9a high level of inhaled medications should be prescribed as they are 
associated with a rapid onset of action and fewer side-effects for a given 
therapeutic effect, 
* the use of combination drugs should be limited as they do not allow for 
flexible dosing. 
9 the use of antibiotics in managing an acute attack should be minimised as 
there is no clear evidence of any resulting benefit. 
6.2.2.3 Data man ip ulationlineth odology 
In order to critically evaluate the prescribing data for asthma, all the searches except 
where specified involved drugs matched to a diagnosis code of asthma. The following 
searches involving both sexes were performed within the database: 
* all asthma consultations for both Phases combined, no matching of drugs to 
diagnoses, 
e asthma consultations in children <16 years of age, for both Phases combined, 
* asthma consultations in children <16 years of age for both Phases combined, no 
matching of drugs to diagnosis, 
* asthma consultations in adults ý! 16 years, for both Phases combined, 
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e asthma consultations in adults ýý 16 years, no matching of drugs to diagnosis for 
both Phases combined, 
all Phase I prescriptions for asthma in all ages combined, 
all Phase 11 prescriptions for asthma in all ages combined, 
* all Phase I study group new drug prescriptions for asthma in all ages combined, 
* all Phase 11 study group new drug prescriptions for asthma in all ages combined, 
For the country by country comparative prescribing results section, it was decided 
to combine the data from Phases I and 11 as this was likely to provide a more meaningful 
illustration of the overall prescribing patterns compared with looking at the trends in 
each of the Phases separately. In the results tables, the data were presented in order of 
prescribing volume in terms of the number of items prescribed. The drug data for 
asthma were sorted based on the following classification: 
I Short actingP2 agonists 
2 Long actingP2 agonists 
3 Inhaled corticosteroids 
Oral corticosteroids 
5 Cromoglycate and related therapy 
6 Antimuscarinic bronchodilators 
7 Antihistamines 
8 Antibacterials 
9 Theophyllines 
10 Nasal sprays 
11 Drug entities prescribed for asthma present in combination form only 
12 Asthma appliances (peak flow meters, spacers and nebulisers) 
13 Miscellaneous group of drugs prescribed for asthma including: expectorants 
mucolytic agents; cough suppressants and sympathornimetic decongestants. 
14 Other drug entities prescribed for asthma 
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Although included in the overall denominator because of being matched to asthma 
diagnoses, categories 7,10,11,13 and 14 were merged into one group, as they imply 
related morbidity. The resulting mixed group was heavily weighted in terms of the 
number of prescribed items, towards categories 13 and 14 and so it could largely be 
defined as consisting mainly of drugs of limited proven clinical value. For discussion 
purposes, it was decided to keep groups 8 and 12 as separate. 
6.2.3 Results 
6.2.3.1 Morbiditylprevalence patterns 
Asthma was the sixth most common diagnosis overall accounting for 3.5% of the 
total number of consultations in general practice. The proportion of asthma 
consultations varied from 1.8% in Italy to 5.8% in Ireland (mean 3.4%, SD 1.6) (Table 
6.62). The proportion of patients presenting with asthma who received treatment varied 
from 84% in Scotland to 98% in Portugal and Spain (mean 92%, SD 5.5). 
6.2.3.2 Prescribing performance indicators 
6.2.3.2.1 Concordance with drugs recommended in the European Formulary 
No significant differences were found either in the concordance with drugs 
recommended in the EF Table 6.63 between study and control groups from Phases I to 
11 (p = 0.83) or between countries (p = 0.34). The largest difference between the control 
and intervention groups from Phase I to Phase 11 in the trend towards European 
Formulary recommended drugs was in England which was found to be statistically 
significant (p = 0.02). The concordance levels were measured using all prescription 
categories combined because of the 5,159 prescriptions for asthma in the study, only 
15405 (27%) were for newly prescribed items. 
Overall, the greatest concordance with the European Formulary can be seen to have 
occurred in England with a level of almost 90%, followed by Scotland and Northern 
Ireland with approximately 80% concordance. The lowest level of Formulary 
concordance was found in Italy where the level was just below the 50% mark. 
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Of the drugs recommended in the Formulary for asthma, short acting P2 agonists 
were the most commonly prescribed (Table 5.48). Salbutamol was the short acting P2 
agonist drug of choice in all the countries, as well as being the most commonly 
prescribed drug overall for asthma. From study group Phases I to 11, there were 
substantial increases in the prescribing of salbutamol in Belgium and Italy. In Belgium, 
from Phases I to 11, the reduction in prescribing of fenoterol almost equated to the 
increase in salbutamol use there. From Phases I to II, the level of beclomethasone use 
increased by nearly 30% overall; within countries, notable increases in its use were 
found in England and Northern Ireland but these were not statistically significant 
Although terbutaline remained the fourth most common drug used overall in the study 
groups from Phase I to Phase 11, in Northern Ireland its level decreased from 21% to 
8.7%. 
6.2.3.2.2 Range of drugs prescribed 
The reduction in the range of drugs prescribed from Phases I to Il was greater in the 
study group compared with the control group overall (Table 6.65) but this was not found 
to be statistically significant (p = 0.10). No significant difference was found between 
countries either (p = 0.34). Nevertheless, the reduction of the range within the study 
group from Phases I to 11 was found to be significant (p = 0.02), whilst the reduction in 
the control group was not significant (p = 0.62). The Spanish data were excluded from 
these analyses due to the number of recorded consultations in Phase 11 being halved. 
Within countries from Phases I to 11, there was a trend towards a greater reduction 
in the range within the study groups of Belgium, England, Northern Ireland and 
Scotland compared with their corresponding control groups. Of these, the greatest 
difference between study and control groups occurred in Belgium but this difference 
was not significant (p = 0.09). 
Approximately eight different items were prescribed on average for asthma by each 
of the GPs in Ireland which was the largest range found to be used. Excluding Spain for 
the above reasons, the smallest range was found in Portugal where just over four 
different items were prescribed on average per GP. 
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6.2.3.2.3 Prescribing of inhaled corticosteroids 
Using the number of patient consultations as a proxy for the number of patients 
seen (it was clearly possible for a single patient to be seen on more than one occasion), 
the percentage of treated asthma patients on inhaled corticosteroids for all ages 
combined (Table 6.62) varied from 23% in Italy to 47% in Northern Ireland (mean 35%, 
SD 9.7). The Spanish data were not included in this comparison as the formulation of 
the steroids could not be inferred. 
As previously mentioned, for the study group overall, from Phases I to 11, the level 
of beclomethasone use increased by nearly 30% (Table 5.48) and within countries, its 
use increased considerably in England and Northern Ireland. For the other inhaled 
corticosteroids (Table 5.52), the level of budesonide decreased in all the study groups 
from Phases I to 11, except for an increase in its use in Scotland. Fluticasone levels 
remained fairly constant in the study groups from Phases I to 11, except for a notable 
increase in Belgium. 
6.2.3.2.4 Prescribing of inhaled medications 
Relatively high levels of prescribing of inhaled medications (Table 5.48) 
recommended in the Formulary were found to occur in England followed by Northern 
Ireland and the other English speaking countries. The only drug in Table 5.48 not to be 
in an inhaled formulation was prednisolone. 
6.2.3.2.5 Prescribing of combination drugs for asthma 
Of the 5,159 drug entities prescribed for asthma in all the countries combined, only 
252 (4.9%) entities belonged to combination drugs. In children up to 15 years of age, of 
1,538 entities prescribed for asthma, 20 (1.3%) represented combination drugs and in 
adults 16 years and over, of 3,621 items prescribed for asthma, 232 (6.4%) formed part 
of combination drugs. The proportion of drug entities representing combination drugs 
was therefore relatively small. 
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6.2.3.2.6 Prescribing of antibiotics 
The only antibiotic to be prescribed in notable volume was amoxycillin. From 
Table 5.5 1, it can be seen that amoxycillin was the eleventh most commonly prescribed 
drug for asthma in the study with greatest use in Scotland. In study groups from Phases 
I to 11, its use marginally decreased overall. Within countries, the highest level of use 
was found in Belgium in Phase I and Scotland in Phase 11. 
6.2.3.3 Comparisons ofprescribingfor asthma 
6.2.3.33.1 Prescribing in children 
Prescribed inhaled medications (Table 6.68) varied from 72% of all prescribed 
items for asthma in Ireland and Portugal to 87% in Northern Ireland (mean 77%, 
SD 5.6). As stated above, the formulation of the steroids could not be inferred from the 
Spanish data above and so it was excluded from the above comparison. Inhaled 
corticosteroid usage varied from 12% in Portugal to 34% in Northern Ireland 
(mean 21%, SD 8.2). Use of individual corticosteroids also varied widely; Spain used 
no beclomethasone, instead using budesonide in 28% of asthma prescriptions. Northern 
Ireland used fluticasone in 4.5% - more than three times the frequency in any other 
country. In all other countries, beclomethasone was the steroid of choice accounting for 
15% of all asthma prescriptions. Beta2-agonist use (long and short acting combined) 
varied from 24% of all prescribed items for asthma in Italy to 67% in Spain for children 
(mean 45%, SD 1) 
Combination drug items accounted for less than 1.3% of asthma prescriptions for 
children. Cromoglycate use alone varied from 0% in Spain to 7.3% in Italy 
(mean 3.6%, SD 2.7). Methylxanthine use varied from none in England to 8.8% in 
Ireland (mean 3.8%, SD 3). Antibiotic prescribing in children at consultations for 
asthma varied from none in Spain and Portugal to 7.3% in Belgium (mean 2.9%, 
SD 2.5). 
6.2.3.3.2 Prescribing in adults 
Prescribed inhaled medications (Table 6.69) varied from 54% in Italy to 78% in 
England (mean 68%, SD 9.1), with the Spanish data again being excluded from the 
252 
Effect of the European Formulary in isolation 
comparison. Inhaled corticosteroid usage varied from 14% in Italy to 31% in Northern 
Ireland (mean 23%, SD 6.7). Spain used beclomethasone in 6% of asthma prescriptions 
but budesonide in 22% and Northern Ireland used beclomethasone in 16% but 
budesonide in 13%. In all other countries, beclomethasone was again the steroid of 
choice accounting for 17% of asthma prescriptions overall. Beta2-agonist use (long- and 
short -acting combined) varied from 27% in Belgium to 48% in Spain (mean 40%, 
SD 7). 
For adults, combination drug items accounted for less than 6.4% of prescription 
items for asthma. Methylxanthine use varied from 0.8% in England to 23% in Italy 
(mean 10%, SD 9). Antibiotic prescribing for adults varied from 0.6% in Portugal to 
5% in Scotland (mean 2.9%, SD 1.3). 
6.2.4 Discussion 
It is clear from the data that despite the real Progress made in international 
consensus on asthma management3 9 1, patterns of asthma prescribing in general practice 
vary considerably as does the frequency of asthma diagnosis. If prescribing were more 
in concordance with the European Formulary and other published guidelines392,393, 
one would expect more consistent asthma treatment, minimal antibiotic use and no 
prescribing of drugs of limited clinical value. The variation in proportions of patients 
with asthma suggests that there may well be differences in the diagnostic labelling of 
asthma as indicated by other studies. 3 763 793 953 96 
Some cautions should be considered in interpreting this data. Firstly, this study has 
used the prescribed item as a unit of prescribing volume which in reality gives no 
consistent indication of the quantity of drug prescribed. Secondly, another important 
confounder is the difference in organisation of general practice in the various countries 
and the difference in distribution of asthma patients between the primary and secondary 
care sector, which make it difficult to compare the patient populations in the various 
countries. 
The results detailed are not easily comparable with other published research as the 
drug and morbidity data presented are solely based on consecutive face-to-face 
consultations with GPs. A highly significant difference in the mean percentage of 
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patients consulting GPs with asthma was found between countries. Despite the 
variation in the number of participating GPs between countries (Table 6.62), this study 
appears to be consistent with others in that similar trends of high asthma prevalence in 
the UK and Ireland and low in the southern European countries have been 
reported. 37-3,393,3395 Different studies have varying methods of data collection, sample 
sizes and age groups with some studies relying only on GP and patient recall and/or 
questionnaires. Whilst this study avoided these sources of bias, there remains a problem 
with GP-labelled asthma diagnosis in all such studies. 
The mean percentage of asthma patients who received a drug prescription for 
asthma was very high in all the countries as might be expected but there was still a 
significant difference between them (Table 6.62). The data indicate that asthmatic 
patients in the UK are approximately 10% less likely to receive a prescription than in 
the other countries (excluding Belgium). The converse to this was found in the 
European Community Respiratory Health Survey published in 1996396 where patients 
with a diagnosis of asthma in Italy and Spain were 10% less likely to be using asthma 
medication than in the UK. This difference could be due to a higher level of 
undertreatment in Mediterranean regions compared with UK centres resulting in less 
asthma medication use, as found in the ECRHS study. The difference in this study, 
could be due to a greater emphasis on reviewing asthmatic patients in the UK compared 
with Mediterranean countries with a consequent greater proportion of prescription-less 
consultations for asthma. In addition,, there is a greater likelihood of high prevalence of 
associated co-morbidity amongst populations where asthma is more prevalent - as in the 
UK. Therefore, some of these patients may be consulting for treatment of any one of an 
associated co-morbid condition and the recording of asthma by the GP may only be part 
of the patient's medical history without requiring a prescription at that time. 
When investigating the prescribing performance indicators, all the prescription 
categories were combined rather than using just the new prescription subset, as only 
27% of the 5,159 asthma drug entities were for newly prescribed items. For the two 
main indicators, the Formulary concordance and the range of drugs prescribed, there 
were found to be no significant differences between control and study groups from 
Phase I to Phase 11. In England, a significant difference was found between the control 
and study groups with a trend towards increased Formulary concordance but this can 
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only be explained as coincidental. From these results,, it can be inferred therefore that 
the provision of written prescribing recommendations alone appeared to have little 
impact on influencing prescribing for asthma. Overall, levels of concordance with the 
European Formulary were generally found to be higher in the UK than in the other 
countries. Also the largest average range of drugs prescribed was found in Ireland but 
this could be explained by the higher prevalence of the condition there. 
The figures for the percentage of treated asthma patients receiving inhaled 
corticosteroids -a potential quality marker, varied considerably (Table 6.62), with the 
levels in Belgium and Northern Ireland being approximately double those in Italy and 
Scotland. Prescribing for asthma could be of a better quality in countries where higher 
levels were found, however the figures for inhaled corticosteroid use may be 
contaminated in some countries by the oral use of steroids such as budesonide. In 
addition, presenting the ratio between prescribed beta-2 agonists compared with the 
country's total percentage for inhaled drugs would not have been an entirely accurate 
measure as a small but possibly varying proportion of beta-2 agonists may have been 
oral formulations. 
Of the remaining prescribing indicators, generally higher levels of inhaled drugs 
were prescribed in the English speaking regions which is important as inhaled drugs act 
directly on the airways and are associated with a more rapid onset of action and fewer 
side-effects for a given therapeutic effect. 6 Prescribing of combination drugs is an 
indicator of inappropriate prescribing in the treatment of asthma, as they do not allow 
for flexible dosing. 279 From this study, less than 5% of the 5,159 drug entities 
prescribed for asthma represented part of combination medicines. Lastly, of the 
antibiotics used for asthma, amoxycillin was the only one to be of notable use (Table 
5.51) and the lowest levels of it were found in Italy, Portugal and Spain. Relatively 
higher levels of antibiotics were found to be prescribed for children in Belgium and 
Ireland and for adults in Italy and Scotland (Table 6.68 and Table 6.69). Overall, 
considerably lower levels were found in Portugal and Spain than elsewhere. One reason 
for this could be, as mentioned earlier, that where the prevalence of asthma is greater, 
there is an increased likelihood of co-morbidity presenting and consequently an artificial 
link made of drugs (for these associated conditions) with a diagnosis of asthma. 
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The levels of inhaled drug use appear to be fairly high in all the countries for 
children, which may be considered satisfactory. In adults, there appears to be a much 
greater variation in the level of inhaled drug use between countries, with high levels in 
the UK centres and low levels in the other countries. There was a low prevalence of 
inhaled steroids (both for children and adults) in Italy with a high prevalence in the UK, 
which is consistent with data reported in the ECRHS. 396 Inhaled bronchodilator use is 
also broadly similar between our study and the ECRHS. 
In Belgium, Italy and Portugal where particularly low levels of inhaled anti- 
asthmatics were found in adults, there appeared to be high levels of oral 
methylxanthines prescribed. This may suggest inappropriate prescribing of these drugs 
as low levels of more severe night-time related asthma symptoms have been reported in 
these areas compared with the British Isles. 397 High levels of aminophylline and 
theophylline prescribing have also been reported in other countries. 3 98,3 99 The 
prescribing of oral methylxanthines does have a place within asthma guidelines but not 
as major drug management. 
High levels of 'all other drugs prescribed for asthma' were found in Belgium, Italy 
and Portugal. This group consisted largely of drugs of limited clinical value and thus 
may also be perceived as indicators of inappropriate prescribing. 
With the continued introduction of new and revised guidelines for the management 
of asthma, both in consensus391,393,400 and ev'dence-based392 form, the therapeutic 
management of most cases of asthma should now be relatively straight-forward - 
although many challenges remain in the organisational management of this condition 
especially in long term patient management. The considerable variation in most aspects 
of asthma prescribing between the countries sampled in this study suggests that there is 
still much room for improvement. 
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Results from the Delphi Study 
CHAPTER SEVEN 
RESULTS FROM THE TWO-STAGE DELPHI PESCRIBING 
INFLUENCES QUESTIONNAIRE STUDY 
7.1 QUESTIONNAIRIE NUMBER ONE 
7.1.1 The response rate 
Of the 241 stage one questionnaires sent out to the GP participants in the eight 
countries (Section 3.2.3), 181 (75%) responses were returned. Although nearly 60% of 
the questionnaires were returned on the first mailing, a follow up reminder was 
necessary. Of the 181 replies, eight (3%) questionnaires (3 Belgian, 3 English and 2 
Portuguese) were returned uncompleted and could not be used in the analysis. Of these 
eight GPs, five had changed addresses, two had retired and one had died. The 
remaining 173 (72%) completed questionnaires (Table 7.70) were used for the various 
analyses. Within the individual countries, the responses for stage one were all above 
60%, except for Portugal (55%). 
7.1.2 Age and gender profiles of participating GPs 
Table 7.71 shows that 113 (65%) of the 173 GPs were male and 60 (35%) were 
female. There were considerably more male than female GP participants in all the 
countries, except for England and Portugal. The majority of GP respondents 89 (51%) 
fell into the 40-49 year age band in all of the countries, apart from Spain. 
7.1.3 Practice type and location 
Most of the GP respondents, 123 (71%) were found to be working in group 
practices/health centres with other GPs (Table 7.72). Group practices appeared to be 
overwhelmingly the norm in Belgium, Spain and in the UK, whereas in Italy, all the 
GPs with one exception, worked alone. A more mixed style of practice was found in 
Ireland and Portugal, although there were more group practices in Ireland than in 
Portugal. 
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In the study, 86 (50%) of the GPs described the location of their practice as urban 
(Table 7.72). Within individual countries, the majority were consistently urban based 
except for GPs in Ireland where most were situated in a mixed urban/rural environment. 
For all the countries combined, only 9 (5%) GPs overall said they worked exclusively in 
a rural setting and the remaining 45% were fairly evenly split between a mixed 
urban/rural or inner city type of practice. 
7.1.4 GPs involvement in training doctors and the time period since qualification 
In this study, 113 (65%) GPs were involved in training doctors (Table 7.72). 
Within individual countries, the majority of GPs were involved in this way except for 
those in Italy, Northern Ireland and Portugal. 
From Table 7.72, it can be seen that the average number of years the GP 
respondents had been qualified varied from on average 15 years in Spain to 22 years in 
Ireland and Scotland (mean 19 years, SD 2.5). 
7.1.5 Age of consulting patient population 
Of the 173 doctor respondents, 147 (85%) had patients under the age of 14. Of the 
26 remaining GPs, 19 were in Spain and their replies indicated that their patient 
population did not include children under the age of 14; the remaining five GPs were in 
Italy and stated likewise. The majority of GPs 167 (97%) in this study saw patients over 
the age of 65 years old. 
7.1.6 Hours worked/week, patients seen/week and patient consultation length 
The mean number of hours worked in primary care in one week (Table 7.73) varied 
over two fold from 28 hours in Italy to 58 hours in Ireland (mean 42, SD 8.9). There 
were broad similarities in the mean number of patients consulted in one week in each of 
the countries (excluding Belgium and Ireland, 101 and 168 respectively), varying from 
116 in Portugal and Scotland to 13 4 in Spain (mean 12 1, SD 6.6). The mean duration of 
each patient consultation varied from 8 minutes in Spain to 19 minutes in Belgium 
(mean 12, SD 4). 
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7.1.7 Consultations with pharmaceutical sales representatives and patients 
The mean number of pharmaceutical industrial representatives seen in four weeks 
(Table 7.74) varied from 0 in Belgium and England to 32 in Portugal (mean 12, SD 13) - 
A relatively high number of pharmaceutical representatives were also seen in Italy and 
Spain. Comparing the mean number of patients consulted with that of drug industry 
representatives over a four week period produced a marked contrast in ratios from one 
drug representative seen for every 5,648 patients consulted in Belgium to one 
pharmaceutical representative seen for every 15 patients in Portugal. The ratios 
highlighted notable differences between countries indicating that in southern European 
regions particularly high numbers of drug company representatives were seen there by 
GPs,, while by comparison, relatively little communication appeared to take place 
between drug representatives and GPs in Belgium and in the UK. 
7.1.8 The most important influence on prescribing 
Of the 173 GPs who returned questionnaire stage one, in response to the open 
ended question, 167 cited a top main influence on their personal prescribing. Of these 
responses: 
* the most popular was medical literature selected by 26 GPs, 
9 the second most popular was the efficacy of a drug selected by 15 doctors, 
* the third was a practice formulary/prescribing policy as selected by II doctors, 
* nine GPs stated that personal experience and familiarity with the drug as the top 
influence,, while nine others sited budgets and government health policy first, 
* three groups of eight GPs each selected: the cost of a drug, using a 
regional/national formulary and the opinions and pressure of discussion with 
colleagues, as their number one influence. 
For the remainder of the open ended question responses, 164 GPs stated a second 
main prescribing influence, 160 provided a third, 141 listed a fourth, while 114 GPs 
recorded a fifth main influence on their prescribing since the start of the prescribing 
study. 
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All the responses received were separated into seven categories/themes of likely 
influence (Annex 9) namely: 
I. drug factors 
2. education/information factors 
patient factors 
4. pharmaceutical industry factors 
5. general medical practitioner factors 
6. regulatory factors 
7. work related factors 
7.2 QUESTIONNAIRE NUMBER TWO 
7.2.1 The response rate 
For the stage two questionnaire, 154 (64%) responses were received which was 
slightly lower than the stage one response (Table 7.70). For this second round, two 
follow up reminder questionnaire mailings were necessary in order to bring the overall 
response rate to above 60%. There were three countries, namely Portugal, Scotland and 
Spain where a 60% level was not reached. 
7.2.2 Overall rank order of the different categories of influence 
For all GPs combined, 'drug factors' were perceived to be the most important 
category of influence, whereas pharmaceutical industry related factors were considered 
the least influential category (Table 7.75). Although there was an evident gradation in 
the hierarchy of the remaining categories, opinion was less distinct. Patient factors 
received the second greatest number of first preferences but summation of the scores for 
the different ranked positions, resulted in education/information factors being 
marginally the second most important category of influence overall and patient factors 
the third. For the fifth and sixth most important categories of influence, despite twice as 
many GPs indicating that workplace factors were the least (seventh) important category 
of influence compared with regulatory factors, their overall weighted totals were 
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similar. Overall, regulatory factors were perceived as slightly more influential in fifth 
place, than workplace factors in sixth position. 
As a consequence of there being different numbers of GP respondents from the 
various countries, those countries with greater numbers could produce a slight bias in 
the overall ranking of the different categories of influence overall (Table 7.75). 
Nevertheless by comparing the overall ranking of the categories of influence with their 
ranking in the individual countries, inter-country variations would be identified. 
7.2.3 Rank order of the categories of influence in the different countries 
Drug factors were the number one category of influence in most countries, but in 
Belgium and England they were second (Table 7.76). Pharmaceutical industry related 
influences were the least influential category in most countries, except for Portugal and 
Italy where they were fifth and sixth respectively. General practitioner factors were the 
fourth most influential category in most countries apart from England and Scotland 
where they were positioned in third place, whereas workplace factors were considered to 
be the fifth most influential category in all the countries except in Ireland and Italy. For 
the remaining three categories of influence: education/information; patient; and 
regulatory factors, there was slightly less agreement between the countries as to their 
precise order. Finally, the order of the perceived influence of workplace, regulatory; 
and industrial factors were fifth, sixth and seventh positions respectively by GPs in 
Belgium, England, Northern Ireland, Scotland and Spain. 
When comparing Table 7.75 with Table 7.76, in the former, regulatory factors were 
the fifth most important category for all the GPs combined, whereas in the latter, 
workplace factors were consistently perceived to be more influential than regulatory 
factors. 
7.2.4 Comparison of the GP ranking profiles in the different countries 
In Table 7.76,, with the exception that GP factors in England were perceived to be 
equally as important an influence as patient factors there, the Belgian and English 
doctors appeared to be the most similar in what they perceived to influence their 
prescribing. 
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For the Irish GPs, their category rank order was identical to that of all the GP 
respondents combined in Table 7.75. The first four categories of influence occurred in 
the same order to those of the Portuguese and Spanish GPs- 
In Italy, the GPs perceived patient influences to be the equally most important 
influential category together with drug factors. Pharmaceutical industry influences were 
in sixth place and considered more influential than workplace factors. 
Patient influences were also ranked fairly high by the GPs in Northern Ireland and 
Scotland where they were the second most important category. The order of the four 
least important categories of influence were the same in Northern Ireland as those of the 
GPs in Belgium and Spain. 
The Portuguese GPs rated the influence of pharmaceutical industry factors more 
highly than in any other country. These influences were ranked to have as equal an 
impact as workplace factors and to be more important than regulatory factors. In 
Portugal, regulatory factors were perceived to be less influential than in any of the other 
countries. 
Scottish GPs rated general practitioner factors in third place (similar to their 
English counterparts), which was higher than elsewhere. Education/information factors 
were rated in fourth place which was lower than elsewhere. 
Spain was the only country in which the ranking for each of the influential 
categories was consistent with the collective ranking of the other countries. 
7.3 DISCUSSION 
The overall response rates were above 60% in both questionnaires one and two 
which met the target level. Portugal was the only country where the 60% target was not 
attained for both questionnaires and consequently it is possible that non-responders 
could have modified the response there. Due to the geographical distance over which 
the research was taking place, it is difficult to know how the response rate could have 
been improved as one reminder was sent out for the first questionnaire and two 
reminders subsequent to the second questionnaire. In addition, cOPies of the first 
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questionnaire were included with all mailings of the second questionnaire to GP non- 
responders from the first stage. 
From the GPs age category breakdowns, the Belgian and Spanish doctors were on 
average the youngest from all the countries. This appeared to link up fairly well with 
the number of years since qualification, where the Belgian and Spanish GPs were noted 
to have the lowest mean number of years recorded, thus confirming a degree of accuracy 
in the way responders were completing the questionnaire. 
In the study, the workplace distribution of the GPs was partially influenced by the 
location of the co-ordinators who generally worked in towns or cities. With the 
exception of GPs in Italy, Northern Ireland and Portugal, the majority were also 
involved in training doctors to become GPs. These two factors support the fact that the 
participants were unlikely to be entirely representative of the GP populations within 
their countries. 
The style of general practice (single-handed/group practice) and the differences in 
the age profiles of the patients who consult GPs varied from country to country. They 
are indicative of fundamental differences in health care practice between European 
countries which can influence prescribing patterns. 210,213 Although where both single 
handed and group practices exist within a country, the GP may choose between them. 
From the ranges of hours worked and patients seen per week in the different 
countries, it is likely that some of the GP participants worked part-time. Of the different 
participating countries surveyed, Belgium is the only one which had an open access 
health care system. An abundance of doctors, associated with the probability of 
increased pressure to satisfy patients there, would be likely to result in a greater instance 
of home visits in Belgium than in the other countries. The Belgian GPs also recorded a 
longer than average length of doctor-patient consultation time than was found in the 
other countries. This helps to explain why the mean number of patients seen in one 
week were lowest in Belgium. 
The mean number of pharmaceutical industrial representatives consulted over a four 
week period revealed extreme differences between countries. The relatively high 
number of drug representatives seen on average in southern European countries, 
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suggests that the GPs appear to have relied on them as a major source of drug 
information. 
From the second questionnaire, of the seven different categories of influence, a 
fairly clear pattern emerged of which were positioned the top, middle and bottom ranked 
categories. As a consequence of there being different numbers of GP respondents from 
the various countries, those countries with greater numbers could produce a slight bias 
in the overall ranking of the different categories of influence overall. For example, the 
number of Irish and Italian GPs responding, represented almost a third of the total 
respondents in the second questionnaire and there was a corresponding bias towards 
regulatory factors by the GPs in these two countries. This explained the difference 
between the order of this category and workplace factors in Table 7.75 for the overall 
data combined compared with Table 7.76 for that of the individual countries. 
Within the individual countries, the most notable findings were firstly that Italy was 
the only country where GPs perceived patient factors to be the joint most important 
influence on their prescribing. Secondly in Scotland, education and information factors 
were rated lower than elsewhere. Thirdly, regulatory factors which could be interpreted 
as the only category which formally controls the GPs prescribing, were relatively low 
down the category rank order in all of the countries. Lastly, industrial factors were 
perceived to be the least influential category in all the countries except for two of the 
three southern European regions which could be associated with the high number of 
sales representatives seen (and honestly admitted) by GPs there. 
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CHAPTER EIGHT 
DISCUSSION 
8.1 INTRODUCTION 
The fundamental purpose of the European Formulary Research Project was to 
establish the degree of acceptability and use of the European Formulary by GPs in 
different countries in order to further the development of a final version which was 
intended to be published. Being the only full-time employee associated with the study 
enabled me to develop a range of research questions and hypotheses which I have 
explored. Consolidation of this work constitutes the submission of this thesis for an 
academic research doctorate. In my independent research I have: 
9 performed background literature reviews on drug formularies and prescribing 
patterns, factors influencing prescribing, quality prescribing and European 
health care systems, 
9 created the primary hypothesis for the main prescribing study, 
* developed the diagnosis and drug coding frames, 
e collated and coded the drug and diagnosis/symptom data as well as entering 
the data using purpose written software, 
* provided annual feedback on the project data to the co-ordinators in the 
different participating countries, 
* taken part in debating the final content and format of the educational 
intervention, 
9 conducted all the necessary prescribing analyses as appropriate, 
* created a second major hypothesis which formed the basis of a two-stage Delphi 
prescribing influences questionnaire study which I designed and carried out. 
The subsidiary questionnaire study was linked to the main prescribing study by 
involving the same GP participants and attempted to establish perceived influences on 
GP prescribing in the different countries. By exploring these perceived influences, it 
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was anticipated that this would contribute and support constructive explanation of the 
variations in drug utilization found in the main prescribing study. 
In this chapter, each study is discussed in turn from three main perspectives, namely 
theoretical considerations, methodological considerations and practical considerations. 
Firstly, the theoretical considerations section reflects on the two main hypotheses which 
formed the basis of the two separate studies and discusses the extent to which these 
were achieved. This step is facilitated by unraveling the hypotheses into discrete 
components which form natural subheadings for discussion. Secondly, the critique of 
the methodological design and procedure of the two studies forms the methodological 
considerations section. The limitations of each study are also discussed. Thirdly, the 
practical considerations heading incorporates discussion of the interpretation of the 
results and what the implications of these are. In addition, a summary is made of the 
key messages that should be conveyed to the main players associated with disease and 
medicines management, namely: doctors, pharmacists, policy makers, the 
pharmaceutical industry and patients. The chapter closes with some suggestions for 
future research and a final conclusion to the thesis. Discussion of the main findings 
from the results and how they relate to other published literature was included at the end 
of each results section. 
There may be alternative ways of discussing the interpretation of the data than this 
proposed format and, not surprisingly, some of the issues raised tend to overlap with the 
different section headings. However, by adopting this proposed structure, an 
appropriate level of focus can be applied to the different aspects of the work in this 
thesis. 
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8.2 THEORETICAL CONSIDERATIONS 
Two hypotheses were drawn up which formed the basis of the two studies. The 
first study was designed to capture GP prescribing data from two distinct time periods 
with an educational intervention mid-way between. 
8.2.1 The prescribing study 
The first major hypothesis postulated that: the planned implementation of a 
multinational consensus-based European Formulary in primary care will result in more 
rational prescribing. 
8.2.1.1 The multinational consensus-based European Formulary 
The first study involved up to 40 GPs from eight European countries being 
randomised into control and intervention groups. As part of an educational intervention 
to improve certain aspects of prescribing, the GPs in the intervention group each 
received a copy of the multinational consensus-based European Formulary. 
For the above hypothesis to be investigated, a formulary based on sound 
pharmacological and therapeutic principles had to be produced which would 
recommend the most cost-effective drug or group of drugs for a specific indication. 
This production task proved to be highly complex (as explained below) and it took 
approximately six years (1987-1993) to develop a framework formulary with an 
additional two years to produce a European Formulary acceptable for field testing. 
The aim (Section 2.1.7) was to produce a handy reference manual which included 
recommendations of both drug and non-drug treatments most appropriate for the 
majority (90%) of conditions presenting in primary care. Some leeway (10%) was 
allowed for conditions requiring specialist treatment. It was proposed that the manual 
should be widely acceptable and useful for the diverse groups of GPs throughout 
Europe. The concept of a formulary was not new though, as many general practice 
formularies were already widely established in some parts of Europe, (Section 2.1.5) yet 
certain countries such as Portugal had no national, regional or local formularies in use at 
the time. Although different countries had different needs and requirements, it became 
crucially apparent that what was consistently lacking was an explanation of why 
289 
Discussion 
particular preparations are recommended. Consequently, it was decided to also develop 
a second more detailed Appendix document, which included references from national 
drug and therapeutics bulletins as well as reputable journals supporting the drugs 
selected in the European Formulary. 
With continuing political integration of the European Community, the concept of a 
multi-national European Formulary to promote standardisation of quality prescribing 
and control drug expenditure throughout the continent was both revolutionary and 
desirable and the acceptability of the free movement of doctors would also be 
facilitated. It has been established that the most successful formularies are ones which 
have involved multi-disciplinary collaboration 100,10 1,13 0,401 and so it seemed logical 
for a team of general practitioners, pharmacists and clinical pharmacologists to form the 
European Formulary Group. Hospital formularies, which are often more sophisticated 
documents, commonly involve additional experts such as microbiologists who provide 
advice on local antibiotic sensitivity patterns and help recommend the most cost- 
effective antibiotics for inclusion within their formulary. 402-40 5 With the intention 
that the European Formulary should cover such a large geographical area, the efficacy 
of antibiotics was likely to vary greatly and consequently the need for local 
microbiological expertise was reduced. 
There were approximately 50 major contributors from 17 countries involved in the 
development of the European Fon-nulary, of whom 10 individuals formed the Editorial 
Board and three had the responsibility for compiling the final draft for field testing. The 
various contributors worked in teams on separate therapeutic sections based on where 
they perceived their areas of expertise and knowledge to be most relevant. The most up- 
to-date reputable drug and therapeutics literature sources in the relevant area of therapy 
were reviewed and specialist advice was consulted where necessary. When completed, 
the therapeutic sections were presented at meetings and the Editorial Board had the 
responsibility for updating the work in the light of the discussions that had taken place. 
Prior to the 1990s, many of the studies reported in the literature which compared 
the cost-effectiveness of drugs, were often sponsored by the pharmaceutical industry 
which exposed them to potential and usually unquantifiable bias. 
406 Since the 
European Formulary development process of a decade ago, there has been a growing 
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cultural move towards more evidence-based medicine using meta-analyses and 
systematic reviews in the development of prescribing guidelines. 120,407,408 
Nevertheless, the strategy of consensus-based agreement such as that adopted in the 
construction of the European Formulary demonstrated a valuable stage in the process of 
change towards independent review which is what is both needed and perceived by GPs 
to be the way forward. 409 
Although drug selection in the European Formulary was primarily based on the 
principles of efficacy, safety and cost, the reality was that the consensus-based 
development process was very much compromised. Apart from the immediate 
problems of geography, communication and language, the European Formulary Group 
operated in a part-time voluntary capacity and members found that it was difficult to 
maintain the momentum of formulary development with the relatively fast rate of 
change in therapeutics, such as in the area of lipid-regulating drugs. Due in part to the 
lack of financial backing, membership of the European Formulary Group changed but 
this had various advantages and disadvantages. The main disadvantage of a fluctuating 
membership was the erosion of continuity. With fewer people involved, another 
disadvantage was that a high level of contribution was required by all concerned, but an 
advantage was that the decision making process was made relatively more efficient. 
Whereas increased numbers of members from a wider geographical range had the 
advantage of requiring a lower level of individual contribution. To reach a consensus 
decision satisfying all concerned, was much more complex with a larger number, and 
although this was Potentially a useful development, there was a need for careful control 
and undoubtedly more resources. 
Frequency of doctor-patient encounters, resulting diagnoses, subsequent prescribing 
and drug consumption are all influenced to a certain degree by different cultural and 
societal biases. In the United States for example, the heart is viewed as a mechanical 
pump and physical blockage is largely believed to be responsible for heart pathology24, 
but in Germany, the heart is considered to be an organ that has life on its own and 
pulsates in response to a number of different stimuli, including emotions. In 1981, total 
sales (in German marks) of nitrates used for angina in countries with roughly similar 
populations and age distributions were 176 million DM in West Germany, compared 
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with 73 million DM in France and 18 million DM in the UK. 24 Around that time, the 
American rates of frequency for coronary bypass operations were 28 times that of some 
European countries. 24 One consequence of this difference in cardiovascular medical 
culture was that pharmaceutical industrial research and development of heart drugs in 
Germany was particularly vigorous which consequently resulted in greater use of these 
drugs. Another reason for high use of heart drugs is because Herzinsuffuzuenz (cardiac 
insufficiency) and low blood pressure are diagnoses which are routinely made and 
treated in Germany41041 1, but are neither accepted nor treated in most other 
countries. 412 Furthermore, low blood pressure is perceived to be a proxy for longer life 
in most developed countries. 24 
The management of intermittent claudication was one area of particular controversy 
in the development of the European Formulary. Although a universally recognised 
diagnosis, it is one where the issue of prescribing cerebro-vascular dilator drugs is 
highly controversial since the few controlled- studies carried out have shown little 
improvement in walking distance ability for those so treated. 6 On a European scale, a 
formulary which omitted cerebro-vascular dilators would not be readily acceptable in 
France, Germany and the southern European countries, whereas in several northern 
European countries, including the Netherlands, Scandinavia and the UK, a formulary 
which included such drugs would have less credibility. The consensus reached by the 
European Formulary Group was to recommend pentoxifylline for use in severe cases 
only. This compromise, though still unsatisfactory to many, was based on the 
philosophy that if a drug was going to be prescribed then it is more rational to be 
consistent and just prescribe one, preferably the most cost-effective. 
Huge differences exist in drug availability throughout European countries. At the 
time of the first European Formulary meeting in 1988, Germany had 11,000 drugs in the 
Rote Liste compendium (Red List) and the UK had approximately 3,000 licensed 
medicinal products prescribable on the National Health service. 
16,24,413 Similarly, 
there were wide differences in the numbers of licensed medicinal products for sale to the 
public in the different countries. Of the countries participating in the study, the number 
of licensed medicinal OTC products at the end of the 1980s varied from 3,382 in 
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Portugal to 8,747 in Belgium. 414 In the former West Germany, there were 21,000 
licensed medicinal products available for sale - the highest number anywhere in Europe. 
Associated with the widely differing numbers of medicines available in EU member 
countries, there are differences in the legal status of medicines in those countries and the 
ways in which they are controlled. Since the early 1990s, there has been a programme 
of deregulation of selected medicines for human use from prescription only to non- 
prescription status in several European countries. Increasing the range of medicines 
available from pharmacies without a prescription has occurred as a result of the attempt 
by governments and health care systems to increase patient self medication4l5,416, 
thereby reducing the cost burden on insurance or national health care systems. Such 
changes have taken place in most European countries and there has been particular 
promotion of self-medication in France, Germany, Netherlands, Norway, Spain and the 
UK. 18 Increasing the number of OTC drugs available has advantages such as in 
providing a more integrated primary health care role for the community phan-nacist and 
relative ease of their availability for the patient but negative consequences include an 
increased risk of potential drug interactions and the danger of patients wanting 'a pill for 
every ill,. 417 Attitude towards these changes by doctors and pharmacists varies 
according to whether they perceive them to be complementary or counterproductive in 
relation to their practice in their indigenous health care system. In Belgium, France, 
Ireland, Italy and Spain, doctors are largely opposed to such moves, whereas in 
Germany, the Netherlands and the UK, doctors are fairly supportive towards the belief 
that people should take more responsibility for their health. 418 In nearly all countries, 
pharmacists have a positive attitude towards these reforms as long as the availability of 
medicines remains essentially through the pharmacy. 418 For example, in the 
Netherlands, where there is now competition between pharmacies and drug stores for 
the distribution of OTC medicines, pharmacists are less positive. While the Royal 
Pharmaceutical Society of Great Britain supports the appropriate deregulation of 
selected medicines being switched to be under the supervision of a pharmacist, there are 
reservations about medicines being later added to the general sales list (GSL). 
lbuprofen was first deregulated from prescription only medicine (POM) to pharmacy (P) 
status in 1983 but in 1995, when ibuprofen was deregulated to GSL (general sales list) 
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statuS419, it became available from a range of outlets including petrol stations, 
newsagents and supermarkets which prompted a request to the Medicines Control 
Agency to review its current practice. 420 
Traditionally, drug availability has depended upon how rigorous the regulatory 
measures are within a country. In 1992, the medicines classification Directive 
92/26/EEC was implemented with the intention of unifying the distribution of 
medicines in Europe. 418 Although this has formed the basis for which medicines have 
been switched from one legal classification to another, the number of medicinal classes 
varies from country to country. Despite there not having been the same degree of 
promotion of self-medication in countries such as Belgium, Ireland and Portugal, it may 
well be that several of the drugs which have been deregulated in other countries in 
recent years are already available without a prescription in these three countries. Many 
medicines when deregulated are only available to the public in a restricted quantity and 
the strength is often lower than that of the prescription version. Important examples of 
drugs available without a prescription in some European countries include certain: 
antifungals, bronchodilators, H2-receptor antagonists and a range of NSAIDs. 418 
Particular problems for the European Formulary Group included instances where, for 
example bendrofluazide which was only available in certain countries had become 
accepted as the drug of first-line treatment there. 
The range of different formulations of drugs which exist includes oral capsules, 
tablets, powder sachets, suspensions and syrups as well as topical creams, drops, gels 
and ointments. The availability of different formulations of the same active drug also 
varies from country to country, for example fluoroquinolones such as ciprofloxacin are 
used topically in the treatment of eye infections but eye drop preparations are not 
available in all countries. 20 Occasionally, the availability of different formulations of 
combination drugs varies too from country to country reflecting differences in both 
licensing applications and licensing practice. The same drug can have different 
marketing authorisation indications from country to country and even within a country 
the licensed indications can depend on whether the drug is prescription only or not. 
Marketing authorisation indications may extend and dosage of a drug may also change 
with time as experience of drug use develops. 
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In developing the European Formulary, there were difficulties in standardising 
dosages for treating conditions as these were often found to differ from country to 
country. For example in the management of pain, there was debate over the 
appropriateness of the level of opioid content in compound analgesics and the 
consequent total daily dose. Standardising dosages is made easier where accepted 
definitions and guidelines have already been generated by special bodies or interest 
groups on an international scale - for example in the areas of asthma391 and 
hypertension346. Similarly, standardising the duration of treatment is also an issue that 
has to be considered, for example in the treatment of urinary tract infections where three 
day, five day and seven day courses of antibiotics are prescribed. 288 The duration of 
treatment can also be associated with the strength of the active drug and hence the 
degree of aggressiveness of the treatment strategy. The age of the patient is also a 
dependent factor. 
In January 1994, EC Directive 92/27/EEC came into force requiring the use of the 
Recommended International Non-proprietary Name (rINN) for medicinal substances to 
be phased in. 6 One of the aims of the European Formulary was that drugs should be 
presented by their generic name. However, generic names approved in countries may 
not always be synonymous with the rINN. Where they are not identical, some generic 
drug names, for example cephalexin and lignocaine in the UK, are easily substituted 
with their rINNs - cefalexin and lidocaine. However, other substitutions have the 
potential to cause confusion, for example adrenaline and dothiepin become rINNs 
epinephrine and dosulepin respectively. In addition, prescribing by generic drug name 
was not routinely practised in some European countries, including Italy, Portugal and 
Spain at the time of this study421-423, and so many prescribers would not have been 
familiar with either the rINN or their national equivalent approved name. The situation 
is further complicated by the way in which brand names of the same drug from the same 
manufacturer often differ between countries. Although the European Formulary Group 
agreed to use generic name terminology, the fact that there was no standard uniform 
drug nomenclature which European GPs would be guaranteed to be familiar with, was a 
problem. 
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Probably one of the most disruptive and unpredictable factors in developing the 
European Formulary was the inconsistency of drug prices between countries which 
nevertheless influence prescribing. The extent of this was not fully appreciated by 
members of the European Formulary Group in the initial stages of the Formulary 
development process. Government and industrial price and profit controls are largely 
responsible for determining the cost of drugs in different countries. 21 Difficulties have 
been reported with drug prices varying markedly within countries too, especially 
between primary and secondary care causing problems with the provision of seamless 
patient care upon admission to hospitals and later discharge back into the 
community. 130,279 Differences in drug prices caused a particular dilemma for the 
European Formulary Group in the area of antibiotic drug selection where it is 
recognised that resistance to antibiotics is a global problem. When considering the 
third-line treatment of urinary tract infections, the European Formulary Group wanted to 
limit the recommendation of fluoroquinolones in order not to jeopardise their future 
effectiveness but in Spain, for example, nalidixic acid was the most cost-effective 
fluoroquinolone compared with norfloxacin in the UK. 423 Ironically the Spanish GPs 
appeared to prescribe norfloxacin in preference to nalidixic acid in the treatment of 
UTIs. (Section 5.2) Co-amoxiclav was another example of an antibiotic that was 
relatively cheap to prescribe in Spain in comparison with the UK cost. 
Despite the difficulties faced by the European Formulary Group, a European 
Formulary and Appendix were developed recommending treatment for 66 conditions, 
deemed to be the most commonly presenting conditions in primary care (Annex 4). 
There were 126 drugs recommended in the European Formulary which were available in 
all the European countries where its use was being implemented and tested. In certain 
places where recommended drugs represented examples of a therapeutic group in which 
various drugs could serve as alternatives, a special clause was used which enabled the 
selection of equivalent drugs depending upon their availability and comparative cost in 
a country. An example was the use of fluoroquinolones for the third-line management 
of UTIs. In certain situations however, such as in the first-line management of 
hypertension, the European Formulary appeared to be fairly rigid in the selection of 
hydrochlorothiazide as the choice of thiazide diuretic. In the UK, hydrochlorothiazide is 
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more expensive than bendrofluazide and appears to offer no significant clinical 
advantage. 6 
With the complex nature of developing the European Formulary, the Editorial 
Board were faced with deciding whether the Formulary was intended to be a 'jack of all 
trades' i. e. a rough guide to prescribing in general practice, or a 'master of some' i. e. to 
focus and become an authority on certain specified areas of prescribing which when 
targeted could have a significant impact on prescribing practice. Ultimately, it was the 
objective of the European Formulary Group to publish the European Formulary and 
Appendix by marketing them both as educational tools and as a foundation upon which 
practitioners throughout Europe could develop their own formulary tailored to local 
requirements and in so doing foster a degree of ownership (Section 2.1.5). 
One of the fundamental questions, which I believe was not properly addressed, was 
whether the purpose of the European Formulary was to be diagnosis-led or drug-led. If 
it was intended to be diagnosis-led then should symptoms commonly presenting in 
general practice but which tend to lack credibility as definite diagnoses, for example 
fatigue, itching, and pyrexia of unknown origin, be included? If the European 
Formulary was to be drug-led, then should conditions be included where there is no real 
controversy over the choice of therapy once the diagnosis is made, for example 
hypothyroidism and hyperthyroidism? Also should conditions where drug therapy is 
not routinely recommended first-line, for example sprains and strains, be included? 
All the shortcomings discussed above may therefore have diminished the potential 
influence of the European Formulary and Appendix. Other factors can also determine 
the level of success of a formulary such as its launch and promotion and how these 
aspects of the European Formulary were managed are now discussed in the next section. 
8.2.1.2 The planned implementation 
With the development of a consensus-based European Formulary in 1995, the 
members of the Editorial Board were now in a position to use this draft for field testing 
among GPs in Belgium, England, Ireland, Italy, Northern Ireland, Portugal, Scotland 
and Spain. To achieve maximum success, planning the implementation should have 
involved in detail how best to optimise the behaviour change of the prescribers. Ways 
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to achieve such behaviour changes have been considered by others. 424-426 The more 
lines of communication involved when trying to implement change then the more the 
messages are likely to get distorted. 427 As the validity of a rigorously designed 
uniform intervention did not form part of the remit of the study, it has not been possible 
to adequately test this aspect of the hypothesis. However, the proposal for BIOMED 
funding did state that a standard formulary and information pack concentrating on 
antibiotics and NSAIDs would be made available for the GPs in the intervention group 
prior to the second data collection. Additionally, the doctors in the intervention group 
in each country would either attend a one day meeting or would each be visited by their 
co-ordinator. The precise nature and details of the intervention were to be agreed at a 
later date. 
At the annual co-ordinators weekend meeting in April 1995,1 participated in 
establishing the strategy for the planned implementation of the European Formulary and 
educational intervention. It was agreed that the intervention protocol needed to be 
standardised so that the same procedure would occur in each country. Whilst it was 
recognised that certain additional factors, such as the individual performing the exercise 
(i. e. the co-ordinator), would differ, the co-ordinators were all respected opinion leaders 
within their localities. The intervention was to consist of the European Formulary, 
together with all the sections of the Appendix relevant to antibiotics and NSAIDs and a 
refined list summarising the most important prescribing messages from the Appendix 
associated with each drug group. It was decided that the intervention group GPs would 
receive the educational package between one and two weeks prior to the date of an 
agreed meeting. 
Subsequently, the actual implementation of the educational intervention did 
however vary from country to country, although all GPs were mailed with the same 
educational literature. The method and extent of communication varied between 
countries. In England, communication was via the telephone with one of the partners in 
each of the intervention practices. In Spain, the co-ordinator met all the intervention 
group GPs at the various GP centres on five separate occasions. Each of these five 
workshops lasted for one hour's duration and enabled debate and discussion about the 
educational material. The thoroughness of the implementation process depended on the 
dedication and enthusiasm of the GP participants as well as the commitment and 
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persistence of the different co-ordinators trying to fit in with the busy daily schedules of 
the GPs. 
8.2.1.3 Primary care 
This research has concentrated on addressing the prescribing practices of primary 
care doctors in eight European countries. With the exception of Belgium, a gatekeeping 
system operates in the project countries where GPs control access to all other levels of 
health care (Annex 1). Consequently these countries have a similar organisational 
structure with the general practitioner often at the centre of health care, although the 
delivery of that care may be variable. 
In Italy for example, there are community-based paediatricians and children under 
twelve years old have to be registered with one266 and in an attempt to co-ordinate care, 
prescriptions written by specialists such as paediatricians have to be endorsed by the 
patient's own GP. In Spain, there are additional support units in primary care as well as 
the network of GPs. 266 These units include maternity and child health centres, mental 
health centres, physiotherapy units and family planning centres. Whilst GPs still act as 
gatekeepers to these services, the responsibility for children's prescribing lies with 
community-based paediatricians and this potentially can have a marked effect on the 
prescribing profiles of GPs. For example, research has shown that the prescribing levels 
(in terms of the number of items) in children up to four years of age are not reached 
again till the 45 to 54 year old age group. 428,35 Also prescribing volume and cost is 
known to be greater in females up to the age of 55 years old and hence the availability 
of maternity and family planning centres is also likely to have an effect on the 
prescribing volume of GPs. 
Other characteristics of general practice have also been found to vary widely 
between countries (Annex 1). The duration of the consultation has been proposed as a 
simple proxy measure of quality of care with longer consultations being more thorough 
and relevant to the patients needs. 
211 Shorter consultations have been associated with 
the more frequent use of a prescription to terminate the consultation30 whereas those 
GPs who allow ten minutes or more for each consultation have been found to prescribe 
fewer antibiotics. 
211 The reported duration of GP-patient encounters in the project 
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countries varied from four minutes in Spain to eleven minutes in Belgium and this may 
have influenced the pattern of prescribing. 
Even within the primary care setting of a country, variations in health care practice 
have been found to have a marked effect on factors such as prescribing volume. Until 
recently in the UK, GP practices could chose whether they wanted to be fundholders or 
non-fundholders. Fundholding practices were allocated extra budgets to pay for a 
patient's secondary care in addition to their primary care needs. 266 As a result of such 
incentives, fundholding was found to contain increases in prescribing costs in the short 
term214 but longer term effects were not as positive. 216 
Although primary care is only part of the entire health care delivery system, 
targeting general practitioners prescribing behaviour is necessary as it is widely reported 
that in the region of 85% of the prescribing volume in the UK takes place in primary 
care. 30 Consequently, this represents the bulk of drug expenditure which is considered 
to equate to 80% of the cost of all medicines236 and despite differences in health care 
practice it is probable that this dominance prevails generally in western Europe, 
especially where a gatekeeping system exists (Annex 1). 
8.2.1.4 More rational prescribing 
Over 25 years ago Parish first defined rational prescribing as being 'appropriate for 
the patient, effective, safe and economical'. 37 Although others have since contributed 
to this definition, the general interpretation by Parish is still widely accepted today. 
However,, difficulty has been found in finding adequate tools which can be used to 
measure and compare rational prescribing. 58 Even when valid measures have been 
identified, it is rarely possible to apply them to prescribing on a large scale. 
Consequently, one of the attractions of using the proportion of drugs prescribed 
generically as a crude indicator of rational prescribing is that it can be potentially 
measured on a continuous basis for all GPs in the UK. Unfortunately, as already noted, 
generic prescribing was not routinely practised throughout Europe, so the generic 
prescribing rate could not be used as an international quality indicator. 
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Formularies are a standard against which rational prescribing can, to a large extent, 
be practically and more meaningfully assessed, especially as their development is 
generally based on the core principles of rational prescribing, namely efficacy, safety 
and cost. The effect of formularies in a variety of settings has been widely documented 
in the UK since the early 1980s. Studies of formularies have highlighted that: formulary 
development need not restrict drug choice122, involvement can be associated with 
higher levels of prescribing recommended agents124, adherence is higher with new 
prescribing for acute conditions than with repeat prescribing for established 
therapies124, implementing recommendations have generated considerable cost 
savings123', use can reduce the range of drugs prescribed286, development can educate 
prescribers90, adoption can improve patient compliance127 but that formularies which 
are not regularly updated eventually stagnate and become obsolete. 72 
The research presented in this thesis has assessed the degree of rational prescribing 
before and after the educational intervention by using core and miscellaneous 
prescribing performance indicators. The core indicators were: 
9 concordance with Formulary recommended drugs for a particular condition 
Go the diversity of prescribing measured by the range of drugs used 
* whether consultations resulting in a prescription reduced where appropriate. 
Regarding the diversity or range of prescribing, physicians in general can only keep 
up-to-date with the profiles (contra-indications, dosages, formulations, indications, 
interactions, side-effects, strengths and treatment duration) of a limited number of 
medications. The rationale behind drug selection by doctors has been found to become 
increasingly inefficient when presented with a larger number of choices of therapy. 429 
High quality prescribing is therefore associated with the use of a relatively limited 
number of drugs. 72,242 The miscellaneous prescribing performance indicators used 
were ones specifically tailored to the area of prescribing being investigated. For 
example, the use of combination drug forms such as potassium- sparing diuretics, can 
confuse prescribers as problems may arise when changes in dosage schedules are 
needed and hence their use should be minimised. Although combination drugs may 
contribute to and improve patient compliance, it is difficult to justify their use as the 
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combined cost of the drug entities prescribed separately is usually more economical-279 
The prescribing analyses focused in particular on the category of new prescriptions as it 
was perceived that current prescribing would be more likely to change data subsequent 
to the educational intervention, as opposed to influencing a review of repeat prescribing. 
8.2.1.5 Conclusion 
The first major hypothesis in this thesis was partially proven. The hypertension and 
asthma results sections indicate that receipt of the European Formulary alone had little 
effect in improving prescribing. Whereas the NSAID and antibiotic data (for throat 
infections in particular) indicate that for some of the prescribing performance areas 
considered there were statistically significant improvements after the educational 
intervention in some countries. Occasionally there was also the odd perverse result 
where the control group appears to have demonstrated a greater improvement in 
prescribing compared with the intervention group. Therefore it is important to add an 
element of caution in the interpretation of these results and one has to bear in mind that 
there are a number of variables interacting having an impact on the results. With respect 
to the educational intervention, it was not possible to identify whether the catalyst for 
change was provision of the referenced Appendix, or verbal discussion and debate of the 
main prescribing messages between the co-ordinators and their intervention group GPs 
singularly or collectively combined. 
8.3 METHODOLOGICAL IMPLICATIONS 
8.3.1 The prescribing study 
The European prescribing study described was successful in obtaining prospective 
prescribing data of 138,615 diagnoses and 130,657 drug entities from 101,544 doctor- 
patient consultations over two distinct time periods from 235 GPs in eight European 
countries (3 centres within the UK). Half of the GPs received an educational 
intervention between the two periods of data recording and there were 218 GPs who 
completed both phases of the study. 
The draft multinational consensus-based European Formulary and Appendix 
documents used for field testing in the intervention were original. There had never 
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previously been an enterprise to produce a formulary over such a wide geographical 
scale involving so many countries and cultures. In 1994 when funding was made 
available to investigate whether use of the European Formulary would improve cost- 
effective prescribing, very few international multi-centre primary care based drug 
utilization studies had been previously initiated before, nor have there been since. 
In order to attempt to prove or disprove the first hypothesis, a controlled- study 
design was necessary with two groups exposed to the same conditions within a country 
differing only for the intervention group which received the educational package 
(including European Formulary) half-way through the experiment. Consequently, any 
change in prescribing behaviour that ensued between the control and intervention 
groups could be said to be attributable to the educational intervention. As others have 
done430,, this study was also designed for data to be recorded by the GPs in the different 
countries at precise intervals (Autumn 1994 and 1995) working to a similar time scale. 
This was necessary as it is recognised that there are seasonal fluctuations in diagnostic 
patterns, hence different types of drugs may be prescribed and the quantities in which 
some drugs are utilized can be very variable. 
The Prescribing data recorded comprised those drugs which were issued and their 
prescription category linked to diagnoses, together with patient age and gender. Such 
information is unique as data sets with this linkage are not routinely available for 
comparative purposes on a wide scale in any country to date. (Section 2.1.3.2) This 
enabled a more meaningful evaluation of the range of prescribing scenarios, including 
for instance whether or not a NSAID is deemed necessary or whether the choice of 
antibiotic is the most suitable for a presenting infection. Recording of the drugs being 
prescribed to patients for other conditions provided the possibility of greater insight into 
therapeutic management decisions - for example, the prescribing of an ACE inhibitor 
for first-line management of hypertension when the patient was also a diabetic. 349 
Information available on the age of patients treated by the GPs allowed a consideration 
of the different safety profiles of drugs, for example the degree to which NSAIDs with 
longer half-lives often associated with more serious side-effects were being prescribed 
for the elderly. The recording of the sex of the patient was important in order to 
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determine, for example, the prevalence of urinary tract infections in females compared 
with those in males. 
A medical statistician was consulted about appropriate sample sizes of GPs who 
should be recruited in each country. The proposed target of 40 GP participants per 
country proved somewhat difficult to achieve, as primarily there was no financial 
incentive for GPs to take part in this study. This proved to be a crucial prerequisite in 
some countries, such as Germany. The recording of data was a time consuming task for 
already busy doctors and the control group doctors did not have the added benefit of 
receiving the educational intervention, although they were promised a copy of the 
European Formulary upon completion of the study. Consequently the GPs who were 
recruited were mostly enthusiastic volunteers, many of whom were known personally to 
the co-ordinators and were either interested in prescribing or were keen to participate in 
research. In Northern Ireland,, an attempt was made to obtain a random sample and the 
net result was that only 13 GPs agreed to participate out of a target of 40, which 
exemplified the difficulties experienced with this recruitment method. The overall 
sample was therefore less likely to be truly representative of the GP populations within 
the different countries, with the possible exception of Northern Ireland. Any potential 
bias occurring as a consequence of recruiting potentially more enthusiastic GPs could 
have tended to produce artificially better results and the levels of drug utilization found 
would be likely to reflect more informed use. Thus there could be an underestimation of 
the variations that really exist. 
Recruitment was generally restricted to the geographical regions of the local co- 
ordinators. However in Belgium, the GP subjects were from a wide geographical radius 
as a regional formulary was already well established in the immediate locality of the co- 
ordinator which it was feared might bias results and also make recruitment of doctors 
more difficult. Other regional formularies were known to exist in the immediate 
vicinity of co-ordinators in England, Northern Ireland and Scotland but it was not 
possible to avoid these areas as formularies are generally widely available in these 
countries. The locality of a GP is likely to determine the socio-economic mix of his/her 
patient population and studies have shown that social deprivation is linked to morbidity 
and therefore prescribing. 
431 Consequently, the actual location of the co-ordinator in 
each country could indirectly have influenced the data collected and collated. The 
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North East of England, for example, is generally more deprived than other areas of 
England; unemployment in the North East was 9.8% in 1997 compared with 6.9% for 
the whole of England. 432 Recruitment of GPs in the Newcastle upon Tyne region, in 
the North East of England, could therefore result in prescribing patterns which may be 
atypical of those in the country at large. 
To enable easier administration of the educational package, the co-ordinators 
attempted to select GPs in group practices or health centres where possible. This could 
have potentially been a confounding factor as those factors which influence prescribing 
by GPs in group practices have been found to be different from those influencing solo 
practices. For example, commercial information has been found to be preferred by 
doctors who were practicing alone. 156 Once recruited to the study, the doctors were 
randomized between control and intervention group practices in order to minimise 
potential bias. Overall, the study had a remarkably low drop out rate; only 17 GPs 
(7.2%) from Phase I did not participate in Phase IL This was attributed to the high level 
of enthusiasm of the participants and it is probably unlikely that such a high level of 
involvement would have been achieved with a completely random, representative 
sample of the GP population. 
Whereas there was a multidisciplinary group of individuals involved in the 
development of the European Formulary, the co-ordinators in the prescribing study were 
all GPs associated with either academia or GP training bodies except in Portugal. In 
Portugal there were two co-ordinators, one a pharmacist and the other a physician, both 
of whom were based in teaching hospitals but importantly they had good links with 
community-based family doctors. All the co-ordinators were members of the Editorial 
Board and/or were co-authors of the two documents. Although the educational 
intervention strategy was agreed by all the co-ordinators, its success could have varied 
depending on the personality of the individual co-ordinator administering the 
intervention but the study had no real control over this aspect. It would have been 
impractical to standardise this procedure by having the same individual administering 
the i ntervention in all the countries on a similar time scale. Even though all the GPs 
were provided with project guidelines, translated as appropriate, and no language 
barriers existed between each co-ordinator and his/her cohort of recruited GPs, there 
were still occasional anomalies in the prescribing data supplied. The most common 
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misinterpretation was the fact that several GPs fell short of recording 200 consecutive 
patient consultations where a prescription was issued in addition to those intervening 
consultations where no prescription was issued. Instead, some just recorded information 
from 200 consecutive consultations, irrespective of prescriptions. GPs also appeared to 
be uncertain about whether to include appliances, dressings, reagents and vaccinations 
within the 200 consecutive prescriptions requested. The study design did not anticipate 
the fact that some consultations which did not result in a prescription may have actually 
involved GP advice for patients to purchase OTC medicines, such as dispersible aspirin 
75mg tablets for antiplatelet use. Although the guidelines issued to the GPs were 
translated as appropriate from English by the co-ordinators, ideally they should have 
been back-translated for validation purposes. 
As a result of financial and time constraints, the European Formulary and Appendix 
which formed the core part of the educational intervention were only printed and 
available in English which was probably a potentially important confounding factor. 
Even where GP participants had a good understanding of the English language, this 
aspect could have decreased its level of user-friendliness and effectiveness as a rapid 
consultation guide during patient consultations which was one of the main objectives of 
the European Formulary. As previously mentioned, all the drugs were listed in their 
generic name form only which may not have been easily recognisable in southern 
European countries where generic prescribing has not been routinely practised. 
Nevertheless all the drugs recommended in the documents were well established ones 
which were available in all the participating European countries. 
The data collected in this study were from face-to-face consultations with GPs and 
so there was probably a bias towards patients with more acute problems and possibly 
those who were less compliant with treatment regimens who needed to revisit their GP. 
This created some difficulties when trying to compare morbidity patterns and drug 
consumption data within the study with other published findings433 because of the 
differences in data collection. It proved necessary for all the data recording 
consultations to be made on paper as unfortunately, those countries with electronic 
prescribing were unable to submit data in a usable format as their systems did not 
readily adapt to the requirements of the project. Electronic data were generally unable 
to include either patient consultations where no prescription was issued or identify the 
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category of the prescription required. This was disappointing as one study has shown 
that the recording of data electronically in general practice can be highly accurate with 
100% of all consultations where a prescription was issued being logged onto the 
computer. 434 Electronic transfer of information could have enabled the data collection 
process to have been significantly faster and less tedious than by manual processing. 
Some important prescribing data were not always routinely collected which would 
have enabled more detailed accurate and meaningful analyses to have been performed, 
including the dosage, treatment duration, formulation, quantity prescribed and strength 
of the medication. Although linkage of drugs to diagnoses enabled determination of 
whether the drugs were being prescribed for appropriate indications, it is possible that 
the dosage frequency and duration of treatment of an appropriate drug may have been 
contrary to the European Formulary or to a manufacturer's guidelines. The omission of 
such additional information meant that this extra analysis was not possible. Each 
pharmaceutical preparation has a recommended dose and dosage frequency which in the 
UK is found in the drug data sheet. 191 Although the manner in which a drug is 
prescribed is at the discretion of the prescriber, it is advisable that the guidelines set out 
in the data sheet are used as they are set following the result of stringent testing by 
manufacturers and are part of the marketing authorisation. 
Associated with the duration of treatment, it would have been useful to have known 
the date on which medication on repeat prescriptions was first started, in order to 
confirm whether this was rational. However it was not intended that the data revealed 
the complete current medical history of each patient but represented a snap shot of 
prescribing at a point in time i. e. the data recorded were prescription(s) that patients 
were receiving for specified conditions at the time of the consultation. Where a drug 
was prescribed which was recommended in the European Formulary but in a 
formulation that was not endorsed by the Formulary, it was not possible to make the 
necessary adjustment to the data analyses. For example where diclofenac was 
prescribed in a modified release preparation or as a topical gel, this artificially enhanced 
the level of concordance with the European Formulary because the study was concerned 
only with the recording, classification and coding of generic drug names. Nevertheless 
307 
Discussion 
it was possible to separate the data into single entity non-combination drugs as well as 
combination drugs for analyses if necessary. 
Data were collected on the type and origin of the prescriptions (N, A, R or H) though 
these categories were sometimes problematic in interpretation. 'N' drugs were clearly 
defined but many drugs which were recorded as repeats would have originally been 
initiated by hospital doctors, for example insulin. The results recorded in this study for 
hospital prescriptions do not completely reflect all hospital-initiated prescribing and are 
generally lower than has been reported elsewhere. 30 Spain recorded the highest 'H' 
prescription rates which may be as a result of the combination of short consultations and 
high referral rates which seem to characterise primary care in that country. In this study, 
there were lower numbers of 'R' prescriptions recorded than some others have found. 30 
This probably reflects the fact that only face-to-face prescriptions were recorded. 
Systems by which patients are transferred onto repeat prescription registers may also 
vary between countries as well as the way in which they are monitored. For example, 
patients requiring repeat prescriptions for asthma in the UK may be reviewed by 
practice nurses in asthma clinics without the need for intervention by the GP. Thus the 
mechanism for repeat prescribing is likely to influence the numbers of 'R' prescriptions 
recorded. Despite the difficulties in this study with prescription categories, their 
inclusion was highly important in the prescribing analyses performed as it was 
considered that the new prescribing category would be the most likely to be influenced 
following the educational intervention. Where prescribing data are available across 
countries, such as PACT data in England, these do not indicate which prescriptions are 
new as distinct from repeats and so lacks sophistication in this respect. 65 
The methodology was developed from previous studies which had a more localised 
setting of prescription data capture. 124 International data sources which were available 
were assessed to see if they could be useful in this survey. The methods derived and 
used were considered to be the most comprehensive and practical for the constraints of 
manpower and the time frame available for the study. 
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8.3.1.1 Limitations 
If this study were to be repeated then it would be imperative that a random, 
representative sample of GPs should be recruited in all the participating countries, 
although the number of participants likely to drop out between Phase I to Phase 11 would 
probably be higher than it was with volunteers. A rewrite of the European Formulary 
would be required which took into account the clinical conditions presenting in primary 
care that the present edition omitted to include. Consideration as to whether some of the 
most commonly prescribed non-Formulary drugs should be included would also be 
required. In order to make the European Formulary more acceptable to its users, it 
would need to be translated into the various national languages and also back-translated 
in order to validate the process. Also in order to optimise the quality of data collection a 
larger scale pilot involving GPs independent of the research should be carried out 
initially and with respect to validating the data management process, an error rate should 
be established. 
Rational prescribing takes time to implement and initiatives to improve prescribing 
need to be regularly reinforced in order for the proposed effect to be first achieved and 
secondly sustained. 90,154,167,223 If this study was to be repeatbd, ideally a greater 
volume of prescribing data should be analysed over a prolonged period to explore any 
sustained change in prescribing behaviour and to assess how a positive improvement 
could be subsequently maintained after a more robust series of interventions. If the 
same volume of data were collected then in order to increase the volume of data specific 
to the areas being investigated, one should consider whether the recording of 200 
consultations associated with new prescriptions for antibiotics and/or NSAIDs only for 
example would be of more value. 
A shortcoming of the type of information collected in this study is that it lacks 
outcome data i. e. we do not know the ultimate success or failure of the present treatment 
strategy for a given condition. Nor do we know whether first and second-line drugs 
have previously been tried and found to be ineffective or produced undue side-effects, 
for example in the antibiotic treatment of bacterial infections. It is conceivable that the 
same patient could have revisited the GP before inclusion in the requested quota of data 
on 200 consecutive patient consultations and because the patients were number coded 
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for anonymity, this was not known. In Belgium, the likelihood of a patient returning to 
the same doctor before 200 consecutive patients have received prescriptions could be 
less likely as there is no patient registration system with GPs (Annex 1). Ultimately, a 
knowledge of previous drug outcomes would have been particularly beneficial when 
critically evaluating the level of rational prescribing within the different countries. 
Some indication of this would have been possible if an appropriate additional category 
of prescription to those discussed earlier had been included in the methodology. 
To minimise some of the limitations in this study considerably more financial 
resources would have been required. For example in order to deliver a more successful, 
uniform intervention, ideally a salaried academic detailer trained to make use of the 
marketing techniques used by pharmaceutical industrial companies should be located in 
each country. The content of the intervention should also be reviewed because with 
varying antibiotic sensitivity patterns around Europe for example, antibiotics may not 
have been a particularly suitable area to attempt to analyse, even though a global or 
European strategy is urgently needed to contain increasing antimicrobial resistance. 435 
These identified methodological limitations should be kept in perspective as in 
practice, many GPs did provide additional prescribing information and it was possible to 
infer the formulation of many of the drugs prescribed. As different formulations of the 
same generic drug name often appear in different therapeutic classification systems, 
where for example an antibiotic was in an oral form as opposed to a topical form, it was 
possible to code these separately. Unfortunately to request any additional information at 
the recording stage was not feasible. It would have made the processing of data even 
more complicated and time consuming and some of the GPs may not have been as 
willing to participate if required to supply additional data. 
Future use of more sophisticated computers and computer software in general 
practices should facilitate better recording of patient information and easier electronic 
transfer of data. This could prevent GPs having to put unnecessary time and effort into 
manually recording the necessary information and would therefore limit finances 
otherwise incurred to pay for their participation. Those responsible for maintaining 
computer patient medical records in general practices should be able to add extra 
information specially for research purposes with relative ease, such as consultations 
310 
Discussion 
where no prescription was issued and if prescribed medication was hospital-initiated. It 
should also be possible to have access to complete current medical histories to patients' 
to enable a more accurate assessment of rational prescribing as well as confirming 
whether patient referral was necessary. One major advantage would be that inclusion of 
information such as the drug dosage, formulation, strength and duration of treatment 
would enable use of internationally accepted Defined Daily Doses (DDDs) as a unit of 
comparative drug utilization measurement. Should information on consecutive patient 
consultations still have to be manually recorded then arguably the most desirable piece 
of additional information would be the duration of treatment. Knowledge of this 
together with the other fields of information recorded in this study would still enable 
measurement of DDI)s and would not require much more effort on the part of GPs 
alongside coding, data entry and data analyses. 
Finally for a comprehensive drug utilization study, it would be necessary for OTC 
medicine use especially deregulated medicines, to be included. 436 To facilitate such an 
investigation on a wider scale, increased compatibility and standardisation of computer 
software are needed with internationally recognised measures of patient outcomes. 
8.4 PRACTICAL CONSIDERATIONS 
8.4.1 The prescribing study 
There were indications that in some countries marked changes did occur whilst 
virtually no changes were found in others. Three generic indicators were used to 
measure the prescribing performance and issues around these will be discussed in turn. 
With respect to concordance with the European Formulary for overall prescribing, 
there was found to be a highly statistically significant difference in the movement 
towards the Formulary by the study group compared with the control group, although 
this difference of a 4.2% swing may appear modest. The concordance levels between 
countries varied between approximately 35% in Portugal and 60% in England but are 
likely to be an overestimate of the true concordance for the reasons previously explained 
(Section 3.1.3.11). This was lower than anticipated as one of the aims of the Formulary 
was to provide appropriate treatment for a minimum of 90% of patients with common 
conditions requiring a drug prescription. One regional formulary in Scotland (Grampian 
311 
Discussion 
Formulary) has reported up to 90% concordance 132 by its users, although the study did 
not measure the concordance of drugs linked to their appropriate indications. There are 
several reasons for the poor relative performance of the European Formulary. Firstly, 
the reason for the higher concordance level with the Grampian Formulary was because it 
was neither developed nor intended for use on a geographical scale comparable to that 
of the European Formulary. Secondly, general practice formularies are usually tailored 
to local requirements, for example to reflect regional differences in antibiotic sensitivity, 
whereas the European Formulary, intended for use over such a large geographical scale, 
could not easily adapt in that way. Thirdly, the Formulary and Appendix were not 
translated into all the different languages of the project countries but distributed in 
English and this would have presented a major barrier in its use to some GPs. Fourthly, 
the average percentage of presenting diagnoses in each country covered by the European 
Formulary was lower than 70% everywhere confirming that the content of the 
Formulary was deficient in some areas. Fifthly, the average levels of diagnoses covered 
by the Formulary per country were higher than the average drug concordance levels 
suggesting that either the Formulary was too restricted in the drugs that were 
recommended and/or a proportion of the GPs prescribing was inappropriately outside 
the Formulary recommendations. 
With the more specific drug and diagnostic areas investigated in this thesis there 
was a more definite link of drugs prescribed with their indication and consequently the 
concordance levels were more accurate. Comparing these levels between the countries 
revealed that prescribing in the UK regions was consistently more in line with the 
recommendations of the European Formulary in all the areas investigated except in the 
prescribing for hypertension where the concordance levels were relatively low 
everywhere. As a result of these higher concordance levels, there was less scope for 
improvement by UK GPs compared with those from the other countries and as a 
consequence there were more notable trends (some statistically significant) towards 
increased use of the Formulary by the Belgian, Italian and Portuguese GPs in particular. 
The second main prescribing performance indicator was the diversity of prescribing 
and there was found to be a highly significant reduction in the range of drugs prescribed 
after the educational intervention between the study and the control group overall. 
Spain recorded the highest average range and this still remained high in Phase II even 
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though the Spanish GPs recorded only half the requested number of consultations 
resulting in a prescription. Other countries with a high recorded range included 
Portugal, Italy and Belgium. It is postulated that differences in the range of drugs 
prescribed by the GPs in the different countries could be due to three principal factors. 
Firstly in some countries, where the number of drugs available on the market is high 
there is likely to be more choice of both combination and single entity products. 16 
Secondly, the total number of active drug entities recorded and coded in the data would 
inevitably increase as a result of more combination products being available and used in 
Belgium and southern European countries. Thirdly, in English speaking regions GPs 
have already been encouraged to use fewer combination products in the promotion of 
better prescribing. 279 
The higher the range of drugs used, the greater is the diversity of prescribing which 
is also usually indicative of both poorer quality242 and even potentially 'dangerous' 
prescribing. 4.37 However, this indicator of prescribing is dependent on the number of 
consultations; the lower the number of consultations, the higher in proportion the range 
is likely to be and this can be seen in the Spanish data from Phase 11. Within the areas 
investigated in this thesis, the English, followed by the Scottish and then Northern Irish 
GPs prescribed from the smallest ranges of drugs. Therefore the Belgian, southern 
European and to a lesser extent the Irish GPs again had more scope to improve in their 
prescribing practices compared with the GPs from the UK regions. After the 
educational intervention, positive changes with respect to prescribing from a smaller 
range were especially evident in Belgium. 
The third main indicator measured was the percentage of doctor-patient 
consultations which resulted in a prescription. This was found to be higher in southern 
European countries than elsewhere which compares well with published OECD data250 
which indicates that there is a relatively higher number of prescription items per person 
in these countries than in northern Europe. One of the main reasons for these 
differences is likely to be associated with the duration of patient-doctor consultations. 
For example, GPS in Spain are known to have characteristically short patient 
consultations266 where there may be a strong tradition of terminating a consultation by 
issuing a prescription. In English speaking regions, there are relatively longer doctor- 
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patient consultations resulting in less priority being given to the issue of a prescription 
but a greater emphasis placed on patient counselling. In open access health care 
systems such as in Belgium where GPs are paid a fee-per- service, due to greater 
competition between doctors there is more pressure on satisfying the patient. This is 
likely to increase the percentage of doctor-patient consultations which result in a 
prescription and although this aspect could not be measured from the Belgian data, 
comparing the average number of prescriptions per capita from countries with open 
access health care systems from OECD data supports this argument. 250 
In the areas of UTI, throat infection and LRTI prescribing, there was a marked 
decrease in the use of co-trimoxazole in both the study and control groups from Phase I 
to Phase 11. The prescribing of co-trimoxazole was strongly discouraged by the 
European Formulary but during the early part of data collection in this study the UK 
Committee on Safety of Medicines also issued a cautionary warning about the 
sulphamethoxazole component. 438 Which of these two medicines had the greater 
impact on the GP prescribing in this respect in this study is difficult to determine. 
However, this does prove that the European Formulary was right up-to-date in its advice 
in this area and that in principle its potential for influence was appropriate but that the 
study limitations may have reduced its impact. 
General factors which contribute to differences in antibiotic prescribing are regional 
drug sensitivity data and regional price variations. As previously mentioned 
(Section 8.2.1.1), for the third-line management of UTIs, the European Formulary 
Group were forced into recommending consistent prescribing of the most cost-effective 
fluoroquinolone in a country instead of specifically naming one. Despite this, the 
message to constrain fluoroquinolone prescribing did not appear to have any impact as 
their use varied from over two-thirds of newly prescribed antibiotics for UTIs in 
southern European countries to less than 10% in the UK. 
From the prescribing patterns that were recorded for throat infections and NSAIDs, 
I 
the educational intervention appeared to have some success. Importantly, there was a 
highly significant increase in simple analgesic use by the intervention group compared 
with the control group in both areas of prescribing. However 
for throat infections, there 
were inappropriately high levels of amoxycillin used particularly 
in Ireland, Italy, 
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Portugal, Scotland and Spain and this is indicative of irrational prescribing. For 
NSAIDs, it appeared that the European Formulary only covered about 60-65% of the 
diagnoses for which these drugs were prescribed and therefore with this shortcoming, 
the Formulary could only ever expect to have limited success in changing prescribing 
practices. The intervention appears to have had a mixed impact on the prescribing for 
LRTIs and little impact on the prescribing for UTIs. 
The areas of hypertension and asthma were also investigated to determine whether 
receipt of the European Formulary alone may have any impact on prescribing. The 
study found that the 'passive' dissemination of the Formulary and thus receipt of written 
material alone appeared to have virtually no impact on the prescribing for either 
condition, compared with the 'active' verbal communication by the co-ordinators about 
the rational prescribing of antibiotics and NSAIDs. Other researchers have also reported 
that printed material has limited success in isolation and that there is a need to reinforce 
this with other methods of education and communication such as by face-to-face 
interaction. 154439 Interventions involving feedback associated with practitioner 
performance has been found to be particularly effective439 but due to the volume of 
data and only one researcher employed full-time on the study, this was not possible. 
There were limitations with the two therapeutic areas selected when assessing the 
'passive' effect of the Formulary. For example, despite hypertension being the most 
commonly occurring diagnosis and almost exclusively managed by GPs, the number of 
newly prescribed antihypertensives were so small that all the prescription categories had 
to be combined when measuring the effect of the Formulary. With the asthma data, 
again all the prescription categories were combined as the number of newly prescribed 
items were relatively low. Also, there are problems with GP-labelled asthma and 
hypertension, for example it was suspected that where some patients consulted for 
treatment of an associated co-morbid condition, occasionally subsequent treatment was 
just recorded under a label of either asthma or hypertension. 
Medicines are obtained by consumers within different health care systems via a 
variety of routes. As more medicines are being switched from prescription only to non- 
prescription status in different European countriesI8, patients are being encouraged to 
visit the pharmacist before seeking the advice of the general practitioner. 
440 As a 
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consequence, there is evidence to suggest that OTC medicine use is increasing. 440,441 
In the NSAIDs results section, diclofenac was the most commonly prescribed but it is 
not known whether for economical reasons prescribers were recommending the use of 
OTC NSAIDs and/or other medicines to patients in some cases. Thus it is not possible 
to assess what impact the educational intervention may have had on the increased 
consumption of OTC simple analgesics and NSAIDs. With the range of OTC NSAIDs 
available in different European countries (Table 8.1 overleaf), it is likely that inclusion 
of this data would have altered the NSAID utilization patterns. 
Table 8.1 Non-steroidal anti-inflammatory drug status in different European 
countries 18 
Ingredient France Germany Italy Netherlands UK 
Diclofenae (oral) + Rx + Rx Rx 
Etofenamate (topical) N. R. + + N. R. N. R. 
Ibuprofen (oral) + + + + + 
Ibuprofen (topical) + + + + + 
Ketoprofen (topical) + + + + + 
Naproxen (topical) N. R. Rx + Rx N. R. 
Piroxicam (topical) Rx + + Rx + 
Available OTC,, Rx = Prescription-only, N. R. = Not registered or not marketed 
Another important factor which may explain differences between the countries is 
that health care professionals in English-speaking countries have the added advantage of 
a relatively long history of prescribing support both at a local level and nationally in 
comparison to most other European countries. 4 These include: 
well established drug formularies, 6,7 8,8 0,81, 
the production of monthly information bulletins such as the Drug and 
Therapeutics Bulletin, the MeReC Bulletin and Bandolier which review the cost- 
effective management of topical therapeutic areas, 
the provision of regular feedback in the form of PACT data to GPs on their 
prescribing practices, 
40 
a network of prescribing advisers which attempt to contain prescribing 
costs, 51,63 
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* pharmacists, in recent years based in GP practices reviewing prescribing. 102 
All these initiatives attempt to increase the awareness and knowledge of the 
prescriber with the intention of rationalising prescribing and containing prescribing 
costs. The higher concordance with many of the drug recommendations of the 
European Formulary probably echo messages previously given to the GPs in the English 
speaking regions in the study. Drug regulation in the UK is under stricter control than 
Belgium and the southern European countries which is reflected in the narrower range 
of more effective and safer drugs licensed in the UK for a given condition. Finally, 
health care professionals in English-speaking countries have the added advantage that 
the most international reputable journals are all primarily published in the English 
language. These factors are likely to have increased the extent to which drug choice 
was more in agreement with the European Formulary by GPs in the UK and to a lesser 
extent in Ireland. 
Whilst other European countries explore the potential for adopting some of these 
initiatives, the effort devoted to optimising the cost-effectiveness of the health care 
service in the UK continues unabated. Advances in the use of information technology 
in the UK have enabled electronic PACT data (ePACT) to be available via an electronic 
link directly form the Health Authority to the individual GP practice. 32 This electronic 
PACT data provides a breakdown of GP prescribing profiles down to individual drug 
level for analytical and comparative purposes and it can be provided on a monthly basis. 
In 1997 an on-line version of the BNF became available. This has the added advantages 
of being easily accessed in the doctor-patient consultation as well as in the pharmacy 
and facilitates regular update of the text compared with the printed version which is 
produced every six months. In 1998 the PRODIGY project was launched in the UK. 171 
This system provides the GP with a software program providing decision support for 
which drugs to prescribe, based on the evidence of efficacy, safety and cost. This 
project was based on a study in the Netherlands called PRESCRIPTOR166 which was 
terminated due to limited success there. Results from the PRODIGY project to date 
appear to be positive but this in-part has been as a result of the heavy financial backing 
by the DoH in the UK. 
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The last few years has seen a change both in the way information is disseminated 
and in the way we communicate. Today most of the reputable sources of health related 
information are available on the Internet either freely or accessible via subscription. To 
help push forward the boundaries of health care practice in primary care in the new 
millennium, the DoH in the UK has developed the NHS intranet as a medium of 
communication and information access and strives to have all GP practices on-line in 
the near fature. 6 In order to improve the effectiveness of medicines management and to 
promote more rational prescribing, the NHS intranet may allow pharmacists and general 
practitioners to have access to each others relevant information while maintaining 
patient confidentiality. The Royal Pharmaceutical Society of Great Britain has set up a 
working party looking at the use of computer technology in primary care with the view 
to the standardisation of all general practice and pharmacy systems. 442 This would 
allow interchange of data between pharmacies, general practice surgeries / health 
centres, the Prescription Pricing Authority and preferably hospitals. Such a system 
could eliminate the paper-based prescription form. The implications of this technology 
for future studies of this nature are that the data may be directly downloaded from 
computer systems, eliminating the time-consuming process of data recording, 
collection, coding and subsequent entry. 
To achieve this level of sophistication on a Europe wide scale, many hurdles need 
to be overcome starting with an agreed drug and morbidity classification system, 
followed by accepted tools which can measure rational prescribing adequately. Five 
years ago, it was estimated that in the UK every 1% reduction in prescribing costs 
would release L34 million to spend on other aspects of health care. 30 It is first 
necessary to know more about patient health outcomes, including how quality of life 
factors, can be suitably measured to assess whether more rational prescribing has been 
achieved. These factors are becoming increasingly important and need to be recognised 
in the future development of drug formularies. 
Some important international collaborative developments in the field of drug 
utilization have taken place and continue to do so. The World Health Organisation 
Anatomical Therapeutic Chemical (ATC) and the Defined Daily Dose (DDD) coding 
systems were establishment nearly 30 years ago and undergo continuous updating. 229 
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The ATC classification and the DDD methodology have become widely accepted on an 
international level and their use includes drug consumption statistics; monitoring of 
adverse drug reactions; drug catalogues and reimbursement schemes. 443 Even in the 
UK where the Read Code classification system is institutional253, DDDs as a unit of 
measurement are being increasingly adopted by health authorities. While each country 
has its own regulatory body, in 1995 an EU Directive has provided pharmaceutical 
companies with alternative procedures for obtaining marketing authorisations through a 
centralised procedure or Mutual recognition which has resulted in the opening of the 
European Medicines Evaluation Agency (EMEA) whose aims include the facilitation of 
the free movement of drugs within the European Union. 444 More recently, there has 
been a move to standardise international drug nomenclature6 which would also facilitate 
the further development of a European Formulary. European legislation now requires 
the production of standardised patient pack medicines which should contribute to better 
patient concordance with treatment. 
Drug consumption can be expressed in a variety of ways including cost, volume, 
prescribed daily dose and defined daily dose. 229 In this thesis, all analyses are 
concerned with the number of drugs (or the active ingredients of combination products) 
as a measure of volume. While this is a measure of GP prescribing practice, it does not 
contain enough information on the volume to allow the direct calculation of costs. 229 
However,, measuring frequencies linked to morbidity, as has been done in this research 
is of value as it provides descriptions of prescribing patterns229 and measures certain 
aspects of rational prescribing, which are indicators of cost-effectiveness. As mentioned 
earlier, this thesis lacks information on outcome data with respect to efficacy and safety 
of GP selected drugs in individual patients. Outcome measures, including patient 
concordance with drug regimens as well as any differences between drugs prescribed 
and drugs actually dispensed, would have been invaluable. In an ideal situation, 
measuring patient-centred indicators, such as the rate of relief of symptoms in those 
with acute self-limiting diseases, would be valuable in relation to the effect of formulary 
implementation. The face-to-face patient consultations in general practice which were 
recorded in this study were not necessarily fully representative of the population at 
large, which makes comparisons difficult with those from different studies as well as 
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with different national morbidity data sets. Consequently, reviewing the literature to 
identify appropriate quality indicators compatible with the data set has also proved 
difficult. 
320 
Discussion 
8.5 THEORETICAL CONSIDERATIONS 
The second study involved the same GP participants who provided information on 
factors perceived to influence their prescribing to help explain some of the findings in 
the first study. 
8.5.1 The Delphi prescribing influences study 
The second major hypothesis postulated that: explanation of the varying effects of 
the European Formulary and the educational intervention in the different countries will 
be assisted by identification of the main influences on the participating GPs' 
prescribing. 
8.5.1.1 The effects of the European Formulary and educational intervention 
The educational intervention involved three different types of potential influence. 
* The distribution of the Formulary to all the GPs in the intervention group. 
e The distribution of parts of the Appendix associated with the areas specifically 
being targeted in the educational intervention to all the intervention group GPs. 
* Verbal discussion between the co-ordinators and their intervention group GPs 
which involved debating the main messages of the educational intervention. 
From the prescribing study, there were two general main findings. Firstly, some 
aspects of the intervention appear to have been successful in certain countries and 
secondly, analyses of the collated data revealed that there were wide variations between 
countries in presenting diagnoses / symptoms and drug prescribing patterns. 
Consequently the following three questions were raised: 
1. What are the reasons for the variable effects of the European Formulary and 
the variations in prescribing patterns? 
2. Are the differences in health care systems between countries, in particular the 
drug regulatory factors, responsible for the variations in prescribing? 
3. How far can the drug and diagnosis data be critically compared and contrasted 
when it represents a snapshot of prescribing at a limited point in time? 
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To help explore these questions, it is necessary to consider what information was 
already available. 
From the literature review on health care systems across Europe (Annex 1), it is 
known how care is co-ordinated in each country. In Belgium, an open access system 
exists where there is no patient registration with GPs and the patient has a free choice of 
GP or specialist (the latter may also work as a GP in their spare time). In the remaining 
participating countries, a gatekeeping system exists where GPs control access to most 
other levels of health care. The type of health care system has implications for 
prescribing research. Where there is greater competition between doctors, such as in an 
open access system, one would expect that the pressure to satisfy patients needs is 
greater, one consequence of which is that there may be a high number of patient 
consultations that result in a prescription. One may also expect there to be a lower 
patient referral rate by GPs in this type of system where doctors are generally 
remunerated on a fee-for-service basis because of the resulting incentive to provide as 
wide a range of services as possible in primary care. 445,446 
Between countries there may be differences in drug availability and the market 
authorisation of drugs may also change over time. These factors have been traditionally 
determined by the regulatory bodies within a country whose actions are dictated by 
health policies and national legislation although since the establishment of the 
EMEA444, this is now changing. Government health policy also largely dictates the 
nature of a countries' health care system and consequently there are differences in per 
capita spending on health care as well as differences in the percentage of Gross 
Domestic Product (GDP) spent on drugs and health care between countries. 250 While 
these issues are likely to contribute to variations in prescribing patterns between 
countries, up to 80% of patients consulting GPs have common conditions which can 
potentially be treated in standard ways. 
30 In addition, all the drugs recommended in the 
European Formulary were available in all of the participating countries which could 
help to limit the problems of GPs faced with different drug choices from country to 
country. 
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However, it is important to recognise that the intervention in this study was an 
educational/information-type of influence as distinct from the multitude of other factors 
which potentially influence GP prescribing behaviour. 
8.5.1.2 The main influences on GPs prescribing 
The factors that influence the prescribing-decision making process have been 
discussed in (Section 2.2). There appear to be no published reports of research which 
have investigated the factors perceived to influence the prescribing practices of a pan 
European group of GPs. Also, there does not appear to be anything published on how 
GPs rate the perceived importance of different prescribing influences, with the 
exception of GPs having rated their use of different information sources. 156 
Within a country, health care system/regulatory influences are generally going to be 
standardised but largely out of the control of the GP. Between countries these factors 
447 will be much more significant and should help to explain the differences. 
Consequently for the purposes of undergoing an investigation of perceived influences 
on GP prescribing between countries, I propose that they could broadly be divided up 
into health care system/regulatory influences and those independent of this. 
Alternatively, this can be described as influences which GPs are potentially in control of 
and those factors which are outside their control. If the majority of GPs perceive health 
care system/regulatory factors to be amongst the most important influences, then the 
value in critically comparing and contrasting prescribing data between countries is 
limited. Whereas if the converse is found and health care system/regulatory factors are 
found to be of minimal importance, then this coupled with the equal availability in all 
the countries of drugs recommended in the European Formulary means that critically 
evaluating all the prescribing data can be justified. 
8.5.1.3 Conclusion 
The main hypothesis for the prescribing influences study could neither be proven 
nor disproven. Attempting to establish a causal relationship by statistically correlating 
the findings from the two-stage Delphi questionnaire exercise with the GPs drug and 
diagnosis data from the previous study was not advised because of differences in sample 
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sizes between countries and the volume of prescribing data per individual GP not being 
large enough. 
8.6 METHODOLOGICAL IMPLICATIONS 
8.6.1 The Delphi prescribing influences study 
The first stage prescribing influences questionnaire was successfully completed by 
173 GPs, representing a response rate of 72% and the second stage Delphi questionnaire 
achieved an overall response rate of 64% (154 GPs). These were considerable 
achievements as response rates to questionnaire surveys among general practitioners are 
declining. 448 This study was original in obtaining a consensus-based list of categories 
of influences ranked in order of perceived importance. 
In order to minimise bias and due to the countries having markedly different health 
care systems, an appropriate method of data collection had to be used in order to obtain 
information on the perceived factors influencing the GP participants prescribing. When 
selecting the method used, the exceptional geographical spread of the GP participants 
had to be recognised and taken into account. By using questionnaires, as well as 
perceived influences on prescribing, information on other factors known to be an 
influence, such as the demographic profiles and the working environment of the GPs, 
could also be obtained simultaneously. Collecting this wide ranging information by 
face-to-face interviews with the GPs would not have been feasible for a variety of 
reasons, including lack of finances, language barriers and time factors as well as the 
difficulties associated with follow-up interviews. Verbal communication with each GP 
via the telephone would not have been practical either, principally because of the 
language barriers. 
In the development stage of the first questionnaire, initially a four page 
questionnaire was developed. This needed to be validated and so was piloted among 20 
university researchers in the Department of Primary Health Care (Newcastle University 
Medical School). Following some amendments another pilot was performed, on this 
occasion being distributed to the European Formulary 
GP participants from the 
Newcastle region. Subsequent to this process, instead of attempting to require the GPs 
in the different European countries to complete the questionnaire with sentences in 
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English, it was designed with closed questions answered by ticking boxes, or numerical 
or one word answers with the exception of one open-ended question. To avoid the 
problem of language barriers, the questionnaire needed to be translated, which it was 
thought would increase the likelihood of questionnaires being completed and hence the 
response rate. By reducing the length of the questionnaire and condensing it to fit onto 
one page of A4 paper, it was anticipated that this might optimise the response rate but 
consideration had to be given to ensure that some important questions were not lost. 
In order to determine the amount of time the GPs invested in primary care, the GPs 
were asked the number of days they worked each week. This was considered to be a 
relatively crude measure and so the question was amended to ask how many hours a GP 
worked each week. From the two pilot questionnaires it was also thought that by 
introducing a list of potential influences for GPs to rate, there could be an element of 
bias as this could possibly lead GPs in a certain direction. Additionally by presenting 
GPs from different health care systems with a predetermined list of influences 
developed in the UK, this would be likely to be associated with a UK health care 
perspective and thus could bias responses too. Ultimately it was decided to ask the GPs 
what they perceived to influence their personal prescribing and then, in order to 
establish consensus agreement on these perceived factors, it was decided to adopt a two- 
stage Delphi technique as effectively used by others. 264,449 
The refined prototype questionnaire required translation into Dutch, French, Italian, 
Spanish and Portuguese. Due to the specialist nature of the questionnaire, translation 
ideally needed to be performed by individuals with the relevant knowledge of the 
appropriate health care practice terminology. This was made possible by my approach 
to a number of pharmacists and physicians independent of the research at an overseas 
conference who co-operated and performed the initial translations. The relevantly 
translated questionnaire was subsequently sent to the appropriate co-ordinator (from the 
previous prescribing study) in each country for back translation as has been done with 
other international questionnaire studies. 
333 Obtaining accurate translations was 
important as this had been a major limitation to the implementation of the European 
Formulary. The process also enabled confirmation of the appropriateness of the 
terminology used and the relevance of the questions in the context of primary care in the 
different countries. For example, the terms 'fundholding' and 'non-fundholding' were 
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irrelevant as these were only applicable in the UK and 'family doctor' as opposed to 
general practitioner is the standard terminology in Portugal. As GPs may either not 
realise or may not be forthcoming about disclosing the extent of the influence of the 
pharmaceutical industry upon their prescribing, an additional question was considered 
necessary. This question asked the GP how many industrial sales representatives he/she 
had met up with in the past four weeks. 
The second stage questionnaire, to be completed by the same GPs, was based on the 
responses to the open question in the first questionnaire regarding perceived influences 
on their own prescribing. These responses had been translated where necessary. From 
the responses to the open-ended question 86 different influences were cited by the GPs. 
From this list, there was some degree of overlap and the list was condensed to 59 factors 
under seven category themes of influence which were identified. In the second stage 
Delphi questionnaire, the GPs were supplied with the composite list and had to rate the 
seven categories of influence in order of decreasing importance. 
If the study had only involved GPs in the UK, a category heading related to hospital 
influences would have been appropriate and necessary. As many specialists in southern 
European countries are community-based, these related factors seemed to fit best under 
the heading of general medical practitioner factors as it is down to their clinical 
discretion whether, for example, hospital/specialist influences are adopted or not. 
Although the different influences were classified under the most appropriate category 
headings, this process was not entirely precise. For example, whilst 
hospital/regional/national and international formularies were all classified under the 
education/information factors category, a practice formulary was considered to be more 
of a work-based factor associated with practice policy and prescribing protocols despite 
being a means of education and information. There were also some subtle differences of 
emphasis between various factors such as the cost of a drug which was classed as a 
'drug factor' but a GPs drug budget was a 'regulatory factor'. Some influences were 
specific to certain countries such as, the presence of a practice pharmacist in the UK. 
Nevertheless, it was considered that all the categories contained factors which had some 
degree of influence on prescribing in any country and therefore the GPs were asked to 
rate the seven categories in order of importance. 
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The entire list of influences were what the GPs themselves perceived to influence 
their prescribing and so it was possible that it did not necessarily encompass all the 
factors that could be said to be influential. For example, there was no mention of 
cultural or media influences and whilst many GPs referred to the safety, side-effects and 
tolerability of drugs, there was no mention of drug interactions being a perceived 
influence. A few GPs did mention polypharmacy prescribing being a potential 
influence and this could be associated with drug interactions and/or patient compliance. 
Translations of the standard cover letters which were mailed with the questionnaires 
and the reminder letters sent to non-responders were also made by the co-ordinators. As 
the second stage Delphi questionnaire only consisted of one question (related to the 
open-ended question from the first questionnaire) no back translation was considered to 
be necessary. With no financial incentive for the GPs to complete the questionnaires, an 
appreciative feedback in the form of a six page summary of the main prescribing study 
was mailed to all participants and the cost of the return postage for the questionnaire 
was included. 
All these various procedures were performed as it was necessary to produce 
standard questionnaires and to optimise the response rate in order to best fulfil the 
proposed aims and objectives (Section 3.2.1) of the study. 
8.6.1.1 Limitations 
This study involved identifying the perceived prescribing influences on the GP 
participants from the previous study but as already mentioned the volunteer nature of 
the GPs meant that they were not representative of the populations from within their 
countries. However, while future studies should if possible obtain random samples of 
GPs, the primary purpose of this follow up study was an attempt to explain some of the 
findings from the former study. 
This two-stage Delphi questionnaire study was mailed between August 1998 - 
February 1999, four years after the initial prescribing data collection period. This was 
potentially problematic in that the GPs were asked to 
list the main perceived influences 
to have acted on their prescribing from Autumns of 1994 and 1995 when they recorded 
the prescribing data. There may have been an element of recall 
bias here, especially as 
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health care practice changes and reforms are constantly taking place which can affect 
prescribing behaviour. For example at the time of initial data collection, generic 
prescribing was not practised in Belgium, Italy, Portugal and Spain. Since that time it 
has become possible for GPs in all four countries to prescribe a limited number of 
medicines generically. 18,266 
In the Delphi research model, it is recommended that initial and follow-up 
questionnaire mailings should be sent out at precise six weekly intervals in order to 
allow adequate time for responses while maintaining the momentum of the study. 264 
The timescale of this Delphi exercise had to be extended because of the geographical 
distance involved and extra time for postal delivery and return of the questionnaires and 
reminders. 
When questioning the GPs about the number of hours worked and patients seen in 
one week, there could have been discrepancies in GPs working part-time, home visits as 
opposed to office-based consultations and those working on-call. In order to obtain an 
indication of the amount of time invested by GPs and their workload, this question had 
to cover all these aspects of primary care as it was not practical to ask about each area 
due to the restricted length of the questionnaire. As doctor-patient consultations in 
Belgium tend to take place in peoples' homes, office-based consultations do not exist in 
the same way there as in other countries and so a general question was of more 
relevance. 
Although the overall response rate from the first questionnaire was 72% and from 
the second stage it was 64%, which was highly acceptable, not all countries achieved 
these levels. Portugal, Spain, Scotland and Italy were below 70% in stage one and 
Portugal, Spain and Scotland were below 60% in stage two. It is feasible that 
information on non-responders from these countries could have affected the results. 
One possible reason for a lower response rate in Spain was that although the 
questionnaires were translated into Spanish, all the participants were actually from the 
Catalan region which has a different language in everyday use. Although bilingual, the 
GPs may have been more receptive to the questionnaire if it had been translated into the 
Catalonian language. In Scotland, it was only possible to obtain the contact name of the 
senior partner in each of the practices from where GPs had 
been recruited in order to 
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preserve anonymity. As it was not possible to write personally by name to the Scottish 
GPs, this seems to have adversely affected the response rate, despite enclosing the 
necessary numbers of covering letters, questionnaires and stamped addressed envelopes. 
8.7 PRACTICAL CONSIDERATIONS 
8.7.1 The prescribing influences study 
From the first questionnaire, it was evident that the majority of GPs in the different 
countries were working in group practices, with the exception of practitioners in Italy 
and Portugal. The published information available which compares the style of practice 
in different countries2l9,445,450 corresponds well to that found in this study, except for 
Belgium and Spain. Inevitably the nature of practice is liable to change and evolve with 
time and this can affect comparisons with earlier data. These differences are often 
dependent upon a variety of factors including the type of health care reforms within a 
country, the locality of the practice and the age of the GP. In Spain for example, there 
used to be a fairly even mix of solo and group practices but, as a result of health reforms 
in the early-mid I 990s266, there was a move towards a network of primary care health 
centres with GPs working in groups. This trend could explain the anomaly between 
previous reported levels and the fact that all the Spanish GP respondents were working 
in groups. In countries where there is a mixture of solo and group practices, the solo 
practices are more likely to be found in rural settings such as in Ireland, where the 
population is more scattered and therefore smaller for a given distance, when compared 
with more urban areas. 
The work place distribution of the GPs was likely to be influenced by the location 
of the majority of co-ordinators who were based in towns or cities, as earlier 
communication with the co-ordinators had indicated that one of the criteria for GP 
selection was geographical convenience for them. This fits in well with the 
questionnaire responses where half the GPs described the location of their practice as 
urban. The GP participants were all volunteers and associated with the fact that they 
were enthusiastic and likely to be more informed than the average was the finding that 
in all the countries except for Italy, Northern Ireland and Portugal, the majority were 
involved in training doctors to become GPs. 
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Analysis of the age of the patient populations consulting GPs in the different 
countries confirmed that all the Spanish GPs and almost 20% of the Italian GPs did not 
have patients under 14 years of age. This is likely to influence GP prescribing patterns, 
especially in terms of the prescribing volume for treating conditions often presenting in 
children, such as acute respiratory tract infections. 35 The fact that children are seen by 
GPs in some European countries and not in others is indicative of fundamental 
differences in health care practice between countries in the management of children in 
primary care. 
Comparing the GP workloads revealed that the average number of hours worked 
per week was greatest in the English speaking countries and Belgium and lowest in the 
southern European regions. At the extreme, the average number of hours worked in 
Ireland was more than double those in Italy. This could be subject to a number of 
variables such as the number of GPs working part-time and it is not known whether the 
number of hours worked included home visits and time spent on-call. The mean 
number of patients seen in one week by each of the GPs in the different countries is 
fairly similar except in Ireland, but this correlates to the higher number of reported 
hours worked there. Comparing the ratio of hours worked to patients seen suggests that 
there is a greater number of patients seen by GPs in Italy and Spain during their working 
week i. e. shorter consultation times. The lowest number of patients seen for the hours 
worked occurred in Belgium which may be associated with the perceived need to retain 
patient loyalty in the absence of a patient registration system and to ask questions 
otherwise previously recorded in a registration system. 
The duration of the consultation has been proposed as a simple proxy measure of 
quality of care. 211 Longer consultations have been found to be more thorough and 
relevant to the patients needs and those GPs who allow 10 minutes or more for each 
consultation have been found to prescribe less antibiotics. From the data collected, the 
mean duration of the consultation in the different countries was found to vary widely. 
The average Belgian patient-doctor consultation lasted over twice the length of 
consultations in England, Northern Ireland and Spain. Although the 
figures in our study 
indicate that the consultations were much longer than previously reported data from 
these countries2l9,445,450,5 the relative positions of the countries 
in comparison with 
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each other are similar. Belgium is the only country in the study with an open-access 
health care system with no patient registration and consequently patient consultations 
may tend more often to incur GP visits to patients homes, resulting in longer times spent 
with patients than office-based appointments. GPs in open access systems are paid on a 
fee-per-itern basis and so there is a tendency to provide a wider range of services in 
primary care which may also lead to longer consultations. Currently, there is a surplus 
number of doctors in Belgium and this may be associated with additional pressures to 
satisfy patients with consequently longer consultations. In contrast, the Spanish GPs 
reported relatively short average consultation times and thus a high number of patients 
were seen by GPs per week during their time spent in primary care. Also, in northern 
European countries there may be more of an emphasis on patient counselling and thus 
longer consultations than the norm in southern Europe. Such time constraints are also 
likely to result in greater use of the prescription to terminate the consultation as 
confirmed by others. 30 These factors may all contribute to influencing the 
characteristics of prescribing and prescription volume. 
Within the UK, research has found that more highly qualified groups of doctors are 
not as greatly influenced by commercial sources of information as their less qualified 
colleagues. 156 However it may be that the system for progressing to post-graduate 
qualifications is closely associated with the medical culture within a particular country. 
Therefore, this may not necessarily be exclusively either a reflection of the knowledge 
base or motivation of GPs, or be indicative of the extent in any other country of 
continuing education opportunities available to practitioners. Nor may it be related to 
the fact that older GPs will have had more time to obtain post-graduate qualifications. 
Nevertheless in this study, the highest number of qualifications were recorded by the 
English speaking GPs and may be compared with the southern European GPs who met a 
relatively high proportion of drug representatives on whom they presumably relied as a 
routine source of drug information. The number and frequency with which GPs meet 
pharmaceutical industrial representatives is likely to be an influence on some aspects of 
prescribing practice. Research has shown that the more drug representatives who are 
seen, the greater the likelihood of prescribing more newly 
introduced drugs and the 
wider the range of products that a GP 
is likely to prescribe than otherwise 
(Section 2.2.8). There is also a tendency for those GPs who see drug representatives 
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regularly to be older and in single-handed practices. Attempting to statistically correlate 
these published findings with the GPs and their prescribing data in this study was not 
possible because of the sample sizes and the volume of data available. 
In the second stage of the Delphi questionnaire, of the seven categories of 
influence, there was sufficient consensus between the countries to establish a structured 
order from the category of most importance to the category of least importance. The 
rank order reflected some of the findings from the first stage questionnaire which 
reinforced its validity. For example, whilst six of the eight countries indicated that 
pharmaceutical industrial influences were the least important category, the Italian GPs 
considered that work-based factors were least important and the Portuguese regulatory 
factors. Work-based factors are mainly associated with health care professional 
interaction and, as all but one of the Italian GPs were single-handed, it is not surprising 
that this category was perceived to be the least important prescribing influence. Also, 
the relatively high number of drug representatives seen by Italian and Portuguese GPs 
explains why they perceived industrial influences to be of more importance than 
elsewhere. 
Probably the most revealing finding from the second questionnaire was that, 
regulatory factors were considered to be the least important category in Portugal, the 
least important category but one in five other countries and ranked in fifth position in 
Ireland and Italy. This is of professional significance and importance because GPs are 
capable of controlling the majority of influences within the remaining categories which 
may affect their decision making. The critical evaluation of prescribing data between 
these countries from this perspective is thus justified. 
In summary, identification of the main influences on prescribing has assisted 
discussion of prescribing behaviour and highlighted difficulties which have affected the 
uptake of the European Formulary and the associated educational intervention in the 
different participating countries. 
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8.8 RECOMMENDATIONS 
From the research which has been conducted, the following list of 
recommendations are made. 
9 Any future edition of a European Formulary should be translated into different 
European languages and would be more credible if its development process shifted 
from consensus-based to evidence-based. 
9 Different international drug and diagnosis classification systems do exist but all 
have limitations and consequently specific coding systems were developed for this 
research. In future international agreement would be beneficial in order to 
standardise research methodology and facilitate comparisons between studies. 
9 Any future educational intervention of the type conducted in the prescribing study 
would need to be better standardised to reinforce the educational material in order 
to facilitate comparisons of the outcomes. 
e GP prescribing patterns were found to vary widely in this research (despite the 
majority of doctors being volunteers having an active interest in prescribing) which 
suggest that there is a definite need for international evidence-base guidelines. 
* In order to optimise the analysis of future drug utilization and prescribing studies, 
it is crucial that prescribed drugs should be linked to patient morbidity. 
* Prescribing quality indicators need to be developed further to include patient and 
treatment outcomes (quality of life etc. ) and they also need to be linked to 
morbidity. 
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9A future European Formulary should place more emphasis on the use of equivalent 
drugs depending on availability and the comparative cost in a country (e. g. 
hydrochlorothiazide in most European countries and bendrofluazide in the UK). 
* The Delphi study identified that patient influences were perceived by GPs to be an 
important influence on prescribing. One avenue for future prescribing 
interventions 
should be to improve patient education. 
*A greater use of independent sources of drug information should be encouraged in 
southern European countries where GPs reported relatively high contact rates with 
pharmaceutical industry representatives compared with their northern European 
colleagues. 
In making these recommendations it is acknowledged that the influences on the 
prescribing process are multifactorial and the potential influence of a European 
Formulary should be seen in that context. 
334 
Discussion 
8.9 FUTURE WORK 
The research in the prescribing study has concentrated on comparing and 
contrasting prescribing patterns as well as attempting to improve aspects of prescribing. 
The latter has involved assessing the prescribing performance by using a variety of 
measures including, the level of concordance with the European Formulary and the 
range of drugs used. Future research needs to involve international collaboration to 
establish accepted outcome measures for assessing rational prescribing which can be 
converted into quality indicators, such as the optimum range of drugs that a prescriber 
should use to treat a condition. They need to be produced in all therapeutic areas 
incorporating prescribing for both acute as well as chronic disorders and their 
development should also include patient outcomes, such as quality of life factors, and 
rational use of new drugs. In addition, they should be flexible enough to be applied to 
OTC drug use where appropriate as well as to prescribed drug consumption. Most 
importantly clear agreement is necessary on the use of a generally accepted diagnostic 
and therapeutic classification system. This sort of international collaboration could be 
co-ordinated through groups such as WONCA (World Organisation of Family Doctors) 
and FIP (International Pharmaceutical Federation) and the WHO. 
Once developed, internationally agreed quality indicators could be used to assess 
just how successful different types of interventions are in inducing changes in 
prescribing habits. GPs recruited to future research studies should be consulted over 
which areas of their prescribing they would like to see improved and/or identify those 
areas where evidence-based guidance is lacking. Studies should encompass GPs from a 
variety of European countries to determine the level of success of different types of 
intervention (including the effect of an internationally accepted formulary available on 
the world wide web) as well as to identify whether interventions are more successful in 
those with gatekeeping or open access health care systems. 
The two-stage Delphi questionnaire study has compared what GPs perceive to 
influence their prescribing in participating countries. To compliment this study, it 
would be very useful to determine to what extent patients in different countries expect to 
receive a prescription as well as the expectations of patients who receive prescribed 
medication. Although there has been some research on this in the UK202,207, by 
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comparing patients 1) expectations in the different countries, cultural influences on 
prescribing could be better identified. 
Of the different categories of influence rated by the GPs, patient factors were cited 
as one of the most important influences on general practitioners prescribing in all the 
countries. Further research is needed to investigate how the potential to promote 
rational prescribing may be affected and constructively influenced by patient 
influencing factors. Identification of what consumers/patients' expectations and 
knowledge are of OTC and prescribed medicines could help in the development of 
patient educational interventions to promote more appropriate and rational use of 
antibiotics for example and encourage greater patient participation in their own 
healthcare. 
If a similar study were to be repeated with adequate resources, then by recruiting an 
appropriate sample size of GPs in different countries and with an adequate volume of 
prescribing data, an attempt could be made to establish whether a causal relationship 
exists between perceived influences and the corresponding prescribing of GPs. 
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8.10 OVERALL CONCLUSIONS 
The first study is original in collating prescribing data in such detail from face-to- 
face doctor-patient consultations in primary care in Belgium, England, Ireland, Italy, 
Northern Ireland, Portugal, Scotland and Spain. The results indicate that there was an 
improvement in the prescribing practices within certain therapeutic areas by GPs after 
the educational intervention which included distribution of the European Formulary. 
These changes were mainly in increasing the proportion of prescribed drugs which were 
listed in the Formulary and reducing the range of items prescribed. The findings 
therefore indicate that some aspects of the methods employed in this study were capable 
of bringing about a change in clinical practice but also suggest that sustained prescribing 
support is essential as well as the need for innovative prescribing support in the future. 
With respect to formularies, it is important to recognise that they can only have an 
impact in certain ways and their influence will always be affected by cultural beliefs, 
government policy and actions and reimbursing procedures. The variations in 
prescribing by GPs in different European countries are likely to be multifactorial, but 
can in part be explained by differences in drug availability, drug prices, marketing 
authorisations, medical education and training, pre-existing availability of national, 
regional and practice formularies, profit controls and industrial promotion. While these 
differences remain, the role of a European Formulary maybe partly limited. However 
should there be a move towards standardization in these areas,, a multidisciplinary 
European prescribing initiative such as a future edition of the European Formulary is 
feasible. Future potential compilers of European Formularies need to take these factors 
into consideration. The present European Formulary can still serve as a reference 
document for the development of both future European Formularies and for national and 
regionally tailored formularies. The Portuguese Department of Health has confirmed 
that it is undertaking further trials of the European Formulary as a potential national 
formulary. Meanwhile interventions to improve drug utilization are most likely to be 
successful when pursued at local and national levels. 
The second study is also original in having collated perceived influences on GP 
prescribing from Belgium, England, Ireland, Italy, Northern Ireland, Italy, Portugal, 
Scotland and Spain. The results indicate that there are differences in demographic 
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characteristics that can explain variations in prescribing behaviour and that there was a 
fairly consistent consensus between countries with respect to perceived influences on 
prescribing following categorisation into separate themes of influence. 
While there are differences in health care systems between countries, GPs implied 
that the factors which are most important in influencing their prescribing are factors 
which are of a common professional character between doctors wherever they are in 
practice. This adds to evidence confirming that there is a continuing place for 
promoting rational prescribing through education and information such as in the 
development and use of prescribing guidelines, provided that such initiatives are 
realistic in their objectives, are executed appropriately and maintained with adequate 
resources. 
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ANNEX ONE 
HEALTH CARE SYSTEMS ACROSS WESTERN EUROPE 
ALI INTRODUCTION 
Health care systems vary widely across Europe with both public and private health 
facilities coexisting in all European countries. Each country's health care system has 
evolved not only as a result of medically related factors but greatly determined by other 
aspects of its society, especially its social, religious, political and economic organisation. 25 
Other key influencing factors in their development include: geography, climate, and the 
demographic characteristics of the population. 451 The most significant influencing factors 
have been and continue to be national wealth (and the proportion of it given to health care) 
and the extent of social deprivation and inequality. 445 
This section will focus particular attention on comparing and contrasting the 
differences and similarities between primary care as part of the overall health care systems 
in the countries from where doctors participated in this European Formulary Project 
(including France, Germany, the Netherlands and Norway which were unable to provide 
adequate data for analysis). In addition, the characteristics of primary care doctors as part 
of the primary health care team will also be reviewed. Comparisons will also be made with 
the United States (US) where appropriate. 
Cross-national comparisons of health care system data may be subject to distorting 
factors but the data referred to in this section are obtained from a range of reference sources 
which appear to be fairly consistent. 21 While changes in health care as a result of 
government interventions, for example, do occur from year to year between European 
countries447, their general position with respect to one another in terms of cost and 
pharmaceutical consumption has remained surprisingly stable over the past three 
decades. 21 One important explanation for this is that the differences between European 
countries' prescribing patterns are based on deep rooted variations in medical culture and 
training rather than just the effects of contrasting price and profit controls for 
medicines. 25.24 
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A1.1.1 Primary Care 
Primary care is only a part of the entire health care delivery system, which also 
includes secondary and tertiary care. Before primary health care services are utilised, self- 
care is widely practised and it is important to recognise that in Europe, as in North 
America, between 80 - 90% of all health related activities, including diagnosis, treatment 
and rehabilitation as well as prevention and health promotion are conducted by individuals 
without professional advice. 452 This is substantiated by data on the volume of use of non- 
prescription remedies which greatly exceeds that of prescribed medicines. 418 
At the World Health Organisation (WHO) conference at Alma Ata in 1978453, 
primary health care was defined as, 
I essential health care based on practical, scientifically sound and socially acceptable methods 
and technology, made universally available in the community through their full participation 
and at a cost that the community and country can afford to maintain at every stage of their 
develo ment in the spirit of se4f reliance and determination. It forms an integral part both of 
the country's health system, of which it is the central function and main focus, and of the 
overall social and economic development of the community. It is the first level of contact of 
individuals, the family and the community with the national health care system bringing health 
care as close as possible to where people live and work, and constitutes the first element of a 
continuing health care process. ' 
Alternatively, primary care can simply be defined as the most basic and most 
accessible form of professional health care available to the population of a country. 
266 
However, this definition does not encompass all the aspects of primary health care in 
developed countries, such as those of Western Europe where the organisation, equipment 
and staffing can be sophisticated and complex. 
The primary care doctor, general practitioner (GP) or family doctor, although often at 
the centre of activities is only one of several health care professionals belonging to a 
multidisciplinary primary health care team network. Other primary health care 
professionals include: community pharmacists, dentists, health visitors, midwives, nurses, 
opticians and physiotherapists. The concept of the primary 
health care team is most 
developed and established in the Netherlands, Scandinavia, Spain and the UK. 
266 
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Primary health care can be said to involve three elei-nents of modern health care: 
" prevention of disease 
" early diagnosis, subsequent treatment and/or referral 
" treatment of all ailments requiring non-hospitalisation or non-specialist 
treatment. 266 
Problems with this categorisation arise when it is applied to different health care 
systems. It can easily be applied to health services in for example Italy, Spain and the UK, 
where patients visit a GP or another member of the primary care team who responds to 
their symptoms and treats their presenting problem. If their condition merits specialist 
care, they will then be referred to a specialist or hospital for the necessary treatment. In 
these countries, GPs are responsible for the patient, act on their behalf and provide co- 
ordination of care. 
In other countries for example Belgium, France and Germany, the situation is 
different. The patient has a free choice of doctor or office-based specialist for their first 
point of contact with the system and as the patient is not registered with one particular 
doctor, there is less co-ordination of care. Instead of primary, secondary and tertiary levels 
of care,, a more appropriate way to define the levels of care in these countries might be as 
ambulatory and in-patient care. In this situation, ambulatory care encompasses all primary 
care-based services as well as services from office-based specialists and hospital visits on 
an out-patient basis. 266 
A1.1.2 Primary care led health services 
Primary health care is emerging as the focus of future health care in many developed 
countries, whereas traditionally the major decisions about health care provision have been 
made at higher levels within the system, especially where no gatekeeper roles exist. In 
some European countries, such as the UK, this focus is already evident with primary care 
groups managing their own budgets and having increased commissioning powers. 
4 
Health care reforms in Italy and Spain over the past 20 years have had the effect of 
devolving decision and policy making power more to regions. Changes in other European 
countries are more gradual and continue to 
be so, for example in France primary care is still 
relatively fragmented and has 
little influence. In Germany, whilst the number of GPs per 
365 
10,000 population has risen since 1960, the percentage of doctors who are GPs has fallen. 
The financial status of doctors who are GPs is poor; doctors are paid on a per treatment 
basis which rewards procedures on the basis of their complexity and special i sation. 45 0 
Doctors in Germany thus have a financial incentive to develop a specialisation of some 
description in order to generate a higher income level. 
The main problems currently facing all health care systems world-wide are the 
challenges of rising expectations, escalating costs, budget limitation and an increasing 
proportion of older people resulting in uncontrolled demand. 454 Medical costs in 10 
Western European countries rose by an average of 4.1% in real terms each year between 
1970 and 1990, while real economic growth during the same period increased by only 2.7% 
annually. 451 In Belgium, government spending for health care increased by a staggering 
45% during the 10 years since 1984.451 
The key drivers for changes in primary health care are developments in diagnostic, 
pharmaceutical and surgical technology and the rising costs associated with a combination 
of these developments and limitless demand. 451 In the early 1990s, primary care services 
in the UK represented over 90% of all health care activity and yet consumed less than 19% 
(including drug costs) of total NHS expenditure. 455 In contrast, the provision of hospital 
and community health services consumed at least 70% of NHS expenditure. With statistics 
such as these, governments are increasingly recognising that primary care is capable of 
being a more cost-effective sector for the provision of health care than secondary or tertiary 
care. Most population health needs can now be met in primary care and this is likely to 
continue to increase with major pharmaceutical innovations such as treatment for 
gastrointestinal ulcers which previously required surgery but can now be treated and often 
cured with a GP's prescription. In addition, the potential role of primary care in disease 
prevention and early detection will possibly provide even greater opportunities to contain 
health care expenditure in many areas. 
As the focus of health care provision shifts towards primary care, it is inevitable that 
there will be increased demands and expectations placed upon the GP in co-ordinating 
patient care. To compensate for this 
increased workload burden, the roles of other 
members of the primary health care team are 
developing and diversifying; for example, 
there is an increasing role for the community pharmacist in managing the treatment of 
minor illnesses, providing prescribing advice and reviewing patient prescribed medication. 
4 
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Renewed recognition of the treating of minor ailments has been facilitated by the 
deregulation of the prescription-only status of selected medicines. 18 The availability of 
these medicines without prescription from pharmacies has helped to move the cost of 
treatment onto the patient. 456 Changes in the legal classification of selected medicines and 
promotion of self-medication by government regulatory agencies have occurred 
particularly in northern European countries. 418 
A1.2 COMPARISON OF HEALTH CARE SYSTEMS 
A1.2.1 Health care organisation 
All the health care systems in Western Europe are planned centrally by one or more 
government ministries. The ministry provides planning and legislative support and controls 
the financing of the system. Below this level, the number of layers of management and 
how health care is controlled are particular to each country. In France and the UK, the 
system is controlled centrally, subsequent layers of management are directly responsible to 
the ministry of health and have little independence. In Germany, Spain and Italy, the 
system is decentralised and national plans are implemented by independent local bodies 
which have a degree of autonomy and are able to pass their own legislation. In all of the 
systems, the health care providers are organised into national bodies which negotiate pay 
levels and lobby the government over relevant current issues. 
450 
A1.2.2 Health care funding 
The major differences between health care systems in Europe depends upon their 
method of funding. Belgium, France, Germany and the Netherlands rely upon some form 
of social insurance, with both public and private providers. Italy, Scandinavia, Spain, and 
the UK rely upon taxation, with providers controlled directly by the health service. Each 
national system differs in detail and in Italy, social security and state funds provide 
health 
care funding whereas in Spain and the UK most of the health care 
is paid out of general 
taxation. In Scandinavian countries where hospitals are owned and run almost exclusively 
by the state or local government, private nursing homes also exist. 
457 
In Germany, social insurance for health was first introduced under Bismarck in the 
19th century and in those countries which 
have a social insurance system it is carried out 
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via a number of independent companies called Sick Funds under the regulation of the 
national government. 457 Enrolment in an insurance scheme is usually obligatory for all 
low paid workers and funds are collected from salaried workers and the self-employed by 
means of national social security contributions. Insurance-based health care is not however 
an example of a free market in health; in all these countries, as well as exerting some 
control over running the schemes, the government plays a major part in determining the 
premiums paid by workers and the fees paid by the schemes to doctors and hospitals. 266 
Typically there is a system of annual negotiation arnong all the parties involved, in 
particular government, sickness funds, private insurers, hospitals and medical associations 
at which the premiums and benefits for the next year are agreed. 
In the UK and Spain, the government has direct control over the level of spending and 
allocates a budget to the system. This leads to greater control over spending and appears to 
produce a more efficient system. 266 One major difference between the member states of 
the EU and the United States is that all countries in the EU have accepted for many years 
the principle of health care provision as a right for the whole population. 
A1.2.3 Health care expenditure 
For most countries in Europe, per capita health spending averages approximately E900 
(Table 1). 250,458 Germany and France have the highest expenditure on health in Europe. 
In 1995, Germany spent 10.4% of its Gross Domestic Product (GDP) and France 9.8%, 
which equates to fl, 286 and fl, 178 per capita respectively. They were second only to the 
US, which spent 14.2% of GDP in 1995, equating to f2,229 per capita. From the countries 
considered in this thesis, Spain, Ireland and the UK were the lowest spenders, each 
spending under 7% of GDP in 1995, amounting to L648, E666 and E751 respectively per 
capita. 2509458 
There are many factors influencing the expenditure on health. These include the 
expectations and demands of patients, demography, morbidity, health care professionals 
salaries compared with the rest of the population and the overall efficiency of the system 
including administrative costs. 
446 In the German and French systems of social insurance, 
both public and private providers have some 
degree of flexibility in the prices charged 
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which is in contrast with the more highly regulated system and standard pricing for services 
in Ireland, Italy, Spain and the UK. 266 
It has been suggested that the higher the percentage of GDP a country is prepared to 
spend on health, the richer and more developed the society becomes. 451 Despite this, the 
wide variation between 6% and I I% in the percentage of GDP spent on health care does 
not entirely correlate with national wealth or even with the state of a nation's health. 459 
There is an observable slight trend for richer countries to spend more of their GDP on 
health than poorer ones and in cash terms they will usually spend more on medicines. 250 
Yet less affluent countries like Portugal spend more on pharmaceuticals relative to their 
total health budgets than do wealthier members of the European Union (EU). 250 In 
general, the EU nations with the highest medicine prices at home also have the most 
successful foreign trade records (the Netherlands is an exception) and the lowest volumes 
of domestic prescribing (Germany is an exception). 21 On a country by country basis, the 
Netherlands is an unusual example of a nation that combines lower than average domestic 
pharmaceutical consumption and spending, with relatively high medicine prices. France by 
contrast has relatively low pharmaceutical prices but high domestic usage with over five 
times more prescriptions per capita/annum than in the UK (Table 2) and proportionately 
high medicine costs per head. These differences are reflected in the proportion of the 
Netherlands gross national product and percentage of GDP spent on medicines (0.46%) 
which is half that of France (0.94%) (Table 1). 
In northern EU states, such as Germany, the Netherlands and the UK, over the counter 
medicine (OTC) sales accounted for nearly a fifth of the total value of the medicines 
market at the end of the 1980s. 21 At the same time in France, Italy, Portugal and Spain 
OTC sales represented only 5-10% of sales. By 1993, as a result of expansion of the OTC 
market, OTC sales in the northern EU states represented nearly a third of the total value of 
the medicines market and sales in France and the Mediterranean countries had risen to 
between 10 - 20% and continue to rise to this day. 
18 
The UK combines relatively modest domestic consumption of and spending on 
medicines with a strong balance of trade and unusually 
high research spending. Largely 
because of Department of Health controls introduced in the 1970s it has unusually low 
levels of domestic spending on pharmaceutical promotion. Overall, about 10% of all 
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national health service (NHS) pharmaceutical revenue goes on promotion; equivalent 
European figures are about 15 - 20%. 21 
A1.2.4 Characteristics of primary care doctors 
A1.2.4.1 Remuneration 
Member countries within the EU have different systems for remunerating GPs. 
Doctors in general practice may be paid on a capitation basis (the level of which often 
depends on the age and morbidity characteristics of the practice population), fee-for-service 
(in which the procedure or item of service is the unit of payment), salaried or they may be 
paid by a combination of these methods sometimes involving allowances (fixed payments 
for certain overhead costs, such as personnel and office expenses, additional services and 
continuing professional development (CPD) (Table 1). 445,446 Cultural, political, 
professional and social factors influence the method of paying GPs and where payment 
modes are mixed, physicians are paid differently depending on the type of service rendered. 
Different types of remuneration systems have been known to influence the working 
behaviour of practitioners. 459 For example, GPs who were paid a fee-for-service increased 
their provision of services resulting in reduced referral rates, compared with those GPs who 
were paid on a capitation basis. 460 
A1.2.4.2 Gatekeeping and co-ordination of care 
A GP acts as a gatekeeper when he/she has the authority to restrict the patients use of 
other parts of the health care system. In Ireland, Italy, the Netherlands, Norway, Portugal, 
Spain and the UK, a gatekeeping system exists where GPs control access to most other 
levels of health care. Whereas in Belgium, France and Germany, an open access system 
exists where the patient has a free choice of doctor and specialist. The level of control the 
GP has over the patient's use of other health care services thus varies from country to 
country. In EU countries, the gatekeeping role ranges from being non-existent (France) to 
major (UK and Netherlands). 
266 There is an inverse relationship between the importance 
of the gatekeeping function and the emphasis that is placed on the role of primary care in 
the health care system of each country. Where the influence of primary care providers is 
considerable as in the UK, gatekeeping is important but where primary care is not 
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emphasised as in France, neither is a gatekeeping function at any level of health care 
provision. 266 
Gatekeeping systems represent the single most important mechanism for containing 
the largest costs in any health care system, namely those for hospital services455 because a 
GP's prescription or referral is required for diagnostic services, visits to specialists and 
hospital visits. Also, when GPs screen patients before referring them to specialists, the 
incidence of true disease among patients seen by specialists is increased and the role of the 
specialist is more heavily focused on more differentiated and more severe diseases. 461 
This may be seen as contributing further to their specialist expertise and efficiency. 
In countries where GPs act as gatekeepers, patients are required to register with a GP 
to receive any service from the medical system. Patients have a free choice of GP within a 
geographical area as long as there is a choice available. In certain countries for example 
Italy and the UK, patients can change their GP, whereas in others for example Spain, 
special circumstances are required. Gatekeeper GPs also have the responsibility of 
providing co-ordinated care for the patient; they also keep records of their patients and are 
required to pass them on when the patient changes doctor. 
As well as the GP being part of the primary care team, in countries where they act as 
gatekeepers, team work also takes place between GPs and specialists across the primary- 
secondary care interface. A recent qualitative study by an academic GP in the South West 
of England has found a high level of respect between the two branches of the medical 
profession with both expressing a desire and enthusiasm to work together. 
462 Such 
teamwork is much more limited in open access systems where relationships are likely to be 
much more transient and distant. Formal co-ordination of primary and secondary care in 
Italy requires a specialist's prescription to be endorsed by the GP, a system which is stricter 
than elsewhere. 266 
In Belgium, France and Germany, the situation is entirely different and patients have 
the choice of 'shopping around' for a GP or an office-based specialist as required. This 
system leads to problems in the co-ordination of care as there is no organised system of 
transferring patient medical records between physicians. In Germany, larger GP practices 
are being encouraged with the intention of providing a greater range of services and there 
is 
also an increased focus on improving training 
for GPs. 463 In France, patients often visit 
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their doctor with a fixed outcome in mind and there is even anecdotal evidence of patients 
visiting a succession of doctors until they receive their required diagnosis or 
prescription. 266 This uncontrolled system may be a contributing factor to the high number 
of script items per capita per annum dispensed in France (Table 2). 250 In Belgium, France 
and Germany, patients need a physician's referral for hospital stays, except in an 
emergency. In Germany, patients will be frequently supervised in hospital by the same 
office-based physician whom they first visited. 266 
A1.2.4.3 Practice organisation and workload 
There is a gradual trend across Europe of GPs joining together in group practices to 
share facilities or work in health centres owned by a health insurance agency or their 
government. Group organisation is favoured as it offers practitioners greater flexibility and 
stability, enhances the likelihood of multi -disc ipl inary teamwork and increases the range of 
facilities available under one roof for the needs of patients. 
Health centres are more common in public vertically integrated systems; solo practice 
is the modal form in countries where GPs are paid a fee for service (Table 1), with the 
exception of Italy (capitation but 90% of GPs work in solo practices). 445 In countries with 
mixed group practice and solo practice, the relative proportions of each varies. This also 
varies with time and even some of the most up-to-date published figures rapidly become 
outdated with changes in health policies. For example in Spain, where almost half of GP 
practices were solo practices, this has been steadily decreasing since the mid 1990s with 
changes in health care refon-ns that have seen a move towards multidisciplinary primary 
care health centres. 266 
There is a considerable variation in the numbers of GPs and the proportion of GPs 
among all doctors both between and within countries, with Belgium and France at one 
extreme and Spain and the Netherlands at the other. 
454 In Belgium, France and Germany 
where there are no defined practice populations, GPs tend to be located in and around the 
cities. Countries with defined practice populations are more likely to have community 
involvement of practitioners which could be because they are more likely to know about 
community health problems and to become involved with addressing these problems. 
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Historically GPs in the Scandinavian countries, Portugal and Spain combine work as a 
family physician and a public health officer. 445 
Many other characteristics of general practice have been found to vary widely between 
countries including: consultation time, number of consultations per week, patient list sizes, 
population per GP, physician contacts per patient per year, prescribing of generic drugs, 
prescription items dispensed per patient per year, roles of the GP, membership of GP 
organisations and education and training. 21,219,250,445,450,458,464 However, 
considerable variation has also been found within nations, especially when comparing 
characteristics of GPs or their practices between urban and rural locations. 445,465 
A1.3 SUMMARY AND CONCLUSION 
Health service provision in isolation cannot compensate for the result of social 
inequality but health services can positively influence health and can reduce the impact of 
social inequality on health. 445 On the other hand, access to primary care services may 
have little impact on health when other social services are underdeveloped and where 
resources for public health education are relatively inadequate. 466 
Primary health care has been found to be most developed and successful in 
Scandinavia, the Netherlands and the UK which involve patient registration and control of 
access to health care by GPs. 465 There is some evidence that countries with gatekeeping 
systems have better health levels, increased patient satisfaction and lower costs. 467 A 
study in 1991 by Starfield, a medic in the Department of Health Policy Management, The 
John Hopkins University School of Medicine, Baltimore, compared data of 12 reputable 
indicators of health (mortality figures, death rates, life expectancies and birth weights) in 
seven Northern European countries, Australia, Canada and the USA and found the best 
results were in the Netherlands and Sweden. 466 Disappointingly, the UK which also 
operates a gatekeeping system was found to have the second worst results overall. 
The past two decades have seen substantial growth in health expenditure in all EU 
countries with the exception of those in Scandinavia, which has applied some restraints 
towards the EU average. Health expenditure per capita has grown in the UK but the rate of 
growth has been slow compared with most countries. 
446 However, from the 
aforementioned health indicators study466, per capita spending does not guarantee high 
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performance with respect to health indicators as the US has the highest level of spending 
per capita in the world250 and yet was ranked only joint seventh out of the ten countries 
compared by Starfield. 466 
There are many underlying reasons for the considerable diversity in general practice 
between European countries which involve human resources, the organisation of health 
systems, the status of the discipline in individual countries and systems and levels of 
payments which have evolved over the years. 454 Countries with essentially market- 
orientated systems are depending more on regulation and cost containment and countries 
with health systems based on careful planning and control are adopting more market-based 
structures. 454 In an attempt to curtail the extremes in diversity, to limit health care costs 
and to promote the free movement of doctors468, a number of charters469, directives and 
policies2l have been proposed and implemented in order to reform the different health care 
systems. In the most extreme circumstances, the French implemented independently 
developed mandatory prescribing guidelines for GPs in 1994, fining doctors E2,000 who do 
not comply. 470 
In the past couple of years, the US has succeeded in preventing health care costs from 
rising for the first time in two decades. This seems to be associated with the wide 
distribution of managed care plans in which much of the population has been encouraged to 
invest in. 457 Managed care is about managing individual episodes of care in order to 
reduce costs and possibly raise quality and it has similarities with GP fundholding in the 
UK. However, others would consider managed care to be a form of negative rationing with 
reduced costs stemming from restrictions imposed on patients with little choice. 
Nevertheless, The World Bank considers that managed care holds the biggest hope for 
developing health services in the developing world and only time will reveal if this delivery 
of health care is exported and emerges in the form of European-style health maintenance 
organisations. 471 
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Al. 4 IMPLICATIONS FOR PRESCRIBING RESEARCH 
Health care systems are different and their rate of change is primarily dependent upon 
the political agenda within a country. Consequently, the results from research related to 
this field have to be interpreted in the light of the variations that exist. The most important 
confounding factors with respect to prescribing research appear to include: the presence or 
not of a gatekeeping system; drug availability and regulation; the cost of medicines to the 
consumer and how well established local and national prescribing initiatives are. 
It is likely that the prescribing practices of GPs in countries where a gatekeeping 
system exists are more comparable than otherwise because of the organisation of care and 
reduced competition between doctors as explained previously. For the purposes of the 
research in this thesis, a gatekeeping system operated in all countries except for Belgium. 
Drug availability from country to country is problematic both in terms of the differing 
degrees to which GPs are potentially overwhelmed by large choices and with respect to 
drug costs which are not comparable between countries and thus cause difficulties when 
attempting to assess cost-effectiveness. Also, OTC availability will inevitably contribute to 
differences in prescribing patterns and drug utilization from country to country as 
governments increasingly attempt to push the expenditure onto the consumer resulting in 
patients self-medicating. In addition, the contribution consumers/patients have to make 
towards the cost of the drugs bill varies from country to country. An improvement in cost- 
effective prescribing in some countries, for example the UK, may generate more money for 
other areas of healthcare. Whereas in other countries, for example Belgium and Portugal, 
cost-effective prescribing is more notably in the patients immediate interest, as it saves 
them money. 
Finally, in countries where systems for prescribing support are well established such as 
in the UK, GP prescribing tends to be more conservative than otherwise. The implications 
with respect to this study are that access to a European Formulary, whilst presenting new 
messages for doctors in some countries may only repeat what 
has already been stated in 
others. Therefore other than serving as a possible means of reinforcement, prescribing 
interventions on this scale would be expected to have variable degrees of impact 
in 
different countries. However, if it is agreed that efficacy and safety of medicines are 
primarily two of the most important criteria upon which 
drug selection should be based, all 
375 
other things being equal then there could be a place for a European Formulary developed 
on the principles of evidence-based medicine. 
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ANNEX TWO 
European Formulary 
General Practice Prescribing Study 
Guidelines for completion of enclosed forms 
PLEASE RECORD ALL FACE TO FACE PATIENT CONTACT, whether a prescription is issued or not, until you have collected 200 patients who have received a prescription. 
Please do not write in shaded areas. 
COLUMN I 
The first column is for numbering those patients receiving a prescription of any kind, please 
include but do not number any patient who does not receive a prescription. We need 200 
patients receiving a prescription. 
COLUMN 2 
The second column specifies gender -M (male) F (female) I (inter sex). (this will be very 
rare! ) 
COLUMN 3 
The third column is for the age of the patient. 
COLUNM 4 
The fourth column is for diagnosis. Please use a separate line for each different diagnosis. 
If diagnosis is certain please specify. Where diagnosis is not certain please give general nature 
of the problem e. g. SORIE THROAT is better than diagnosis of PHARYNGITIS; 
ABDOMINAL PAIN is better than IRRITABLE BOWEL SYNDROME unless this has 
been clearly diagnosed. In some cases diagnoses are everi more unclear. In the UK patients 
often present as 'Tired all the Time' (TATT) or 'Run down' meaning feeling generally unwell 
with no specific symptoms, please specify these as ill with no defined symptoms. Your co- 
ordinator will translate these diagnoses from your own language as nearly as possible into the 
English equivalent. Please record a diagnosis for every drug prescribed, even if there is 
more than one drug for the same diagnosis. You may use ditto marks (") where 
appropriate. 
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COLUMN5 
Please leave blank for coding later. 
COLUNM 6 
The sixth column is for drug treatment. Please indicate clearly which drug is associated with 
which diagnosis. You do not need to include directions for use. Always use a new line for 
every drug prescribed. If a patient asks for a drug on repeat prescription please include + 
diagnosis in Column 4. Please use generic names where possible. 
N. B. Please indicate the formulation of NSAIDs. 
COLUMN 7 
Please leave blank for coding later. 
COLUMN8 
This column indicates whether or not a prescribed drug is a combination. Please put a bold C 
when a combined drug is prescribed e. g. paracetamol + codeine. If not a combination drug 
please put NC. 
COLUMN 9 
This column is for Category of Prescription: 
N If a drug is prescribed for a patient's new problem uninfluenced by any 
previous prescription the patient has received, put a bold N. 
A If a drug is prescribed and requested by the patient, as a result of having 
been prescribed on a previous occasion by another doctor, put a bold A. 
R If a drug is prescribed as a regular repeated prescription, put a bold R. 
H If a drug was prescribed as directed by a hospital or specialist, please 
put a bold H. 
Thank you for your co-operation. 
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ANNEXFOUR 
DIAGNOSES - FORMULARY 
GASTROINTESTINAL 4; VqTFM 'r][71131%41[XTAII fýAnV 
I 
001 Non-ulcer dyspepsia (incl. epigastric pain) 
002 Oesophagitis 
00) Nausea/vomiting (+vertigo) 
004 1 Peptic ulcers 
005 Irritable bowel syndrome 
006 Constipation 
007 Diarrhoea 
008 Ulcerative colitis/Crohn's disease 
009 Anal discomfort 
010 Cho lecystitis/gal Istones 
046 Terminal care 
I 
OTHER COMMON SYMPTOMS 
048 Fatigue 
SELECTED PROBLEMS IN INFECTIOUS 
DISEASE 
057 Anti-viral therapy 
CARDIOVASCULAR SYSTEM URINARY SYSTEM 
013 Hyperlipidaernia (hypercholesterolaemia) 
014 Hypertension 
015 1 Angina pectoris 
016 Secondary prevention of MI 
017 Arrhythmias 
018 Heart failure 
019 1 Intermittent claudication 
020 Hypotension 
021 Venous disorders 
022 Acute myocardial infarction 
RESPIRATORY SYTEM 
027 Cough (croup) 
028 Lower RT infection (chest, acute 
ronchitis) 
029 Asthma 
ýLLERGY 
031 Allergy 
CFNTR AT, NERVOUS SYSTEM 
032 Pain (sore, ache) 
033 Migraine 
034 Epilepsy 
035 Neuralgia (sciatica, carpal tunnel) 
036 Parkinson's disease 
037 Insomnia 
038 Anxiety (agitation) 
039 Depression 
040 Psychosis 
041 Dementia (+ memory disorders) 
042 Acute ischaemic stroke 
043_ Secondary prevention of stroke/TIA= 
382 
059 Urinary infections 
060 Renal colic/Calcinosis (stones) 
GENITAL TRACT 
062 Sexually transmitted diseases 
063 Vaginal discharge 
ENDOCRINE SYSTEM 
1 
066 Non-insulin dependent diabetes 
067 Hypothyroidism 
068 Hyperthyroidism 
069 Goitre 
070 Contraception 
071 Premenstrual syndrome/dysmenorrhoea 
072 Postmenopausal osteoporosis 
BLOOD 
1 
074 1 Deficiency anaernia 
CONNECTIVE TISSUE, JOINTS & BONES 
076 Arthropathies 
077 Gout and hyperuricernia 
EYES 
079 Eye conditions in EF 
EAR, NOSE AND OROPHARVNX 
080 Acute otitis media 
081 Acute pharyngitis/tonsillitis 
082 A ute sinusitis 
083 
j 
Mouth disorders 
SKIN 
086 Acne vulgaris 
087 Eczema/dry skin (+den-natitis) 
088 Psoriasis 
089 Fun-aal infections Z: ) 
090 Warts (verruca) 
091 Parasitic skin infestations 
PLACEBOS 
Placebos 
DOCTOR'S BAG 
097 The doctor's bag 
383 
ANNEX FIVE 
DIAGNOSES - NON-FORMULARY 
GASTROINTESTINAL SYSTEM 
101 Colon + urinary disorders 
102 GI bleeding (haemoptysis) 
103 GI protection 
104 Other GI disorders (hiatus hemia, 
pancreatitis etc. ) 
105 Abdominal pain (colic, cramp) 
106 Biliary colic 
107 Duodenitis 
108 Gastritis 
109 Reflux 
CARDIOVASCULAR SYSTEM 
170 Ascites/Oedema 
171 Other CV disorders/disease (arteritis, 
atherosclerosis, bypass, cardiopathy) 
172 Peripheral vascular disease (Raynaud's 
syndrome) 
17-33 Valve disorders 
174 Ischaemic heart disease 
175 Thrombosis/Embolism 
176 Lymphadenopathy 
(dyskinesia, paralysis, paraesthesiae, tremor 
etc) 
314 Neurosis 
315 Cerebrovascular disorders 
316 Confusion/Senile 
352 Behaviour/Personality problems 
INFECTIONS 
380 Cellulitis 
3 )81 Viral infections/illness 
382 Intestinal parasites 
3 383 Tuberculosis 
384 Ulcer (not mouth/Gl) 
386 Tooth/dental problems 
387 Cyst/swelling 
188 Abscesses (not teeth) 
389 Other systemic infections 
URINARY SYSTEM 
458 Other renal disorders 
521 Colostomy disorder 
520 1 Incontinence 
RESPIRATORY SYTEM 
240 Other respiratory disorders (pleurisy, 
respiratory failure etc) 
241 Chronic bronchitis (COPD/COAD) 
242 Pneumonia 
243 Toxic inhalation/ingestion/overdose 
244 Upper RT infection 
245 Respiratory tract infection 
246 Bronchitis 
247 Catarrh/Exudate/Sputum/Block 
248 Common cold/"Flu" 
249 Rhinitis 
ALLERGY 
385 Drug allergy (ADRs, S/Es, iatrogenic 
conditions) 
, r-r wTP A 1, NERVOUS SYSTEM 
051 Headache 
310 )ýýb-use/Addiction/Dependency 
312 
313 
Neuritis/polyneuritis 
europathy/other CNS disorders 
GENITAL TRACT 
390 Itch/discomfort/inflammation 
519 Gynaecological infection 
ENDOCRINE SYSTEM 
311 Liver disorders/disease 
450 Addisons syndrome 
451 Growth disorders 
452 Hepatitis 
453 HRT/Menopause (post) 
454 Hyperglycaernia 
455 Insulin depend diabetes 
456 Hypoglycaemia 
457 Osteoporosis (men) 
459 Other womens problems 
460 Other mens problems 
461 Other endocrine conditions (diabetes 
insipidus) 
462 Diabetes (not specified) 
463 Exocrine disorders 
384 
BLOOD 
660 Pregnancy/ante natal 
661 Other blood disorders (glandular fever) 
CONNECTIVE TISSUE, JOINTS & BONES 
056 Low back pain 
728 Anatomical/con genital disorders 
(hereditary) 
729 Disc problems (prolapsed etc) 
733 0 Weird M/S disorders (e. g. cracks, 
degeneration t) 
731 Dystrophy/Multiple Sclerosis 
7 
-3) 
2 Fractures (where 44pain " not written) 
7)-) M/S disorders (pain + inflammation) 
7-34 Other M/S disorders (e. g. cramps + spasm 
etc) 
7 33 7 Hernia related 
73 8 Injury + trauma (excl eye) 
739 Trauma? 
EYES 
800 Other eye conditions (glaucoma etc) ZD 
EAR, NOSE AND OROPHARYNX 
869 Ear? (otitis, discharge, earache) :M 
870 All other ear conditions (otitis externa, 
hearing deficiency etc) 
871 Other mouth/throat related disorders 
873 Sore throat/throat infection (hoarseness) 
872 Other nasal conditions 
SKIN 
7.36 Wounds/bums/lacerations/lesions 
(including infections) 
940 Hair problems (include folliculitis) 
941 Other skin infection s/problems (ind nails) 
942 
1 
Rash (not allergic) 
MALIGNANT DISEASE & 
IMMUNOSUPPRESSION 
589 Neoplasm/Hyperplasia/Polyp 
590 Cancers (malignant) 
591 Non-malignant turnours 
592 Organ transplants 
801 Immune response related disorders 
MISCELLANEOUS 
049 Itching 
050 Fever 
056 Prophylaxis of infectious diseases (vaccines 
including malaria) 
350 Weakness (asthenia) 
351 III/TATT (no definite symptoms) 
352 ME (post viral fatigue) 
735 Surgery (ectomy) + post op conditions 
888 Stress 
889 Other diagnoses (vasovagal attack, faint, 
blackout) 
996 Uncertain diagnosis (prescriber is unsure) 
997 Un identifiable/untran slated 
998 Diet/nutrition/weight disorders 
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ANNEX SIX 
Prescribing influences and your working environment 
Note: please write in BLOCK CAPITALS and use numerals where possible. 
I Male 0 Female 0 
2 Age (years) <3 0 CI 30-39 0 40-49 C3 50-59 C3 60+ 0 
3 Do you work i) alone C3 or ii) in a group practice C1 
4 Which of these best describes the location of your working practice? (please tick only one) 
rural C3 mixed urban/rural C3 urban C3 inner city/city centre C3 
Yes No 
5 Are you involved in training doctors to become GPs? 
6 Do patients who consult you include i) children < 14 years? 
ii) adults > 65 years? M 
7 Number of years since qualification as a doctor? 
_ 
ears 
8 Please list all the post-graduate qualifications you have and the year of the achievement? 
9 How many drug industry sales representatives have met with you in the last 4 weeks? 
10 On average how many hours do you work in primary care in one week? hours 
11 On average how many patients do you see in primary care in one week? patients 
12 How long (in minutes) is your average consultation with each patient? minutes 
13 Please list in order of importance the five main influences which you believe have 
acted on your personal prescribing since the autumn of 1994. 
i) 
ii) 
iii) 
iv) 
V) 
THANK YOU for taking time to complete this questionnaire. The individual questionnaires will 
remain confidential. Please return the questionnaire to Guy Jepson in the enclosed envelope. 
(Dept. Primary Health Care, The Medical School, Newcastle upon Tyne, NE2 4HH, UK) 
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ANNEX SEVEN 
August 1998 
Doctors Name 
Work Address 
city 
COUNTRY 
Dear Dr 
European Formulary Research Project 
Thank you for participating in the European Formulary project (August 1994 - July 1997) 
and for providing your invaluable prescribing data. The educational intervention which 
included distribution of the European Formulary resulted in more rational prescribing in 
Belgium, Italy and Portugal. A short summary of the project final report is enclosed for 
your interest. 
To help me explain why variations into the effect of the Formulary occurred in the different 
countries,, I should like to ask for your help in answering this brief and simple one page 
questionnaire. As well as perceived influences on prescribing, the questionnaire also asks 
for a few working environment and demographic details so that the profiles of the 
participants from the different countries can be compared. All the answers to the final 
question will be combined in a list and categorised under different themes of influence. In 
a few weeks time you will receive a brief follow up questionnaire asking you to rank the 
influencing categories in order of decreasing importance which you believe have acted on 
your personal prescribing since the autumn of 1994. The results of these questionnaires 
will contribute to the completion of a PhD thesis which should also help to raise the 
profile of the European Formulary. 
Please will you post the questionnaire back to me in Newcastle upon Tyne in the reply 
paid envelope enclosed. All replies will be treated in complete confidence. Should you 
have any queries about the questionnaire, please contact me in Newcastle upon Tyne by 
telephone on: +44 191 222 5891 or fax on +44 191 222 7892. 
Thank you for your response. 
Yours sincerely 
Guy Jepson 
Research Pharmacist 
E-mail: G. M. H. Jepson@newcastle. ac. uk 
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ANNEX NINE 
prescribinLy 
a) Drug factors 
Cost 
C f 
c) Patient factors 
Clinical indication/diagnosis/symptoms 
ost-e fectiveness 
D 
Other diagnoses/symptoms of the patient osage frequency Treatment outcome Eff icacy Patient age Formulation 
Perception that drugs are: 
liable to abuse, unnecessary or useless 
Patient compliance/palatability/tolerability 
Patient acceptability/expectation/feedback/ 
pressure/request 
New drugs Patient education 
New indications for a drug Patient's family 
Number of treatment days Patient's finances 
Polypharmacy Patients need 
Safety/side-effects d) Pharmaceutical industry factors 
b) Education/information factors Industrial agent/detailer/representative 
Conferences/courses/lectures/meetings/ 
personal research/training/training period 
Industry: 
advertising/marketing/promotion/publicity 
Continuing Me al Education (CME) Pharmaceutical company literature/data 
sheet 
Evidence-based medicine e) General medical practitioner 
factors 
Formularies: 
hospital/regional/national/internationaI 
Colleagues/partners/peers - 
discussion, opinions, pressure 
Guide I ines/protoco Is/standards/ - 
local, national, new, evidence-based, 
scientific, therapeutic 
Discussion/sessions with community 
pharmacists 
Literature - 
drug and medical journals, drug information 
bulletins, newsletters, scientific publications, 
textbooks, medical newspapers 
Hospital/specialist directed - 
discharge medication/letter 
Local/national drug advice/information units Convenience 
Small group learning Custom/experience/familiarity 
Involvement in training doctors Knowledge 
University/University organised GP health 
centre training 
Scepticism of new drugs 
g) Work based factors 
(health cent re/office/p ra ctice/su rgery) 
Membership of pre scrib ing/therapeutics 
committee 
Computer access Consultation length/time pressure 
Fundholding f) Regulatory Factors 
Group meetings Budgets/indicative prescribing scheme 
Practice agreement/behaviour/pol icy Equal drug availability internationally 
Practice audit/clinical targets Generic prescribing 
Practice fon-nulary/pre scribing protocols Government policy 
Practice nurse Health authority/board/region prescribing 
advisers 
Practice pharmacist Incentive payments/schemes 
Working in a group environment Prescribing feedback data 
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ANNEXTEN 
January 1999 
Doctors Name 
Work Address 
City 
COUNTRY 
Dear Dr 
European Formulary Research Project 
Enclosed please find a very short final follow up questionnaire further to the one 
you received last August on Prescribing influences and the doctors working 
environment. After analysing the responses to this questionnaire, I have managed to 
separate all the factors influencing prescribing into seven different categories/themes 
of influence. 
Please can you rank these categories of influence in order of most important-(D to 
least important-(D, which you believe have acted on your personal prescribing since 
autumn 1994. Thus score a (D by the category which has had the most influence, a 
(2) by the influencing category which has had the second greatest influence and 
continue on till you have scored a (7) by the category which has had the least 
influence on your prescribing. Examples of individual influences which fall into 
each of the categories can be seen separately on the attached sheet. 
Please will you post the questionnaire back to me in Newcastle upon Tyne in the 
reply paid envelope enclosed. All replies will be treated in complete confidence. 
Thank you for taking time to help me with this final stage of my PhD research. 
Happy New Year. 
Yours sincerely 
Guy Jepson 
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